baclofen has been researched along with Clasp-Knife Spasticity in 812 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intrathecal baclofen (ITB) is a treatment option for patients with severe poststroke spasticity (PSS) who have not reached their therapy goal with other interventions." | 9.27 | Intrathecal baclofen therapy versus conventional medical management for severe poststroke spasticity: results from a multicentre, randomised, controlled, open-label trial (SISTERS). ( Abouihia, A; Berthuy, N; Calabrese, A; Cloud, G; Creamer, M; Francisco, GE; Kossmehl, P; Loven, M; Saltuari, L; Ward, AB; Wissel, J; Yochelson, M; Zampolini, M, 2018) |
| "Background and Purpose- Intrathecal baclofen (ITB) is an effective treatment for managing patients with severe poststroke spasticity, who can experience continued pain and decline in their quality of life (QoL)." | 9.27 | Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity. ( Abouihia, A; Calabrese, A; Cloud, G; Creamer, M; Francisco, GE; Kossmehl, P; Saltuari, L; Ward, AB; Wissel, J; Yochelson, M; Zampolini, M, 2018) |
| "Intrathecal treatment of baclofen is an excellent method for spasticity management in children with severe cerebral palsy." | 9.24 | Long-term therapy with intrathecal baclofen improves quality of life in children with severe spastic cerebral palsy. ( Gegenleitner, K; Kraus, T; Novak, M; Singer, G; Steinwender, G; Svehlik, M, 2017) |
| "The aim of this study was to compare the relative efficacy of baclofen and self-applied transcutaneous electrical nerve stimulation (TENS) for the treatment of spasticity in the lower extremities in multiple sclerosis (MS)." | 9.17 | Comparison of the effect of baclofen and transcutaneous electrical nerve stimulation for the treatment of spasticity in multiple sclerosis. ( Golabchi, K; Haghighi, S; Heshmatipour, M; Janghorbani, M; Shaygannejad, V; Vaezi, A, 2013) |
| "This study assessed the effects of continuous intrathecal infusion of baclofen on the gait of ambulant children with cerebral palsy." | 9.14 | Intrathecal baclofen infusion for ambulant children with cerebral palsy. ( Brochard, S; Bussel, B; Filipetti, P; Remy-Neris, O, 2009) |
| "To assess the effectiveness of oral baclofen in reducing spasticity and improving function in children with cerebral palsy." | 9.12 | Oral baclofen in children with cerebral palsy: a double-blind cross-over pilot study. ( Hall, K; Lam, LT; O'Flaherty, S; Scheinberg, A, 2006) |
| "Intrathecal baclofen (ITB) therapy can be very effective in the treatment of intractable spasticity, but its effectiveness and safety have not yet been thoroughly studied in children with cerebral palsy (CP)." | 9.12 | Intrathecal baclofen in children with spastic cerebral palsy: a double-blind, randomized, placebo-controlled, dose-finding study. ( Hoving, MA; Palmans, LJ; Sleypen, FA; Spincemaille, GH; van Raak, EP; Vles, JS, 2007) |
| "The purpose of this article is to describe outcomes of intrathecal baclofen therapy for 29 patients with cerebral palsy, focusing on impairments, functional limitations, and disability." | 9.10 | Functional assessment following intrathecal baclofen therapy in children with spastic cerebral palsy. ( Awaad, R; Awaad, Y; Ham, S; Michon, AM; Munoz, S; Tayem, H, 2003) |
| "To explore whether intrathecal baclofen (ITB) therapy improves ambulation in stroke survivors." | 9.10 | Improvement in walking speed in poststroke spastic hemiplegia after intrathecal baclofen therapy: a preliminary study. ( Boake, C; Francisco, GE, 2003) |
| "The effect of baclofen on the soleus stretch reflex and peripheral muscle function was tested in 10 multiple sclerosis (MS) patients with spasticity in the lower extremities." | 9.09 | Peripheral and central effect of baclofen on ankle joint stiffness in multiple sclerosis. ( Nielsen, JF; Sinkjaer, T, 2000) |
| "The effect of baclofen on walking performance was examined in nine spastic multiple sclerosis patients." | 9.09 | Baclofen increases the soleus stretch reflex threshold in the early swing phase during walking in spastic multiple sclerosis patients. ( Anderson, JB; Nielsen, JF; Sinkjaer, T, 2000) |
| "Seventeen patients with congenital spastic cerebral palsy and six patients with other forms of spasticity were injected intrathecally with doses of placebo or baclofen, 25 micrograms, 50 micrograms, or 100 micrograms, in a randomized, double-blind manner." | 9.07 | Intrathecal baclofen for spasticity in cerebral palsy. ( Albright, AL; Cervi, A; Singletary, J, 1991) |
| "A multi-centre, double-blind study was carried out in 100 patients suffering from chronic spasticity due to multiple sclerosis to compare the effectiveness of tizanidine hydrochloride with that of baclofen." | 9.06 | Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. ( Boisson, D; Eyssette, M; Rohmer, F; Serratrice, G; Warter, JM, 1988) |
| "The anti-spastic effect of a new drug, tizanidine, was compared with that of baclofen in a double-blind clinical trial; 40 seriously handicapped patients with multiple sclerosis (MS) were randomly allocated treatment with one or the other drug for a 6-week period." | 9.06 | The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen. ( Nordal, HJ; Oftedal, SI; Slettebø, M; Stien, R, 1987) |
| "A double-blind trial with two parallel groups was carried out to compare the antispastic effect and tolerability of a new muscle relaxant, tizanidine (DS 103-282), with those of baclofen in the treatment of spasticity due to multiple sclerosis." | 9.05 | A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis. ( Muff, S; Smolenski, C; Smolenski-Kautz, S, 1981) |
| "A double-blind crossover trial against placebo was conducted to assess the effects of the GABA derivative, baclofen, on the disabilities due to muscle spasticity in twenty children suffering from cerebral palsy." | 9.04 | A controlled trial of baclofen in children with cerebral palsy. ( Jackson, AD; Milla, PJ, 1977) |
| "Baclofen is a safe and effective means for treating spasticity associated with multiple sclerosis." | 9.04 | Baclofen for spasticity in multiple sclerosis. Double-blind crossover and three-year study. ( Conomy, JP; Feldman, RG; Foley, JM; Kelly-Hayes, M, 1978) |
| "Baclofen was used in a double-blind crossover placebo-controlled trial to treat spasticity in patients with multiple sclerosis (MS)." | 9.04 | The use of baclofen in treatment of spasticity in multiple sclerosis. ( Paty, DW; Sawa, GM, 1979) |
| "To systematically review the effectiveness of oral baclofen versus placebo or other antispastic oral medications in terms of body function, level of activity, and quality of life in children and adolescents with spastic cerebral palsy who are younger than 18 years." | 8.93 | Effectiveness of Oral Baclofen in the Treatment of Spasticity in Children and Adolescents With Cerebral Palsy. ( Gonzalez, W; Nahuelhual, P; Navarrete-Opazo, AA, 2016) |
| "To determine whether intrathecal baclofen is an effective treatment for spasticity in children with cerebral palsy." | 8.91 | Intrathecal baclofen for treating spasticity in children with cerebral palsy. ( Hasnat, MJ; Rice, JE, 2015) |
| "Studies on the use of intrathecal baclofen (ITB) for ambulant adults with spasticity and/or dystonia of cerebral origin are scarce, and are even more limited for children and adolescents." | 8.87 | Use of intrathecal baclofen therapy in ambulant children and adolescents with spasticity and dystonia of cerebral origin: a systematic review. ( Lewis, J; McCartney, L; Pin, TW; Waugh, MC, 2011) |
| "Intrathecal baclofen (ITB) has become a standard treatment for spasticity in patients with cerebral palsy (CP) over the last ten years." | 8.84 | A review of the complications of intrathecal baclofen in patients with cerebral palsy. ( Kolaski, K; Logan, LR, 2007) |
| "Intrathecal baclofen (ITB) therapy has been increasingly employed for the management of poststroke spastic hypertonia, a complication that can lead to deformity, discomfort, and exacerbation of motor impairments." | 8.83 | Consensus panel guidelines for the use of intrathecal baclofen therapy in poststroke spastic hypertonia. ( Cavalier, S; Francisco, GE; Grissom, S; Schiess, MC; Wiggs, L; Yablon, SA, 2006) |
| "Intrathecal baclofen reduces spasticity in individuals with cerebral palsy." | 8.79 | Intrathecal baclofen in cerebral palsy movement disorders. ( Albright, AL, 1996) |
| "To evaluate the effects of intrathecal baclofen pump (ITBP) therapy on hip dysplasia in young patients with cerebral palsy (CP)." | 8.31 | Does intrathecal baclofen therapy decrease the progression of hip displacement in young patients with cerebral palsy? ( Asma, A; Howard, JJ; McManus, M; Miller, F; Rogers, KJ; Shrader, MW; Ulusaloglu, AC, 2023) |
| "Intrathecal baclofen (ITB) therapy is an effective treatment for spasticity and dystonia in children with cerebral palsy (CP)." | 8.31 | A multicenter initiative to reduce intrathecal baclofen pump surgical site infection: a Cerebral Palsy Research Network quality improvement project. ( Albarqawi, L; Bailes, AF; Bollo, RJ; Browd, SR; Gross, PH; Leonard, JR; Raskin, JS; Rocque, BG, 2023) |
| "The results of this study suggest that baclofen is associated with higher incidences of injury and delirium compared to tizanidine when used for the treatment of musculoskeletal pain." | 8.31 | Safety of baclofen versus tizanidine for older adults with musculoskeletal pain. ( Broder, BI; DiStasio, C; Hui, RL; Lee, EA; Niu, F; Steinberg, SG; Su Zhang, VR, 2023) |
| "This study aimed to determine the risk factors for reconstructive hip surgery after intrathecal baclofen pump application in children with cerebral palsy." | 8.31 | Identification of risk factors for reconstructive hip surgery after intrathecal baclofen therapy in children with cerebral palsy. ( Asma, A; Howard, JJ; Miller, F; Rogers, KJ; Shrader, MW; Ulusaloglu, AC, 2023) |
| "We report the case of a 61-year-old Japanese man with lumbar spinal stenosis who underwent intrathecal baclofen therapy." | 8.31 | Decompression for lumbar spinal stenosis at the intrathecal catheter insertion site during intrathecal baclofen therapy: a case report. ( Ebara, H; Hayashi, H; Inatani, H; Kagechika, K; Kitano, Y; Mori, A; Nakanami, A; Takagi, Y; Toyooka, K; Tsuchiya, H; Yahata, T; Yamada, H, 2023) |
| "The aim of the study was to evaluate the use of a novel technique for baclofen delivery using an intrathecal catheter inserted through a lumbar laminotomy with the tip placed at the cisterna magna (supraspinal baclofen (SSB)) for the treatment of severe generalized secondary dystonia." | 8.12 | Supraspinal baclofen for the treatment of secondary generalized dystonia: A case series. ( BeDell, KK; Ceverha, B; Wu, J; Yeh, BY, 2022) |
| "The purpose of this study is to describe the efficacy and adverse events of neuraxial anesthesia for post-operative pain control in non-ambulatory children with cerebral palsy with pre-existing intrathecal baclofen (ITB) pumps undergoing hip reconstructive or palliative surgery." | 8.12 | Neuraxial anesthesia for post-operative pain control after hip surgery in children with cerebral palsy and pre-existing intrathecal baclofen pumps. ( Ball, MA; Davids, JR; Davidson, LT; Kephart, DT; Kulkarni, VA; Tumber, S, 2022) |
| "Intrathecal baclofen therapy(ITB)is a recognized treatment for spastic paralysis." | 8.12 | [Intrathecal Baclofen Therapy for Spastic Paralysis]. ( Usami, K, 2022) |
| "The purpose of this study was to investigate the incidence of complications in pediatric spastic cerebral palsy (CP) patients weighing less than 20 kg at the time of intrathecal baclofen (ITB) pump implantation and to compare it with spastic CP patients heavier than 20 kg." | 8.12 | Complications of intrathecal baclofen pump treatment in children with spastic cerebral palsy. A comparative analysis of patients weighing over or under 20 kg at the time of implantation. ( Canavese, F; De Coulon, G; Steiger, CN; Tabard-Fougère, A, 2022) |
| "Intrathecal baclofen pump associated central nervous system (CNS) infection and meningitis is a rare but serious complication and may have dire consequences." | 8.02 | Intrathecal Baclofen Pump Infection With Meningitis: Effective Treatment by Radical Debridement and Intrareservoir Baclofen-Vancomycin Co-Infusion. ( Chan, SHS; Chim, S; Ho, ACC; Koljonen, PA; Liu, T; Tsoi, NS; Wong, YW, 2021) |
| "Intrathecal baclofen (ITB) pumps are an effective treatment for spasticity; however infection rates have been reported in 3-26% of patients in the literature." | 7.96 | Reducing Intrathecal Baclofen Related Infections: Service Evaluation and Best Practice Guidelines. ( Bahadur, S; Balaratnam, MS; Brownstone, RM; Christofi, G; Curtis, C; Donnelly, A; Farrell, R; Grieve, J; Keenan, L; Lee, H; Murphy, M; Nayar, M; Padilla, H; Pitceathly, RDS; Shieff, C; Simeoni, S; Stevenson, VL, 2020) |
| "Intrathecal baclofen (ITB) pumps used to manage spasticity in children with cerebral palsy (CP) also improve pain outcomes for some but not all patients." | 7.96 | Investigating the Feasibility of a Modified Quantitative Sensory Testing Approach to Profile Sensory Function and Predict Pain Outcomes Following Intrathecal Baclofen Implant Surgery in Cerebral Palsy. ( Barney, CC; Merbler, AM; Simone, DA; Symons, FJ; Walk, D, 2020) |
| "Two patients previously implanted with intrathecal Baclofen (ITB) pumps for management of intractable spasticity due to multiple sclerosis (MS) were referred to our center for ongoing management of their spasticity." | 7.91 | Intrathecal Baclofen Therapy in Patients With Multiple Sclerosis: Improved Outcomes and Reduced Costs Through Identification of Catheter Malfunction. ( McGuire, JR; Nelson, MES, 2019) |
| "To investigate the effect of intrathecal baclofen (ITB) on function and activity in dyskinetic cerebral palsy (CP)." | 7.88 | Intrathecal baclofen in dyskinetic cerebral palsy: effects on function and activity. ( Askljung, B; Corneliusson, O; Eek, MN; Himmelmann, K; Lindh, K; Olsson, K; Påhlman, M, 2018) |
| "This article details an unreported potential cause of withdrawal symptoms in a patient with cerebral palsy who experienced intrathecal baclofen withdrawal shortly after placement of a baclofen pump with subsequent refill with Gablofen." | 7.88 | An Unreported Cause of Intrathecal Baclofen Withdrawal Symptoms in a Woman With Spastic Cerebral Palsy Who Received Intrathecal Gablofen. ( Duraski, SA; Sayyad, A, 2018) |
| "Objective To assess quantitatively the efficacy of oral baclofen for spasticity poststroke." | 7.88 | Effect of oral baclofen on spasticity poststroke: responders versus non-responders. ( Maeshima, S; Mizuno, S; Shigeru, S; Takeda, K, 2018) |
| "To compare spasticity levels, pain, sleep, fatigue, and quality of life between individuals receiving treatment with intrathecal versus oral baclofen." | 7.83 | Intrathecal Versus Oral Baclofen: A Matched Cohort Study of Spasticity, Pain, Sleep, Fatigue, and Quality of Life. ( Binler, D; Chu, SK; Lee, J; Marciniak, C; Mathur, SN; McCormick, ZL; Neudorf, D, 2016) |
| " In this study the authors analyzed the long term effects of intrathecal baclofen therapy in multiple sclerosis and evalued the benefits of the treatment on spasticity, disability, pain, spasm frequency and rated the incidence of side effects." | 7.83 | Long-term effects of intrathecal baclofen in multiple sclerosis. ( D'Oria, S; Gentile, M; Natale, M; Nero, VV; Rotondo, M; Squillante, E, 2016) |
| "Intrathecal baclofen (ITB) treatment is applied in patients with spastic cerebral palsy (SCP), dystonic cerebral palsy (DCP) and progressive neurological disease (PND)." | 7.83 | The effect of intrathecal baclofen treatment on activities of daily life in children and young adults with cerebral palsy and progressive neurological disorders. ( Becher, J; Bonouvrié, L; Buizer, A; Soudant, D; van Ouwerkerk, W; Vermeulen, RJ; Vles, G, 2016) |
| "Intrathecal Baclofen is available to treat severe generalized spasticity in Multiple Sclerosis (MS) unresponsive to oral drug delivery." | 7.83 | Effects of severe spasticity treatment with intrathecal Baclofen in multiple sclerosis patients: Long term follow-up. ( Gerini, A; Mazzoleni, S; Stampacchia, G, 2016) |
| "Tetrahydrocannabinol:cannabidiol (THC:CBD) oromucosal spray (Sativex®) is an add-on therapy for moderate-to-severe multiple sclerosis (MS)-related drug-resistant spasticity (MSS)." | 7.83 | Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice. ( Trojano, M; Vermersch, P, 2016) |
| "Treatment of severe spasticity and dystonia with intrathecal baclofen (ITB) in children has been shown to be effective and has therefore been employed in the Region of Southern Denmark." | 7.81 | Positive experience with intrathecal baclofen treatment in children with severe cerebral palsy. ( Illum, NO; Kjærsgaard-Hansen, L; Overgård, TM; Søe, M, 2015) |
| "We describe a 6 year-old girl with hydranencephaly who underwent an intrathecal baclofen test dose and developed severe bradycardia." | 7.81 | Profound Bradycardia After Intrathecal Baclofen Injection in a Patient With Hydranencephaly. ( Cain, N; Kinsman, S; Sechrist, C, 2015) |
| "Implantation of an intrathecal baclofen pump is recommended for children with cerebral palsy as a means to improve care and comfort when other options fail to control severe hypertonia." | 7.80 | Improvements in children with cerebral palsy following intrathecal baclofen: use of the Rehabilitation Institute of Chicago Care and Comfort Caregiver Questionnaire (RIC CareQ). ( Baker, KW; Gaebler-Spira, D; Mutlu, A; Tann, B, 2014) |
| "To investigate the effect of intrathecal baclofen (ITB) on sitting in children with cerebral palsy with severe spasticity; and identify potential sub-groups of patients at particular risk of deterioration." | 7.80 | The effect of continuous intrathecal baclofen on sitting in children with severe cerebral palsy. ( Gray, N; Vloeberghs, M, 2014) |
| "To investigate the long-term dosage evolution and complication rate of intrathecal baclofen use in multiple sclerosis and spinal cord injury patients, based on a large population with a long follow-up." | 7.79 | Intrathecal baclofen in multiple sclerosis and spinal cord injury: complications and long-term dosage evolution. ( Degraeuwe, B; Draulans, N; Kiekens, C; Meurrens, T; Nuttin, B; Peers, K; Vermeersch, K, 2013) |
| "Little is known about the long-term effects of Continuous intrathecal Baclofen (CITB) therapy in non-ambulant children with intractable spastic Cerebral Palsy (CP)." | 7.79 | Long-term follow-up on continuous intrathecal Baclofen therapy in non-ambulant children with intractable spastic Cerebral Palsy. ( Bonouvrié, LA; Hoving, MA; Soudant, DL; van Oostenbrugge, RJ; Vermeulen, RJ; Vles, GF; Vles, JS, 2013) |
| "Intrathecal baclofen therapy has been used successfully for intractable spasticity in children with cerebral palsy." | 7.78 | Evaluation of salvage techniques for infected baclofen pumps in pediatric patients with cerebral palsy. ( Fisher, JF; Hester, SM; Lee, MR; Macomson, S; Vender, JR, 2012) |
| "To evaluate the long-term effect of intrathecal baclofen therapy in multiple sclerosis-related spasticity and to evaluate the side-effects of long-term therapy, and the doses of baclofen required." | 7.77 | Treatment of spasticity related to multiple sclerosis with intrathecal baclofen: a long-term follow-up. ( Grønning, M; Rekand, T, 2011) |
| "The aim of the study was to explore the timing of effects of intrathecal baclofen therapy in children with cerebral palsy." | 7.76 | Continuous intrathecal baclofen therapy in children with cerebral palsy - when does improvement emerge? ( Jahnsen, R; Lofterod, B; Ramstad, K; Skjeldal, OH, 2010) |
| "Intrathecal baclofen is an effective treatment for spasticity in patients with cerebral palsy." | 7.76 | Do baclofen pumps influence the development of scoliosis in children? ( Burn, SC; Drake, JM; Zeller, R, 2010) |
| "Two patients with subarachnoid hemorrhage recovered consciousness after intrathecal baclofen administration using an implanted intrathecal baclofen pump delivering 50 microg per day using a simple infusion mode." | 7.76 | Consciousness recovery induced by intrathecal baclofen administration after subarachnoid hemorrhage -two case reports-. ( Hattori, K; Kito, A; Maki, H; Oyama, H; Tanahashi, K, 2010) |
| "Baclofen withdrawal syndrome is a rare and potentially life-threatening condition manifesting with autonomic dysreflexia, high fevers, spasticity, seizures, and multiorgan failure." | 7.76 | Reversible electrocardiogram changes and cardiomyopathy secondary to baclofen withdrawal syndrome. ( Kireyev, D; Poh, KK, 2010) |
| "Seven cases of combination of intrathecal (IT) ziconotide and baclofen therapy in patients with refractory neuropathic pain and spasticity were reviewed." | 7.75 | Intrathecal ziconotide and baclofen provide pain relief in seven patients with neuropathic pain and spasticity: case reports. ( Burton, AW; Danyo, DA; Frost, S; Glanzer, J; Saulino, M; Solanki, DR, 2009) |
| "To describe complications and outcomes of intrathecal baclofen (ITB) therapy in children with spasticity and/or dystonia." | 7.75 | Continuous intrathecal baclofen for children with spasticity and/or dystonia: Goal attainment and complications associated with treatment. ( Dexter, M; Hayden, S; Scheinberg, A; Ward, A, 2009) |
| "To determine whether intrathecal administration of baclofen reduced spastic hypertonia in a hemiplegic patient after hemorrhagic stroke." | 7.74 | [Efficacy of intrathecal baclofen in the treatment of spasticity in stroke]. ( Cantalloube, S; Lamotte, D, 2007) |
| "The aim of this study was to present a case of deep vein thrombosis (DVT) and pulmonary embolism (PE) after an intrathecal baclofen bolus test." | 7.74 | Intrathecal baclofen bolus complicated by deep vein thrombosis and pulmonary embolism. A case report. ( Carda, S; Cazzaniga, M; Pozzi, R; Taiana, C, 2008) |
| "To determine the frequency of pruritus after intrathecal baclofen (ITB) withdrawal and to study the pathophysiology of this symptom." | 7.73 | Pruritus after intrathecal baclofen withdrawal: A retrospective study. ( Ben Smail, D; Bussel, B; Denys, P; Hugeron, C, 2005) |
| "Oral and intrathecal baclofen (ITB) have been associated with epileptic seizures." | 7.73 | Incidence of seizures in patients with multiple sclerosis treated with intrathecal baclofen. ( Bethoux, FA; Boulis, N; Kellinghaus, C; Loddenkemper, T; Schuele, SU; Shook, SJ, 2005) |
| "The objective of this study was to analyze the relationship between epilepsy and intrathecal baclofen by investigating a consecutive sample of 150 children with cerebral palsy or spasticity of cerebral origin who underwent intrathecal baclofen." | 7.73 | Epilepsy and intrathecal baclofen therapy in children with cerebral palsy. ( Buonaguro, V; Curci, D; Iuorno, T; Monforte, S; Motta, F; Scelsa, B, 2005) |
| "We conducted a retrospective study of the case files of 64 multiple sclerosis (MS) patients presenting severe spasticity, who had received intrathecal (IT) baclofen test injections between 1992 and 2004 in a rehabilitation unit." | 7.73 | Intrathecal baclofen for treatment of spasticity of multiple sclerosis patients. ( Ben Smail, D; Bussel, B; Mailhan, L; Peskine, A; Roche, N; Thiébaut, I, 2006) |
| "To determine whether leg muscle stiffness is measurably reduced after intrathecal baclofen (ITB) in subjects with spastic hemiplegia." | 7.72 | Intrathecal baclofen in subjects with spastic hemiplegia: assessment of the antispastic effect during gait. ( Bouilland, S; Bussel, B; Rémy-Néris, O; Tiffreau, V, 2003) |
| "Continuous intrathecal baclofen was effective in treating severe spasticity and dystonia of cerebral origin with major effect on muscles of the lower extremities, pelvis, and back and in particular opisthotonus was relieved." | 7.72 | [Intrathecal baclofen in the treatment of severe spastic tetraplegia and dystonia in children and adolescents]. ( Fischer, C; Hansen, FJ; Illum, NO; Nielsen, OA; Uldall, PV, 2003) |
| " The aim of this paper is to present the result of intrathecal baclofen infusion in treatment of spasticity in patients with cerebral palsy." | 7.72 | [Intrathecal baclofen for treatment of spasticity in patient with cerebral palsy--a preliminary report]. ( Grottel, K; Huber, J; Idzior, M; Jóźwiak, M; Szulc, A, 2003) |
| "This study was undertaken to determine the efficacy of intrathecal baclofen therapy in patients who suffer spasticity after a stroke." | 7.71 | Intrathecal baclofen for spasticity caused by thrombotic stroke. ( Gwartz, BL, 2001) |
| "To determine whether continuous intrathecal baclofen infusion (CIBI) would decrease spasticity and improve function in children with spastic cerebral palsy." | 7.71 | Continuous intrathecal baclofen infusion for children with cerebral palsy: a pilot study. ( Chaseling, R; Dexter, M; O'Flaherty, S; Scheinberg, A, 2001) |
| "We report the treatment of severe neuropathic pain in a patient with ED and the combined intrathecal application of baclofen and morphine in 5 patients with severe spasticity related pain." | 7.71 | Combined intrathecal baclofen and morphine infusion for the treatment of spasticity related pain and central deafferentiation pain. ( Becker, R; Bertalanffy, H; Gatscher, S; Uhle, E, 2002) |
| "A 29-year-old man with C6 tetraplegia (ASIA A) using an implanted baclofen pump and intrathecal catheter infusion system for spasticity control developed severe spasticity, hyperthermia, hypotension, rhabdomyolysis, and disseminated intravascular coagulation after catheter disconnection." | 7.70 | Hyperthermia, rhabdomyolysis, and disseminated intravascular coagulation associated with baclofen pump catheter failure. ( Christopherson, MW; Reeves, RK; Stolp-Smith, KA, 1998) |
| "Intrathecal baclofen infusion (IBI) is an effective treatment for spasticity secondary to cerebral palsy (CP)." | 7.70 | Intrathecal baclofen infusion and subsequent orthopedic surgery in patients with spastic cerebral palsy. ( Albright, AL; Gerszten, PC; Johnstone, GF, 1998) |
| "In this case study we describe a dual approach to the palliation of difficult muscle spasms using intrathecal baclofen via a fully implanted system, together with the homeopathic approach to symptom control." | 7.70 | Intrathecal baclofen and homeopathy for the treatment of painful muscle spasms associated with malignant spinal cord compression. ( Hicks, F; Thompson, E, 1998) |
| "The purpose of the study was to analyze the relative cost of selective functional posterior rhizotomy (SFPR) and continuous intrathecal baclofen in the treatment of children with severe spastic quadriplegia related to cerebral palsy." | 7.69 | Cost analysis of continuous intrathecal baclofen versus selective functional posterior rhizotomy in the treatment of spastic quadriplegia associated with cerebral palsy. ( Daneshvar, H; Evans, D; Kestle, JR; Steinbok, P, 1995) |
| "A report on pregnancy in a quadriplegic patient treated with a high dose of 1000 mcg/24 h continuous intrathecal baclofen infusion using an implanted drug delivery system (Synchromed, Medtronic, USA)." | 7.68 | Pregnancy in a quadriplegic patient treated with continuous intrathecal baclofen infusion to manage her severe spasticity. Case report. ( Delhaas, EM; Verhagen, J, 1992) |
| "We reviewed a 10% random sample of charts from an outpatient clinic for multiple sclerosis to determine the frequency with which baclofen was prescribed for spasticity in high doses (greater than 80 mg/d)." | 7.68 | High-dose oral baclofen: experience in patients with multiple sclerosis. ( Giesser, BS; LaRocca, NG; Scheinberg, LC; Smith, CR, 1991) |
| "Sixteen patients suffering from spasticity due to multiple sclerosis were treated with baclofen and tizanidine in a partially blind cross-over study." | 7.67 | Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients. ( Hoogstraten, MC; Minderhoud, JM; van der Ploeg, RJ; van Marle, S; vd Burg, W; Vreeling, A, 1988) |
| "Baclofen, 90 mg daily, was given to a patient with stiff-man syndrome diagnosed by electromyography and clinical criteria." | 7.66 | Baclofen in the treatment of stiff-man syndrome. ( Korsvik, H; Miller, F, 1981) |
| "The mean daily dosage alleviating spasticity on the hemiparetic side-without affecting the nonparetic side-was 119 microg/day (range 50 to 360 microg/day)." | 6.74 | Limitations of intrathecal baclofen for spastic hemiparesis following stroke. ( Kofler, M; Quirbach, E; Saltuari, L; Schauer, R; Singer, M, 2009) |
| "Clinical signs and symptoms of spasticity include hypertonia, involuntary movements (spasms, clonus), decreased range of motion, contractures, and often spasm-related pain." | 6.73 | Intrathecal baclofen for spasticity-related pain in amyotrophic lateral sclerosis: efficacy and factors associated with pain relief. ( Bethoux, FA; Boulis, NM; Gogol, DM; Harrison, M; McClelland, S; Pioro, EP; Schwetz, KM; Stough, DK; Sutliff, MH, 2008) |
| "Dystonia was associated with cerebral palsy in 71% of participants." | 6.70 | Intrathecal baclofen for generalized dystonia. ( Albright, AL; Barry, MJ; Ferson, SS; Shafton, DH, 2001) |
| "An ITB pump was inserted to manage spasticity." | 6.66 | Severe Neuromuscular Scoliosis Implicated by Dysfunction of Intrathecal Baclofen Pump: Case Report and Review of the Literature. ( Apostolopoulou, K; Panagopoulos, D; Themistocleous, M, 2020) |
| "Tizanidine (Sirdalud) was compared to baclofen (Lioresal) in a randomized, double-blind, cross-over trial." | 6.66 | Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. ( Bass, B; Bouchard, S; Cameron, MG; Ebers, GC; Hader, W; Noseworthy, JH; Rice, GP; Weinshenker, B, 1988) |
| "Because of severe spasticity, many of these patients undergo intrathecal baclofen pump placement before, during, or after posterior spinal fusion." | 6.52 | Scoliosis, spinal fusion, and intrathecal baclofen pump implantation. ( Scannell, B; Yaszay, B, 2015) |
| "Oral antispasticity medications are useful in managing mild spasticity but are frequently ineffective in controlling moderate to severe spasticity, because patients often cannot tolerate the adverse effects of increasing doses." | 6.47 | Intrathecal baclofen in multiple sclerosis: too little, too late? ( Bennett, SE; Bethoux, F; Erwin, A; Gudesblatt, M; Hughes, M; Koelbel, S; Plunkett, R; Sadiq, S; Stevenson, VL; Thomas, AM; Tornatore, C; Zaffaroni, M, 2011) |
| "Usually, the evaluation of spasticity is carried out by the Asworth Scale although there is not yet general accordance on the validity of this scale." | 6.44 | Management of spasticity in multiple sclerosis by intrathecal baclofen. ( Dario, A; Tomei, G, 2007) |
| "Baclofen is mainly an antispastic drug and the main indication of ITB is generalized lower limb spasticity in spinal cord injury and multiple sclerosis." | 6.44 | Intrathecal baclofen in the treatment of spasticity, dystonia and vegetative disorders. ( Menei, P; Richard, I, 2007) |
| "Baclofen is also used for control of dystonia due to cerebral palsy or reflex sympathetic dystrophy." | 6.42 | Clinical application of drug pump for spasticity, pain, and restorative neurosurgery: other clinical applications of intrathecal baclofen. ( Hori, T; Taira, T, 2003) |
| "Symptomatic treatment of Multiple Sclerosis (MS) is crucial, since it helps to lessen the limitations that affect patients' daily lives." | 5.91 | Effects of intrathecal Baclofen in reducing tremors in patients with multiple sclerosis. ( Aldarwish, WA; Ali, EN, 2023) |
| "In this case, treatment of severe spasticity and nociceptive pain was required while avoiding potentially lethal side effects of sudden baclofen withdrawal." | 5.62 | Baclofen bridging, weaning protocol and pain management of a person with T6 paraplegia who required removal of intrathecal baclofen pump due to wound infection. ( Agha, H; Davis, C; Roth, J, 2021) |
| "Multiple sclerosis is a neurological disease that presents with various symptoms; in some cases it is progressive and highly disabling, requiring invasive techniques to treat pain and spasticity." | 5.62 | Intrathecal baclofen pump exchange in multiple sclerosis. Factors affecting baclofen efficacy and dose adjustement. A case report. ( Alonso Rodríguez, E; Blázquez Calvo, V; Lloreda Herradón, P; Miyagi Yonamine, M, 2021) |
| "The majority were on multiple spasticity medications." | 5.62 | Evaluation of the cognitive benefits of intrathecal baclofen pump implantation in people with intractable multiple sclerosis related spasticity. ( Buchanan, K; Doogan, C; Farrell, R; Keenan, E; Lee, H; Mulhert, N; Padilla, H; Stevenson, VL; Summers, M, 2021) |
| "His severe spasticity made positioning and care difficult, and intense pain required multiple hospitalizations." | 5.51 | The Palliative Use of Intrathecal Baclofen in Niemann-Pick Disease Type C. ( Buxton, K; Nimec, DL; Stone, SS; Ubeda Tikkanen, A; Ullrich, CK, 2019) |
| "Demographics, spasticity scores (Ashworth), spasm score (Penn), stiffness, pain and discomfort (Visual Analogue Scale), mobility (10 M walk), spasticity treatment, and ITB doses were analysed longitudinally." | 5.51 | Intrathecal baclofen for multiple sclerosis related spasticity: A twenty year experience. ( Buchanan, K; Farrell, R; Keenan, L; Sammaraiee, Y; Stevenson, V; Yardley, M, 2019) |
| "The treatment of spasticity and dystonia in these patients is difficult partly due to the relentless nature of this progressive disorder." | 5.48 | Intrathecal baclofen treatment an option in X-linked adrenoleukodystrophy. ( Ehrstedt, C; Hjartarson, HT; Tedroff, K, 2018) |
| "Melatonin is an effective treatment in MS patients and experimental autoimmune encephalomyelitis (EAE), a mouse model of MS." | 5.48 | Spasticity Treatment Ameliorates the Efficacy of Melatonin Therapy in Experimental Autoimmune Encephalomyelitis (EAE) Mouse Model of Multiple Sclerosis. ( Farhadi, N; Ghareghani, M; Sadeghi, H; Zibara, K, 2018) |
| "Change of spasticity was evaluated using the Modified Ashworth Scale." | 5.46 | Outcomes of intrathecal baclofen therapy in patients with cerebral palsy and acquired brain injury. ( Chae, M; Chang, JW; Chang, WS; Cho, HE; Cho, SR; Lee, KC; Yoon, YK, 2017) |
| "The current treatment of spasticity in patients with Sjögren-Larsson syndrome is largely symptomatic, given that no effective causal therapy treatments are available." | 5.46 | Intrathecal Baclofen Therapy for the Treatment of Spasticity in Sjögren-Larsson Syndrome. ( Harter, DH; Hersh, A; Hidalgo, ET; Orillac, C; Rizzo, WB; Weiner, HL, 2017) |
| " Following botulinum toxin A treatment, clinical improvement led to the gradual reduction of baclofen or tizanidine dosing to one-third of the former dose." | 5.43 | Comparison of Efficacy and Side Effects of Oral Baclofen Versus Tizanidine Therapy with Adjuvant Botulinum Toxin Type A in Children With Cerebral Palsy and Spastic Equinus Foot Deformity. ( Aksoy, SN; Dai, AI; Demiryürek, AT, 2016) |
| "The baclofen pump was then removed." | 5.42 | [Complete remission of consciousness disturbances and spasticity due to a severe subarachnoid hemorrhage after intrathecal baclofen therapy: a case report]. ( Asahi, T; Kashiwazaki, D; Koh, M; Kuroda, S; Matsumura, N, 2015) |
| "For spinal spasticity, they are typically in the order of 100-300 μg/day." | 5.42 | Intrathecal Baclofen therapy in Germany: Proceedings of the IAB-Interdisciplinary Working Group for Movement Disorders Consensus Meeting. ( Berweck, S; Chatzikalfas, A; Dressler, D; Ebke, M; Frank, B; Hesse, S; Huber, M; Krauss, JK; Mücke, KH; Nolte, A; Oelmann, HD; Pickenbrock, H; Saberi, FA; Schmutzler, M; Schönle, PW; Van der Ven, C; Veelken, N; Vogel, M; Vogt, T, 2015) |
| "Baclofen is the most commonly-prescribed antispasmodic after SCI." | 5.41 | Intrathecal and Oral Baclofen Use in Adults With Spinal Cord Injury: A Systematic Review of Efficacy in Spasticity Reduction, Functional Changes, Dosing, and Adverse Events. ( D'Amico, JM; Dietz, N; Harkema, SJ; Wagers, S, 2023) |
| "Treatment of children with movement disorders associated with CP increased slowly in the 1970s and 1980s but accelerated rapidly in the 1990s with the introduction of lumbar dorsal rhizotomies and intrathecal baclofen." | 5.41 | Spasticity and movement disorders in cerebral palsy. ( Albright, AL, 2023) |
| "Four children had untreated scoliosis and corrective surgery was being contemplated." | 5.38 | Cervical implantation of intrathecal baclofen pump catheter in children with severe scoliosis. ( Ammar, A; Ingale, H; Moussa, A; Muquit, S; Ughratdar, I; Vloeberghs, M, 2012) |
| "Spasticity is the major etiology for hip dislocation in nonambulatory cerebral palsy patients." | 5.38 | A comparison of hip dislocation rates and hip containment procedures after selective dorsal rhizotomy versus intrathecal baclofen pump insertion in nonambulatory cerebral palsy patients. ( Ayyangar, RN; Caird, MS; Craig, CL; Farley, FA; Hensinger, RN; Hurvitz, EA; Nowicki, P; Silva, S; Vanderhave, KL, 2012) |
| "Although spasticity is a common symptom in children with cerebral palsy, weakness may be a much greater contributor to disability." | 5.35 | Oral baclofen increases maximal voluntary neuromuscular activation of ankle plantar flexors in children with spasticity due to cerebral palsy. ( Kukke, S; McGill, K; Rose, J; Sanger, TD; Sherman-Levine, S; van Doornik, J, 2008) |
| "Successful treatment of severe spasticity represents an imperative of symptomatic therapy of multiple sclerosis (MS) due to a significant improvement of physical, psychic and social rehabilitation of MS patients, as well as a long-term cost savings for the additional treatments of conditions arising from uncontrolled severe spasticity." | 5.33 | [Treatment of severe spacticity in multiple sclerosis by continuous intrathecal baclofen]. ( Antić, B; Arsić, S; Dincić, E; Obradović, D; Perić, P, 2006) |
| "A 33-year-old man with refractory spasticity due to diffuse white matter injury was admitted for ITB treatment." | 5.33 | Intrathecal baclofen toxicity and deep coma in minutes. ( Hanci, L; Hanci, M; Hanimoglu, H; Tanriverdi, T; Tunali, Y, 2006) |
| "Baclofen (Lioresal) is a drug of choice to treat spasticity and is increasingly being administered intrathecally via an implantable pump in cases refractory to oral therapy." | 5.32 | Intrathecal baclofen withdrawal mimicking sepsis. ( Amin, Y; Kao, LW; Kirk, MA; Turner, MS, 2003) |
| "Rett syndrome is a neurodevelopmental disorder primarily affecting girls and women." | 5.32 | Intrathecal baclofen for spasticity management in Rett syndrome. ( Clairmont, AC; George, RJ; Johnson, EW; Kadyan, V, 2003) |
| "Twelve patients with intractable spasticity caused by spinal cord injuries underwent implantation of a programmable continuous infusion pump after significant reduction in spasticity following an intrathecal test bolus of baclofen." | 5.31 | Continuous intrathecal infusion of baclofen in patients with spasticity caused by spinal cord injuries. ( Darwish, N; Gaab, MR; Glaeser, E; Korenkov, AI; Niendorf, WR, 2002) |
| "To study the electromiographic (EMG) parameters and to evaluate the therapeutic efficacy of a combination of central (baclofen, baclosan) and peripheral (incobotulotoxinA, xeomin) muscle relaxants in the treatment of post-stroke spasticity (PSS)." | 5.30 | [Combination of central and peripheral muscle relaxants in the treatment of post-stroke spasticity]. ( Frunza, DN; Iskra, DA; Koshkarev, MA; Kovalenko, AP, 2019) |
| " We describe a 39-year-old quadriplegic women who, over a 16-week period, developed clinical signs of baclofen toxicity confirmed by progressively rising serum baclofen levels while on a conventional stable dosing regimen." | 5.29 | Baclofen toxicity in a patient with subclinical renal insufficiency. ( Aisen, ML; Dietz, M; Kutt, H; McDowell, F, 1994) |
| "Oral baclofen improves cerebral spasticity mildly, but its activity is limited because of its poor lipid solubility." | 5.29 | Baclofen in the treatment of cerebral palsy. ( Albright, AL, 1996) |
| " Effective dosage was 60 +/- 31 micrograms in the entire group." | 5.28 | Intraspinal baclofen in the treatment of severe spasticity and spasms. ( Closa, C; Garcia-Fernandez, L; Guitart, JM; Jodar, R; Muxi, T; Noguer, M; Rubio, E; Sahuquillo, J, 1991) |
| "Intrathecal baclofen (ITB) is a treatment option for patients with severe poststroke spasticity (PSS) who have not reached their therapy goal with other interventions." | 5.27 | Intrathecal baclofen therapy versus conventional medical management for severe poststroke spasticity: results from a multicentre, randomised, controlled, open-label trial (SISTERS). ( Abouihia, A; Berthuy, N; Calabrese, A; Cloud, G; Creamer, M; Francisco, GE; Kossmehl, P; Loven, M; Saltuari, L; Ward, AB; Wissel, J; Yochelson, M; Zampolini, M, 2018) |
| "Background and Purpose- Intrathecal baclofen (ITB) is an effective treatment for managing patients with severe poststroke spasticity, who can experience continued pain and decline in their quality of life (QoL)." | 5.27 | Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity. ( Abouihia, A; Calabrese, A; Cloud, G; Creamer, M; Francisco, GE; Kossmehl, P; Saltuari, L; Ward, AB; Wissel, J; Yochelson, M; Zampolini, M, 2018) |
| "Intrathecal treatment of baclofen is an excellent method for spasticity management in children with severe cerebral palsy." | 5.24 | Long-term therapy with intrathecal baclofen improves quality of life in children with severe spastic cerebral palsy. ( Gegenleitner, K; Kraus, T; Novak, M; Singer, G; Steinwender, G; Svehlik, M, 2017) |
| "The aim of this study was to compare the relative efficacy of baclofen and self-applied transcutaneous electrical nerve stimulation (TENS) for the treatment of spasticity in the lower extremities in multiple sclerosis (MS)." | 5.17 | Comparison of the effect of baclofen and transcutaneous electrical nerve stimulation for the treatment of spasticity in multiple sclerosis. ( Golabchi, K; Haghighi, S; Heshmatipour, M; Janghorbani, M; Shaygannejad, V; Vaezi, A, 2013) |
| "This study assessed the effects of continuous intrathecal infusion of baclofen on the gait of ambulant children with cerebral palsy." | 5.14 | Intrathecal baclofen infusion for ambulant children with cerebral palsy. ( Brochard, S; Bussel, B; Filipetti, P; Remy-Neris, O, 2009) |
| "To assess the effectiveness of oral baclofen in reducing spasticity and improving function in children with cerebral palsy." | 5.12 | Oral baclofen in children with cerebral palsy: a double-blind cross-over pilot study. ( Hall, K; Lam, LT; O'Flaherty, S; Scheinberg, A, 2006) |
| "Intrathecal baclofen (ITB) therapy can be very effective in the treatment of intractable spasticity, but its effectiveness and safety have not yet been thoroughly studied in children with cerebral palsy (CP)." | 5.12 | Intrathecal baclofen in children with spastic cerebral palsy: a double-blind, randomized, placebo-controlled, dose-finding study. ( Hoving, MA; Palmans, LJ; Sleypen, FA; Spincemaille, GH; van Raak, EP; Vles, JS, 2007) |
| "To determine the impact of intrathecal baclofen (ITB) therapy on outcomes of functional independence, pain, subjective improvement, performance, and standard measures of spasticity." | 5.11 | A clinical study of intrathecal baclofen using a programmable pump for intractable spasticity. ( Guillaume, D; Roeste, G; Van Havenbergh, A; Vidal, J; Vloeberghs, M, 2005) |
| "Baclofen and tizanidine are both used for the treatment of muscle spasticity of spinal origin." | 5.10 | Cost-effectiveness comparison of tizanidine and baclofen in the management of spasticity. ( Anderson, PM; Lloyd, AC; Rushton, DN, 2002) |
| "The purpose of this article is to describe outcomes of intrathecal baclofen therapy for 29 patients with cerebral palsy, focusing on impairments, functional limitations, and disability." | 5.10 | Functional assessment following intrathecal baclofen therapy in children with spastic cerebral palsy. ( Awaad, R; Awaad, Y; Ham, S; Michon, AM; Munoz, S; Tayem, H, 2003) |
| "To explore whether intrathecal baclofen (ITB) therapy improves ambulation in stroke survivors." | 5.10 | Improvement in walking speed in poststroke spastic hemiplegia after intrathecal baclofen therapy: a preliminary study. ( Boake, C; Francisco, GE, 2003) |
| "To evaluate long-term results of chronic intrathecal Baclofen infusion on the spasticity, on the spasms and to evaluate the side-effects of the intrathecal Baclofen in patients with supraspinal spasticity." | 5.10 | Long-term intrathecal Baclofen infusion in supraspinal spasticity of adulthood. ( Bono, G; Casagrande, F; Dario, A; Di Stefano, MG; Grossi, A, 2002) |
| "Continuous intrathecal infusion of baclofen is capable of maintaining a reduction in spasticity and dystonia in both the upper and lower extremities of TBI patients." | 5.09 | Long-term continuously infused intrathecal baclofen for spastic-dystonic hypertonia in traumatic brain injury: 1-year experience. ( Grabb, P; Guin-Renfroe, S; Hadley, MN; Meythaler, JM, 1999) |
| "The effect of baclofen on the soleus stretch reflex and peripheral muscle function was tested in 10 multiple sclerosis (MS) patients with spasticity in the lower extremities." | 5.09 | Peripheral and central effect of baclofen on ankle joint stiffness in multiple sclerosis. ( Nielsen, JF; Sinkjaer, T, 2000) |
| "The effect of baclofen on walking performance was examined in nine spastic multiple sclerosis patients." | 5.09 | Baclofen increases the soleus stretch reflex threshold in the early swing phase during walking in spastic multiple sclerosis patients. ( Anderson, JB; Nielsen, JF; Sinkjaer, T, 2000) |
| " This study examines the value of intrathecally administered baclofen in the treatment of 19 children with severe spasticity of cerebral origin: eight of whom sustained brain injury associated with trauma, near drowning, or cardiac arrest; 10 with cerebral palsy (spastic quadriplegia); and one child with Leigh's disease." | 5.08 | Intrathecally administered baclofen for treatment of children with spasticity of cerebral origin. ( Armstrong, RW; Cochrane, DD; Farrell, K; Fife, SE; Kube, SD; Steinbok, P, 1997) |
| "This study assessed the safety and efficacy of intrathecal baclofen in the treatment of intractable spasticity caused by spinal cord injury or multiple sclerosis." | 5.07 | Intrathecal baclofen for treatment of intractable spinal spasticity. ( Abel, NA; Smith, RA, 1994) |
| "A total of 93 patients with intractable spasticity due to either spinal cord injury (59 cases), multiple sclerosis (31 cases), or other spinal pathology (three cases) were entered into a randomized double-blind placebo-controlled screening protocol of intrathecal baclofen test injections." | 5.07 | Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. ( Cahill, D; Coffey, JR; Gill, B; Herman, R; Levy, R; Meythaler, J; Ordia, J; Park, TS; Shetter, AG; Steers, W, 1993) |
| "Seventeen patients with congenital spastic cerebral palsy and six patients with other forms of spasticity were injected intrathecally with doses of placebo or baclofen, 25 micrograms, 50 micrograms, or 100 micrograms, in a randomized, double-blind manner." | 5.07 | Intrathecal baclofen for spasticity in cerebral palsy. ( Albright, AL; Cervi, A; Singletary, J, 1991) |
| "In a double-blind comparative study, the therapeutic efficacy and safety of three centrally effective antispasmodics (Tetrazepam, Baclofen and Tizanidine) in patients suffering from multiple sclerosis with spastic motor disturbances of the lower extremities was to be examined." | 5.06 | [Comparative double-blind study of the effectiveness and tolerance of baclofen, tetrazepam and tizanidine in spastic movement disorders of the lower extremities]. ( Paulig, M; Pellkofer, M, 1989) |
| "A multi-centre, double-blind study was carried out in 100 patients suffering from chronic spasticity due to multiple sclerosis to compare the effectiveness of tizanidine hydrochloride with that of baclofen." | 5.06 | Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. ( Boisson, D; Eyssette, M; Rohmer, F; Serratrice, G; Warter, JM, 1988) |
| "The anti-spastic effect of a new drug, tizanidine, was compared with that of baclofen in a double-blind clinical trial; 40 seriously handicapped patients with multiple sclerosis (MS) were randomly allocated treatment with one or the other drug for a 6-week period." | 5.06 | The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen. ( Nordal, HJ; Oftedal, SI; Slettebø, M; Stien, R, 1987) |
| "A double-blind trial with two parallel groups was carried out to compare the antispastic effect and tolerability of a new muscle relaxant, tizanidine (DS 103-282), with those of baclofen in the treatment of spasticity due to multiple sclerosis." | 5.05 | A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis. ( Muff, S; Smolenski, C; Smolenski-Kautz, S, 1981) |
| "A double-blind crossover trial against placebo was conducted to assess the effects of the GABA derivative, baclofen, on the disabilities due to muscle spasticity in twenty children suffering from cerebral palsy." | 5.04 | A controlled trial of baclofen in children with cerebral palsy. ( Jackson, AD; Milla, PJ, 1977) |
| "Baclofen is a safe and effective means for treating spasticity associated with multiple sclerosis." | 5.04 | Baclofen for spasticity in multiple sclerosis. Double-blind crossover and three-year study. ( Conomy, JP; Feldman, RG; Foley, JM; Kelly-Hayes, M, 1978) |
| "Baclofen was used in a double-blind crossover placebo-controlled trial to treat spasticity in patients with multiple sclerosis (MS)." | 5.04 | The use of baclofen in treatment of spasticity in multiple sclerosis. ( Paty, DW; Sawa, GM, 1979) |
| "Intrathecal baclofen is an expanding accepted treatment for children with cerebral palsy and other causes of spasticity and dystonia." | 4.98 | Intrathecal Baclofen Therapy-Practical Approach: Clinical Benefits and Complication Management. ( Ben-Pazi, H; Beni-Adani, L; Winter, G, 2018) |
| "To systematically review the effectiveness of oral baclofen versus placebo or other antispastic oral medications in terms of body function, level of activity, and quality of life in children and adolescents with spastic cerebral palsy who are younger than 18 years." | 4.93 | Effectiveness of Oral Baclofen in the Treatment of Spasticity in Children and Adolescents With Cerebral Palsy. ( Gonzalez, W; Nahuelhual, P; Navarrete-Opazo, AA, 2016) |
| "To determine whether intrathecal baclofen is an effective treatment for spasticity in children with cerebral palsy." | 4.91 | Intrathecal baclofen for treating spasticity in children with cerebral palsy. ( Hasnat, MJ; Rice, JE, 2015) |
| "To review the available evidence on the effectiveness of intrathecal baclofen in the treatment of spasticity in individuals with spinal cord injuries (SCIs) at least 6 months post-injury or diagnosis." | 4.90 | Examining the effectiveness of intrathecal baclofen on spasticity in individuals with chronic spinal cord injury: a systematic review. ( Hsieh, J; Janzen, S; Mays, R; McIntyre, A; Mehta, S; Teasell, R; Townson, A; Wolfe, D, 2014) |
| "Studies on the use of intrathecal baclofen (ITB) for ambulant adults with spasticity and/or dystonia of cerebral origin are scarce, and are even more limited for children and adolescents." | 4.87 | Use of intrathecal baclofen therapy in ambulant children and adolescents with spasticity and dystonia of cerebral origin: a systematic review. ( Lewis, J; McCartney, L; Pin, TW; Waugh, MC, 2011) |
| "Intrathecal baclofen (ITB) has become a standard treatment for spasticity in patients with cerebral palsy (CP) over the last ten years." | 4.84 | A review of the complications of intrathecal baclofen in patients with cerebral palsy. ( Kolaski, K; Logan, LR, 2007) |
| "Intrathecal baclofen (ITB) therapy has been increasingly employed for the management of poststroke spastic hypertonia, a complication that can lead to deformity, discomfort, and exacerbation of motor impairments." | 4.83 | Consensus panel guidelines for the use of intrathecal baclofen therapy in poststroke spastic hypertonia. ( Cavalier, S; Francisco, GE; Grissom, S; Schiess, MC; Wiggs, L; Yablon, SA, 2006) |
| "Baclofen is used for treatment of the spasticity of spinal origin that is a common sequela of spinal cord injury and multiple sclerosis; spasticity occurs in about 50% of patients affected by these disorders." | 4.82 | A benefit-risk assessment of baclofen in severe spinal spasticity. ( Dario, A; Tomei, G, 2004) |
| "The authors describe a patient who experienced a prolonged course of intrathecal baclofen withdrawal syndrome after removal of an implantable baclofen pump for treatment of pump infection and meningitis." | 4.82 | Prolonged intrathecal baclofen withdrawal syndrome. Case report and discussion of current therapeutic management. ( Douglas, AF; Schwartz, DR; Weiner, HL, 2005) |
| "Intrathecal baclofen reduces spasticity in individuals with cerebral palsy." | 4.79 | Intrathecal baclofen in cerebral palsy movement disorders. ( Albright, AL, 1996) |
| "To evaluate the use of intrathecal baclofen for the treatment of muscle spasticity in patients with spinal cord injury." | 4.78 | Intrathecal baclofen for severe spasticity secondary to spinal cord injury. ( Lewis, KS; Mueller, WM, 1993) |
| "To evaluate the effects of intrathecal baclofen pump (ITBP) therapy on hip dysplasia in young patients with cerebral palsy (CP)." | 4.31 | Does intrathecal baclofen therapy decrease the progression of hip displacement in young patients with cerebral palsy? ( Asma, A; Howard, JJ; McManus, M; Miller, F; Rogers, KJ; Shrader, MW; Ulusaloglu, AC, 2023) |
| "Intrathecal baclofen (ITB) therapy is an effective treatment for spasticity and dystonia in children with cerebral palsy (CP)." | 4.31 | A multicenter initiative to reduce intrathecal baclofen pump surgical site infection: a Cerebral Palsy Research Network quality improvement project. ( Albarqawi, L; Bailes, AF; Bollo, RJ; Browd, SR; Gross, PH; Leonard, JR; Raskin, JS; Rocque, BG, 2023) |
| "37-year-old with T9 motor complete paraplegia with ITB presented in baclofen withdrawal." | 4.31 | Interaction between a smartphone and intrathecal baclofen pump case report. ( Filipetto, F; Trbovich, M; Walden, J, 2023) |
| "The results of this study suggest that baclofen is associated with higher incidences of injury and delirium compared to tizanidine when used for the treatment of musculoskeletal pain." | 4.31 | Safety of baclofen versus tizanidine for older adults with musculoskeletal pain. ( Broder, BI; DiStasio, C; Hui, RL; Lee, EA; Niu, F; Steinberg, SG; Su Zhang, VR, 2023) |
| "Intrathecal baclofen (ITB) is a proven, effective treatment for refractory spasticity and chronic pain, with applications ranging from spinal cord injury to amyotrophic lateralsclerosis (ALS)." | 4.31 | Management of high-dose intrathecal baclofen pump explant: A case report. ( Agrawal, M; Belisle Haley, C; Dayal, R; Newton, K; Yeung, B, 2023) |
| "This study aimed to determine the risk factors for reconstructive hip surgery after intrathecal baclofen pump application in children with cerebral palsy." | 4.31 | Identification of risk factors for reconstructive hip surgery after intrathecal baclofen therapy in children with cerebral palsy. ( Asma, A; Howard, JJ; Miller, F; Rogers, KJ; Shrader, MW; Ulusaloglu, AC, 2023) |
| "We report the case of a 61-year-old Japanese man with lumbar spinal stenosis who underwent intrathecal baclofen therapy." | 4.31 | Decompression for lumbar spinal stenosis at the intrathecal catheter insertion site during intrathecal baclofen therapy: a case report. ( Ebara, H; Hayashi, H; Inatani, H; Kagechika, K; Kitano, Y; Mori, A; Nakanami, A; Takagi, Y; Toyooka, K; Tsuchiya, H; Yahata, T; Yamada, H, 2023) |
| "Для поиска статей по теме обзора использовали базу данных PubMed и ключевые слова «cerebral palsy», «spasticity», «dystonia», «selective dorsal rhizotomy», «selective neurotomy», «intrathecal baclofen therapy», «spinal cord stimulation», «deep brain stimulation»." | 4.31 | [Methods and results of neurosurgical treatment of cerebral palsy]. ( Dekopov, AV; Isagulyan, ED; Tomsky, AA, 2023) |
| "Pregnant women with spinal cord injuries are often advised to continue oral baclofen during pregnancy to manage spasticity, though the potential for adverse events in neonates is not well understood." | 4.12 | Neonatal baclofen withdrawal following intrauterine exposure. ( Daunter, AK; Mousigian, MA; Neil Knierbein, EE; Rosenblum, SA, 2022) |
| "The aim of the study was to evaluate the use of a novel technique for baclofen delivery using an intrathecal catheter inserted through a lumbar laminotomy with the tip placed at the cisterna magna (supraspinal baclofen (SSB)) for the treatment of severe generalized secondary dystonia." | 4.12 | Supraspinal baclofen for the treatment of secondary generalized dystonia: A case series. ( BeDell, KK; Ceverha, B; Wu, J; Yeh, BY, 2022) |
| "The purpose of this study is to describe the efficacy and adverse events of neuraxial anesthesia for post-operative pain control in non-ambulatory children with cerebral palsy with pre-existing intrathecal baclofen (ITB) pumps undergoing hip reconstructive or palliative surgery." | 4.12 | Neuraxial anesthesia for post-operative pain control after hip surgery in children with cerebral palsy and pre-existing intrathecal baclofen pumps. ( Ball, MA; Davids, JR; Davidson, LT; Kephart, DT; Kulkarni, VA; Tumber, S, 2022) |
| "This is a case of a 19-year-old male with a history of remote severe traumatic brain injury (TBI) with an intrathecal baclofen (ITB) pump for dystonia management." | 4.12 | Behavioral dysregulation exacerbated by intrathecal baclofen in an adolescent with severe traumatic brain injury. ( Lam, NY; Montagnino, J; Patel, H; Pham, K; Qin, ES, 2022) |
| "Intrathecal baclofen therapy(ITB)is a recognized treatment for spastic paralysis." | 4.12 | [Intrathecal Baclofen Therapy for Spastic Paralysis]. ( Usami, K, 2022) |
| "The purpose of this study was to investigate the incidence of complications in pediatric spastic cerebral palsy (CP) patients weighing less than 20 kg at the time of intrathecal baclofen (ITB) pump implantation and to compare it with spastic CP patients heavier than 20 kg." | 4.12 | Complications of intrathecal baclofen pump treatment in children with spastic cerebral palsy. A comparative analysis of patients weighing over or under 20 kg at the time of implantation. ( Canavese, F; De Coulon, G; Steiger, CN; Tabard-Fougère, A, 2022) |
| "Intrathecal baclofen pump associated central nervous system (CNS) infection and meningitis is a rare but serious complication and may have dire consequences." | 4.02 | Intrathecal Baclofen Pump Infection With Meningitis: Effective Treatment by Radical Debridement and Intrareservoir Baclofen-Vancomycin Co-Infusion. ( Chan, SHS; Chim, S; Ho, ACC; Koljonen, PA; Liu, T; Tsoi, NS; Wong, YW, 2021) |
| "Intrathecal baclofen (ITB) pumps are an effective treatment for spasticity; however infection rates have been reported in 3-26% of patients in the literature." | 3.96 | Reducing Intrathecal Baclofen Related Infections: Service Evaluation and Best Practice Guidelines. ( Bahadur, S; Balaratnam, MS; Brownstone, RM; Christofi, G; Curtis, C; Donnelly, A; Farrell, R; Grieve, J; Keenan, L; Lee, H; Murphy, M; Nayar, M; Padilla, H; Pitceathly, RDS; Shieff, C; Simeoni, S; Stevenson, VL, 2020) |
| "Intrathecal Baclofen (ITB) has become an increasingly common treatment for severe muscle spasticity associated with conditions such as cerebral palsy and spinal cord injury." | 3.96 | Intrathecal Baclofen Overdose With Paradoxical Autonomic Features Mimicking Withdrawal. ( Frawley, MT; Parker-Pitts, CK; Weymouth, CW, 2020) |
| "Baclofen is a derivative of gamma-aminobutyric acid, used mainly for the treatment of muscle spasticity." | 3.96 | An intoxication mimicking brain death: baclofen. ( Arslan, G; Duman, M; Er, A; Karaarslan, U; Koker, A; Köroğlu, T; Özden, Ö, 2020) |
| "Intrathecal baclofen (ITB) pumps used to manage spasticity in children with cerebral palsy (CP) also improve pain outcomes for some but not all patients." | 3.96 | Investigating the Feasibility of a Modified Quantitative Sensory Testing Approach to Profile Sensory Function and Predict Pain Outcomes Following Intrathecal Baclofen Implant Surgery in Cerebral Palsy. ( Barney, CC; Merbler, AM; Simone, DA; Symons, FJ; Walk, D, 2020) |
| "Two patients previously implanted with intrathecal Baclofen (ITB) pumps for management of intractable spasticity due to multiple sclerosis (MS) were referred to our center for ongoing management of their spasticity." | 3.91 | Intrathecal Baclofen Therapy in Patients With Multiple Sclerosis: Improved Outcomes and Reduced Costs Through Identification of Catheter Malfunction. ( McGuire, JR; Nelson, MES, 2019) |
| "To investigate the effect of intrathecal baclofen (ITB) on function and activity in dyskinetic cerebral palsy (CP)." | 3.88 | Intrathecal baclofen in dyskinetic cerebral palsy: effects on function and activity. ( Askljung, B; Corneliusson, O; Eek, MN; Himmelmann, K; Lindh, K; Olsson, K; Påhlman, M, 2018) |
| "This article details an unreported potential cause of withdrawal symptoms in a patient with cerebral palsy who experienced intrathecal baclofen withdrawal shortly after placement of a baclofen pump with subsequent refill with Gablofen." | 3.88 | An Unreported Cause of Intrathecal Baclofen Withdrawal Symptoms in a Woman With Spastic Cerebral Palsy Who Received Intrathecal Gablofen. ( Duraski, SA; Sayyad, A, 2018) |
| "Objective To assess quantitatively the efficacy of oral baclofen for spasticity poststroke." | 3.88 | Effect of oral baclofen on spasticity poststroke: responders versus non-responders. ( Maeshima, S; Mizuno, S; Shigeru, S; Takeda, K, 2018) |
| "Intrathecal baclofen has long been known to be an efficacious treatment of spasticity in children with cerebral palsy." | 3.85 | Lumbar translaminar fenestration for insertion of intrathecal baclofen catheter: a novel technique. ( Al-Shikarchy, H; Chowne, C; Heran, MKS, 2017) |
| "To assess changes in body composition, body weight and resting metabolic rate in patients who received intrathecal baclofen therapy for spasticity." | 3.85 | Changes in body composition after spasticity treatment with intrathecal baclofen. ( Ertzgaard, P; Levi, R; Samuelsson, K; Skogberg, O, 2017) |
| "OBJECTIVE Medically refractory spasticity and dystonia are often alleviated with intrathecal baclofen (ITB) administration through an indwelling catheter inserted in the lumbar spine." | 3.85 | Image-guided intrathecal baclofen pump catheter implantation: a technical note and case series. ( Berde, C; Dasenbrock, HH; O'Brien, CP; Padua, H; Robertson, FC; Robinson, S, 2017) |
| "To compare spasticity levels, pain, sleep, fatigue, and quality of life between individuals receiving treatment with intrathecal versus oral baclofen." | 3.83 | Intrathecal Versus Oral Baclofen: A Matched Cohort Study of Spasticity, Pain, Sleep, Fatigue, and Quality of Life. ( Binler, D; Chu, SK; Lee, J; Marciniak, C; Mathur, SN; McCormick, ZL; Neudorf, D, 2016) |
| "Conventionally, selective dorsal rhizotomy (SDR) has been reserved for ambulant children and implantation of intrathecal baclofen (ITB) pump for non-ambulant children with cerebral palsy." | 3.83 | Selective dorsal rhizotomy as an alternative to intrathecal baclofen pump replacement in GMFCS grades 4 and 5 children. ( Ingale, H; Moussa, AA; Muquit, S; Ughratdar, I; Vloeberghs, MH, 2016) |
| " In this study the authors analyzed the long term effects of intrathecal baclofen therapy in multiple sclerosis and evalued the benefits of the treatment on spasticity, disability, pain, spasm frequency and rated the incidence of side effects." | 3.83 | Long-term effects of intrathecal baclofen in multiple sclerosis. ( D'Oria, S; Gentile, M; Natale, M; Nero, VV; Rotondo, M; Squillante, E, 2016) |
| "Intrathecal baclofen (ITB) treatment is applied in patients with spastic cerebral palsy (SCP), dystonic cerebral palsy (DCP) and progressive neurological disease (PND)." | 3.83 | The effect of intrathecal baclofen treatment on activities of daily life in children and young adults with cerebral palsy and progressive neurological disorders. ( Becher, J; Bonouvrié, L; Buizer, A; Soudant, D; van Ouwerkerk, W; Vermeulen, RJ; Vles, G, 2016) |
| "Intrathecal Baclofen is available to treat severe generalized spasticity in Multiple Sclerosis (MS) unresponsive to oral drug delivery." | 3.83 | Effects of severe spasticity treatment with intrathecal Baclofen in multiple sclerosis patients: Long term follow-up. ( Gerini, A; Mazzoleni, S; Stampacchia, G, 2016) |
| ") in pediatric patients treated with intrathecal baclofen therapy (ITB) for spasticity and/or dystonia." | 3.83 | Comparison between an Ascenda and a silicone catheter in intrathecal baclofen therapy in pediatric patients: analysis of complications. ( Antonello, CE; Motta, F, 2016) |
| "Tetrahydrocannabinol:cannabidiol (THC:CBD) oromucosal spray (Sativex®) is an add-on therapy for moderate-to-severe multiple sclerosis (MS)-related drug-resistant spasticity (MSS)." | 3.83 | Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice. ( Trojano, M; Vermersch, P, 2016) |
| "To perform an analysis of oral baclofen dosage in patients with traumatic spinal cord injuries over time and to ascertain the clinical determinants of long-term baclofen dosage trends." | 3.81 | Baclofen dosage after traumatic spinal cord injury: a multi-decade retrospective analysis. ( Anderson, WS; Cheng, JJ; Sunshine, A; Veerakumar, A; Ye, X; Zorowitz, RD, 2015) |
| "Treatment of severe spasticity and dystonia with intrathecal baclofen (ITB) in children has been shown to be effective and has therefore been employed in the Region of Southern Denmark." | 3.81 | Positive experience with intrathecal baclofen treatment in children with severe cerebral palsy. ( Illum, NO; Kjærsgaard-Hansen, L; Overgård, TM; Søe, M, 2015) |
| "The authors report an unusual case of intrathecal baclofen withdrawal due to the perforation and subsequent leakage of a baclofen pump catheter in a patient with spastic cerebral palsy." | 3.81 | Baclofen pump catheter leakage after migration of the abdominal catheter in a pediatric patient with spasticity. ( Aldana, PR; Dastgir, A; MacGregor, TL; Ranalli, NJ, 2015) |
| "We describe a 6 year-old girl with hydranencephaly who underwent an intrathecal baclofen test dose and developed severe bradycardia." | 3.81 | Profound Bradycardia After Intrathecal Baclofen Injection in a Patient With Hydranencephaly. ( Cain, N; Kinsman, S; Sechrist, C, 2015) |
| "Implantation of an intrathecal baclofen pump is recommended for children with cerebral palsy as a means to improve care and comfort when other options fail to control severe hypertonia." | 3.80 | Improvements in children with cerebral palsy following intrathecal baclofen: use of the Rehabilitation Institute of Chicago Care and Comfort Caregiver Questionnaire (RIC CareQ). ( Baker, KW; Gaebler-Spira, D; Mutlu, A; Tann, B, 2014) |
| "To investigate the effect of intrathecal baclofen (ITB) on sitting in children with cerebral palsy with severe spasticity; and identify potential sub-groups of patients at particular risk of deterioration." | 3.80 | The effect of continuous intrathecal baclofen on sitting in children with severe cerebral palsy. ( Gray, N; Vloeberghs, M, 2014) |
| "This single-center study investigated adverse events that occurred in children and adolescent patients treated with intrathecal baclofen (ITB) therapy for spasticity and/or dystonia." | 3.80 | Analysis of complications in 430 consecutive pediatric patients treated with intrathecal baclofen therapy: 14-year experience. ( Antonello, CE; Motta, F, 2014) |
| "Dantrolene can be combined with baclofen to better treat spasticity, but may cause muscular weakness and dysphagia." | 3.80 | Pharyngeal spasticity due to dantrolene. ( Amorelli, V; Avantaggiato, P; Clementi, E; Galbiati, S; Lanfranchi, M; Locatelli, F; Pozzi, M; Radice, S; Rizzi, G; Strazzer, S; Tufarulo, L, 2014) |
| "Intrathecal baclofen (ITB) is a reversible treatment that reduces muscle tone to ameliorate spasticity and dystonia in patients with cerebral palsy (CP)." | 3.80 | Indwelling intrathecal catheter with subcutaneous abdominal reservoir: a viable baclofen delivery system in severely cachectic patients. ( Ellenbogen, JR; Kumar, R; Pettorini, BL; Sneade, C; Waqar, M; Williams, D; Zebian, B, 2014) |
| "To investigate the long-term dosage evolution and complication rate of intrathecal baclofen use in multiple sclerosis and spinal cord injury patients, based on a large population with a long follow-up." | 3.79 | Intrathecal baclofen in multiple sclerosis and spinal cord injury: complications and long-term dosage evolution. ( Degraeuwe, B; Draulans, N; Kiekens, C; Meurrens, T; Nuttin, B; Peers, K; Vermeersch, K, 2013) |
| "Little is known about the long-term effects of Continuous intrathecal Baclofen (CITB) therapy in non-ambulant children with intractable spastic Cerebral Palsy (CP)." | 3.79 | Long-term follow-up on continuous intrathecal Baclofen therapy in non-ambulant children with intractable spastic Cerebral Palsy. ( Bonouvrié, LA; Hoving, MA; Soudant, DL; van Oostenbrugge, RJ; Vermeulen, RJ; Vles, GF; Vles, JS, 2013) |
| "Intrathecal baclofen therapy has been used successfully for intractable spasticity in children with cerebral palsy." | 3.78 | Evaluation of salvage techniques for infected baclofen pumps in pediatric patients with cerebral palsy. ( Fisher, JF; Hester, SM; Lee, MR; Macomson, S; Vender, JR, 2012) |
| "To evaluate the long-term effect of intrathecal baclofen therapy in multiple sclerosis-related spasticity and to evaluate the side-effects of long-term therapy, and the doses of baclofen required." | 3.77 | Treatment of spasticity related to multiple sclerosis with intrathecal baclofen: a long-term follow-up. ( Grønning, M; Rekand, T, 2011) |
| "We describe two patients in whom serious bradycardia and arterial hypotension occurred after a small intrathecal baclofen (ITB) test bolus." | 3.77 | Cardiovascular alterations heralded by intrathecal baclofen bolus. ( Bramanti, P; D'Aleo, G; D'Aleo, P; Kofler, M; Rifici, C; Saltuari, L, 2011) |
| "Spasticity and dystonia in children with cerebral palsy has been treated with intrathecal baclofen therapy (ITB) at the Royal Children's Hospital, Melbourne, Australia (RCH) since 1999." | 3.77 | Intrathecal baclofen therapy: benefits and complications. ( Antolovich, G; Olesch, C; Reddihough, D; Zdolsek, HA, 2011) |
| "The aim of the study was to explore the timing of effects of intrathecal baclofen therapy in children with cerebral palsy." | 3.76 | Continuous intrathecal baclofen therapy in children with cerebral palsy - when does improvement emerge? ( Jahnsen, R; Lofterod, B; Ramstad, K; Skjeldal, OH, 2010) |
| "Intrathecal baclofen is an effective treatment for spasticity in patients with cerebral palsy." | 3.76 | Do baclofen pumps influence the development of scoliosis in children? ( Burn, SC; Drake, JM; Zeller, R, 2010) |
| "Two patients with subarachnoid hemorrhage recovered consciousness after intrathecal baclofen administration using an implanted intrathecal baclofen pump delivering 50 microg per day using a simple infusion mode." | 3.76 | Consciousness recovery induced by intrathecal baclofen administration after subarachnoid hemorrhage -two case reports-. ( Hattori, K; Kito, A; Maki, H; Oyama, H; Tanahashi, K, 2010) |
| "Baclofen withdrawal syndrome is a rare and potentially life-threatening condition manifesting with autonomic dysreflexia, high fevers, spasticity, seizures, and multiorgan failure." | 3.76 | Reversible electrocardiogram changes and cardiomyopathy secondary to baclofen withdrawal syndrome. ( Kireyev, D; Poh, KK, 2010) |
| " She had previously received an intrathecal baclofen infusion pump to relieve the spasticity of cerebral palsy." | 3.75 | Epidural analgesia in labor for a woman with an intrathecal baclofen pump. ( Ali Sakr Esa, W; Barsoum, S; Tetzlaff, JE; Toma, I, 2009) |
| "Seven cases of combination of intrathecal (IT) ziconotide and baclofen therapy in patients with refractory neuropathic pain and spasticity were reviewed." | 3.75 | Intrathecal ziconotide and baclofen provide pain relief in seven patients with neuropathic pain and spasticity: case reports. ( Burton, AW; Danyo, DA; Frost, S; Glanzer, J; Saulino, M; Solanki, DR, 2009) |
| "A male patient with adrenoleukodystrophy and a baclofen pump implant was admitted to the urology department with bladder stones." | 3.75 | Retraction of an intrathecal baclofen infusion catheter following suprapubic cystotomy: a case report. ( Heesakkers, JP; Martens, FM; Somford, DM; van den Burg, MJ; van Kuppevelt, DH, 2009) |
| "To describe complications and outcomes of intrathecal baclofen (ITB) therapy in children with spasticity and/or dystonia." | 3.75 | Continuous intrathecal baclofen for children with spasticity and/or dystonia: Goal attainment and complications associated with treatment. ( Dexter, M; Hayden, S; Scheinberg, A; Ward, A, 2009) |
| "A 52-year-old woman with bilateral leg spasticity because of spinal multiple sclerosis underwent baclofen pump implantation, which was subcutaneously placed in the right upper quadrant." | 3.75 | Tangled catheter as a rare cause of baclofen pump malfunction. ( Fukuhara, T; Kuyama, H; Namba, Y; Tanaka, T, 2009) |
| "To determine whether intrathecal administration of baclofen reduced spastic hypertonia in a hemiplegic patient after hemorrhagic stroke." | 3.74 | [Efficacy of intrathecal baclofen in the treatment of spasticity in stroke]. ( Cantalloube, S; Lamotte, D, 2007) |
| "A personal case study that looks at the use of Intrathecal Baclofen to relieve the spasticity related to cerebral palsy; improving personal function and enhancing quality of life." | 3.74 | Intrathecal Baclofen: a discussion on impact that medical advances can have on the individual and the implications this has for a society that is built on an ethic of social medicine. ( Baddeley, AA, 2008) |
| " After the first admission of 5 mg of oral Baclofen, he collapsed in bed with extreme bradycardia, hypotension, hyperventilation and decreased oxygen saturation." | 3.74 | Heart conduction problems in a tetraplegic patient caused by a single therapeutic dosage of Baclofen. ( Slim, EJ; Smit, CA, 2008) |
| "The aim of this study was to present a case of deep vein thrombosis (DVT) and pulmonary embolism (PE) after an intrathecal baclofen bolus test." | 3.74 | Intrathecal baclofen bolus complicated by deep vein thrombosis and pulmonary embolism. A case report. ( Carda, S; Cazzaniga, M; Pozzi, R; Taiana, C, 2008) |
| "To determine the frequency of pruritus after intrathecal baclofen (ITB) withdrawal and to study the pathophysiology of this symptom." | 3.73 | Pruritus after intrathecal baclofen withdrawal: A retrospective study. ( Ben Smail, D; Bussel, B; Denys, P; Hugeron, C, 2005) |
| "Oral and intrathecal baclofen (ITB) have been associated with epileptic seizures." | 3.73 | Incidence of seizures in patients with multiple sclerosis treated with intrathecal baclofen. ( Bethoux, FA; Boulis, N; Kellinghaus, C; Loddenkemper, T; Schuele, SU; Shook, SJ, 2005) |
| "During the 1990s three new techniques to reduce spasticity and dystonia in children with cerebral palsy (CP) were introduced in southern Sweden: selective dorsal rhizotomy, continuous intrathecal baclofen infusion and botulinum toxin treatment." | 3.73 | Prevention of severe contractures might replace multilevel surgery in cerebral palsy: results of a population-based health care programme and new techniques to reduce spasticity. ( Andersson, S; Düppe, H; Hägglund, G; Lauge-Pedersen, H; Nordmark, E; Pedertsen, HL; Westbom, L, 2005) |
| "The objective of this study was to analyze the relationship between epilepsy and intrathecal baclofen by investigating a consecutive sample of 150 children with cerebral palsy or spasticity of cerebral origin who underwent intrathecal baclofen." | 3.73 | Epilepsy and intrathecal baclofen therapy in children with cerebral palsy. ( Buonaguro, V; Curci, D; Iuorno, T; Monforte, S; Motta, F; Scelsa, B, 2005) |
| "Intrathecal baclofen pumps for the management of severe spasticity are being used more often in children with cerebral palsy." | 3.73 | Posterior cervical approach for intrathecal baclofen pump insertion in children with previous spinal fusions. Technical note. ( Liu, JK; Walker, ML, 2005) |
| "We conducted a retrospective study of the case files of 64 multiple sclerosis (MS) patients presenting severe spasticity, who had received intrathecal (IT) baclofen test injections between 1992 and 2004 in a rehabilitation unit." | 3.73 | Intrathecal baclofen for treatment of spasticity of multiple sclerosis patients. ( Ben Smail, D; Bussel, B; Mailhan, L; Peskine, A; Roche, N; Thiébaut, I, 2006) |
| "Intrathecal baclofen therapy is an effective means of treating intractable spasticity and dystonia in the pediatric and adult population." | 3.73 | Identification and management of intrathecal baclofen pump complications: a comparison of pediatric and adult patients. ( Hester, S; Lee, MR; Rekito, A; Vender, JR; Waller, JL, 2006) |
| "The good clinical response to treatment of spasticity and rigidity, improved quality of life, pain reduction and patient satisfaction with short length of admission demonstrate the efficacy of intrathecal baclofen therapy." | 3.73 | Continuous intrathecal baclofen administration by a fully implantable electronic pump for severe spasticity treatment: our experience. ( Bucolo, GE; Castiglione, A; Fazzio, S; Guglielmino, A; Mangiameli, S; Patti, F; Pittalà, G; Sorbello, M; Zingale, SF, 2006) |
| "To determine whether leg muscle stiffness is measurably reduced after intrathecal baclofen (ITB) in subjects with spastic hemiplegia." | 3.72 | Intrathecal baclofen in subjects with spastic hemiplegia: assessment of the antispastic effect during gait. ( Bouilland, S; Bussel, B; Rémy-Néris, O; Tiffreau, V, 2003) |
| "Continuous intrathecal baclofen was effective in treating severe spasticity and dystonia of cerebral origin with major effect on muscles of the lower extremities, pelvis, and back and in particular opisthotonus was relieved." | 3.72 | [Intrathecal baclofen in the treatment of severe spastic tetraplegia and dystonia in children and adolescents]. ( Fischer, C; Hansen, FJ; Illum, NO; Nielsen, OA; Uldall, PV, 2003) |
| "We present a case of a 38-year-old male with complete T9 spastic paraplegia for 15 years, treated with intrathecal baclofen for 11 years." | 3.72 | Subdural catheter migration may lead to baclofen pump dysfunction. ( Cahana, A; Pasquier, Y; Schnider, A, 2003) |
| " The aim of this paper is to present the result of intrathecal baclofen infusion in treatment of spasticity in patients with cerebral palsy." | 3.72 | [Intrathecal baclofen for treatment of spasticity in patient with cerebral palsy--a preliminary report]. ( Grottel, K; Huber, J; Idzior, M; Jóźwiak, M; Szulc, A, 2003) |
| "The objective of this study was to characterize the population of multiple sclerosis (MS) patients suffering from spasticity and to evaluate treatment patterns, including intrathecal baclofen (ITB) delivery, related to patient quality of life (QOL)." | 3.72 | Prevalence and treatment of spasticity reported by multiple sclerosis patients. ( Hadjimichael, OC; Preiningerova, J; Rizzo, MA; Vollmer, TL, 2004) |
| " He developed perinephric haematoma while he was taking warfarin as prophylactic for deep vein thrombosis." | 3.71 | How should an infected perinephric haematoma be drained in a tetraplegic patient with baclofen pump implanted in the abdominal wall? - A case report. ( Hughes, PL; Oo, T; Sett, P; Singh, G; Soni, BM; Vaidyanathan, S; Watt, JW, 2002) |
| "This study was undertaken to determine the efficacy of intrathecal baclofen therapy in patients who suffer spasticity after a stroke." | 3.71 | Intrathecal baclofen for spasticity caused by thrombotic stroke. ( Gwartz, BL, 2001) |
| "Intrathecal baclofen (ITB) can reduce spasticity in adults and children with cerebral palsy." | 3.71 | Improvement of sleep apnea in a patient with cerebral palsy. ( Gaebler-Spira, D; Harvey, RL; McCarty, SF, 2001) |
| "To determine whether continuous intrathecal baclofen infusion (CIBI) would decrease spasticity and improve function in children with spastic cerebral palsy." | 3.71 | Continuous intrathecal baclofen infusion for children with cerebral palsy: a pilot study. ( Chaseling, R; Dexter, M; O'Flaherty, S; Scheinberg, A, 2001) |
| " In particular, intrathecal baclofen therapy has shown efficacy and safety in the management of spasticity and dystonia in children." | 3.71 | Subfascial implantation of intrathecal baclofen pumps in children: technical note. ( Doyle, WK; Feldman, DS; Kopell, BH; Sala, D; Weiner, HL; Wisoff, JH, 2001) |
| "We report the treatment of severe neuropathic pain in a patient with ED and the combined intrathecal application of baclofen and morphine in 5 patients with severe spasticity related pain." | 3.71 | Combined intrathecal baclofen and morphine infusion for the treatment of spasticity related pain and central deafferentiation pain. ( Becker, R; Bertalanffy, H; Gatscher, S; Uhle, E, 2002) |
| "A 29-year-old man with C6 tetraplegia (ASIA A) using an implanted baclofen pump and intrathecal catheter infusion system for spasticity control developed severe spasticity, hyperthermia, hypotension, rhabdomyolysis, and disseminated intravascular coagulation after catheter disconnection." | 3.70 | Hyperthermia, rhabdomyolysis, and disseminated intravascular coagulation associated with baclofen pump catheter failure. ( Christopherson, MW; Reeves, RK; Stolp-Smith, KA, 1998) |
| "Intrathecal baclofen infusion (IBI) is an effective treatment for spasticity secondary to cerebral palsy (CP)." | 3.70 | Intrathecal baclofen infusion and subsequent orthopedic surgery in patients with spastic cerebral palsy. ( Albright, AL; Gerszten, PC; Johnstone, GF, 1998) |
| "In this case study we describe a dual approach to the palliation of difficult muscle spasms using intrathecal baclofen via a fully implanted system, together with the homeopathic approach to symptom control." | 3.70 | Intrathecal baclofen and homeopathy for the treatment of painful muscle spasms associated with malignant spinal cord compression. ( Hicks, F; Thompson, E, 1998) |
| "The purpose of the study was to analyze the relative cost of selective functional posterior rhizotomy (SFPR) and continuous intrathecal baclofen in the treatment of children with severe spastic quadriplegia related to cerebral palsy." | 3.69 | Cost analysis of continuous intrathecal baclofen versus selective functional posterior rhizotomy in the treatment of spastic quadriplegia associated with cerebral palsy. ( Daneshvar, H; Evans, D; Kestle, JR; Steinbok, P, 1995) |
| "To test the efficacy of intrathecal baclofen in various movement disorders, 18 patients with dystonia, head trauma, cerebral palsy, rigidity, or painful spasms underwent a trial of intrathecal baclofen." | 3.69 | Intrathecal baclofen for motor disorders. ( Gianino, JM; Penn, RD; York, MM, 1995) |
| "This study was performed to compare the effects of continuous intrathecal baclofen infusion (CIBI) and selective posterior rhizotomy (SPR) on upper extremity (UE) spasticity and range of motion in children with cerebral palsy." | 3.69 | Effects of continuous intrathecal baclofen infusion and selective posterior rhizotomy on upper extremity spasticity. ( Albright, AL; Barry, MJ; Fasick, MP; Janosky, J, 1995) |
| "Intrathecal baclofen (ITB) infusion has been shown to be an effective treatment for spasticity secondary to both cerebral palsy and spinal cord injury." | 3.69 | Effect on ambulation of continuous intrathecal baclofen infusion. ( Albright, AL; Barry, MJ; Gerszten, PC, 1997) |
| "Baclofen is a central nervous system agent that is commonly used for the treatment of muscle spasticity in spinal cord injury patients." | 3.68 | Neurological manifestations of baclofen withdrawal. ( Chancellor, MB; Freedman, MK; Hill, K; Rivas, DA, 1993) |
| "To determine if continuous intrathecal baclofen infusion (CIBI) would provide continuous relief of spasticity in patients with spasticity of cerebral origin, especially children with cerebral palsy." | 3.68 | Continuous intrathecal baclofen infusion for spasticity of cerebral origin. ( Albright, AL; Barron, WB; Fasick, MP; Janosky, J; Polinko, P, 1993) |
| "Rapid baclofen withdrawal is known to cause markedly increased spasticity, but high fever associated with this complication has not been reported." | 3.68 | Hyperthermia associated with baclofen withdrawal and increased spasticity. ( Hurvitz, EA; Mandac, BR; Nelson, VS, 1993) |
| "A report on pregnancy in a quadriplegic patient treated with a high dose of 1000 mcg/24 h continuous intrathecal baclofen infusion using an implanted drug delivery system (Synchromed, Medtronic, USA)." | 3.68 | Pregnancy in a quadriplegic patient treated with continuous intrathecal baclofen infusion to manage her severe spasticity. Case report. ( Delhaas, EM; Verhagen, J, 1992) |
| "We reviewed a 10% random sample of charts from an outpatient clinic for multiple sclerosis to determine the frequency with which baclofen was prescribed for spasticity in high doses (greater than 80 mg/d)." | 3.68 | High-dose oral baclofen: experience in patients with multiple sclerosis. ( Giesser, BS; LaRocca, NG; Scheinberg, LC; Smith, CR, 1991) |
| "Sixteen patients suffering from spasticity due to multiple sclerosis were treated with baclofen and tizanidine in a partially blind cross-over study." | 3.67 | Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients. ( Hoogstraten, MC; Minderhoud, JM; van der Ploeg, RJ; van Marle, S; vd Burg, W; Vreeling, A, 1988) |
| "The efficacy of intrathecally administered baclofen was demonstrated in three patients with different types of muscular hypertonia (supraspinal rigidity, spasms shortly after spinal trauma, spasms for many years induced by multiple sclerosis) using integrated electromyography." | 3.67 | The effect of intrathecal baclofen on electrical muscle activity in spasticity. ( Börner, U; Dralle, D; Hoffmann, O; Müller, H; Zierski, J, 1987) |
| "The intrathecal administration of baclofen by way of an implanted subcutaneous drug delivery system is described in a patient with a severe spastic paraparesis due to multiple sclerosis." | 3.67 | Intrathecal baclofen for severe spasticity. ( Hankey, GJ; Perlman, D; Stewart-Wynne, EG, 1986) |
| "Sudden withdrawal of baclofen has been shown to provoke hallucinations." | 3.67 | Baclofen pseudopsychosis: case report. ( Roy, CW; Wakefield, IR, 1986) |
| "Baclofen, commonly used to reduce severe muscle spasms in patients with spinal cord injuries, is also active in the brain." | 3.66 | A possible neurochemical basis for the neuropsychiatric aspects of baclofen therapy. ( Keegan, DL; Kirby, AR; Richardson, JS, 1983) |
| "Baclofen, 90 mg daily, was given to a patient with stiff-man syndrome diagnosed by electromyography and clinical criteria." | 3.66 | Baclofen in the treatment of stiff-man syndrome. ( Korsvik, H; Miller, F, 1981) |
| "The influence of spasticity, experienced by the patients with a spinal cord injury, on their quality of life was analyzed before the surgery and 12 months after it." | 3.30 | Neuromodulation and quality of life for patient with spasticity after spinal cord injury. ( Biktimirov, A; Bryukhovetskiy, I; Sharma, A; Sharma, HS, 2023) |
| "In ambulatory patients with spasticity, there is a justifiable concern that ITB treatment may compromise ambulatory function by reducing the heightened muscle tone, thereby unmasking underlying muscle weakness." | 3.01 | The impact of intrathecal baclofen on the ability to walk: A systematic review. ( Balakrishnan, S; Lee, HP; Win, T, 2023) |
| "For other causes of dystonia, and in particular dystonia due to acquired brain injury, improvements following surgery are more modest and variable." | 3.01 | Neurosurgical management of elevated tone in childhood: interventions, indications and uncertainties. ( Lumsden, DE, 2023) |
| "The average percent reduction in dystonia was 29." | 3.01 | Deep brain stimulation and intrathecal/intraventricular baclofen for glutaric aciduria type 1: A scoping review, individual patient data analysis, and clinical trials review. ( Hofmann, K; Keating, RF; Oluigbo, CO; Shlobin, NA, 2023) |
| "Basic spasticity treatment begins in the primary healthcare service and includes physiotherapy, occupational therapy and oral spasmolytics, while treatment with botulinum toxin and baclofen pump is carried out by the specialist healthcare services." | 3.01 | Spasticity treatment in Norwegian hospitals. ( Rekand, T; Simic, J; Østlie, K, 2023) |
| "The causes of spasticity are various and include cerebral palsy, spinal cord injury, stroke, multiple sclerosis or other congenital or acquired lesions of the central nervous system (CNS)." | 3.01 | [Surgical procedures for treatment of spasticity]. ( Daigeler, A; Heinzel, J; Hurth, H; Kolbenschlag, J; Morgalla, M; Schuhmann, M, 2023) |
| " Modified Ashworth scale (mAS) score, disability assessment scale (DAS) score, modified medical research council (mMRC) score, the Barthel Index (BI) score, and treatment-emergent adverse effects were evaluated during the follow-up period." | 2.87 | Efficacy and Safety of Botulinum Toxin Type A in Spasticity Caused by Spinal Cord Injury: A Randomized, Controlled Trial. ( Lan, J; Liu, Y; Miao, J; Yan, X, 2018) |
| "The management of spasticity can be achieved through the combination of both nonpharmacological and pharmacological approaches." | 2.82 | Role of Baclofen in Modulating Spasticity and Neuroprotection in Spinal Cord Injury. ( Barreiro-Iglesias, A; de Sousa, N; Monteiro, S; Salgado, AJ; Santos, D; Silva, N, 2022) |
| "We aimed to determine whether antispasticity treatment history influenced the efficacy and safety of add-on THC:CBD oromucosal spray in MS spasticity patients." | 2.82 | Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity. ( Álvarez-Ossorio, L; Haupts, M; Jonas, A; Vila, C; Witte, K, 2016) |
| "The main inclusion criteria were: spastic paraparesis with a negative laboratory and imaging work-up (apart from spinal cord atrophy), unsuccessful trial of oral anti-spasticity drugs." | 2.79 | Intrathecal baclofen therapy for the symptomatic treatment of hereditary spastic paraplegia. ( Boutos, N; Boviatsis, E; Dalivigka, Z; Flaskas, T; Gatzonis, S; Korfias, S; Margetis, K; Sakas, D; Siatouni, A; Stranjalis, G; Themistocleous, M, 2014) |
| "Baclofen was administered at 20 mg/day for 8 weeks; then increased to 40 mg/day for another 8 weeks." | 2.78 | Low-dose baclofen therapy raised plasma insulin-like growth factor-1 concentrations, but not into the normal range in a predictable and sustained manner in men with chronic spinal cord injury. ( Bauman, WA; Cirnigliaro, CM; Kirshblum, SC; La Fountaine, MF; Spungen, AM, 2013) |
| "When a sleep apnea syndrome was preexisting, it was generally severely worsened by the bolus mode of administration." | 2.77 | Pilot study assessing the impact of intrathecal baclofen administration mode on sleep-related respiratory parameters. ( Bensmail, D; Godard, AL; Lofaso, F; Marquer, A; Quera-Salva, MA; Roche, N, 2012) |
| "In the primary analysis, AP significantly improved Ashworth scores compared with placebo over the dosing interval: least-squares mean reduction versus placebo was 0." | 2.76 | Efficacy and safety study of arbaclofen placarbil in patients with spasticity due to spinal cord injury. ( Ayyoub, Z; Bian, A; Chen, D; Huff, FJ; Martinez-Arizala, A; Nance, PW; Stamler, D, 2011) |
| "Oral baclofen dose was positively related to body mass index, but not to extensor or flexor spasticity." | 2.75 | Oral baclofen administration in persons with chronic spinal cord injury does not prevent the protective effects of spasticity on body composition and glucose homeostasis. ( Chiodo, AE; Gater, DR; Gorgey, AS, 2010) |
| "The mean daily dosage alleviating spasticity on the hemiparetic side-without affecting the nonparetic side-was 119 microg/day (range 50 to 360 microg/day)." | 2.74 | Limitations of intrathecal baclofen for spastic hemiparesis following stroke. ( Kofler, M; Quirbach, E; Saltuari, L; Schauer, R; Singer, M, 2009) |
| "Eperisone was judged as "good" by a higher number of physicians and patients than baclofen." | 2.74 | Efficacy and tolerability of eperisone and baclofen in spastic palsy: a double-blind randomized trial. ( Bresolin, N; Pecori, A; Zucca, C, 2009) |
| "Severity of spasticity and overall health-related quality of life were also assessed." | 2.73 | Effects of intrathecal baclofen on perceived sexual functioning in men with spinal cord injury. ( Bilsky, G; Bowman, B; Jones, ML; Leslie, DP, 2008) |
| "This therapy is indicated in severe spasticity of cerebral or spinal origin that is unresponsive to oral antispastic medications." | 2.73 | Intrathecal antispastic drug application with implantable pumps: results of a 10 year follow-up study. ( Koulousakis, A; Kuchta, J, 2007) |
| "Clinical signs and symptoms of spasticity include hypertonia, involuntary movements (spasms, clonus), decreased range of motion, contractures, and often spasm-related pain." | 2.73 | Intrathecal baclofen for spasticity-related pain in amyotrophic lateral sclerosis: efficacy and factors associated with pain relief. ( Bethoux, FA; Boulis, NM; Gogol, DM; Harrison, M; McClelland, S; Pioro, EP; Schwetz, KM; Stough, DK; Sutliff, MH, 2008) |
| "In a group of 17 patients with spastic hemiparesis, with a different etiology, 2 groups were separated." | 2.73 | [Assessment of spasticity therapy with baclofen pump in children]. ( Swierczyńska, A, 2007) |
| "Improvement in spasticity was seen only in the upper extremity in 6% of subjects, only in the lower extremity in 2%, in both upper and lower extremities in 50% and without specification of location in 41%." | 2.72 | Effectiveness and safety of cervical catheter tip placement in intrathecal baclofen treatment of spasticity: A systematic review. ( Brusse-Keizer, M; Jacobs, NW; Maas, EM; Rietman, HJS, 2021) |
| "We found a significant dose-response relationship between the soleus H/M ratio and CITB dose." | 2.72 | Dose-response relationship between the H-reflex and continuous intrathecal baclofen administration for management of spasticity. ( Hayes, A; Olivier, J; Stokic, DS; Vesovic-Potic, V; Yablon, SA, 2006) |
| " The dosage of ITB increased from a mean of 157 microg/day 3 months after pump insertion to 300 microg/day at 2 years postimplantation, and remained relatively stable thereafter." | 2.71 | Long-term intrathecal baclofen therapy for severe spasticity of cerebral origin. ( Albright, AL; Gilmartin, R; Ivanhoe, CB; Krach, LE; McLaughlin, JF; Swift, D, 2003) |
| "Walking performance and spasticity in lower-extremity muscles were assessed before and at 2, 4, and 6 hours after ITB bolus injection." | 2.71 | Effect of intrathecal baclofen bolus injection on temporospatial gait characteristics in patients with acquired brain injury. ( Horn, TS; Stokic, DS; Yablon, SA, 2005) |
| "Patients with spinal cord injury and spasticity were included in the study." | 2.71 | Transcutaneous electrical nerve stimulation versus baclofen in spasticity: clinical and electrophysiologic comparison. ( Aydin, G; Demir, SO; Keleş, I; Orkun, S; Tomruk, S, 2005) |
| "The effects of ITB on spasticity in the upper and lower extremities were evaluated using the Ashworth Scale." | 2.71 | Performance and complications associated with the synchromed 10-ml infusion pump for intrathecal baclofen administration in children. ( Albright, AL; Awaad, Y; Bloom, K; Boydston, WR; Gilmartin, R; Krach, LE; Muhonen, M; Swift, D; Turner, M; Wright, E; Zidek, KA, 2004) |
| "0001) increase in intrathecal baclofen dosage requirements during the 1-year follow-up period to maintain the reductions in spasm frequency, reflexes and tone." | 2.70 | Intrathecal baclofen in tetraplegia of spinal origin: efficacy for upper extremity hypertonia. ( Burns, AS; Meythaler, JM, 2001) |
| "Dystonia was associated with cerebral palsy in 71% of participants." | 2.70 | Intrathecal baclofen for generalized dystonia. ( Albright, AL; Barry, MJ; Ferson, SS; Shafton, DH, 2001) |
| "Eighteen patients with severe spasticity of cerebral origin, who failed to respond adequately to more conservative treatments, have-been treated with continuous infusion of intrathecal baclofen delivered via an implanted pump." | 2.69 | Treatment of cerebral origin spasticity with continuous intrathecal baclofen delivered via an implantable pump: long-term follow-up review of 18 patients. ( Rawicki, B, 1999) |
| "In 11 patients with spasticity of cerebral origin (mainly cerebral palsy), double-blind scoring of spasticity (Ashworth scale score and visual analog score), spasms, pain, and functional abilities was performed during tests with bolus injections including a placebo control." | 2.69 | Intrathecal baclofen for intractable cerebral spasticity: a prospective placebo-controlled, double-blind study. ( Borghgraef, C; Feys, P; Lagae, L; Nuttin, B; Schrijvers, E; Van Schaeybroeck, P, 2000) |
| "Fourteen spastic MS patients were examined in a placebo controlled double-blind, cross-over trial of oral baclofen treatment." | 2.69 | Effect of baclofen on gait in spastic MS patients. ( Larsen, TK; Orsnes, GB; Ravnborg, M; Sørensen, PS, 2000) |
| "Severe spasticity unresponsive to oral drugs may respond satisfactorily to baclofen delivered intrathecally." | 2.68 | Long-term intrathecal baclofen therapy in patients with intractable spasticity. ( Ablett, DP; Becker, WJ; DeForge, DA; Harris, CJ; Klein, GM; Long, ML, 1995) |
| "Severe spinal spasticity has been shown to be a good indication for continuous intrathecal baclofen infusion (CIBI), but there is only limited experience with this treatment in patients with supraspinal spasticity." | 2.68 | Continuous intrathecal baclofen infusion in severe spasticity after traumatic or hypoxic brain injury. ( Alberti, O; Bauer, BL; Becker, R, 1997) |
| "Eleven patients with spasticity of different etiology and one patient with idiopathic dystonia were studied." | 2.68 | Changes in voluntary motor control induced by intrathecal baclofen in patients with spasticity of different etiology. ( Latash, ML; Penn, RD, 1996) |
| "In twenty-five SCI subjects, antispasticity effects of three putative antispasticity agents [clonidine (an alpha-2 noradrenergic agonist), cyproheptadine (a 5-HT2 antagonist) and baclofen (a GABA-B agonist)] were tested in terms of changes in leg tone as graded by the Ashworth scale (AS), in terms of the vibratory inhibition of the H-reflex (VII) and in terms of the ability of the knee to swing passively in the pendulum test as quantified by video motion analysis." | 2.67 | A comparison of clonidine, cyproheptadine and baclofen in spastic spinal cord injured patients. ( Nance, PW, 1994) |
| " The dosage for all patients more than doubled (P < 0." | 2.67 | Continuous intrathecal baclofen in spinal cord spasticity. A prospective study. ( Cross, LL; Haworth, CS; Meythaler, JM; Steers, WD; Tuel, SM, 1992) |
| "Patients with minimal to moderate spasticity were randomized to one of three sequences to evaluate the effects on MS-related spasticity of baclofen alone, stretching regimen with placebo, placebo alone, and stretching regimen with baclofen." | 2.67 | Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis. ( Brar, SP; Cobble, ND; Franklin, GM; Nelson, LM; Smith, MB, 1991) |
| " Baclofen dosage increased from 182 +/- 135 to 528 +/- 266 mcg/day over the 3-22 month follow-up period." | 2.67 | Continuous infusion of intrathecal baclofen: long-term effects on spasticity in spinal cord injury. ( Donovan, WH; Loubser, PG; Narayan, RK; Russell, KD; Sandin, KJ, 1991) |
| "Quantitative measurements of spasticity were also taken at each session." | 2.67 | The supraspinal anxiolytic effect of baclofen for spasticity reduction. ( Hinderer, SR, 1990) |
| "The independent variable was spasticity medication treatment, where the levels were 40 mg/day and 80 mg/day of baclofen v placebo treatment." | 2.67 | Spasticity in spinal cord injured persons: quantitative effects of baclofen and placebo treatments. ( Deitz, J; deLateur, BJ; Hinderer, SR; Lehmann, JF; Price, R; White, O, 1990) |
| "An ITB pump was inserted to manage spasticity." | 2.66 | Severe Neuromuscular Scoliosis Implicated by Dysfunction of Intrathecal Baclofen Pump: Case Report and Review of the Literature. ( Apostolopoulou, K; Panagopoulos, D; Themistocleous, M, 2020) |
| "This procedure is recommended for spasticity of spinal origin refractory to physiotherapy and oral medication." | 2.66 | Intrathecal baclofen for long-term treatment of spasticity: a multi-centre study. ( Gardner, BP; Gybels, J; Jamous, A; Linderoth, B; Meyerson, BA; Ochs, G; Struppler, A; Teddy, P; Weinmann, P, 1989) |
| "Twenty patients with spinal spasticity caused by multiple sclerosis or spinal-cord injury who had had no response to treatment with oral baclofen received an intrathecal infusion of baclofen or saline for three days." | 2.66 | Intrathecal baclofen for severe spinal spasticity. ( Corcos, D; Gottlieb, G; Kroin, JS; Latash, M; Parke, B; Penn, RD; Savoy, SM, 1989) |
| "Tizanidine (Sirdalud) was compared to baclofen (Lioresal) in a randomized, double-blind, cross-over trial." | 2.66 | Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. ( Bass, B; Bouchard, S; Cameron, MG; Ebers, GC; Hader, W; Noseworthy, JH; Rice, GP; Weinshenker, B, 1988) |
| " Simulations based on mean data suggest that increased drowsiness in the elderly was probably not due to changes in the drug's pharmacokinetic behaviour." | 2.66 | Baclofen in the elderly stroke patient its side-effects and pharmacokinetics. ( Hulme, A; John, VA; MacLennan, WJ; Ritchie, RT; Shotton, PA, 1985) |
| " Percentages of improved patients' spasticity scale, mild adverse effect and severe adverse effect were extracted as outcomes." | 2.58 | A mixed treatment comparison on efficacy and safety of treatments for spasticity caused by multiple sclerosis: a systematic review and network meta-analysis. ( Fu, X; Li, J; Li, M; Ma, Q; Wang, C; Wang, Y; Wu, H; Yang, W, 2018) |
| "Skeletal muscle spasticity is a major physical complication resulting from traumatic brain injury (TBI), which can lead to muscle contracture, joint stiffness, reduced range of movement, broken skin and pain." | 2.55 | Interventions for managing skeletal muscle spasticity following traumatic brain injury. ( Chau, M; Clavisi, O; Gruen, RL; O'Connor, D; Pattuwage, L; Phillips, K; Pitt, V; Synnot, A; Wasiak, J, 2017) |
| "We share our experience of spasticity management with the ITB pump system in five patients at Vilnius University Hospital Santariskiu Klinikos." | 2.55 | Intrathecal Baclofen Therapy for the Treatment of Spasticity in Lithuania. ( Juocevicius, A; Kesiene, J; Kvascevicius, R; Lapteva, O; Mikulenaite, L; Raugalas, R; Rocka, S; Sipylaite, J; Vaitkus, A, 2017) |
| "Oral baclofen has long been a mainstay in the management of spasticity." | 2.55 | Efficacy and safety of oral baclofen in the management of spasticity: A rationale for intrathecal baclofen. ( Calabrese, A; Campo, C; Ertzgaard, P, 2017) |
| "Treatment of spasticity poses a major challenge given the complex clinical presentation and variable efficacy and safety profiles of available drugs." | 2.53 | Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. ( Comi, G; Gold, R; Hartung, HP; Montalban, X; Otero-Romero, S; Sastre-Garriga, J; Soelberg Sørensen, P; Thompson, AJ; Vermersch, P, 2016) |
| " Step dosing can be used for outpatients who cannot return daily." | 2.53 | Best Practices for Intrathecal Baclofen Therapy: Dosing and Long-Term Management. ( Adair, RL; Boster, AL; Gooch, JL; Nelson, ME; Saulino, M; Toomer, A; Urquidez, J, 2016) |
| "When spasticity interferes with comfort, function, activities of daily living, mobility, positioning, or caregiver assistance, patients should be considered for intrathecal baclofen (ITB) therapy." | 2.53 | Best Practices for Intrathecal Baclofen Therapy: Patient Selection. ( Boster, AL; Ivanhoe, CB; McGuire, JR; Ridley, B; Saulino, M; Shilt, JS, 2016) |
| " The first was for loss-of-efficacy and applies to patients with previously well-controlled hypertonia on a stable dosing regimen who have increased spasticity Evaluation includes a targeted history (onset, duration, course, exacerbating/relieving factors, medications, recent procedures), physical examination (neuromuscular, vital signs, mental status), radiologic/laboratory testing (catheter imaging, noxious stimuli, infection, rising CK levels), and pump telemetry (pump interrogation, reservoir volume)." | 2.53 | Best Practices for Intrathecal Baclofen Therapy: Troubleshooting. ( Anderson, DJ; Boster, AL; Doble, J; Farid, R; Gul, F; Konrad, P; Saulino, M, 2016) |
| "Because of severe spasticity, many of these patients undergo intrathecal baclofen pump placement before, during, or after posterior spinal fusion." | 2.52 | Scoliosis, spinal fusion, and intrathecal baclofen pump implantation. ( Scannell, B; Yaszay, B, 2015) |
| " Although ITB has been used for more than 20 years clinically, much is still unknown about the most optimal dosing regimens and intrathecal catheter tip placement." | 2.52 | Intrathecal baclofen bolus dosing and catheter tip placement in pediatric tone management. ( Fournier, CM; Skalsky, AJ, 2015) |
| "Muscle spasms and spasticity constitute a significant problem in patients with spinal cord injury, interfering with rehabilitation and leading to impairments in quality of life in addition to medical complications." | 2.50 | Spasticity and the use of intrathecal baclofen in patients with spinal cord injury. ( Garg, DS; Khurana, SR, 2014) |
| "Severe spastic tone and/or spastic hypertonia can be the most disabling consequences of a neurologic insult, resulting from an excess of muscle tone." | 2.50 | Spasticity and intrathecal baclofen. ( Boyle, AM; Furr-Stimming, E; Schiess, MC, 2014) |
| "A new less invasive treatment of tremor using MR guided focused ultrasound has started and is promising." | 2.49 | [Role of neurosurgical management in movement disorders other than Parkinson disease]. ( Taira, T, 2013) |
| "Improvement was reported in spasticity, spasms, pain, gait, activities of daily life and providing care." | 2.48 | Intrathecal baclofen for progressive neurological disease in childhood: a systematic review of literature. ( Becher, JG; Bonouvrié, LA; van Ouwerkerk, WJ; van Schie, PE; Vermeulen, RJ, 2012) |
| "Local spasticity can be treated with botulinum toxin injections." | 2.48 | Spasticity following spinal cord injury. ( Grønning, M; Hagen, EM; Rekand, T, 2012) |
| "The medicinal treatment of spasticity includes use of oral treatments (baclofène and tizanidine), botulinum toxin, intrathecal baclofène and local application of alcohol or phenol." | 2.48 | [Pharmacological treatment of spasticity in multiple sclerosis]. ( Heinzlef, O; Monteil-Roch, I, 2012) |
| "Oral antispasticity medications are useful in managing mild spasticity but are frequently ineffective in controlling moderate to severe spasticity, because patients often cannot tolerate the adverse effects of increasing doses." | 2.47 | Intrathecal baclofen in multiple sclerosis: too little, too late? ( Bennett, SE; Bethoux, F; Erwin, A; Gudesblatt, M; Hughes, M; Koelbel, S; Plunkett, R; Sadiq, S; Stevenson, VL; Thomas, AM; Tornatore, C; Zaffaroni, M, 2011) |
| "Gabapentin is a novelty, and the working mechanism of cannabis has been elucidated." | 2.46 | Spasticity: revisiting the role and the individual value of several pharmacological treatments. ( Kuks, JB; Lapeyre, E; Meijler, WJ, 2010) |
| "The treatment of spasticity has considerably changed during last years, notably with the generalization of Botulinum toxin use." | 2.46 | Managing spasticity with drugs. ( Simon, O; Yelnik, AP, 2010) |
| "For more generalized spasticity, a number of useful oral agents and intrathecal baclofen are available, each with their positive and negative attributes." | 2.46 | Pharmacologic treatment of spasticity in children. ( Delgado, MR; Tilton, A; Vargus-Adams, J, 2010) |
| " Pharmacists should remain knowledgeable about therapy management in patients receiving treatment for spasticity, including adverse event monitoring, infusion device complications, and dosage adjustments." | 2.45 | Considerations in the treatment of spasticity with intrathecal baclofen. ( Mullarkey, T, 2009) |
| "These include the management of dystonia and chronic neuropathic pain." | 2.44 | Intrathecal baclofen therapy for neurological disorders: a sound knowledge base but many challenges remain. ( Brennan, PM; Whittle, IR, 2008) |
| "Baclofen is an agonisit at gamma-aminobutyric acid (GABA) receptors, and is, therefore, a neuroinhibitor, and decreases spasticity." | 2.44 | [Intrathecal baclofen for severe spasticity]. ( Ueta, T, 2008) |
| "In the spinal spasticity which is characterized by spasms, the Spasm Frequency Scale is useful in order to monitor their frequency." | 2.44 | Intrathecal baclofen therapy in patients with severe spasticity. ( Bramanti, P; D'Aleo, G; Di Bella, P; Marra, GA, 2007) |
| "When assessing a spastic patient alternative treatments such as Botox and peripheral neurotomies must also be considered, particularly in cases of predominantly focal spasticity." | 2.44 | Intrathecal baclofen for the treatment of spasticity. ( Dones, I, 2007) |
| "Usually, the evaluation of spasticity is carried out by the Asworth Scale although there is not yet general accordance on the validity of this scale." | 2.44 | Management of spasticity in multiple sclerosis by intrathecal baclofen. ( Dario, A; Tomei, G, 2007) |
| "Baclofen is mainly an antispastic drug and the main indication of ITB is generalized lower limb spasticity in spinal cord injury and multiple sclerosis." | 2.44 | Intrathecal baclofen in the treatment of spasticity, dystonia and vegetative disorders. ( Menei, P; Richard, I, 2007) |
| "In this report, we present a case of intracranial hypotension secondary to baclofen pump placement." | 2.44 | Intracranial hypotension from intrathecal baclofen pump insertion. A case report and review of the literature. ( Henderson, JM; Lad, SP; Li, G; Lin, SC, 2008) |
| "Methods of evaluation of degree of spasticity were also recalled." | 2.44 | [Physical and other methods therapy of the spasticity in children]. ( Jaworek, M; Renata, K; Swierczyńska, A, 2007) |
| "Symptoms of spasticity are often experienced by individuals with spinal cord injury (SCI) following a period of spinal shock and, in many cases, these symptoms negatively affect quality of life." | 2.43 | Spasticity after spinal cord injury. ( Adams, MM; Hicks, AL, 2005) |
| "While in some children, spasticity may adversely impact the motor abilities, in others, it may help maintain posture and ability to ambulate." | 2.43 | Pharmacologic interventions for reducing spasticity in cerebral palsy. ( Patel, DR; Soyode, O, 2005) |
| "The management of childhood spasticity requires a multidisciplinary effort." | 2.43 | Management of childhood spasticity: a neurosurgical perspective. ( Anderson, RC; Mandigo, CE, 2006) |
| "Treatment with ITB decreases spasticity in the upper and lower extremities and has been associated with improved function and decreased musculoskeletal contractures." | 2.43 | Intrathecal baclofen therapy in children. ( Albright, AL; Ferson, SS, 2006) |
| "Medical management of adult spasticity, a condition of increased muscle tone and deep tendon reflexes, is often challenging and complex." | 2.43 | Intrathecal baclofen in the treatment of adult spasticity. ( Hsieh, JC; Penn, RD, 2006) |
| "The spectrum of antispasticity therapies is fairly broad." | 2.43 | The pharmacological management of spasticity. ( Jacobs, BW; Saulino, M, 2006) |
| "In such patients, treatment of spasticity is warranted." | 2.42 | Anti-spasticity medications. ( Al-Shahrani, AM, 2003) |
| " The pharmacokinetics of baclofen in animal and man after intrathecal administration have been investigated to determine the CSF pharmacokinetic parameters." | 2.42 | [Intrathecal baclofen. Experimental and pharmacokinetic studies]. ( Lazorthes, Y; Sallerin, B, 2003) |
| "The reduction in spasticity led to improvement in ability to transfer and ease of nursing care in the majority of patients." | 2.42 | [Intrathecal baclofen. Literature review of the results and complications]. ( Emery, E, 2003) |
| "Why is it important to treat spastic patients and what treatment does one use? When should one consider a change in the strategy and why is it necessary to have a clear discharge policy from the service to avoid serious logistic problems? The review reiterates the role of physical treatment in the management and thereafter the maintenance of patients with spasticity." | 2.42 | Long-term modification of spasticity. ( Ward, AB, 2003) |
| " Dosage errors can be a source of significant morbidity and the risk is greatest when the clinician is changing solution concentration." | 2.42 | Managing spasticity in spinal cord injury: safe administration of bridge boluses during intrathecal baclofen pump refills. ( Elovic, E; Kirshblum, SC, 2003) |
| "Children with primary dystonia and those with tremor can be treated with deep brain stimulation of the internal globus pallidus and thalamus, respectively." | 2.42 | Neurosurgical treatment of spasticity and other pediatric movement disorders. ( Albright, AL, 2003) |
| "Baclofen is also used for control of dystonia due to cerebral palsy or reflex sympathetic dystrophy." | 2.42 | Clinical application of drug pump for spasticity, pain, and restorative neurosurgery: other clinical applications of intrathecal baclofen. ( Hori, T; Taira, T, 2003) |
| "The treatment of cerebral palsy is directed at repair of the injured brain and at the management of the impairments and disabilities resulting from developmental brain injury." | 2.42 | The treatment of cerebral palsy: What we know, what we don't know. ( Goldstein, M, 2004) |
| "Cerebral palsy is among the most frequent disorders of the growing locomotor apparatus during childhood." | 2.41 | [Botulinum toxin type A in the treatment plan for cerebral palsy]. ( Strobl, W, 2001) |
| "Therapy for spasticity is symptomatic with the aim of increasing functional capacity and relieving discomfort." | 2.41 | Drugs used to treat spasticity. ( Goodkin, DE; Kita, M, 2000) |
| "When excessive spasticity is not sufficiently controlled by physical therapy and pharmacological treatment, patients can have recourse to neurosurgery: neurostimulation, intrathecal baclofen or selective ablative procedures." | 2.41 | Neurosurgery for spasticity. ( Mertens, P; Sindou, MP, 2000) |
| "Assessment of the impact of the spasticity on function (positive and negative), position, care of the patient, and pain should be pursued." | 2.41 | Physiologic and clinical monitoring of spastic hypertonia. ( Dixon, K; Hinderer, SR, 2001) |
| "Among the more common symptoms is spasticity." | 2.41 | Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis. ( Schapiro, RT, 2001) |
| "Pain is a common feature of spasticity and muscle spasms and the reasons for this are discussed in this article." | 2.41 | The management of pain in spasticity. ( Kadies, M; Ward, AB, 2002) |
| "With the introduction of the antispasticity agent, tizanidine hydrochloride (Zanaflex), physicians have requested information about the optimal way to switch appropriate patients from baclofen to tizanidine." | 2.40 | An approach to switching patients from baclofen to tizanidine. ( Brenner, R; Hyman, N; Knobler, R; O'Brien, M; Stephan, T, 1998) |
| "The therapeutic profile of a new antispastic drug cannot be defined solely on the basis of placebo-controlled studies." | 2.39 | Comparative profile of tizanidine in the management of spasticity. ( Davis, C; Emre, M; Groves, L; Lataste, X, 1994) |
| "Multiple sclerosis is a demyelinating disorder of the central nervous system characterized by exacerbations and remissions of symptoms." | 2.38 | Update on multiple sclerosis therapy. ( Mitchell, G, 1993) |
| "Treating severe spasticity with the continuous infusion of intrathecal baclofen through an implantable delivery system is a new and successful alternative to oral medications and ablative surgical procedures." | 2.38 | Intrathecal baclofen for spinal spasticity: implications for nursing practice. ( Gianino, J, 1993) |
| "The pathophysiology of spasticity and the history of posterior rhizotomies are reviewed." | 2.38 | Neurosurgical treatment of spasticity: selective posterior rhizotomy and intrathecal baclofen. ( Albright, AL, 1992) |
| " The 5 events during continuous infusion intoxication only happened in high dosed patients." | 2.38 | Intrathecal baclofen overdose: report of 7 events in 5 patients and review of the literature. ( Brouwers, JR; Delhaas, EM, 1991) |
| "They have been of value in treating pain of cancer and spasticity through spinal subarachnoid catheters." | 2.37 | Drug pumps for treatment of neurologic diseases and pain. ( Penn, RD, 1985) |
| "The functional impairment due to spasticity must be carefully assessed before any treatment is considered." | 2.37 | Management of spasticity. ( Katz, RT, 1988) |
| "Tizanidine has been recently introduced, and early experience with this agent appears to be favourable." | 2.37 | Pharmacotherapy of spasticity: some theoretical and practical considerations. ( Rice, GP, 1987) |
| "Dantrolene is a direct acting muscle relaxant which should be avoided in patients with pre-existing liver damage." | 2.37 | Spasticity and drug therapy. ( Wuis, EW, 1987) |
| "The term cerebral palsy is restricted to non-progressive disorders of motor function, already observed at an early age and due to cerebral lesions." | 2.37 | [Functional neurosurgery of cerebral palsy]. ( Alexandre, F; Angelini, L; Benezech, J; Broggi, G; Claverie, P; Deonna, T; Frerebeau, P; Lazorthes, Y; Siegfried, J; Verdie, JC, 1985) |
| " Extensor spasticity was lower in the high-responders compared to the low-responders as was the dosage of baclofen." | 1.91 | Predictors of muscle hypertrophy responsiveness to electrically evoked resistance training after spinal cord injury. ( Adler, RA; Cardozo, C; Goldsmith, JA; Gorgey, AS; Khalil, RE; Liu, XH; Pan, J, 2023) |
| "We aim to describe associations with spasticity treatment measured primarily by oral baclofen use." | 1.91 | Spasticity treatment patterns among people with multiple sclerosis: a Swedish cohort study. ( Alfredsson, L; Hillert, J; Kockum, I; Montgomery, S; Olsson, T; Piehl, F; Smith, KA; Stridh, P, 2023) |
| "Chronic spasticity causes significant impairment and financial burden." | 1.91 | Assessment of Health Care Costs and Total Baclofen Use Associated With Targeted Drug Delivery for Spasticity. ( Futch, BG; Lad, SP; Lee, HJ; Parente, BA; Spears, CA; Venkatraman, V; Yang, LZ, 2023) |
| " However, adverse effects, administration, and dosing can be barriers to effectiveness." | 1.91 | Is baclofen the least worst option for spasticity management in children? ( Brandenburg, JE, 2023) |
| "To quantify the risk of encephalopathy associated with oral baclofen compared with other muscle relaxants-tizanidine or cyclobenzaprine." | 1.91 | Baclofen and the Risk of Encephalopathy: A Real-World, Active-Comparator Cohort Study. ( Brotman, DJ; Chang, AR; Grams, ME; Hwang, YJ; Inker, LA; Shin, JI, 2023) |
| "Symptomatic treatment of Multiple Sclerosis (MS) is crucial, since it helps to lessen the limitations that affect patients' daily lives." | 1.91 | Effects of intrathecal Baclofen in reducing tremors in patients with multiple sclerosis. ( Aldarwish, WA; Ali, EN, 2023) |
| "The activities related to intrathecal baclofen (ITB) therapy could not be interrupted at the outbreak of COVID-19 pandemic due to possible life-threatening related complications such as withdrawal and over dosage syndromes." | 1.91 | The impact of strategies to manage the COVID-19 pandemic on patients with intrathecal baclofen therapy. ( Burattini, B; D'Ercole, M; Fuggetta, F; Izzo, A; Montano, N; Rapisarda, A, 2023) |
| "Hereditary Spastic Paraparesis (HSP) causes lower limb spasticity, pain and limits ambulation resulting in a negative impact on an individual's quality of life." | 1.72 | The use of intrathecal baclofen for management of spasticity in hereditary spastic paraparesis: A case series. ( Goodden, J; Lodh, R; Mulkeen, A; Peacock, S; Pointon, R; Raza, R; Whelan, H; Wilsmore, C, 2022) |
| "The patient was on ITB for lower limb spasticity." | 1.72 | Baclofen Withdrawal With Reversible Posterior Leukoencephalopathy Syndrome: Bacterial Meningitis Mimicker. ( Hirasawa, N; Nakae, H; Okuyama, M; Satoh, K; Yoshida, K, 2022) |
| "ITB led to significant improvement in spasticity based on MAS scores, which did not correlate to the improvements seen in CRS-R total and subscale scores." | 1.72 | On the recovery of disorders of consciousness under intrathecal baclofen administration for severe spasticity-An observational study. ( Dobesberger, J; Fava, E; Genelin, E; Halbmayer, LM; Hitzenberger, G; Kofler, M; Matzak, H; Pucks-Faes, E; Saltuari, L; Versace, V; Werkmann, M, 2022) |
| "For 4-5 years before this presentation, spasticity in the lower limbs had been exacerbated without any obvious cause." | 1.62 | Intrathecal baclofen therapy for severe spasticity in an adult with tethered cord syndrome: a case report. ( Ebara, H; Hayashi, H; Ishino, Y; Kagechika, K; Kidani, S; Kitano, Y; Nakanami, A; Takagi, Y; Toyooka, K; Tsuchiya, H; Yahata, T; Yamada, H, 2021) |
| "In this case, treatment of severe spasticity and nociceptive pain was required while avoiding potentially lethal side effects of sudden baclofen withdrawal." | 1.62 | Baclofen bridging, weaning protocol and pain management of a person with T6 paraplegia who required removal of intrathecal baclofen pump due to wound infection. ( Agha, H; Davis, C; Roth, J, 2021) |
| "Multiple sclerosis is a neurological disease that presents with various symptoms; in some cases it is progressive and highly disabling, requiring invasive techniques to treat pain and spasticity." | 1.62 | Intrathecal baclofen pump exchange in multiple sclerosis. Factors affecting baclofen efficacy and dose adjustement. A case report. ( Alonso Rodríguez, E; Blázquez Calvo, V; Lloreda Herradón, P; Miyagi Yonamine, M, 2021) |
| "The lack of information about spasticity specific to patients with DoC may result in insufficient or even inappropriate treatment." | 1.62 | Spasticity Management in Persons with Disorders of Consciousness. ( DiTommaso, C; Karri, J; Kothari, S; Li, S; O'Brien, K; Zhang, B, 2021) |
| "This study aims to examine the adverse event (AE) rate for intrathecal baclofen (ITB) therapy in an Australian paediatric population and to clarify type and frequency of AEs." | 1.62 | Adverse events associated with paediatric intrathecal baclofen in Australia: 5 years of data collection. ( Copeland, L; McCartney, L; Tyack, L; Waugh, MC, 2021) |
| "All patients reported improvement in spasticity as measured by clinical examinations and Ashworth scores; 1/5 had complications with the pump related to migration of catheter." | 1.62 | Utility of intrathecal baclofen pump in primary lateral sclerosis. ( Patwa, HS; Raymond, M; Zubair, AS, 2021) |
| " The effects of chronic administration of baclofen on humans have not been investigated to date." | 1.62 | Improvement of Memory Functions in Chronic Spinal Cord Injury After Long-Term Intrathecal Baclofen Delivery for Spasticity Relief. ( Keller, J; Krámská, L; Štětkářová, I, 2021) |
| "The majority were on multiple spasticity medications." | 1.62 | Evaluation of the cognitive benefits of intrathecal baclofen pump implantation in people with intractable multiple sclerosis related spasticity. ( Buchanan, K; Doogan, C; Farrell, R; Keenan, E; Lee, H; Mulhert, N; Padilla, H; Stevenson, VL; Summers, M, 2021) |
| " However, his spasticity and pain then began to worsen with each dosage increase." | 1.62 | Paradoxical reaction to increased doses of intrathecal baclofen in a patient with Leigh syndrome. ( Erlandson, E; Khaliq, F; Santia, C, 2021) |
| " The most commonly used ITB dosing modes were continuous (73%) and flexible (23%)." | 1.62 | Intrathecal baclofen pumps in the management of hypertonia in childhood: a UK and Ireland wide survey. ( Amin, S; Ammar, A; Bellis, L; Brink, P; Calisto, A; Crimmins, D; Eunson, P; Forsyth, RJ; Goodden, J; Kaminska, M; Kehoe, J; Kirkpatrick, M; Kumar, R; Leonard, J; Lodh, R; Lording, A; Lumsden, DE; Martin, K; Miller, R; Mordekar, SR; Pettorini, B; Smith, M; Smith, R; Sneade, C; Vloeberghs, M; Whitney, A; Zaki, H, 2021) |
| "Severe spasticity was due to spinal cord injury (38%), traumatic brain injury (15%), cerebral palsy (13%), multiple sclerosis (11%), stroke (10%), and other (13%)." | 1.62 | Low Rate of Intrathecal Baclofen Pump Catheter-Related Complications: Long-Term Study in Over 100 Adult Patients Associated With Reinforced Catheter. ( Awad, AJ; Feller, CN; Ketchum, N; Nelson, MES; Pahapill, PA, 2021) |
| "Moreover, spasticity is one of the most common of these effects." | 1.62 | [Neurosurgery for Spasticity]. ( Takahashi, J; Uchiyama, T, 2021) |
| "Treatment of spasticity includes oral and intrathecal anti-spastic drugs, muscle injections with relaxant agents, physical therapy, electrical and magnetic stimulation and peripheral nerve stimulation, alone or in various combinations." | 1.56 | Italian consensus on treatment of spasticity in multiple sclerosis. ( Centonze, D; Comi, G; Leocani, L; Otero-Romero, S; Solari, A, 2020) |
| "A mouse model of spasticity was developed by producing incomplete SCI at the 9th thoracic level." | 1.56 | The beneficial aspects of spasticity in relation to ambulatory ability in mice with spinal cord injury. ( Konno, DJ; Kubota, K; Maeda, T; Matsumoto, Y; Nakashima, Y; Okada, S; Saito, T; Tanaka, M; Yokota, K; Yoshizaki, S, 2020) |
| "ITB therapy for the treatment of severe spasticity requires surgical implantation of a programmable infusion system for chronic drug delivery." | 1.56 | Intrathecal Baclofen for Severe Spasticity: Longitudinal Data From the Product Surveillance Registry. ( Eldabe, S; Konrad, P; Molus, L; Plunkett, R; Schiess, MC; Spencer, R; Stromberg, K; Weaver, T, 2020) |
| " After replacement, prerevision and stable postrevision dosage was examined to determine the impact system replacement had on the daily dosage." | 1.56 | Screening Intrathecal Baclofen Pump Systems for Catheter Patency via Catheter Access Port Aspiration. ( Dalal, P; Ewing, E; Le, J; Skalsky, AJ; Yaszay, B, 2020) |
| "Most commonly, severe cases of spasticity are treated surgically with intrathecal baclofen therapy (ITB)." | 1.56 | Spinal cord stimulation and intrathecal baclofen therapy for patients with severe spasticity after spinal cord injury. ( Biktimirov, A; Bryukhovetskiy, I; Sharma, A; Sharma, HS, 2020) |
| "29% had (serious) adverse events (60% of clinical manifestations were prevented by remote double-check control)." | 1.51 | Efficiency and Safety of Aftercare With Intrathecal Baclofen on Location. ( Delhaas, EM; Frankema, SPG; Goslinga-van der Gaag, SME; Huygen, FJPM, 2019) |
| "His severe spasticity made positioning and care difficult, and intense pain required multiple hospitalizations." | 1.51 | The Palliative Use of Intrathecal Baclofen in Niemann-Pick Disease Type C. ( Buxton, K; Nimec, DL; Stone, SS; Ubeda Tikkanen, A; Ullrich, CK, 2019) |
| " Demographic characteristics, clinical diagnoses, date of placement or withdrawal/replacement of intrathecal baclofen infusion pumps, baclofen dosage and complications of intrathecal baclofen infusion pumps were collected." | 1.51 | Intrathecal Baclofen Infusion Pumps in the Treatment of Spasticity: A Retrospective Cohort Study in a Portuguese Centre. ( Barbosa, P; Gomes, A; Midões, AC; Rebelo, V; Reis, PV; Vieira, CR, 2019) |
| "Demographics, spasticity scores (Ashworth), spasm score (Penn), stiffness, pain and discomfort (Visual Analogue Scale), mobility (10 M walk), spasticity treatment, and ITB doses were analysed longitudinally." | 1.51 | Intrathecal baclofen for multiple sclerosis related spasticity: A twenty year experience. ( Buchanan, K; Farrell, R; Keenan, L; Sammaraiee, Y; Stevenson, V; Yardley, M, 2019) |
| "Patients with spasticity treated with intrathecal baclofen." | 1.51 | Accuracy and Precision of the SynchroMed II Pump. ( Binz, K; Emerson, JA; Farid, R; Murdock, F, 2019) |
| "Isolated dystonia or spasticity was infrequently seen, with a mixed picture of dystonia and spasticity ± choreoathetosis identified in 194/275 (70." | 1.51 | Pharmacological management of abnormal tone and movement in cerebral palsy. ( Amin, S; Basu, A; Cadwgan, J; Crowe, B; DeAlwis, Y; Devlin, A; Kumar, R; Lodh, R; Lumsden, DE; Lundy, CT; Mordekar, SR; Smith, M, 2019) |
| "Froin syndrome can impact intrathecal drug delivery and CSF diagnostics." | 1.51 | Froin Syndrome After Spinal Cord Injury. ( Decramer, T; Kiekens, C; Theys, T; Wouters, A, 2019) |
| "The two groups will be matched for spasticity and other important clinical characteristics at baseline." | 1.51 | Comparing the effects of two spasticity management strategies on the long-term outcomes of individuals with bilateral spastic cerebral palsy: a multicentre cohort study protocol. ( Chen, BP; MacWilliams, BA; McMulkin, ML; Munger, ME; Schwartz, MH, 2019) |
| "Baclofen was weaned down and switched to intrathecal ziconotide at 0." | 1.51 | Low-Dose Intrathecal Ziconotide for Spasticity From Primary Lateral Sclerosis: A Case Report. ( Goldstein, RB; Kohan, LR; Zhu, X, 2019) |
| "Nociception Coma Scale-Revised (NCS-R) also changed from 4 to 8 at the same time points." | 1.51 | Late recovery of responsiveness after intra-thecal baclofen pump implantation and the role of diffuse pain and severe spasticity: a case report. ( Aloisi, M; Baldeschi, GC; Buzzi, MG; Cobianchi, MR; Contrada, M; Formisano, R; Niedbala, S; Schiattone, S; Spanedda, F, 2019) |
| "The treatment of spasticity and dystonia in these patients is difficult partly due to the relentless nature of this progressive disorder." | 1.48 | Intrathecal baclofen treatment an option in X-linked adrenoleukodystrophy. ( Ehrstedt, C; Hjartarson, HT; Tedroff, K, 2018) |
| " The Specialized Health Needs Interagency Collaboration (SHNIC) program at the Kennedy Krieger Institute has complied education and materials that explain the use of baclofen pumps in children with spasticity and the role of the school nurse in providing staff training, developing emergency care plans, and creating a safe school environment for children with special health needs." | 1.48 | Hidden Medical Devices in the School Setting: What the School Nurse Needs to Know About the Safe Use of Baclofen Pumps. ( Obst, B; Roesler, M, 2018) |
| "Melatonin is an effective treatment in MS patients and experimental autoimmune encephalomyelitis (EAE), a mouse model of MS." | 1.48 | Spasticity Treatment Ameliorates the Efficacy of Melatonin Therapy in Experimental Autoimmune Encephalomyelitis (EAE) Mouse Model of Multiple Sclerosis. ( Farhadi, N; Ghareghani, M; Sadeghi, H; Zibara, K, 2018) |
| "Patients with a spinal origin of spasticity, a lower modified Rankin Scale and a higher Barthel Index have a higher risk to sustain a complication." | 1.48 | Eleven years' experience with Intrathecal Baclofen - Complications, risk factors. ( Fava, E; Fritz, J; Hitzenberger, G; Laimer, I; Matzak, H; Pucks-Faes, E; Saltuari, L; Verrienti, G, 2018) |
| "To indicate the appropriate baclofen dosage to control severe spasticity of spinal origin and to develop the optimal administration protocol for long-term intrathecal baclofen (ITB) therapy." | 1.48 | The dosage and administration of long-term intrathecal baclofen therapy for severe spasticity of spinal origin. ( Hayashi, T; Kawano, O; Maeda, T; Masuda, M; Morishita, Y; Sakai, H; Takao, T; Ueta, T, 2018) |
| "Patient characteristics, spasticity scores pre/post intrathecal baclofen test dose, and IDDS perioperative implantation records were collected." | 1.48 | Title: Quantifying the change of spasticity after intrathecal baclofen administration: A descriptive retrospective analysis. ( Beck, LA; Bendel, MA; Hoelzer, BC; Lueders, DR; Pingree, MJ; Pittelkow, TP, 2018) |
| "Diazepam 20 mg was used up to three times per day, but didn't seem to improve or reduce the anxiety, agitation, visual or auditory hallucinations." | 1.48 | Delirium tremens in an AUD patient after an intrathecal baclofen pump induced total alcohol abstinence. ( Calvo, ME; Gunnarsson, T; Hao, M; Smith, L, 2018) |
| "Baclofene is a good tool to guarantee patients independence and pain control." | 1.48 | The use ultrasound guided for refilling intrathecal baclofene pump in complicated clinical cases: A practical approach. ( Caruso, P; Manganotti, P; Mazzon, G; Sarra, VM; Tacconi, L, 2018) |
| "Children with cerebral palsy experience spasticity that can be debilitating and cause significant pain and contractures." | 1.46 | Nurse Practitioner Lead Pediatric Baclofen Pump Program: Impact on Safety and Quality of Care. ( Buxton, K; Morgan, A; Rogers, J, 2017) |
| "Change of spasticity was evaluated using the Modified Ashworth Scale." | 1.46 | Outcomes of intrathecal baclofen therapy in patients with cerebral palsy and acquired brain injury. ( Chae, M; Chang, JW; Chang, WS; Cho, HE; Cho, SR; Lee, KC; Yoon, YK, 2017) |
| " Although literature exists regarding the efficacy of ITB, there has been minimal investigation related to dosing in the adult-acquired brain injury population, particularly at long-term duration." | 1.46 | Long-Term Dosing of Intrathecal Baclofen in the Treatment of Spasticity After Acquired Brain Injury. ( Maneyapanda, MB; Marciniak, C; McCormick, ZL; Reger, C, 2017) |
| "Patient 1 was a woman in her 30s with spastic quadriplegia due to subarachnoid hemorrhage." | 1.46 | [Utility of Intraoperative Catheter Myelography during Intrathecal Baclofen Pump Implantation:Report of 2 Cases]. ( Hamauchi, S; Houkin, K; Kano, T; Sasaki, H; Sasamori, T; Seki, T; Takamiya, S; Yabe, I, 2017) |
| "The current treatment of spasticity in patients with Sjögren-Larsson syndrome is largely symptomatic, given that no effective causal therapy treatments are available." | 1.46 | Intrathecal Baclofen Therapy for the Treatment of Spasticity in Sjögren-Larsson Syndrome. ( Harter, DH; Hersh, A; Hidalgo, ET; Orillac, C; Rizzo, WB; Weiner, HL, 2017) |
| " Following botulinum toxin A treatment, clinical improvement led to the gradual reduction of baclofen or tizanidine dosing to one-third of the former dose." | 1.43 | Comparison of Efficacy and Side Effects of Oral Baclofen Versus Tizanidine Therapy with Adjuvant Botulinum Toxin Type A in Children With Cerebral Palsy and Spastic Equinus Foot Deformity. ( Aksoy, SN; Dai, AI; Demiryürek, AT, 2016) |
| "To examine dosing patterns in patients receiving baclofen via intrathecal baclofen pumps to assess for common patterns by diagnosis, ambulation ability, and affected limbs distribution." | 1.43 | Intrathecal Baclofen Dosing Regimens: A Retrospective Chart Review. ( Clearfield, JS; McGuire, J; Nelson, ME; Rein, LE; Tarima, S, 2016) |
| "Significant spasticity would usually be considered a contraindication for deep brain stimulation (DBS) and more suitably treated with intrathecal baclofen (ITB)." | 1.43 | Fractional anisotropy in children with dystonia or spasticity correlates with the selection for DBS or ITB movement disorder surgery. ( Ashkan, K; Ashmore, J; Ball, G; Charles-Edwards, G; Lin, JP; Lumsden, DE; Selway, R, 2016) |
| " Data studied included baseline demographic and injury variables, implantation data, spasticity and function, ITB dosage over time and complications." | 1.43 | Treatment of severe, disabling spasticity with continuous intrathecal baclofen therapy following acquired brain injury: the experience of a tertiary institution in Singapore. ( Chua, KS; King, NK; Law, JH; Ng, WH; Rajeswaran, DK; Rao, JP; Soh, S; Wang, ZM, 2016) |
| "Twelve patients with severe spasticity received four different bolus doses of ITB (0, 25, 50, 75 μg and an optional dose of 100 μg), administered via a catheter with the tip at thoracic level (Th) 10." | 1.43 | A pharmacokinetic-pharmacodynamic model for intrathecal baclofen in patients with severe spasticity. ( Heetla, HW; Molmans, BH; Proost, JH; Staal, MJ; van Laar, T, 2016) |
| "Baclofen is a commonly used medication to treat spasticity in neurologic disorders." | 1.43 | Psychosis Following an Increase in Intrathecal Baclofen. ( Brkic, N; Driver, SP; Lloyd, R; Maneyapanda, MB; Ripley, DL, 2016) |
| "The results suggest that spasticity patients receiving ITB would expect to experience a reduction in cumulative future medical costs relative to anticipated costs in the absence of a pump implant." | 1.42 | Medical cost impact of intrathecal baclofen therapy for severe spasticity. ( Guillemette, S; Hinnenthal, J; Leier, J; Saulino, M, 2015) |
| "Unexpectedly, one emerged from the minimally conscious state and the other from post-traumatic amnesia." | 1.42 | Influence of intrathecal baclofen on the level of consciousness and mental functions after extremely severe traumatic brain injury: brief report. ( Al-Khodairy, AT; Nicolo, D; Vuadens, P; Wicky, G, 2015) |
| "Intrathecal antispastic drug perfusion was used in 123 patients (84." | 1.42 | Infectious Complications of Intrathecal Drug Administration Systems for Spasticity and Chronic Pain: 145 Patients From a Tertiary Care Center. ( Barbosa, P; Gomes, A; Malheiro, L; Santos, L; Sarmento, A, 2015) |
| "The baclofen pump was then removed." | 1.42 | [Complete remission of consciousness disturbances and spasticity due to a severe subarachnoid hemorrhage after intrathecal baclofen therapy: a case report]. ( Asahi, T; Kashiwazaki, D; Koh, M; Kuroda, S; Matsumura, N, 2015) |
| "Fifty-seven patients with refractory spasticity who underwent a continuous ITB trial during the years 2006-2012." | 1.42 | Clinical Experience With Continuous Intrathecal Baclofen Trials Prior to Pump Implantation. ( Buhari, AM; Horton, J; Miljkovic, N; Moossy, JJ; Munin, MC; Phillips, MM; Ramos-Lamboy, M, 2015) |
| "Baclofen is a centrally acting gamma-aminobutyric acid agonist used for the symptomatic relief of skeletal muscle spasm and spasticity in traumatic spinal cord lesions, multiple sclerosis, cerebral palsy, and stroke." | 1.42 | Encephalopathy and hypotonia due to baclofen toxicity in a patient with end-stage renal disease. ( Ijaz, M; Kashif, M; Marquez, JG; Tariq, H, 2015) |
| "For spinal spasticity, they are typically in the order of 100-300 μg/day." | 1.42 | Intrathecal Baclofen therapy in Germany: Proceedings of the IAB-Interdisciplinary Working Group for Movement Disorders Consensus Meeting. ( Berweck, S; Chatzikalfas, A; Dressler, D; Ebke, M; Frank, B; Hesse, S; Huber, M; Krauss, JK; Mücke, KH; Nolte, A; Oelmann, HD; Pickenbrock, H; Saberi, FA; Schmutzler, M; Schönle, PW; Van der Ven, C; Veelken, N; Vogel, M; Vogt, T, 2015) |
| "Cross-sectional data on spasticity severity (using a Numerical Rating Scale, NRS), resource use and HRQoL (using EQ-5D) were collected using a patient questionnaire and chart review." | 1.40 | Costs and quality of life in multiple sclerosis patients with spasticity. ( Borg, S; Nilsson, P; Svensson, J, 2014) |
| "05), while baclofen dosage increased (p = 0." | 1.40 | Intrathecal baclofen therapy in children with severe spasticity: Outcome and complications. ( Altermatt, S; Furrer, C; Meyer-Heim, A; Walter, M, 2014) |
| "Adult patients with spasticity treated with ITB for at least 10 years." | 1.40 | Long-term intrathecal baclofen: outcomes after more than 10 years of treatment. ( Chang Chien, GC; Chu, SK; Marciniak, CM; Mathur, SN; McCormick, Z, 2014) |
| "To assess the frequency and types of adverse events (AEs) related to intrathecal baclofen (ITB) therapy in adults, and associated risk factors." | 1.40 | Occurrence of adverse events in long-term intrathecal baclofen infusion: a 1-year follow-up study of 158 adults. ( Bensmail, D; Borrini, L; Hugeron, C; Jourdan, C; Rech, C; Thiebaut, JB, 2014) |
| "0001) and a correlation between ITB dosage and IIEF scores (ρ = -0." | 1.40 | Sexual dysfunction induced by intrathecal baclofen administration: is this the price to pay for severe spasticity management? ( Bramanti, P; Calabrò, RS; D'Aleo, G; De Cola, MC; Leo, A; Sessa, E, 2014) |
| "Those with a history of prior surgical site infection, chronic systemic infections or osteomyelitis were excluded." | 1.40 | Efficacy of intraoperative vancomycin powder use in intrathecal baclofen pump implantation procedures: single institutional series in a high risk population. ( Ghobrial, GM; Harrop, JS; Jallo, J; Maulucci, CM; Oppenlander, ME; Prasad, S; Saulino, M; Sharan, AD; Singhal, S; Thakkar, V, 2014) |
| "Fewer than 5% of subjects changed oral spasticity medications." | 1.39 | Adherence associated with oral medications in the treatment of spasticity. ( Gillard, P; Graham, GD; Halpern, R; Varon, SF; Zorowitz, RD, 2013) |
| "Reduction of spasticity and spasms frequency were measured 3 months after patients received the implant and at the 1-year follow-up." | 1.39 | Timing of intrathecal baclofen therapy in persons with acquired brain injury: influence on outcome. ( Bordi, L; Calandriello, B; Galli, R; Iardella, L; Logi, F; Posteraro, F, 2013) |
| "In addition to spasticity, TBI patients exhibit enduring cognitive, balance, and other motor impairments." | 1.39 | Effects of acute intrathecal baclofen in an animal model of TBI-induced spasticity, cognitive, and balance disabilities. ( Bose, P; Hou, J; Keener, J; Nelson, R; Nissim, N; Parmer, R; Thompson, FJ; Wacnik, PW, 2013) |
| "These patients suffered from spasticity due to many different diseases." | 1.38 | Intrathecal baclofen therapy for severe spasticity: analysis on a series of 112 consecutive patients and future prospectives. ( Mirone, G; Moraci, A; Natale, M; Rotondo, M, 2012) |
| "37 non ambulant children with severe spasticity were assessed just before implantation of a pump for ITB, and 9 and 18 months afterwards." | 1.38 | Goals and outcomes for non ambulant children receiving continuous infusion of intrathecal baclofen. ( Brimlow, K; Gray, N; Keetley, R; Morton, RE; Vloeberghs, M, 2012) |
| "Our experience shows that low cervical catheter insertion for administration of a test dose of intrathecal baclofen and feasible and safe to perform via the method described." | 1.38 | Cervical catheter placement for intrathecal baclofen test dose: is it safe? ( Ingale, H; Muquit, S; Ughratdar, I; Vloeberghs, M, 2012) |
| "Four children had untreated scoliosis and corrective surgery was being contemplated." | 1.38 | Cervical implantation of intrathecal baclofen pump catheter in children with severe scoliosis. ( Ammar, A; Ingale, H; Moussa, A; Muquit, S; Ughratdar, I; Vloeberghs, M, 2012) |
| " The severity of spasticity as a consequence of brain injury can change during years and it is necessery to follow it with dosage and dynamics of baclofen therapy." | 1.38 | [Results of intrathecal baclofen therapy on spasticity in patients with brain injury]. ( Both, B; Dénes, Z; Klauber, A; Lóránd, E, 2012) |
| "Spasticity is the major etiology for hip dislocation in nonambulatory cerebral palsy patients." | 1.38 | A comparison of hip dislocation rates and hip containment procedures after selective dorsal rhizotomy versus intrathecal baclofen pump insertion in nonambulatory cerebral palsy patients. ( Ayyangar, RN; Caird, MS; Craig, CL; Farley, FA; Hensinger, RN; Hurvitz, EA; Nowicki, P; Silva, S; Vanderhave, KL, 2012) |
| "Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a neurodegenerative disorder characterized by late-infantile onset spastic ataxia and other neurological features." | 1.37 | Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS): typical clinical and neuroimaging features in a Brazilian family. ( Abdala, N; Abdalla, C; Abrahão, A; Barsottini, OG; Braga-Neto, P; Pedroso, JL; Rivero, RL, 2011) |
| "In one patient, the BS along with spastic signs disappeared after intrathecal injection of Baclofen." | 1.36 | The occurrence of the Babinski sign in complete spinal cord injury. ( Dietz, V; Petersen, JA; Schubert, M, 2010) |
| "There are few reports of spasticity treatment for people with ID, and none of functionally meaningful outcomes." | 1.36 | Spasticity treatment facilitates direct care delivery for adults with profound intellectual disability. ( Ayers, GD; Blair, CR; Charles, PD; Gill, CE; Konrad, PE; Putman, MS; Roberts, AG; Taylor, HM, 2010) |
| "Parameters evaluated included daily dosage of medication required, flex vs simple continuous delivery modes, dosing changes, need for other local spasticity treatment, and catheter complications." | 1.36 | Intrathecal baclofen for spasticity management: a comparative analysis of spasticity of spinal vs cortical origin. ( Chiodo, AE; Saval, A, 2010) |
| "A 12-year-old girl suffering from spastic diplegia was implanted with a Medtronic SynchroMed II pump (Medtronic Inc." | 1.36 | Malfunction of SynchroMed II baclofen pump delivers a near-lethal baclofen overdose. ( Charalambides, C; Kostopanagiotou, G; Matsota, P; Sgouros, S; Tsangaris, I, 2010) |
| "During an outcomes study of spasticity treatment at a developmental center for 62 residents with profound intellectual disabilities, either botulinum toxin A (BTX-A), intrathecal baclofen (ITB), or both were recommended with physical and occupational therapy." | 1.36 | Discordance in informed consent response on the basis of demographic factors: brief report. ( Charles, PD; Gill, CE; Harrison, CH; Nunez-Wallace, KR; Taylor, HM, 2010) |
| "Improvement was noted not only in spasticity, but also in pain, management of sleep disturbance, activities of daily living, indoor and outdoor mobility and behavior." | 1.36 | Continual infusion of intrathecal baclofen (ITB): long-term effect on spasticity. ( Abdulsalam, J; Al Khudhairi, D; Aldin, AS; Hamdan, Y; Matthana, MH; Pazdirek, J; Rababah, A, 2010) |
| " Dosing adjustments need to be considered in these patients." | 1.35 | Sexual dysfunction associated with intrathecal baclofen use: a report of two cases. ( Chiodo, AE; Saval, A, 2008) |
| " There are few published guidelines for dosing efficacy and no studies looking at the effect of concentration of ITB on spasticity management." | 1.35 | Effect of intrathecal baclofen concentration on spasticity control: case series. ( Chiodo, AE; Saval, A, 2008) |
| "After surgery, the patients spasticity improved and, 1 year later, he has experienced no further complications during follow-up, requiring an average baclofen dose of 150 microg/day." | 1.35 | Catheter migration after implantation of an intrathecal baclofen infusion pump for severe spasticity: a case report. ( Chan, JY; Chen, MH; Huang, JS; Li, TC; Liu, YK, 2008) |
| "An 11-year-old boy with spasticity and apallic syndrome needed general anesthesia for exchange of a baclofen pump but 2 h later he became increasingly hypothermic, hypotonic with bradycardy and dyspnea." | 1.35 | [Intrathecal baclofen therapy. Overdose during replacement of a medication pump]. ( Koulousakis, A; Kramer, K; Krep, H; Lier, H; Weber, M, 2009) |
| "Patients with spastic quadriplegia secondary to cerebral palsy manifest with severe spasticity and often with neuromuscular scoliosis." | 1.35 | Concomitant correction of spinal deformity and spasticity management with posterior instrumentation and baclofen pump implantation. ( Cabrera, MN; Lai, LP; Shilt, JS; Snow, SB, 2009) |
| "Neurosurgical treatments for spasticity in children include the traditional selective dorsal rhizotomy (SDR) and intrathecal baclofen pumps (ITBPs), which have been widely used in the past decade as an attractive alternative." | 1.35 | Surgical treatment of spasticity in children: comparison of selective dorsal rhizotomy and intrathecal baclofen pump implantation. ( Amini, A; Gooch, J; Grams, B; Kan, P; Kestle, J; Oberg, W; Ploeger, D; Simonsen, S; Walker, M, 2008) |
| "Although spasticity is a common symptom in children with cerebral palsy, weakness may be a much greater contributor to disability." | 1.35 | Oral baclofen increases maximal voluntary neuromuscular activation of ankle plantar flexors in children with spasticity due to cerebral palsy. ( Kukke, S; McGill, K; Rose, J; Sanger, TD; Sherman-Levine, S; van Doornik, J, 2008) |
| " The electronic programmable type has the advantage of flexibility of dosing and frequent change of doses for fine-tuning the patient's optimal dose." | 1.34 | Intrathecal baclofen therapy: indications, pharmacology, surgical implant, and efficacy. ( Ethans, K, 2007) |
| "In children, spasticity is commonly seen in the context of cerebral palsy (CP), but also following head injury, cerebral infarct or other brain insults." | 1.34 | Surgical management of spasticity of cerebral origin in children. ( Sgouros, S, 2007) |
| "An 11-year old girl suffered a diffuse axonal injury after car accident." | 1.34 | [Sudden improvement of all neurological functions after general anesthesia and two-day intrathecal infusion of baclofen in a child with primary brain-stem injury]. ( Grzegorzewski, P; Kawecki, Z; Kwiatkowski, S; Szlachta Jezioro, I, 2007) |
| "Treatment of spasticity with intrathecal baclofen pump implantation is a chance for clinical improvement in patients with severe spasticity." | 1.34 | [The parents expectations after baclofen pump implantation in child with severe spasticity in physical rehabilitation and psychological aspects]. ( Fafara, A; Grzegorzewski, P; Kawecka, J; Kawecki, Z; Kwiatkowski, S, 2007) |
| "Reduction of spasticity and spasms achieved with intrathecally delivered baclofen, leads to functional improvement and pain relief." | 1.33 | Functional outcome of intrathecal baclofen administration for severe spasticity. ( Boviatsis, EJ; Korfias, S; Kouyialis, AT; Sakas, DE, 2005) |
| "The baclofen pump has been utilized in children with refractory spasticity." | 1.33 | Placement of baclofen pumps through the foramen magnum and upper cervical spine. ( Dziurzynski, K; Iskandar, BJ; Mcleish, D; Ward, M, 2006) |
| "In ambulatory patients with spasticity, it is possible that ITB treatment may compromise ambulatory function by unmasking underlying muscle weakness." | 1.33 | Long-term intrathecal baclofen therapy in ambulatory patients with spasticity. ( Sadiq, SA; Wang, GC, 2006) |
| "Muscle spasticity may adversely affect pulmonary function after spinal cord injury (SCI)." | 1.33 | Baclofen pump intervention for spasticity affecting pulmonary function. ( Britton, D; Esselman, P; Goldstein, B; Jones-Redmond, J, 2005) |
| "Successful treatment of severe spasticity represents an imperative of symptomatic therapy of multiple sclerosis (MS) due to a significant improvement of physical, psychic and social rehabilitation of MS patients, as well as a long-term cost savings for the additional treatments of conditions arising from uncontrolled severe spasticity." | 1.33 | [Treatment of severe spacticity in multiple sclerosis by continuous intrathecal baclofen]. ( Antić, B; Arsić, S; Dincić, E; Obradović, D; Perić, P, 2006) |
| " Key recommendations were made in areas including team coordination, patient selection and goals, patient education, patient screening, implant technique, long-term management, individualized dosing options, ongoing evaluation of patient response, appraisal of the integrity of the catheter and infusion system, and appropriate practice resources." | 1.33 | Intrathecal baclofen therapy: ten steps toward best practice. ( Rawlins, PK; Ridley, B, 2006) |
| "baclofen treatment also decreased, where after 5 days of baclofen infusion 1." | 1.33 | Development of baclofen tolerance in a rat model of chronic spasticity and rigidity. ( Fuchigami, T; Hefferan, MP; Marsala, M, 2006) |
| "Transient spinal cord ischemia may lead to a progressive degeneration of spinal interneurons and subsequently to increased hind limb motor tone." | 1.33 | Development of GABA-sensitive spasticity and rigidity in rats after transient spinal cord ischemia: a qualitative and quantitative electrophysiological and histopathological study. ( Galik, J; Hefferan, MP; Kakinohana, M; Kakinohana, O; Marsala, J; Marsala, M; Nakamura, S; Tomori, Z; Yaksh, TL, 2006) |
| "A 33-year-old man with refractory spasticity due to diffuse white matter injury was admitted for ITB treatment." | 1.33 | Intrathecal baclofen toxicity and deep coma in minutes. ( Hanci, L; Hanci, M; Hanimoglu, H; Tanriverdi, T; Tunali, Y, 2006) |
| "In both groups, lower extremity spasticity was significantly reduced." | 1.33 | Cervical catheter tip placement for intrathecal baclofen administration. ( MacDonald, JD; McCall, TD, 2006) |
| "We assessed spasticity and obtained polysomnography, pulmonary function tests, and resting energy expenditure measurements 1 week before and at least 8 days after pump implantation." | 1.33 | Effect of intrathecal baclofen on sleep and respiratory function in patients with spasticity. ( Bensmail, D; Benyahia, S; Bohic, M; Bussel, B; Denys, P; Lofaso, F; Quera Salva, MA; Roche, N, 2006) |
| "The clinical evaluation of a spastic patient is score according to varius internationally approved evaluation scales (Ashworth scale, muscle spasms scale, and FIM disability scale)." | 1.33 | The guidelines for the diagnosis and treatment of spasticity. ( Broggi, G; Dones, I; Nazzi, V, 2006) |
| " Secondary objectives included determining correlations between dosage and age, injury type, location of spasticity, comorbid seizures, or concomitant antispasticity medications." | 1.33 | Oral baclofen and clonidine for treatment of spasticity in children. ( Haase, M; Habersang, R; Lubsch, L; Luedtke, S, 2006) |
| " This method reduces side effects due to a reduction in dosage compared to oral administration." | 1.33 | Paralytic ileus: a complication after intrathecal baclofen therapy. ( Boyer, J; Chirivella, J; Escamilla, B; Ferri, J; Morant, A; Noé, E; Trénor, C, 2006) |
| "Patients that were receiving anti-spasticity medications (e." | 1.32 | Windup of flexion reflexes in chronic human spinal cord injury: a marker for neuronal plateau potentials? ( Benz, EN; Hornby, TG; Rymer, WZ; Schmit, BD, 2003) |
| "Individuals with spasticity were found to have significantly higher levels of disability than those who had no spasticity or clinically insignificant spasticity." | 1.32 | Spasticity in multiple sclerosis. ( Barnes, MP; Kent, RM; McMullen, KM; Semlyen, JK, 2003) |
| "We present a SCI patient, in whom bladder calculi acted as red herring for increased spasticity whereas the real cause was spontaneous extrusion of catheter from intrathecal space." | 1.32 | Bladder stones - red herring for resurgence of spasticity in a spinal cord injury patient with implantation of Medtronic Synchromed pump for intrathecal delivery of baclofen - a case report. ( Hughes, PL; Oo, T; Sett, P; Singh, G; Soni, BM; Vaidyanathan, S; Watt, JW, 2003) |
| "Thirty children with spasticity of cerebral origin receiving ITB therapy." | 1.32 | Oral motor, communication, and nutritional status of children during intrathecal baclofen therapy: a descriptive pilot study. ( Bader, KA; Bjornson, KF; Desmond, SA; Loeser, JD; McLaughlin, JF; Nowak-Cooperman, KM; Russel, M, 2003) |
| "Baclofen (Lioresal) is a drug of choice to treat spasticity and is increasingly being administered intrathecally via an implantable pump in cases refractory to oral therapy." | 1.32 | Intrathecal baclofen withdrawal mimicking sepsis. ( Amin, Y; Kao, LW; Kirk, MA; Turner, MS, 2003) |
| "The history of neurosurgery for spasticity is strongly linked to the beginning of neurosurgery." | 1.32 | [History of neurosurgical treatment of spasticity]. ( Sindou, M, 2003) |
| "Rett syndrome is a neurodevelopmental disorder primarily affecting girls and women." | 1.32 | Intrathecal baclofen for spasticity management in Rett syndrome. ( Clairmont, AC; George, RJ; Johnson, EW; Kadyan, V, 2003) |
| "During 32 months of follow-up, his spasticity has been under excellent control on 55-157 microg baclofen per day." | 1.32 | Spasticity in a child with myelomeningocele treated with continuous intrathecal baclofen. ( Bergenheim, AT; Larsson, E; Shahidi, S; Wendelius, M, 2003) |
| "To report treatment of spasticity in a spinal cord-injured person with intrathecal morphine after the person developed tolerance to intrathecal baclofen." | 1.32 | Treatment of spasticity in a spinal cord-injured patient with intrathecal morphine due to intrathecal baclofen tolerance--a case report and review of literature. ( Mani, RM; Oo, T; Soni, BM; Vaidyanathan, S, 2003) |
| "Baclofen inhibits spasticity by blocking excitatory neurotransmitters in the spinal dorsal horn." | 1.32 | Implantable baclofen pump as an adjuvant in treatment of pressure sores. ( Davison, S; Heckler, F; Kim, S; Mess, SA, 2003) |
| "To ascertain the prevalence of spasticity among adults living in a developmental center and to document the development of spasticity treatment plans for this population." | 1.32 | Spasticity in adults living in a developmental center. ( Charles, PD; Damian, MM; Noel-Spaudling, S; Pfister, AA; Roberts, AG; Taylor, HM, 2003) |
| "Severe hamstring spasticity was encountered in both patients in the immediate post-operative period requiring further surgery." | 1.32 | Total knee replacement in patients with multiple sclerosis. ( Cogley, D; Glynn, M; Shannon, FJ, 2004) |
| "Severe withdrawal symptoms can result, however, if ITB is abruptly withdrawn as a result of equipment malfunctions or human error." | 1.32 | Intrathecal baclofen withdrawal syndrome caused by low residual volume in the pump reservoir: a report of 2 cases. ( Cordioli, Z; Rigoli, G; Terrini, G, 2004) |
| " The average dosage for the total group was 463 micrograms per day (microg/day), and 32% used a simple infusion mode." | 1.32 | Intrathecal baclofen therapy over 10 years. ( Rawlins, PK, 2004) |
| "Twelve patients with intractable spasticity caused by spinal cord injuries underwent implantation of a programmable continuous infusion pump after significant reduction in spasticity following an intrathecal test bolus of baclofen." | 1.31 | Continuous intrathecal infusion of baclofen in patients with spasticity caused by spinal cord injuries. ( Darwish, N; Gaab, MR; Glaeser, E; Korenkov, AI; Niendorf, WR, 2002) |
| "The present study shows that the antispastic effect of intrathecally administered BBT can be quantitatively assessed and visualised using the described method." | 1.31 | Measurement of the effect of a bolus dose of intrathecal baclofen by continuous measurement of force under fibreglass casts. ( Mehrholz, J; Mrass, G; Pause, M; Pohl, M; Rockstroh, G; Rückriem, S, 2002) |
| " During 80 recipient-years of pump operation, 153 treatment-associated adverse events occurred: 27 of these were device-related." | 1.31 | Long-term safety and efficacy of continuous intrathecal baclofen. ( Bjornson, K; Campbell, WM; Ferrel, A; Grant, GA; Graubert, C; Loeser, JD; McLaughlin, JF, 2002) |
| "To quantitatively assess the antispastic effect of intrathecally administered baclofen on muscle stiffness in spastic patients." | 1.31 | Quantitative assessment of intrathecally administered baclofen in spasticity. ( Detrembleur, C; Plaghki, L, 2000) |
| "Especially patients with spinal spasticity due to traumatic spinal cord injury or transverse myelitis showed a dramatic reduction of spasticity and improvement of their Ashworth scores." | 1.31 | [Optimized therapy of spastic syndrome by combination intrathecal baclofen with botulinum toxin]. ( Urban, PP; Vogt, T, 2000) |
| "Three patients with intractable spasticity were treated with intrathecal baclofen." | 1.31 | Dysesthesia perceived as painful spasticity: A report of 3 cases. ( Adamski, E; Fischer, E; Ordia, JI; Spatz, EL, 2001) |
| "A well known drug in the treatment of spasticity is the GABA(B) agonist Baclofen." | 1.31 | Baclofen inhibits ANP-mediated cyclic GMP synthesis in the rat cervical spinal cord. ( de Louw, AJ; de Vente, J; Steinbusch, HP; Steinbusch, HW; Troost, J; Vles, JS, 2002) |
| "Twelve consecutive patients with severe spasticity and hypertonia following acquired brain injury were treated with continuous intrathecal infusion of baclofen via an implanted, programmable infusion pump-catheter system for a minimum of 3 months." | 1.30 | Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report. ( Hadley, MN; McCary, A; Meythaler, JM, 1997) |
| "Severe, uncontrolled spasticity resulting from spinal cord injury (SCI) and multiple sclerosis (MS) can have a profound effect on the patient's ability to function and thus, their quality of life." | 1.30 | Quality of life: effect of reduced spasticity from intrathecal baclofen. ( Gianino, JM; Paice, JA; Shott, S; York, MM, 1998) |
| "35 patients with severe spasticity, 29 of spinal origin and six of supraspinal origin resistant to conservative treatment, had a programmable pump (Synchromed, Medtronic) for continuous intrathecal baclofen infusion implanted." | 1.30 | [Continuous intrathecal infusion of baclofen. A new therapeutic method for spasticity]. ( Berg-Johnsen, J; Lundar, T; Røste, GK; Solgaard, T, 1998) |
| " At 3, 6, and 12 months, our mean baclofen dosage remained below the dosages administered at the T11-T12 level." | 1.30 | Midthoracic catheter tip placement for intrathecal baclofen administration in children with quadriparetic spasticity. ( Grabb, PA; Guin-Renfroe, S; Meythaler, JM, 1999) |
| " The following were taken as evaluation criteria: age, sex, performance status, duration and dosage of previous systemic and current spinal morphine therapy, concomitant analgesic and co-analgesic medication, pretreatment of the dorsal column and neurological dysfunction due to damage either of the nerval plexus or of the medulla spinalis." | 1.29 | Complications of spinal opioid therapy: myoclonus, spastic muscle tone and spinal jerking. ( Bingel, U; Kloke, M; Seeber, S, 1994) |
| "Intrathecal baclofen abolishes spasticity in many patients with neurological diseases but there are few studies on its long-term effectiveness." | 1.29 | Management of severe spasticity with intrathecal baclofen delivered by a manually operated pump. ( Byrnes, D; Crowe, D; Lee, A; Patterson, V; Watt, M, 1994) |
| " We describe a 39-year-old quadriplegic women who, over a 16-week period, developed clinical signs of baclofen toxicity confirmed by progressively rising serum baclofen levels while on a conventional stable dosing regimen." | 1.29 | Baclofen toxicity in a patient with subclinical renal insufficiency. ( Aisen, ML; Dietz, M; Kutt, H; McDowell, F, 1994) |
| " Our data show that there was a significant increase in baclofen dosage needed to control spasticity during the first 12 months post implantation." | 1.29 | Intrathecal baclofen: does tolerance occur? ( Akman, MN; Donovan, WH; Loubser, PG; O'Neill, ME; Rossi, CD, 1993) |
| "Case series evaluating spasticity using clinical scales commonly referenced in contemporary literature, including the Penn Spasm Frequency Scale, the Ashworth Scale, and standard scales of tendon taps, clonus, and plantar stimulation." | 1.29 | Clinical assessment of spasticity in spinal cord injury: a multidimensional problem. ( Kharas, NF; Markowski, J; Priebe, MM; Sherwood, AM; Thornby, JI, 1996) |
| "Clonidine was added to baclofen in the pump reservoir and both drugs were administered intrathecally in combination." | 1.29 | Intrathecal clonidine and baclofen in the management of spasticity and neuropathic pain following spinal cord injury: a case study. ( Middleton, JW; Molloy, AR; Rutkowski, SB; Siddall, PJ; Walker, S, 1996) |
| "Twelve patients with neurogenic bladder dysfunction were also evaluated by a clinically oriented questionnaire and by quantitative urodynamic recordings, before and after pump implantation." | 1.29 | Long-term clinical, electrophysiological and urodynamic effects of chronic intrathecal baclofen infusion for treatment of spinal spasticity. ( Benneton, C; Garcia-Larrea, L; Mertens, P; Millet, MF; Parise, M; Sindou, M, 1995) |
| "Oral baclofen improves cerebral spasticity mildly, but its activity is limited because of its poor lipid solubility." | 1.29 | Baclofen in the treatment of cerebral palsy. ( Albright, AL, 1996) |
| "When clonidine therapy was initiated, the patient responded rapidly with both subjective and objective improvements in her spasticity." | 1.28 | Clonidine in the treatment of brainstem spasticity. Case report. ( Sandford, PR; Sawasky, KB; Spengler, SE, 1992) |
| "These contractures were corrected sufficiently." | 1.28 | [Treatment concepts of tertiary damage of the locomotor system after craniocerebral trauma]. ( Frischhut, B; Saltuari, L, 1992) |
| "Two patients who had severe spinal spasticity with painful flexor spasms were treated with oral baclofen with relief of symptoms." | 1.28 | Pathophysiology and treatment of spasticity: report of two cases. ( Narayanaswamy, AS, 1992) |
| "On the spastic side a reflex with prolonged latencies and durations, as well as with decreased amplitudes and thresholds of both reflex responses was found." | 1.28 | Flexor reflex for assessment of common interneurone activity in spasticity. ( Milanov, IG, 1992) |
| "Thirty patients with old post-stroke spastic hemiparesis took part in the investigation." | 1.28 | Mechanisms of baclofen action on spasticity. ( Milanov, IG, 1992) |
| "Severe spasticity is a major problem in the rehabilitation of patients with dysfunction of the spinal cord or cerebral hemispheres." | 1.28 | Intrathecal baclofen for severe spasticity: five years experience. ( Buffery, S; Perlman, D; Silbert, PL; Stewart-Wynne, EG; Tan, E, 1991) |
| " Effective dosage was 60 +/- 31 micrograms in the entire group." | 1.28 | Intraspinal baclofen in the treatment of severe spasticity and spasms. ( Closa, C; Garcia-Fernandez, L; Guitart, JM; Jodar, R; Muxi, T; Noguer, M; Rubio, E; Sahuquillo, J, 1991) |
| " Even with a very small dosage of Baclofen patients who were previously treated until intoxication without success there was a favorable reduction in spasticity." | 1.28 | [Continuous intrathecal baclofen therapy using an implantable pump system in severe spasticity]. ( Behrens, C; Braunsdorf, WE; Kleiter, K; Kuhlendahl, HD; Volkheimer, A, 1990) |
| " The 18 patients selected for chronic administration were implanted with a programmable pump." | 1.28 | Chronic intrathecal baclofen administration for control of severe spasticity. ( Bastide, R; Carillo, JP; Lazorthes, Y; Sallerin-Caute, B; Verdie, JC, 1990) |
| "Baclofen was for the greater part excreted unchanged by the kidney, 65% (+/- 16)." | 1.28 | Pharmacokinetics of baclofen in spastic patients receiving multiple oral doses. ( Dirks, MJ; Van der Kleijn, E; Vree, TB; Wuis, EW, 1990) |
| "Baclofen was given intrathecally to six patients with severe lower limb spasticity due to traumatic spinal cord injury." | 1.28 | Intrathecal baclofen and the H-reflex. ( Grundy, D; Macdonell, RA; Swash, M; Talalla, A, 1989) |
| "Six patients with long-lasting spasticity resistant to different drug therapies including oral baclofen received a bolus injection of lumbar intrathecal baclofen." | 1.28 | Short-term effects of intrathecal baclofen in spasticity. ( Corcos, DM; Gottlieb, GL; Latash, ML; Penn, RD, 1989) |
| "We report on a group of patients with spasticity not relieved by these methods." | 1.28 | Functional outcome after delivery of intrathecal baclofen. ( Corcos, D; Parke, B; Penn, RD; Savoy, SM, 1989) |
| "The main indication was incapacitating spasticity resistant to oral treatment with baclofen and caused by spinal cord injury or lesion (11 patients), multiple sclerosis (11 patients), infantile cerebral palsy (3 patients) and cerebral injury, hypoxia or ischaemia (5 patients)." | 1.27 | Implanted pump systems for treatment of spasticity. ( Dralle, D; Müller, H; Wurdinger, T; Zierski, J, 1988) |
| "835 and a parallel shift of the probit-log dosage regression line to the right." | 1.27 | Delta-aminovaleric acid antagonizes the pharmacological actions of baclofen in the central nervous system. ( Klockgether, T; Schwarz, M; Sontag, KH; Turski, L; Wüllner, U, 1988) |
| "However, when the spasticity is severe, the systemic administration has to be increased, often without therapeutic effects but frequently with central side-effects." | 1.27 | Intrathecal application of baclofen in the treatment of spasticity. ( Rea, GL; Siegfried, J, 1987) |
| "We present the case of a spastic quadriplegic who developed mental symptoms which resolved when his Baclofen was discontinued." | 1.27 | Reversible electroencephalogram changes associated with administration of baclofen in a quadriplegic patient: case report. ( Lee, L; Riley, TL; Wainapel, SF, 1986) |
| "The baclofen doses were increased over the first few months but then were stabilized or only increased slightly, with the maximum dose being 650 micrograms/day." | 1.27 | Long-term intrathecal baclofen infusion for treatment of spasticity. ( Kroin, JS; Penn, RD, 1987) |
| "Fifty-one spastic patients, divided into four groups, were tested." | 1.27 | Electrophysiological analysis of the mode of action of muscle relaxants in spasticity. ( Delwaide, PJ, 1985) |
| "Baclofen was found to decrease the frequency of firing of tonic gamma motoneurones, and in some cells to inhibit the tonic discharge altogether." | 1.26 | The effects of baclofen on gamma motoneurones supplying gastrocnemius muscle in the rabbit. ( Harrison, FG, 1982) |
| "Twelve spastic patients received single oral doses of a new anti-spastic drug DS103-282 (Sandoz) 6 mg, baclofen 20 mg, and placebo on three separate days." | 1.26 | Double-blind comparison of single doses of DS103-282, baclofen and placebo for suppression of spasticity. ( Hassan, N; McLellan, DL, 1980) |
| "Motor point blocks may partially dampen spasticity in selected muscles of some patients." | 1.26 | Management of spasticity in spinal cord injury. ( Merritt, JL, 1981) |
| "Symptoms of a spastic paresis only develop later when the spinal interneurones are destroyed as a consequence of the lesion of the neuroglia." | 1.26 | Spastic paresis after 6-aminonicotinamide: metabolic disorders in the spinal cord and electromyographically recorded changes in the hind limbs of rats. ( Halbhübner, K; Herken, H; Loos, D; Meyer-Estorf, G, 1976) |
| "In mild spasticity stretch reflexes appear to be suppressed by voluntary effort whereas in severe spasticity they are enhanced." | 1.26 | C0-contraction and stretch reflexes in spasticity during treatment with baclofen. ( McLellan, DL, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 101 (12.44) | 18.7374 |
| 1990's | 135 (16.63) | 18.2507 |
| 2000's | 238 (29.31) | 29.6817 |
| 2010's | 234 (28.82) | 24.3611 |
| 2020's | 104 (12.81) | 2.80 |
| Authors | Studies |
|---|---|
| Takagi, Y | 2 |
| Yamada, H | 2 |
| Ebara, H | 2 |
| Hayashi, H | 2 |
| Kidani, S | 1 |
| Toyooka, K | 2 |
| Ishino, Y | 1 |
| Kitano, Y | 2 |
| Nakanami, A | 2 |
| Kagechika, K | 2 |
| Yahata, T | 2 |
| Tsuchiya, H | 2 |
| Roth, J | 2 |
| Agha, H | 1 |
| Davis, C | 2 |
| Biering-Soerensen, B | 1 |
| Stevenson, V | 2 |
| Bensmail, D | 7 |
| Grabljevec, K | 2 |
| Martínez Moreno, M | 1 |
| Pucks-Faes, E | 6 |
| Wissel, J | 3 |
| Zampolini, M | 3 |
| Biktimirov, A | 3 |
| Pak, O | 1 |
| Bryukhovetskiy, I | 3 |
| Sharma, A | 3 |
| Sharma, HS | 3 |
| Pointon, R | 1 |
| Whelan, H | 1 |
| Raza, R | 1 |
| Peacock, S | 1 |
| Wilsmore, C | 1 |
| Mulkeen, A | 1 |
| Goodden, J | 2 |
| Lodh, R | 3 |
| Marathe, A | 1 |
| Allahabadi, S | 1 |
| Abd-Elsayed, A | 1 |
| Saulino, M | 13 |
| Hagedorn, JM | 1 |
| Orhurhu, V | 1 |
| Karri, J | 2 |
| Mousigian, MA | 1 |
| Rosenblum, SA | 1 |
| Neil Knierbein, EE | 1 |
| Daunter, AK | 1 |
| Satoh, K | 1 |
| Hirasawa, N | 1 |
| Yoshida, K | 1 |
| Okuyama, M | 1 |
| Nakae, H | 1 |
| Bonouvrié, LA | 4 |
| Lagendijk, KE | 1 |
| Beckerman, H | 1 |
| Slot, KM | 1 |
| van de Pol, LA | 1 |
| Buizer, AI | 1 |
| Nuru, M | 1 |
| Maglinger, B | 1 |
| Vessell, M | 1 |
| Simon, JE | 1 |
| Daniels, MW | 1 |
| Anderson, D | 1 |
| Mutchnick, I | 2 |
| Wu, J | 1 |
| Ceverha, B | 1 |
| Yeh, BY | 1 |
| BeDell, KK | 1 |
| Kulkarni, VA | 1 |
| Kephart, DT | 1 |
| Ball, MA | 1 |
| Tumber, S | 1 |
| Davidson, LT | 1 |
| Davids, JR | 1 |
| Balaratnam, MS | 2 |
| Stevenson, VL | 7 |
| Halbmayer, LM | 2 |
| Kofler, M | 11 |
| Hitzenberger, G | 4 |
| Matzak, H | 4 |
| Fava, E | 3 |
| Genelin, E | 2 |
| Werkmann, M | 1 |
| Saltuari, L | 15 |
| Versace, V | 2 |
| Dobesberger, J | 1 |
| Qin, ES | 1 |
| Patel, H | 1 |
| Montagnino, J | 1 |
| Pham, K | 1 |
| Lam, NY | 1 |
| Dietz, N | 1 |
| Wagers, S | 1 |
| Harkema, SJ | 1 |
| D'Amico, JM | 1 |
| Kakodkar, P | 1 |
| Girgis, H | 1 |
| Nabhan, P | 1 |
| Chee, SS | 1 |
| Tu, A | 2 |
| Cinone, N | 1 |
| Santoro, L | 1 |
| Spina, S | 1 |
| Facciorusso, S | 1 |
| Battaglia, M | 1 |
| Baricich, A | 1 |
| Marcogiuseppe, P | 1 |
| Santamato, A | 2 |
| Gorgey, AS | 2 |
| Goldsmith, JA | 1 |
| Khalil, RE | 1 |
| Liu, XH | 1 |
| Pan, J | 1 |
| Cardozo, C | 1 |
| Adler, RA | 1 |
| Lee, HP | 1 |
| Win, T | 1 |
| Balakrishnan, S | 1 |
| Reyes, FI | 1 |
| Herge, WM | 1 |
| Cerza, SL | 1 |
| Savedra, A | 1 |
| Thompson, CE | 1 |
| Usami, K | 3 |
| Wilson, C | 2 |
| Linczer, J | 2 |
| Newman, S | 2 |
| Weyhenmeyer, J | 3 |
| Roper, A | 2 |
| Miller, J | 2 |
| Lee, A | 4 |
| Smith, KA | 1 |
| Piehl, F | 1 |
| Olsson, T | 1 |
| Alfredsson, L | 1 |
| Hillert, J | 1 |
| Kockum, I | 1 |
| Stridh, P | 1 |
| Montgomery, S | 1 |
| Ronchetti, AB | 1 |
| Bertamino, M | 1 |
| Tacchino, CM | 1 |
| Moretti, P | 1 |
| Pavanello, M | 1 |
| Asma, A | 2 |
| Ulusaloglu, AC | 2 |
| Howard, JJ | 3 |
| Rogers, KJ | 2 |
| McManus, M | 2 |
| Miller, F | 3 |
| Shrader, MW | 3 |
| Lumsden, DE | 4 |
| Gunnarsson, S | 3 |
| Lemming, D | 2 |
| Alehagen, S | 2 |
| Bergenheim, T | 1 |
| Gerdle, B | 1 |
| Samuelsson, K | 4 |
| Gormley, M | 2 |
| Bollo, RJ | 1 |
| Gross, PH | 1 |
| Rocque, BG | 1 |
| Browd, SR | 2 |
| Raskin, JS | 3 |
| Leonard, JR | 1 |
| Albarqawi, L | 1 |
| Bailes, AF | 1 |
| McLaughlin, MJ | 1 |
| Fisher, MT | 1 |
| Filipetto, F | 1 |
| Walden, J | 1 |
| Trbovich, M | 1 |
| Venkatraman, V | 1 |
| Spears, CA | 1 |
| Futch, BG | 1 |
| Yang, LZ | 1 |
| Parente, BA | 1 |
| Lee, HJ | 1 |
| Lad, SP | 2 |
| Guil-Ibáñez, JJ | 1 |
| Márquez-Rivas, J | 2 |
| De Rinaldis, M | 1 |
| Gallo, I | 1 |
| Oliva, MC | 1 |
| Trabacca, A | 1 |
| Brandenburg, JE | 2 |
| Srinivasan, R | 1 |
| Su Zhang, VR | 1 |
| Niu, F | 1 |
| Lee, EA | 1 |
| DiStasio, C | 1 |
| Broder, BI | 1 |
| Steinberg, SG | 1 |
| Hui, RL | 1 |
| Hwang, YJ | 1 |
| Chang, AR | 1 |
| Brotman, DJ | 1 |
| Inker, LA | 1 |
| Grams, ME | 1 |
| Shin, JI | 1 |
| Aldarwish, WA | 1 |
| Ali, EN | 1 |
| Cobourn, KD | 1 |
| Patel, N | 1 |
| Tsering, D | 1 |
| Jamshidi, AM | 1 |
| Abousy, M | 1 |
| Myseros, JS | 1 |
| Oluigbo, C | 1 |
| Magge, SN | 1 |
| Keating, RF | 2 |
| Belisle Haley, C | 1 |
| Agrawal, M | 1 |
| Newton, K | 1 |
| Yeung, B | 1 |
| Dayal, R | 1 |
| Rabatin, AE | 1 |
| Driscoll, SW | 1 |
| Fostier, M | 1 |
| Gustin, T | 1 |
| Deltombe, T | 1 |
| Shlobin, NA | 1 |
| Hofmann, K | 1 |
| Oluigbo, CO | 1 |
| Inatani, H | 1 |
| Mori, A | 1 |
| Dekopov, AV | 1 |
| Tomsky, AA | 1 |
| Isagulyan, ED | 1 |
| Chow, JW | 2 |
| Stokic, DS | 8 |
| Benedičič, M | 1 |
| Groleger Sršen, K | 1 |
| Majdič, N | 1 |
| Haber, B | 1 |
| Albright, AL | 16 |
| Strader, S | 1 |
| Assumpcao de Monaco, B | 1 |
| Fruett da Costa, PR | 1 |
| Franceschini, PR | 1 |
| Østlie, K | 1 |
| Simic, J | 1 |
| Rekand, T | 3 |
| Malalla, H | 1 |
| Gorman, KM | 1 |
| Hurth, H | 1 |
| Morgalla, M | 1 |
| Heinzel, J | 1 |
| Daigeler, A | 1 |
| Kolbenschlag, J | 1 |
| Schuhmann, M | 1 |
| Chan, J | 1 |
| Singh, H | 1 |
| Shem, K | 1 |
| Hagemann, C | 1 |
| Schmitt, I | 1 |
| Lischetzki, G | 1 |
| Kunkel, P | 1 |
| Vats, A | 1 |
| Amit, A | 1 |
| Cossar, M | 1 |
| Bhatt, P | 1 |
| Cozens, A | 1 |
| Delhaas, EM | 5 |
| Harhangi, BS | 1 |
| van Doormaal, PJ | 1 |
| Dinkelaar, W | 1 |
| van Es, ACGM | 1 |
| van Assema, DME | 1 |
| Frankema, SPG | 3 |
| van der Lugt, A | 1 |
| Huygen, FJPM | 3 |
| Goslinga-van der Gaag, SME | 1 |
| De Andrés, J | 1 |
| Rubio-Haro, R | 1 |
| De Andres-Serrano, C | 1 |
| Asensio-Samper, JM | 1 |
| Fabregat-Cid, G | 1 |
| Ubeda Tikkanen, A | 1 |
| Buxton, K | 3 |
| Ullrich, CK | 1 |
| Stone, SS | 1 |
| Nimec, DL | 1 |
| Comi, G | 2 |
| Solari, A | 1 |
| Leocani, L | 1 |
| Centonze, D | 1 |
| Otero-Romero, S | 2 |
| Panagopoulos, D | 1 |
| Apostolopoulou, K | 1 |
| Themistocleous, M | 4 |
| Thomas, SP | 1 |
| Addison, AP | 1 |
| Curry, DJ | 1 |
| Yoshizaki, S | 1 |
| Yokota, K | 1 |
| Kubota, K | 1 |
| Saito, T | 2 |
| Tanaka, M | 1 |
| Konno, DJ | 1 |
| Maeda, T | 2 |
| Matsumoto, Y | 1 |
| Nakashima, Y | 1 |
| Okada, S | 1 |
| Donnelly, A | 1 |
| Padilla, H | 3 |
| Simeoni, S | 1 |
| Bahadur, S | 1 |
| Keenan, L | 2 |
| Lee, H | 3 |
| Farrell, R | 3 |
| Curtis, C | 1 |
| Brownstone, RM | 1 |
| Murphy, M | 1 |
| Grieve, J | 1 |
| Shieff, C | 1 |
| Nayar, M | 1 |
| Pitceathly, RDS | 1 |
| Christofi, G | 1 |
| Reis, PV | 1 |
| Vieira, CR | 1 |
| Midões, AC | 1 |
| Rebelo, V | 1 |
| Barbosa, P | 2 |
| Gomes, A | 2 |
| Schiess, MC | 3 |
| Eldabe, S | 2 |
| Konrad, P | 2 |
| Molus, L | 1 |
| Spencer, R | 2 |
| Stromberg, K | 2 |
| Weaver, T | 1 |
| Plunkett, R | 2 |
| Yablon, SA | 8 |
| Skalsky, AJ | 2 |
| Dalal, P | 1 |
| Le, J | 1 |
| Ewing, E | 1 |
| Yaszay, B | 2 |
| Parker-Pitts, CK | 1 |
| Weymouth, CW | 1 |
| Frawley, MT | 1 |
| Iskra, DA | 1 |
| Kovalenko, AP | 1 |
| Koshkarev, MA | 1 |
| Frunza, DN | 1 |
| Lloreda Herradón, P | 1 |
| Blázquez Calvo, V | 1 |
| Miyagi Yonamine, M | 1 |
| Alonso Rodríguez, E | 1 |
| Abraham, M | 1 |
| Gold, J | 1 |
| Dweck, J | 1 |
| Ward, M | 2 |
| Gendreau, J | 1 |
| Panse, N | 1 |
| Holani, K | 1 |
| Gupta, P | 1 |
| Mammis, A | 1 |
| Saenz, A | 1 |
| Grijalba, M | 1 |
| Mengide, JP | 1 |
| Argañaraz, R | 1 |
| Ford, F | 1 |
| Mantese, B | 1 |
| Steinbok, P | 5 |
| Nardone, R | 1 |
| Sebastianelli, L | 1 |
| Brigo, F | 1 |
| Golaszewski, S | 1 |
| Trinka, E | 1 |
| Zhang, B | 1 |
| O'Brien, K | 1 |
| DiTommaso, C | 1 |
| Kothari, S | 2 |
| Li, S | 1 |
| Lemée, JM | 1 |
| Chinier, E | 1 |
| Bernard, F | 1 |
| Gallet, C | 1 |
| Menei, P | 4 |
| Tyack, L | 1 |
| Copeland, L | 1 |
| McCartney, L | 2 |
| Waugh, MC | 2 |
| Sammaraiee, Y | 2 |
| Keenan, E | 2 |
| Buchanan, K | 3 |
| Farrell, RA | 1 |
| Whelan, A | 1 |
| Patterson, E | 1 |
| Montgomery, K | 1 |
| McVeigh, S | 1 |
| Short, C | 1 |
| Zubair, AS | 1 |
| Raymond, M | 1 |
| Patwa, HS | 1 |
| Tabard-Fougère, A | 1 |
| Canavese, F | 1 |
| Steiger, CN | 1 |
| De Coulon, G | 1 |
| Štětkářová, I | 2 |
| Krámská, L | 1 |
| Keller, J | 1 |
| Koljonen, PA | 1 |
| Chan, SHS | 1 |
| Liu, T | 1 |
| Ho, ACC | 1 |
| Chim, S | 1 |
| Tsoi, NS | 1 |
| Wong, YW | 1 |
| de Sousa, N | 1 |
| Santos, D | 1 |
| Monteiro, S | 1 |
| Silva, N | 1 |
| Barreiro-Iglesias, A | 1 |
| Salgado, AJ | 1 |
| Summers, M | 1 |
| Doogan, C | 1 |
| Mulhert, N | 1 |
| Pearson, RP | 1 |
| Hoang, LK | 1 |
| Roufail, J | 1 |
| Muhonen, MG | 1 |
| Galion, AW | 1 |
| Khaliq, F | 1 |
| Santia, C | 1 |
| Erlandson, E | 1 |
| Gburek-Augustat, J | 1 |
| Krause, M | 1 |
| Bernhard, M | 1 |
| Sorge, I | 1 |
| Gräfe, D | 1 |
| Siekmeyer, M | 1 |
| Nestler, U | 1 |
| Merkenschlager, A | 1 |
| Amin, S | 2 |
| Ammar, A | 3 |
| Bellis, L | 1 |
| Brink, P | 1 |
| Calisto, A | 1 |
| Crimmins, D | 1 |
| Eunson, P | 3 |
| Forsyth, RJ | 1 |
| Kaminska, M | 1 |
| Kehoe, J | 1 |
| Kirkpatrick, M | 1 |
| Kumar, R | 3 |
| Leonard, J | 1 |
| Lording, A | 1 |
| Martin, K | 1 |
| Miller, R | 1 |
| Mordekar, SR | 2 |
| Pettorini, B | 1 |
| Smith, M | 2 |
| Smith, R | 1 |
| Sneade, C | 2 |
| Whitney, A | 1 |
| Vloeberghs, M | 8 |
| Zaki, H | 1 |
| Decramer, T | 2 |
| Theys, T | 4 |
| Feller, CN | 1 |
| Awad, AJ | 1 |
| Nelson, MES | 2 |
| Ketchum, N | 1 |
| Pahapill, PA | 1 |
| Jacobs, NW | 1 |
| Maas, EM | 1 |
| Brusse-Keizer, M | 1 |
| Rietman, HJS | 1 |
| Hägglund, G | 2 |
| Hollung, SJ | 2 |
| Ahonen, M | 1 |
| Andersen, GL | 2 |
| Eggertsdóttir, G | 1 |
| Gaston, MS | 1 |
| Jahnsen, R | 2 |
| Jeglinsky-Kankainen, I | 1 |
| Nordbye-Nielsen, K | 1 |
| Tresoldi, I | 1 |
| Alriksson-Schmidt, AI | 1 |
| Patel, A | 1 |
| Stegelmann, S | 1 |
| Ordaz, JD | 1 |
| Desai, V | 1 |
| Angulo-Parker, F | 1 |
| Cartwright, S | 1 |
| Fritsch, G | 1 |
| Flory, P | 1 |
| Coon, A | 1 |
| Johnson, SK | 1 |
| Delima, S | 1 |
| Schmitz, NS | 1 |
| Krach, LE | 3 |
| Coles, LD | 1 |
| Schrogie, J | 1 |
| Cloyd, JC | 1 |
| Kriel, RL | 1 |
| D'Ercole, M | 1 |
| Izzo, A | 1 |
| Fuggetta, F | 1 |
| Rapisarda, A | 1 |
| Burattini, B | 1 |
| Montano, N | 1 |
| Uchiyama, T | 2 |
| Takahashi, J | 1 |
| Heran, MKS | 1 |
| Al-Shikarchy, H | 1 |
| Chowne, C | 1 |
| De Tanti, A | 1 |
| Scarponi, F | 1 |
| Bertoni, M | 1 |
| Gasperini, G | 1 |
| Lanzillo, B | 1 |
| Molteni, F | 1 |
| Posteraro, F | 2 |
| Vitale, DF | 1 |
| Zanpolini, M | 1 |
| Stewart, K | 1 |
| Hutana, G | 1 |
| Kentish, M | 1 |
| Evans, SH | 1 |
| Cameron, MW | 1 |
| Burton, JM | 1 |
| Morgan, A | 1 |
| Rogers, J | 1 |
| Yoon, YK | 1 |
| Lee, KC | 1 |
| Cho, HE | 1 |
| Chae, M | 1 |
| Chang, JW | 1 |
| Chang, WS | 1 |
| Cho, SR | 1 |
| Hjartarson, HT | 1 |
| Ehrstedt, C | 1 |
| Tedroff, K | 1 |
| Mobolaji-Lawal, M | 1 |
| Chaudhuri, R | 1 |
| Marsh, RH | 1 |
| Miller, ES | 1 |
| Bhatia, K | 1 |
| Bakare, AA | 1 |
| Eek, MN | 1 |
| Olsson, K | 1 |
| Lindh, K | 1 |
| Askljung, B | 1 |
| Påhlman, M | 1 |
| Corneliusson, O | 1 |
| Himmelmann, K | 1 |
| Synnot, A | 1 |
| Chau, M | 1 |
| Pitt, V | 1 |
| O'Connor, D | 1 |
| Gruen, RL | 1 |
| Wasiak, J | 1 |
| Clavisi, O | 1 |
| Pattuwage, L | 1 |
| Phillips, K | 1 |
| Lee, BS | 1 |
| Jones, J | 1 |
| Lang, M | 1 |
| Achey, R | 1 |
| Dai, L | 1 |
| Lobel, DA | 1 |
| Nagel, SJ | 1 |
| Machado, AG | 1 |
| Bethoux, F | 2 |
| Bonouvrie, L | 2 |
| Ertzgaard, P | 3 |
| Ghaderi Berntsson, S | 1 |
| Creamer, M | 2 |
| Cloud, G | 2 |
| Kossmehl, P | 2 |
| Yochelson, M | 2 |
| Francisco, GE | 9 |
| Ward, AB | 4 |
| Abouihia, A | 2 |
| Berthuy, N | 1 |
| Calabrese, A | 3 |
| Loven, M | 1 |
| Revol, B | 1 |
| Jullian-Desayes, I | 1 |
| Bailly, S | 1 |
| Mallaret, M | 1 |
| Tamisier, R | 1 |
| Agier, MS | 1 |
| Lador, F | 1 |
| Joyeux-Faure, M | 1 |
| Pépin, JL | 1 |
| Obst, B | 1 |
| Roesler, M | 1 |
| Ghareghani, M | 1 |
| Zibara, K | 1 |
| Sadeghi, H | 1 |
| Farhadi, N | 1 |
| Duraski, SA | 1 |
| Sayyad, A | 1 |
| Chang, EY | 1 |
| Ehsan, A | 1 |
| Lam, SK | 1 |
| Mayer, RR | 1 |
| Vedantam, A | 1 |
| A Staggers, K | 1 |
| Harris, DA | 1 |
| Pan, IW | 1 |
| Fu, X | 1 |
| Wang, Y | 1 |
| Wang, C | 1 |
| Wu, H | 1 |
| Li, J | 1 |
| Li, M | 1 |
| Ma, Q | 1 |
| Yang, W | 1 |
| Verrienti, G | 2 |
| Laimer, I | 1 |
| Fritz, J | 2 |
| Mizuno, S | 1 |
| Takeda, K | 1 |
| Maeshima, S | 1 |
| Shigeru, S | 1 |
| Horn, F | 1 |
| Petrík, M | 1 |
| Dúbravová, D | 1 |
| Hornová, J | 1 |
| Brennerová, K | 1 |
| Bzduch, V | 1 |
| Kalyvas, AV | 1 |
| Drosos, E | 1 |
| Korfias, S | 4 |
| Gatzonis, S | 5 |
| Sakas, DE | 6 |
| Hacene, B | 1 |
| Draulans, N | 4 |
| Kawano, O | 1 |
| Masuda, M | 1 |
| Takao, T | 1 |
| Sakai, H | 1 |
| Morishita, Y | 1 |
| Hayashi, T | 1 |
| Ueta, T | 2 |
| Pittelkow, TP | 1 |
| Bendel, MA | 1 |
| Lueders, DR | 1 |
| Beck, LA | 1 |
| Pingree, MJ | 1 |
| Hoelzer, BC | 2 |
| Winter, G | 1 |
| Beni-Adani, L | 1 |
| Ben-Pazi, H | 1 |
| Selge, C | 1 |
| Bausewein, C | 1 |
| Remi, C | 2 |
| Calvo, ME | 1 |
| Gunnarsson, T | 1 |
| Smith, L | 1 |
| Hao, M | 1 |
| Caruso, P | 1 |
| Mazzon, G | 1 |
| Sarra, VM | 1 |
| Tacconi, L | 1 |
| Manganotti, P | 1 |
| Koker, A | 1 |
| Arslan, G | 1 |
| Özden, Ö | 1 |
| Karaarslan, U | 1 |
| Er, A | 1 |
| Duman, M | 1 |
| Köroğlu, T | 1 |
| Arroyo González, R | 1 |
| Schauer, R | 2 |
| Balsara, K | 1 |
| Jea, A | 1 |
| Yardley, M | 1 |
| Yan, X | 1 |
| Lan, J | 1 |
| Liu, Y | 1 |
| Miao, J | 1 |
| Wankhede, V | 1 |
| Buchser, E | 1 |
| González-Pombo, M | 1 |
| Berntsson, SG | 1 |
| Gauffin, H | 1 |
| Melberg, A | 1 |
| Holtz, A | 1 |
| Landtblom, AM | 1 |
| Farid, R | 3 |
| Binz, K | 1 |
| Emerson, JA | 1 |
| Murdock, F | 1 |
| Crowe, B | 1 |
| Basu, A | 1 |
| Devlin, A | 1 |
| DeAlwis, Y | 1 |
| Lundy, CT | 1 |
| Cadwgan, J | 1 |
| Rizzo, G | 1 |
| Bussolin, L | 1 |
| Genitori, L | 1 |
| Zicca, A | 1 |
| Messeri, A | 1 |
| Lenge, M | 1 |
| Giordano, F | 1 |
| Wouters, A | 1 |
| Kiekens, C | 4 |
| Ross Raftemo, AE | 1 |
| Mahendran, A | 1 |
| Jahnsen, RB | 1 |
| Lydersen, S | 1 |
| Vik, T | 1 |
| McGuire, JR | 3 |
| Munger, ME | 1 |
| Chen, BP | 1 |
| MacWilliams, BA | 1 |
| McMulkin, ML | 1 |
| Schwartz, MH | 1 |
| Zhu, X | 1 |
| Kohan, LR | 1 |
| Goldstein, RB | 1 |
| Formisano, R | 1 |
| Aloisi, M | 2 |
| Contrada, M | 1 |
| Spanedda, F | 1 |
| Schiattone, S | 1 |
| Niedbala, S | 1 |
| Cobianchi, MR | 1 |
| Baldeschi, GC | 1 |
| Buzzi, MG | 1 |
| Barney, CC | 1 |
| Merbler, AM | 1 |
| Simone, DA | 1 |
| Walk, D | 1 |
| Symons, FJ | 1 |
| Baker, KW | 1 |
| Tann, B | 1 |
| Mutlu, A | 1 |
| Gaebler-Spira, D | 2 |
| Shaygannejad, V | 1 |
| Janghorbani, M | 1 |
| Vaezi, A | 1 |
| Haghighi, S | 1 |
| Golabchi, K | 1 |
| Heshmatipour, M | 1 |
| Halpern, R | 1 |
| Gillard, P | 1 |
| Graham, GD | 1 |
| Varon, SF | 1 |
| Zorowitz, RD | 2 |
| Svensson, J | 1 |
| Borg, S | 1 |
| Nilsson, P | 1 |
| Vivek, V | 1 |
| Kavar, B | 1 |
| Hogg, M | 1 |
| Eisen, DP | 1 |
| Butzkueven, H | 1 |
| Roels, E | 1 |
| Nuttin, B | 4 |
| Peers, K | 2 |
| Graham, LA | 1 |
| Vermeersch, K | 1 |
| Degraeuwe, B | 1 |
| Meurrens, T | 1 |
| Vles, GF | 2 |
| Soudant, DL | 2 |
| Hoving, MA | 3 |
| Vermeulen, RJ | 3 |
| van Oostenbrugge, RJ | 1 |
| Vles, JS | 6 |
| Bauman, WA | 2 |
| La Fountaine, MF | 1 |
| Cirnigliaro, CM | 1 |
| Kirshblum, SC | 2 |
| Spungen, AM | 1 |
| Walter, M | 2 |
| Altermatt, S | 2 |
| Furrer, C | 2 |
| Meyer-Heim, A | 2 |
| Calandriello, B | 1 |
| Galli, R | 1 |
| Logi, F | 1 |
| Iardella, L | 1 |
| Bordi, L | 1 |
| McIntyre, A | 1 |
| Mays, R | 1 |
| Mehta, S | 1 |
| Janzen, S | 1 |
| Townson, A | 1 |
| Hsieh, J | 1 |
| Wolfe, D | 1 |
| Teasell, R | 1 |
| Gray, N | 2 |
| Freeman, ED | 1 |
| Eldrige, JS | 1 |
| Moeschler, SM | 1 |
| Taira, T | 3 |
| Margetis, K | 4 |
| Korfias, SI | 1 |
| Boutos, N | 2 |
| Stranjalis, G | 2 |
| Boviatsis, E | 2 |
| Mathur, SN | 2 |
| Chu, SK | 2 |
| McCormick, Z | 1 |
| Chang Chien, GC | 1 |
| Marciniak, CM | 1 |
| Markianos, M | 1 |
| Kalamatianos, T | 1 |
| Sakas, D | 3 |
| Motta, F | 5 |
| Antonello, CE | 2 |
| Borrini, L | 1 |
| Thiebaut, JB | 3 |
| Hugeron, C | 2 |
| Rech, C | 1 |
| Jourdan, C | 1 |
| Lipták, J | 1 |
| Ghosh, D | 1 |
| Mainali, G | 1 |
| Khera, J | 1 |
| Luciano, M | 1 |
| Locatelli, F | 1 |
| Pozzi, M | 1 |
| Avantaggiato, P | 1 |
| Lanfranchi, M | 1 |
| Tufarulo, L | 1 |
| Amorelli, V | 1 |
| Rizzi, G | 1 |
| Radice, S | 1 |
| Galbiati, S | 1 |
| Clementi, E | 1 |
| Strazzer, S | 1 |
| Papageorgiou, G | 1 |
| Politis, K | 1 |
| Siatouni, A | 2 |
| Calabrò, RS | 1 |
| D'Aleo, G | 3 |
| Sessa, E | 1 |
| Leo, A | 1 |
| De Cola, MC | 1 |
| Bramanti, P | 5 |
| Cardoso, AL | 1 |
| Quintaneiro, C | 1 |
| Seabra, H | 1 |
| Teixeira, C | 1 |
| Khan, A | 1 |
| Albrecht, E | 1 |
| Heetla, HW | 3 |
| Staal, MJ | 4 |
| Proost, JH | 2 |
| van Laar, T | 3 |
| Ghobrial, GM | 1 |
| Thakkar, V | 1 |
| Singhal, S | 1 |
| Oppenlander, ME | 1 |
| Maulucci, CM | 1 |
| Harrop, JS | 1 |
| Jallo, J | 1 |
| Prasad, S | 1 |
| Sharan, AD | 1 |
| Reynolds, RM | 1 |
| Morton, RP | 1 |
| Walker, ML | 4 |
| Massagli, TL | 1 |
| Dalivigka, Z | 1 |
| Flaskas, T | 1 |
| Khurana, SR | 1 |
| Garg, DS | 1 |
| Waqar, M | 1 |
| Ellenbogen, JR | 1 |
| Zebian, B | 1 |
| Williams, D | 1 |
| Pettorini, BL | 1 |
| Guillemette, S | 1 |
| Leier, J | 1 |
| Hinnenthal, J | 1 |
| Berweck, S | 2 |
| Lütjen, S | 2 |
| Voss, W | 1 |
| Diebold, U | 1 |
| Mücke, KH | 2 |
| Aisch, A | 1 |
| Ostertag, B | 1 |
| Friedrich, M | 1 |
| Wagner, C | 1 |
| Kudernatsch, M | 1 |
| Granel, M | 1 |
| Kluger, G | 1 |
| Ludwikowski, B | 1 |
| Peraud, A | 1 |
| Rauchenzauner, M | 1 |
| Schroeder, AS | 1 |
| Sprinz, A | 1 |
| Wienand, R | 1 |
| Wilken, B | 1 |
| Kästner, S | 1 |
| Zeches, C | 1 |
| Mall, V | 2 |
| Naito, Y | 1 |
| Riordan, J | 1 |
| Murphy, P | 1 |
| Berman, CM | 1 |
| Eppinger, MA | 1 |
| Mazzola, CA | 1 |
| Rush, R | 1 |
| Kumbhare, D | 1 |
| Pistoia, F | 1 |
| Sacco, S | 2 |
| Sarà, M | 2 |
| Franceschini, M | 1 |
| Carolei, A | 2 |
| Al-Khodairy, AT | 1 |
| Wicky, G | 1 |
| Nicolo, D | 1 |
| Vuadens, P | 1 |
| Ravindra, VM | 1 |
| Ray, WZ | 1 |
| Sayama, CM | 1 |
| Dailey, AT | 1 |
| Scannell, B | 1 |
| Fournier, CM | 1 |
| Furr-Stimming, E | 1 |
| Boyle, AM | 1 |
| Veerakumar, A | 1 |
| Cheng, JJ | 1 |
| Sunshine, A | 1 |
| Ye, X | 1 |
| Anderson, WS | 1 |
| Overgård, TM | 1 |
| Kjærsgaard-Hansen, L | 1 |
| Søe, M | 1 |
| Illum, NO | 2 |
| Malheiro, L | 1 |
| Santos, L | 1 |
| Sarmento, A | 1 |
| Asahi, T | 1 |
| Kashiwazaki, D | 1 |
| Koh, M | 1 |
| Matsumura, N | 1 |
| Kuroda, S | 1 |
| Phillips, MM | 1 |
| Miljkovic, N | 1 |
| Ramos-Lamboy, M | 1 |
| Moossy, JJ | 1 |
| Horton, J | 1 |
| Buhari, AM | 1 |
| Munin, MC | 1 |
| Ijaz, M | 1 |
| Tariq, H | 1 |
| Kashif, M | 1 |
| Marquez, JG | 1 |
| Dai, AI | 1 |
| Aksoy, SN | 1 |
| Demiryürek, AT | 1 |
| Dastgir, A | 1 |
| Ranalli, NJ | 1 |
| MacGregor, TL | 1 |
| Aldana, PR | 1 |
| Narendran, RC | 1 |
| Duarte, RV | 1 |
| Valyi, A | 1 |
| Dressler, D | 1 |
| Chatzikalfas, A | 1 |
| Ebke, M | 1 |
| Frank, B | 1 |
| Hesse, S | 1 |
| Huber, M | 1 |
| Krauss, JK | 1 |
| Nolte, A | 1 |
| Oelmann, HD | 1 |
| Schönle, PW | 1 |
| Schmutzler, M | 1 |
| Pickenbrock, H | 1 |
| Van der Ven, C | 1 |
| Veelken, N | 1 |
| Vogel, M | 1 |
| Vogt, T | 2 |
| Saberi, FA | 1 |
| Kishima, H | 1 |
| Navarrete-Opazo, AA | 1 |
| Gonzalez, W | 1 |
| Nahuelhual, P | 1 |
| Sechrist, C | 1 |
| Kinsman, S | 1 |
| Cain, N | 1 |
| McCormick, ZL | 2 |
| Binler, D | 1 |
| Neudorf, D | 1 |
| Lee, J | 1 |
| Marciniak, C | 2 |
| Clearfield, JS | 1 |
| Nelson, ME | 3 |
| McGuire, J | 1 |
| Rein, LE | 1 |
| Tarima, S | 1 |
| Zheng, K | 1 |
| Brodsky, JB | 1 |
| Ingale, H | 3 |
| Ughratdar, I | 4 |
| Muquit, S | 3 |
| Moussa, AA | 1 |
| Vloeberghs, MH | 2 |
| Hasnat, MJ | 1 |
| Rice, JE | 1 |
| Frémondière, F | 1 |
| Lacoeuille, F | 1 |
| Sher, A | 1 |
| Couturier, O | 1 |
| Richard, I | 3 |
| Dinomais, M | 1 |
| Thakur, SK | 1 |
| Rubin, BA | 1 |
| Harter, DH | 4 |
| Devine, O | 1 |
| Harborne, A | 1 |
| Lo, WB | 1 |
| Weinberg, D | 1 |
| Ciras, M | 1 |
| Price, R | 2 |
| Ashmore, J | 1 |
| Ball, G | 1 |
| Charles-Edwards, G | 1 |
| Selway, R | 1 |
| Ashkan, K | 1 |
| Lin, JP | 1 |
| Wang, ZM | 1 |
| Law, JH | 1 |
| King, NK | 1 |
| Rajeswaran, DK | 1 |
| Soh, S | 1 |
| Rao, JP | 1 |
| Ng, WH | 1 |
| Chua, KS | 1 |
| Trojano, M | 2 |
| Natale, M | 2 |
| D'Oria, S | 1 |
| Nero, VV | 1 |
| Squillante, E | 1 |
| Gentile, M | 1 |
| Rotondo, M | 2 |
| Becher, J | 1 |
| Soudant, D | 1 |
| Buizer, A | 1 |
| van Ouwerkerk, W | 1 |
| Vles, G | 1 |
| Stampacchia, G | 1 |
| Gerini, A | 1 |
| Mazzoleni, S | 1 |
| Molmans, BH | 1 |
| Vidal, J | 3 |
| Slof, J | 1 |
| Serrano, D | 1 |
| Marqués, T | 1 |
| Kumru, H | 1 |
| Benito-Penalva, J | 1 |
| Mietton, C | 1 |
| Nuti, C | 1 |
| Dohin, B | 1 |
| Bayle, B | 1 |
| Fernandez, B | 1 |
| Poirot, I | 1 |
| Gautheron, V | 2 |
| Vuillerot, C | 1 |
| Haupts, M | 1 |
| Vila, C | 1 |
| Jonas, A | 1 |
| Witte, K | 1 |
| Álvarez-Ossorio, L | 1 |
| Sastre-Garriga, J | 1 |
| Hartung, HP | 1 |
| Soelberg Sørensen, P | 1 |
| Thompson, AJ | 1 |
| Vermersch, P | 2 |
| Gold, R | 1 |
| Montalban, X | 1 |
| Maneyapanda, MB | 2 |
| Driver, SP | 1 |
| Ripley, DL | 1 |
| Lloyd, R | 1 |
| Brkic, N | 1 |
| Narang, S | 1 |
| Srinivasan, SK | 1 |
| Zinboonyahgoon, N | 1 |
| Sampson, CE | 1 |
| Boster, AL | 4 |
| Adair, RL | 1 |
| Gooch, JL | 3 |
| Toomer, A | 1 |
| Urquidez, J | 1 |
| Bennett, SE | 2 |
| Bilsky, GS | 2 |
| Gudesblatt, M | 2 |
| Koelbel, SF | 1 |
| Ivanhoe, CB | 5 |
| Ridley, B | 2 |
| Shilt, JS | 2 |
| Anderson, DJ | 1 |
| Doble, J | 1 |
| Gul, F | 1 |
| Turner, M | 5 |
| Miesel, K | 1 |
| Cochran, FR | 1 |
| Fehrmann, E | 1 |
| Markert, M | 1 |
| O'Dell, MW | 1 |
| Saigal, R | 1 |
| Goyal, L | 1 |
| Yadav, R | 1 |
| Agrawal, A | 1 |
| Mital, P | 1 |
| Patel, B | 1 |
| Lindsay, C | 1 |
| Kouzouna, A | 1 |
| Simcox, C | 1 |
| Pandyan, AD | 1 |
| Kvascevicius, R | 1 |
| Lapteva, O | 1 |
| Kesiene, J | 1 |
| Vaitkus, A | 1 |
| Mikulenaite, L | 1 |
| Raugalas, R | 1 |
| Sipylaite, J | 1 |
| Rocka, S | 1 |
| Juocevicius, A | 1 |
| Reger, C | 1 |
| Agarwal, S | 1 |
| Patel, T | 1 |
| Shah, N | 1 |
| Patel, BM | 1 |
| Takamiya, S | 1 |
| Sasamori, T | 1 |
| Hamauchi, S | 1 |
| Seki, T | 1 |
| Kano, T | 1 |
| Yabe, I | 1 |
| Sasaki, H | 1 |
| Houkin, K | 1 |
| Skogberg, O | 1 |
| Levi, R | 1 |
| Robinson, S | 1 |
| Robertson, FC | 1 |
| Dasenbrock, HH | 1 |
| O'Brien, CP | 1 |
| Berde, C | 1 |
| Padua, H | 1 |
| Tanaka, K | 1 |
| Campo, C | 1 |
| Kraus, T | 1 |
| Gegenleitner, K | 1 |
| Svehlik, M | 1 |
| Novak, M | 1 |
| Steinwender, G | 1 |
| Singer, G | 1 |
| Hidalgo, ET | 1 |
| Orillac, C | 1 |
| Hersh, A | 1 |
| Rizzo, WB | 1 |
| Weiner, HL | 4 |
| Barker, E | 1 |
| Jones, ML | 1 |
| Leslie, DP | 1 |
| Bilsky, G | 1 |
| Bowman, B | 1 |
| Saval, A | 3 |
| Chiodo, AE | 4 |
| Patti, F | 2 |
| Pappalardo, A | 1 |
| Lo Fermo, S | 1 |
| Cimino, V | 1 |
| Castiglione, A | 2 |
| Zappia, M | 1 |
| Brennan, PM | 1 |
| Whittle, IR | 1 |
| Quirbach, E | 1 |
| Singer, M | 1 |
| Ali Sakr Esa, W | 1 |
| Toma, I | 1 |
| Tetzlaff, JE | 1 |
| Barsoum, S | 1 |
| Li, TC | 1 |
| Chen, MH | 2 |
| Huang, JS | 1 |
| Chan, JY | 1 |
| Liu, YK | 1 |
| Burton, AW | 1 |
| Danyo, DA | 1 |
| Frost, S | 1 |
| Glanzer, J | 1 |
| Solanki, DR | 1 |
| Martens, FM | 1 |
| Somford, DM | 1 |
| van Kuppevelt, DH | 1 |
| van den Burg, MJ | 1 |
| Heesakkers, JP | 1 |
| Matsuda, R | 1 |
| Nishimura, F | 1 |
| Hirabayashi, H | 1 |
| Motoyama, Y | 1 |
| Mishima, H | 1 |
| Park, YS | 1 |
| Nakase, H | 1 |
| Sakaki, T | 1 |
| Brochard, S | 1 |
| Remy-Neris, O | 3 |
| Filipetti, P | 2 |
| Bussel, B | 10 |
| Kliphuis, C | 1 |
| Bresolin, N | 1 |
| Zucca, C | 1 |
| Pecori, A | 1 |
| Dan, B | 2 |
| Becher, JG | 3 |
| Pascual-Pascual, SI | 1 |
| Pauwels, P | 1 |
| Røste, GK | 2 |
| Bowden, M | 1 |
| Gater, DR | 1 |
| Petersen, JA | 1 |
| Schubert, M | 1 |
| Dietz, V | 2 |
| Mullarkey, T | 1 |
| Kramer, K | 1 |
| Weber, M | 1 |
| Koulousakis, A | 2 |
| Lier, H | 1 |
| Krep, H | 1 |
| Peerdeman, SM | 1 |
| de Groot, V | 1 |
| Feller, RE | 1 |
| Saulino, MF | 1 |
| Cabrera, MN | 1 |
| Lai, LP | 1 |
| Snow, SB | 1 |
| Ward, A | 1 |
| Hayden, S | 1 |
| Dexter, M | 2 |
| Scheinberg, A | 3 |
| Fjelstad, AB | 1 |
| Hommelstad, J | 1 |
| Sorteberg, A | 1 |
| Yelnik, AP | 3 |
| Simon, O | 2 |
| Chaleat-Valayer, E | 1 |
| Decq, P | 1 |
| Dehail, P | 1 |
| Quentin, V | 1 |
| Marque, P | 1 |
| Parratte, B | 1 |
| Pellas, F | 1 |
| Rousseaux, M | 1 |
| Trocello, JM | 1 |
| Uzzan, M | 1 |
| Dumarcet, N | 1 |
| Ramstad, K | 1 |
| Lofterod, B | 1 |
| Skjeldal, OH | 1 |
| Morton, CM | 1 |
| Rosenow, J | 1 |
| Wong, C | 1 |
| Kirschner, KL | 1 |
| Su, W | 1 |
| Yegappan, C | 1 |
| Carlisle, EJ | 1 |
| Clase, CM | 1 |
| Burn, SC | 1 |
| Zeller, R | 1 |
| Drake, JM | 1 |
| Charles, PD | 4 |
| Gill, CE | 3 |
| Taylor, HM | 4 |
| Putman, MS | 1 |
| Blair, CR | 2 |
| Roberts, AG | 3 |
| Ayers, GD | 1 |
| Konrad, PE | 2 |
| Sivakumar, G | 2 |
| Yap, Y | 1 |
| Tsegaye, M | 1 |
| Oyama, H | 1 |
| Kito, A | 1 |
| Maki, H | 1 |
| Hattori, K | 1 |
| Tanahashi, K | 1 |
| Sgouros, S | 3 |
| Charalambides, C | 1 |
| Matsota, P | 1 |
| Tsangaris, I | 1 |
| Kostopanagiotou, G | 1 |
| Nunez-Wallace, KR | 1 |
| Harrison, CH | 1 |
| Dvorak, EM | 1 |
| Benecke, R | 1 |
| Patejdl, R | 1 |
| Gómez-Soriano, J | 1 |
| Goiriena, E | 1 |
| Taylor, J | 1 |
| Ross, JC | 1 |
| Cook, AM | 1 |
| Stewart, GL | 1 |
| Fahy, BG | 1 |
| Haranhalli, N | 1 |
| Anand, D | 1 |
| Wisoff, JH | 2 |
| Blate, M | 1 |
| Khan, AA | 1 |
| Birks-Agnew, I | 1 |
| Bullock, P | 1 |
| Rushton, D | 1 |
| Lapeyre, E | 1 |
| Kuks, JB | 1 |
| Meijler, WJ | 1 |
| Panza, F | 1 |
| Ranieri, M | 1 |
| Amoruso, MT | 1 |
| Amoruso, L | 1 |
| Frisardi, V | 1 |
| Solfrizzi, V | 1 |
| Fiore, P | 1 |
| Oshiro, M | 1 |
| Hefferan, MP | 3 |
| Kakinohana, O | 2 |
| Lukacova, N | 1 |
| Sugahara, K | 1 |
| Yaksh, TL | 2 |
| Marsala, M | 3 |
| Miracle, AC | 1 |
| Fox, MA | 2 |
| Ayyangar, RN | 2 |
| Vyas, A | 1 |
| Mukherji, SK | 1 |
| Quint, DJ | 1 |
| Tilton, A | 1 |
| Vargus-Adams, J | 1 |
| Delgado, MR | 1 |
| Kireyev, D | 1 |
| Poh, KK | 1 |
| Erwin, A | 1 |
| Koelbel, S | 1 |
| Sadiq, S | 1 |
| Thomas, AM | 1 |
| Tornatore, C | 1 |
| Zaffaroni, M | 1 |
| Hughes, M | 1 |
| Ucar, T | 1 |
| Kazan, S | 1 |
| Turgut, U | 1 |
| Samanci, NK | 1 |
| Priano, L | 1 |
| Zara, GP | 1 |
| El-Assawy, N | 1 |
| Cattaldo, S | 1 |
| Muntoni, E | 1 |
| Milano, E | 1 |
| Serpe, L | 1 |
| Musicanti, C | 1 |
| Pérot, C | 1 |
| Gasco, MR | 1 |
| Miscio, G | 1 |
| Mauro, A | 1 |
| Al Khudhairi, D | 2 |
| Aldin, AS | 1 |
| Hamdan, Y | 1 |
| Rababah, A | 1 |
| Matthana, MH | 1 |
| Pazdirek, J | 1 |
| Abdulsalam, J | 1 |
| Grønning, M | 2 |
| Chung, CY | 1 |
| Chen, CL | 1 |
| Wong, AM | 1 |
| Balch, RJ | 1 |
| Gofeld, M | 1 |
| Nance, PW | 3 |
| Huff, FJ | 1 |
| Martinez-Arizala, A | 1 |
| Ayyoub, Z | 1 |
| Chen, D | 1 |
| Bian, A | 1 |
| Stamler, D | 1 |
| Pedroso, JL | 1 |
| Braga-Neto, P | 1 |
| Abrahão, A | 1 |
| Rivero, RL | 1 |
| Abdalla, C | 1 |
| Abdala, N | 1 |
| Barsottini, OG | 1 |
| Pin, TW | 1 |
| Lewis, J | 1 |
| Bischoff, A | 1 |
| Rifici, C | 4 |
| D'Aleo, P | 1 |
| Hettiarachchi, HD | 1 |
| Hsu, Y | 1 |
| Harris, TJ | 1 |
| Penn, R | 3 |
| Linninger, AA | 1 |
| Zdolsek, HA | 1 |
| Olesch, C | 1 |
| Antolovich, G | 1 |
| Reddihough, D | 1 |
| Mahvash, M | 1 |
| Maslehaty, H | 1 |
| Warneke, N | 1 |
| Doukas, A | 1 |
| Petridis, AK | 1 |
| Mehdorn, HM | 1 |
| van Schie, PE | 1 |
| van Ouwerkerk, WJ | 1 |
| Mirone, G | 1 |
| Moraci, A | 1 |
| Escaldi, SV | 1 |
| Cuccurullo, SJ | 1 |
| Terzella, M | 1 |
| Petagna, AM | 1 |
| Strax, TE | 1 |
| Marquer, A | 1 |
| Roche, N | 5 |
| Godard, AL | 1 |
| Lofaso, F | 2 |
| Quera-Salva, MA | 1 |
| Bassani, L | 1 |
| Morton, RE | 1 |
| Brimlow, K | 1 |
| Keetley, R | 1 |
| Murdock, FA | 1 |
| Bonnett, A | 1 |
| Mawhinney, TP | 1 |
| Chance, D | 1 |
| Waters, JK | 1 |
| Hewett, JE | 1 |
| Teernstra, OP | 1 |
| Hagen, EM | 1 |
| Moussa, A | 1 |
| Heinzlef, O | 1 |
| Monteil-Roch, I | 1 |
| Lawson, EF | 1 |
| Wallace, MS | 1 |
| Mugglestone, MA | 1 |
| Murphy, MS | 1 |
| Nakanishi, K | 1 |
| Fukawa, N | 1 |
| Yoshioka, H | 1 |
| Murakami, S | 1 |
| Nakano, N | 1 |
| Kato, A | 1 |
| Hattori, N | 1 |
| Hirayama, T | 1 |
| Katayama, Y | 1 |
| Rauf, J | 1 |
| Akhtar, J | 1 |
| Khealani, BA | 1 |
| Ali, L | 1 |
| Nguyen, HS | 1 |
| Cohen-Gadol, AA | 1 |
| Castro-Gago, M | 1 |
| Pérez-Gay, L | 1 |
| Gómez-Lado, C | 1 |
| Angeli, C | 1 |
| Ochsner, J | 1 |
| Harkema, S | 1 |
| Pritula, SL | 1 |
| Ayyangar, R | 2 |
| Hester, SM | 1 |
| Fisher, JF | 1 |
| Lee, MR | 2 |
| Macomson, S | 1 |
| Vender, JR | 2 |
| Dénes, Z | 1 |
| Klauber, A | 1 |
| Both, B | 1 |
| Lóránd, E | 1 |
| Silva, S | 1 |
| Nowicki, P | 1 |
| Caird, MS | 1 |
| Hurvitz, EA | 2 |
| Farley, FA | 1 |
| Vanderhave, KL | 1 |
| Hensinger, RN | 1 |
| Craig, CL | 1 |
| Bose, P | 1 |
| Hou, J | 1 |
| Nelson, R | 1 |
| Nissim, N | 1 |
| Parmer, R | 1 |
| Keener, J | 1 |
| Wacnik, PW | 1 |
| Thompson, FJ | 1 |
| Kurenkov, AL | 1 |
| Batysheva, TT | 1 |
| Vinogradov, AV | 1 |
| Ziuziaeva, EK | 1 |
| Korenkov, AI | 1 |
| Niendorf, WR | 1 |
| Darwish, N | 1 |
| Glaeser, E | 1 |
| Gaab, MR | 1 |
| Vaidyanathan, S | 4 |
| Soni, BM | 4 |
| Hughes, PL | 2 |
| Singh, G | 3 |
| Watt, JW | 2 |
| Oo, T | 3 |
| Sett, P | 2 |
| Rushton, DN | 1 |
| Lloyd, AC | 1 |
| Anderson, PM | 1 |
| Pohl, M | 2 |
| Rockstroh, G | 2 |
| Rückriem, S | 2 |
| Mehrholz, J | 2 |
| Mrass, G | 1 |
| Pause, M | 2 |
| Alden, TD | 1 |
| Lytle, RA | 1 |
| Park, TS | 4 |
| Noetzel, MJ | 1 |
| Ojemann, JG | 1 |
| Seri, S | 1 |
| Campbell, WM | 1 |
| Ferrel, A | 1 |
| McLaughlin, JF | 3 |
| Grant, GA | 1 |
| Loeser, JD | 2 |
| Graubert, C | 1 |
| Bjornson, K | 1 |
| Hornby, TG | 1 |
| Rymer, WZ | 1 |
| Benz, EN | 1 |
| Schmit, BD | 1 |
| Al-Shahrani, AM | 1 |
| Gilmartin, R | 2 |
| Swift, D | 2 |
| Barnes, MP | 2 |
| Kent, RM | 1 |
| Semlyen, JK | 1 |
| McMullen, KM | 1 |
| Greenberg, MI | 1 |
| Hendrickson, RG | 1 |
| Awaad, Y | 2 |
| Tayem, H | 1 |
| Munoz, S | 1 |
| Ham, S | 1 |
| Michon, AM | 1 |
| Awaad, R | 1 |
| Bjornson, KF | 1 |
| Nowak-Cooperman, KM | 1 |
| Russel, M | 1 |
| Bader, KA | 1 |
| Desmond, SA | 1 |
| Brown, TR | 1 |
| Meythaler, JM | 7 |
| Roper, JF | 1 |
| Brunner, RC | 1 |
| Tiffreau, V | 1 |
| Bouilland, S | 1 |
| Kao, LW | 1 |
| Amin, Y | 1 |
| Kirk, MA | 1 |
| Turner, MS | 1 |
| Sindou, M | 3 |
| Sallerin, B | 3 |
| Lazorthes, Y | 7 |
| Emery, E | 1 |
| Hansen, HJ | 2 |
| Hansen, FJ | 1 |
| Fischer, C | 1 |
| Uldall, PV | 1 |
| Nielsen, OA | 1 |
| Oberg, WA | 2 |
| Grams, B | 3 |
| Ward, LA | 3 |
| Kadyan, V | 1 |
| Clairmont, AC | 1 |
| George, RJ | 1 |
| Johnson, EW | 1 |
| Colachis, SC | 1 |
| Rea, GL | 2 |
| Elovic, E | 3 |
| Boake, C | 2 |
| Bergenheim, AT | 1 |
| Wendelius, M | 1 |
| Shahidi, S | 1 |
| Larsson, E | 1 |
| Mani, RM | 1 |
| Hori, T | 1 |
| Nemoto, A | 1 |
| Graves, CR | 1 |
| Groomes, TE | 1 |
| Pfister, AA | 2 |
| Damian, MM | 2 |
| Koch, R | 1 |
| Strik, H | 1 |
| Mess, SA | 1 |
| Kim, S | 1 |
| Davison, S | 1 |
| Heckler, F | 1 |
| Signorelli, CD | 1 |
| Lavano, A | 1 |
| Volpentesta, G | 1 |
| Chirchiglia, D | 1 |
| Signorelli, F | 1 |
| Bono, F | 1 |
| Ferraro, G | 1 |
| Sibille, M | 1 |
| Veltri, C | 1 |
| Piragine, G | 1 |
| Serra, S | 1 |
| Scola, P | 1 |
| Pardatcher, S | 1 |
| Pardatcher, K | 1 |
| Santangelo, E | 1 |
| Pasquier, Y | 1 |
| Cahana, A | 1 |
| Schnider, A | 1 |
| Noel-Spaudling, S | 1 |
| Jóźwiak, M | 1 |
| Idzior, M | 1 |
| Huber, J | 1 |
| Szulc, A | 1 |
| Grottel, K | 1 |
| Yeh, RN | 1 |
| Nypaver, MM | 1 |
| Deegan, TJ | 1 |
| Boviatsis, EJ | 2 |
| Kouyialis, AT | 2 |
| Boutsikakis, I | 1 |
| Taha, J | 1 |
| Favre, J | 1 |
| Janszen, M | 1 |
| Galarza, M | 1 |
| Taha, A | 1 |
| Goldstein, M | 1 |
| Plassat, R | 1 |
| Perrouin Verbe, B | 1 |
| Menegalli, D | 1 |
| Mathé, JF | 1 |
| O'Connell, M | 1 |
| Wong, TZ | 1 |
| Forkheim, KE | 1 |
| Jain, M | 1 |
| Shipes, SW | 1 |
| Fuchs, HE | 1 |
| Dario, A | 4 |
| Tomei, G | 3 |
| Zafonte, R | 1 |
| Lombard, L | 1 |
| Rizzo, MA | 1 |
| Hadjimichael, OC | 1 |
| Preiningerova, J | 1 |
| Vollmer, TL | 1 |
| Li, Y | 1 |
| Li, X | 1 |
| Harvey, PJ | 1 |
| Bennett, DJ | 1 |
| Zahavi, A | 1 |
| Geertzen, JH | 2 |
| Middel, B | 2 |
| Staal, M | 2 |
| Rietman, JS | 2 |
| Strobl, W | 1 |
| Atiyeh, BS | 2 |
| Hayek, SN | 2 |
| Skaff, GS | 1 |
| Araj, AM | 1 |
| Chamoun, RB | 2 |
| Kesiktas, N | 1 |
| Paker, N | 1 |
| Erdogan, N | 1 |
| Gülsen, G | 1 |
| Biçki, D | 1 |
| Yilmaz, H | 1 |
| Ethans, KD | 1 |
| Schryvers, OI | 1 |
| Casey, AR | 1 |
| Gerçek, A | 1 |
| Baykan, N | 1 |
| Dağçinar, A | 1 |
| Ozek, MM | 1 |
| Shannon, FJ | 1 |
| Cogley, D | 1 |
| Glynn, M | 1 |
| Rigoli, G | 1 |
| Terrini, G | 1 |
| Cordioli, Z | 1 |
| Smith, J | 1 |
| Rawlins, PK | 2 |
| Lew, SM | 1 |
| Psaty, EL | 1 |
| Abbott, R | 2 |
| Qian, Y | 1 |
| Ances, BM | 1 |
| Pruitt, A | 1 |
| Choi, B | 1 |
| Moonis, G | 1 |
| Ben Smail, D | 3 |
| Denys, P | 3 |
| Nagasawa, T | 1 |
| Abe, Y | 1 |
| Honda, M | 1 |
| Oka, A | 1 |
| Morota, N | 1 |
| Nihei, K | 1 |
| Schuele, SU | 1 |
| Kellinghaus, C | 1 |
| Shook, SJ | 1 |
| Boulis, N | 1 |
| Bethoux, FA | 2 |
| Loddenkemper, T | 1 |
| Milano, JB | 1 |
| Neto, MC | 1 |
| Hunhevicz, SC | 1 |
| Arruda, WO | 1 |
| Ramina, R | 1 |
| Barros, E | 1 |
| Adams, MM | 1 |
| Hicks, AL | 1 |
| Scamoni, C | 1 |
| Picano, M | 1 |
| Casagrande, F | 2 |
| Andersson, S | 1 |
| Düppe, H | 1 |
| Lauge-Pedersen, H | 1 |
| Pedertsen, HL | 1 |
| Nordmark, E | 1 |
| Westbom, L | 1 |
| Dziurzynski, K | 1 |
| Mcleish, D | 1 |
| Iskandar, BJ | 1 |
| Horn, TS | 1 |
| Douglas, AF | 1 |
| Schwartz, DR | 1 |
| Aydin, G | 1 |
| Tomruk, S | 1 |
| Keleş, I | 1 |
| Demir, SO | 1 |
| Orkun, S | 1 |
| Buonaguro, V | 2 |
| Scelsa, B | 1 |
| Curci, D | 1 |
| Monforte, S | 1 |
| Iuorno, T | 1 |
| Hu, MM | 1 |
| Baguley, IJ | 1 |
| Bailey, KM | 1 |
| Slewa-Younan, S | 1 |
| Hayes, A | 2 |
| Liu, JK | 1 |
| Muhonen, M | 1 |
| Boydston, WR | 1 |
| Zidek, KA | 1 |
| Wright, E | 1 |
| Bloom, K | 1 |
| Guillaume, D | 1 |
| Van Havenbergh, A | 1 |
| Roeste, G | 1 |
| Patel, DR | 1 |
| Soyode, O | 1 |
| Sadiq, SA | 2 |
| Wang, GC | 1 |
| Bowery, NG | 1 |
| Britton, D | 1 |
| Goldstein, B | 1 |
| Jones-Redmond, J | 1 |
| Esselman, P | 1 |
| Peskine, A | 1 |
| Mailhan, L | 1 |
| Thiébaut, I | 1 |
| Perić, P | 1 |
| Antić, B | 1 |
| Dincić, E | 1 |
| Obradović, D | 1 |
| Arsić, S | 1 |
| Hester, S | 1 |
| Waller, JL | 1 |
| Rekito, A | 1 |
| Taricco, M | 1 |
| Pagliacci, MC | 1 |
| Telaro, E | 1 |
| Adone, R | 1 |
| Pattisapu, JV | 1 |
| Vesovic-Potic, V | 1 |
| Olivier, J | 1 |
| Skaf, GS | 1 |
| Al Araj, A | 1 |
| Schnitzler, A | 1 |
| Genêt, F | 1 |
| Caldas, C | 1 |
| Delpierre, Y | 1 |
| Fuchigami, T | 1 |
| Mandigo, CE | 1 |
| Anderson, RC | 1 |
| van Kranen-Mastenbroek, VH | 1 |
| van Raak, EP | 2 |
| Spincemaille, GH | 2 |
| Hardy, EL | 1 |
| Nakamura, S | 1 |
| Kakinohana, M | 1 |
| Galik, J | 1 |
| Tomori, Z | 1 |
| Marsala, J | 1 |
| Tunali, Y | 1 |
| Hanimoglu, H | 1 |
| Tanriverdi, T | 1 |
| Hanci, L | 1 |
| Hanci, M | 1 |
| Ferson, SS | 2 |
| Hsieh, JC | 1 |
| Penn, RD | 16 |
| McCall, TD | 1 |
| MacDonald, JD | 2 |
| Guglielmino, A | 1 |
| Sorbello, M | 1 |
| Fazzio, S | 1 |
| Zingale, SF | 1 |
| Bucolo, GE | 1 |
| Pittalà, G | 1 |
| Mangiameli, S | 1 |
| Hall, K | 1 |
| Lam, LT | 1 |
| O'Flaherty, S | 2 |
| Quera Salva, MA | 1 |
| Benyahia, S | 1 |
| Bohic, M | 1 |
| Wiggs, L | 1 |
| Cavalier, S | 1 |
| Grissom, S | 1 |
| Rababa, A | 1 |
| Saddiqui, MN | 1 |
| Even-Schneider, A | 1 |
| Dones, I | 3 |
| Nazzi, V | 1 |
| Broggi, G | 3 |
| Rice, J | 1 |
| O'Donnell, M | 1 |
| Armstrong, R | 1 |
| Lamotte, D | 1 |
| Cantalloube, S | 1 |
| Lubsch, L | 1 |
| Habersang, R | 1 |
| Haase, M | 1 |
| Luedtke, S | 1 |
| Jacobs, BW | 1 |
| Teive, HA | 1 |
| Fulkerson, DH | 1 |
| Boaz, JC | 1 |
| Luerssen, TG | 1 |
| Cipolla, F | 1 |
| Onorati, P | 1 |
| Scoppetta, C | 1 |
| Albertini, G | 1 |
| Deer, TR | 1 |
| Raso, LJ | 1 |
| Garten, TG | 1 |
| Morant, A | 1 |
| Noé, E | 1 |
| Boyer, J | 1 |
| Escamilla, B | 1 |
| Trénor, C | 1 |
| Ferri, J | 1 |
| Chirivella, J | 1 |
| Latorre, JM | 1 |
| de Lissovoy, G | 1 |
| Matza, LS | 1 |
| Green, H | 1 |
| Werner, M | 1 |
| Edgar, T | 1 |
| Stignani, C | 1 |
| Panourias, IG | 2 |
| Ethans, K | 1 |
| Marra, GA | 1 |
| Di Bella, P | 1 |
| Dykstra, D | 1 |
| Stuckey, M | 1 |
| DesLauriers, L | 1 |
| Chappuis, D | 1 |
| Krach, L | 1 |
| Kuchta, J | 1 |
| Petropoulou, KB | 1 |
| Rapidi, CA | 1 |
| Ceulemans, B | 1 |
| van Rhijn, J | 1 |
| Kenis, S | 1 |
| Krols, R | 1 |
| Laridon, A | 1 |
| Van Havenbergh, T | 1 |
| Palmans, LJ | 1 |
| Sleypen, FA | 1 |
| Kan, P | 1 |
| Gooch, J | 1 |
| Amini, A | 1 |
| Ploeger, D | 1 |
| Oberg, W | 1 |
| Simonsen, S | 1 |
| Walker, M | 1 |
| Kestle, J | 1 |
| Baddeley, AA | 1 |
| McClelland, S | 1 |
| Boulis, NM | 1 |
| Sutliff, MH | 1 |
| Stough, DK | 1 |
| Schwetz, KM | 1 |
| Gogol, DM | 1 |
| Harrison, M | 1 |
| Pioro, EP | 1 |
| Smit, CA | 1 |
| Slim, EJ | 1 |
| Poopatana, CA | 1 |
| Duhon, BS | 1 |
| Müller, H | 6 |
| Grzegorzewski, P | 3 |
| Kawecki, Z | 3 |
| Swierczyńska, A | 3 |
| Fafara, A | 2 |
| Kwiatkowski, S | 4 |
| Szlachta Jezioro, I | 1 |
| Kawecka, J | 2 |
| Andrade, EO | 1 |
| Charles, D | 1 |
| Li, G | 1 |
| Lin, SC | 1 |
| Henderson, JM | 1 |
| Kolaski, K | 1 |
| Logan, LR | 1 |
| Hattan, E | 1 |
| Angle, MR | 1 |
| Chalk, C | 1 |
| Mizusawa, H | 1 |
| Ando, Y | 1 |
| Kanaide, M | 1 |
| Uezono, Y | 1 |
| van Doornik, J | 1 |
| Kukke, S | 1 |
| McGill, K | 1 |
| Rose, J | 1 |
| Sherman-Levine, S | 1 |
| Sanger, TD | 1 |
| Carda, S | 1 |
| Cazzaniga, M | 1 |
| Taiana, C | 1 |
| Pozzi, R | 1 |
| Renata, K | 1 |
| Jaworek, M | 1 |
| Fukuhara, T | 1 |
| Tanaka, T | 1 |
| Namba, Y | 1 |
| Kuyama, H | 1 |
| Vernino, S | 1 |
| McEvoy, K | 1 |
| Kroin, JS | 5 |
| Harrison, FG | 1 |
| Keegan, DL | 1 |
| Richardson, JS | 1 |
| Kirby, AR | 1 |
| Sandyk, R | 1 |
| Pedersen, E | 1 |
| Young, RR | 6 |
| Delwaide, PJ | 5 |
| McLellan, DL | 3 |
| Kirubakaran, V | 1 |
| Mayfield, D | 1 |
| Rengachary, S | 1 |
| Mårtensson, A | 1 |
| Newman, PM | 1 |
| Nogues, M | 1 |
| Newman, PK | 1 |
| Weightman, D | 1 |
| Hudgson, P | 1 |
| Destee, A | 1 |
| Delaney, JF | 1 |
| Kiesswetter, H | 1 |
| Flamm, J | 1 |
| Hennrich, F | 1 |
| Summer, K | 1 |
| Schober, W | 1 |
| Knutsson, E | 1 |
| Dimitrijevic, MR | 1 |
| Sherwood, AM | 2 |
| Smolenski, C | 1 |
| Muff, S | 1 |
| Smolenski-Kautz, S | 1 |
| Corston, RN | 1 |
| Johnson, F | 1 |
| Godwin-Austen, RB | 1 |
| DeLisa, JA | 1 |
| Little, J | 1 |
| Melnick, ME | 1 |
| Shellenberger, MK | 1 |
| Hassan, N | 1 |
| Tibbs, PA | 1 |
| Young, AB | 1 |
| Walsh, JW | 1 |
| Bean, JR | 1 |
| Ghose, K | 1 |
| Holmes, KM | 1 |
| Matthewson, K | 1 |
| Korsvik, H | 1 |
| Silverglat, MJ | 1 |
| Merritt, JL | 1 |
| Burton, L | 1 |
| Martí-Vilalta, JL | 1 |
| Costa-Jussá, F | 1 |
| Roig, C | 1 |
| McDowell, FH | 1 |
| Lossius, R | 1 |
| Martín Ruiz, E | 1 |
| Molina-Negro, P | 1 |
| Martínez-Lage, J | 1 |
| Sáenz, MJ | 1 |
| Bujanda, M | 1 |
| Barry, MJ | 4 |
| Hoffmann, P | 1 |
| Daneshvar, H | 1 |
| Evans, D | 1 |
| Kestle, JR | 1 |
| Rawlins, P | 2 |
| Bertman, LJ | 1 |
| Advokat, C | 1 |
| York, MM | 3 |
| Paice, JA | 2 |
| Conçalves, J | 1 |
| García-March, G | 3 |
| Sánchez-Ledesma, MJ | 3 |
| Onzaín, I | 1 |
| Broseta, J | 3 |
| Teddy, PJ | 1 |
| Mitchell, G | 1 |
| Ali, A | 1 |
| York, M | 1 |
| Khorasani, A | 1 |
| Peruzzi, WT | 1 |
| Campbell, SK | 1 |
| Almeida, GL | 1 |
| Corcos, DM | 3 |
| Dressnandt, J | 2 |
| Auer, C | 1 |
| Conrad, B | 2 |
| Servello, D | 1 |
| Brock, S | 1 |
| Lataste, X | 1 |
| Emre, M | 1 |
| Groves, L | 1 |
| Akman, MN | 2 |
| Loubser, PG | 5 |
| Fife, CE | 1 |
| Donovan, WH | 4 |
| Jamous, A | 4 |
| Kennedy, P | 1 |
| Psychol, C | 1 |
| Grey, N | 1 |
| Helén, P | 1 |
| Kuurne, T | 1 |
| Kloke, M | 1 |
| Bingel, U | 1 |
| Seeber, S | 1 |
| Parziale, JR | 1 |
| Akelman, E | 1 |
| Herz, DA | 2 |
| Ochs, GA | 1 |
| Patterson, V | 1 |
| Watt, M | 1 |
| Byrnes, D | 1 |
| Crowe, D | 1 |
| Gianino, J | 2 |
| Rivas, DA | 1 |
| Chancellor, MB | 1 |
| Hill, K | 1 |
| Freedman, MK | 1 |
| Barron, WB | 1 |
| Fasick, MP | 2 |
| Polinko, P | 1 |
| Janosky, J | 2 |
| Schurch, B | 1 |
| Gulati, SK | 1 |
| Kronenberg, MF | 1 |
| Bauer, G | 1 |
| Looman, JE | 1 |
| Aisen, ML | 1 |
| Dietz, M | 1 |
| McDowell, F | 1 |
| Kutt, H | 1 |
| Abel, NA | 1 |
| Smith, RA | 1 |
| Lewis, KS | 1 |
| Mueller, WM | 1 |
| Hugenholtz, H | 1 |
| Nelson, RF | 1 |
| Dehoux, E | 1 |
| Narayan, RK | 2 |
| O'Neill, ME | 1 |
| Rossi, CD | 1 |
| Mandac, BR | 1 |
| Nelson, VS | 2 |
| Coffey, JR | 1 |
| Cahill, D | 1 |
| Steers, W | 1 |
| Ordia, J | 1 |
| Meythaler, J | 1 |
| Herman, R | 1 |
| Shetter, AG | 1 |
| Levy, R | 1 |
| Gill, B | 1 |
| Acland, RH | 1 |
| Azouvi, P | 3 |
| Roby-Brami, A | 2 |
| Biraben, A | 1 |
| Thurel, C | 1 |
| Becker, WJ | 1 |
| Harris, CJ | 1 |
| Long, ML | 1 |
| Ablett, DP | 1 |
| Klein, GM | 1 |
| DeForge, DA | 1 |
| Gianino, JM | 2 |
| Pirotte, B | 1 |
| Heilporn, A | 1 |
| Joffroy, A | 1 |
| Zegers de Beyl, D | 1 |
| Wesel, P | 1 |
| Brotchi, J | 1 |
| Levivier, M | 1 |
| Mane, M | 1 |
| Priebe, MM | 1 |
| Thornby, JI | 1 |
| Kharas, NF | 1 |
| Markowski, J | 1 |
| Middleton, JW | 1 |
| Siddall, PJ | 1 |
| Walker, S | 1 |
| Molloy, AR | 1 |
| Rutkowski, SB | 1 |
| Mertens, P | 4 |
| Parise, M | 2 |
| Garcia-Larrea, L | 2 |
| Benneton, C | 1 |
| Millet, MF | 1 |
| Gardner, B | 2 |
| Teddy, P | 3 |
| Bergstrom, E | 1 |
| Wang, D | 2 |
| Ravichandran, G | 1 |
| Sutton, R | 1 |
| Urquart, S | 1 |
| Bodensteiner, JB | 1 |
| Levin, AB | 1 |
| Sperling, KB | 1 |
| Becker, R | 3 |
| Alberti, O | 1 |
| Bauer, BL | 1 |
| Morel, N | 1 |
| Mauguière, F | 1 |
| Im, D | 1 |
| McDonald, CM | 1 |
| Latash, ML | 2 |
| Kuipers-Upmeijer, H | 2 |
| Bouma, J | 2 |
| Oenema, D | 2 |
| Postma, T | 1 |
| Terpstra, S | 2 |
| Stewart, R | 1 |
| Armstrong, RW | 1 |
| Cochrane, DD | 1 |
| Kube, SD | 1 |
| Fife, SE | 1 |
| Farrell, K | 1 |
| McCary, A | 1 |
| Hadley, MN | 2 |
| Broderick, CP | 1 |
| Radnitz, CL | 1 |
| Gerszten, PC | 2 |
| Reeves, RK | 1 |
| Stolp-Smith, KA | 2 |
| Christopherson, MW | 1 |
| Shott, S | 1 |
| Johnstone, GF | 1 |
| Thompson, E | 1 |
| Hicks, F | 1 |
| Sampathkumar, P | 1 |
| Scanlon, PD | 1 |
| Plevak, DJ | 1 |
| Berg-Johnsen, J | 1 |
| Solgaard, T | 1 |
| Lundar, T | 1 |
| Verdié, JC | 5 |
| Casaux, J | 1 |
| Caraoué, F | 1 |
| Sol, JC | 2 |
| Brenner, R | 1 |
| Hyman, N | 1 |
| Knobler, R | 1 |
| O'Brien, M | 1 |
| Stephan, T | 1 |
| Fakhoury, T | 1 |
| Abou-Khalil, B | 1 |
| Blumenkopf, B | 1 |
| Sure, U | 1 |
| Petermeyer, M | 1 |
| Bertalanffy, H | 2 |
| Guin-Renfroe, S | 2 |
| Grabb, P | 1 |
| Gormley, ME | 1 |
| Southgate, HJ | 1 |
| Masterson, R | 1 |
| Rode, G | 1 |
| Beneton, C | 1 |
| Schmitt, M | 1 |
| Boisson, D | 2 |
| Kamensek, J | 2 |
| Marquardt, G | 2 |
| Lorenz, R | 1 |
| Harmon, RL | 1 |
| Huch, K | 1 |
| Kunz, U | 1 |
| Kluger, P | 1 |
| Puhl, W | 1 |
| Grabb, PA | 2 |
| Postma, TJ | 1 |
| Middel, BJ | 1 |
| Rawicki, B | 1 |
| Nielsen, JF | 3 |
| Sinkjaer, T | 2 |
| Green, LB | 1 |
| Lankhorst, GJ | 1 |
| van Bennekom, CA | 1 |
| Vogelaar, TW | 1 |
| Zed, PJ | 1 |
| Stiver, HG | 1 |
| Devonshire, V | 1 |
| Jewesson, PJ | 1 |
| Marra, F | 1 |
| Kirshblum, S | 1 |
| Ridgeway, B | 1 |
| Wallace, M | 1 |
| Gerayli, A | 1 |
| Van Schaeybroeck, P | 1 |
| Lagae, L | 1 |
| Schrijvers, E | 1 |
| Borghgraef, C | 1 |
| Feys, P | 1 |
| Detrembleur, C | 1 |
| Plaghki, L | 1 |
| Galloway, A | 1 |
| Falope, FZ | 1 |
| Orsnes, GB | 1 |
| Sørensen, PS | 1 |
| Larsen, TK | 1 |
| Ravnborg, M | 1 |
| Anderson, JB | 1 |
| Kita, M | 1 |
| Goodkin, DE | 1 |
| Huraibi, HA | 1 |
| Phillips, J | 1 |
| Rose, RJ | 1 |
| Pallatroni, H | 1 |
| Westbrook, H | 1 |
| Fanciullo, GJ | 1 |
| Butler, C | 1 |
| Campbell, S | 1 |
| Urban, PP | 1 |
| Noth, J | 1 |
| Sindou, MP | 1 |
| Robins, B | 1 |
| Boggs, DP | 1 |
| Gwartz, BL | 1 |
| Ordia, JI | 1 |
| Fischer, E | 1 |
| Adamski, E | 1 |
| Spatz, EL | 1 |
| McCarty, SF | 1 |
| Harvey, RL | 1 |
| Le Breton, F | 1 |
| Daviet, JC | 1 |
| Monteil, J | 1 |
| Munoz, M | 1 |
| Dudognon, P | 1 |
| Salle, JY | 1 |
| Chaseling, R | 1 |
| Burns, AS | 1 |
| Kopell, BH | 1 |
| Sala, D | 1 |
| Doyle, WK | 1 |
| Feldman, DS | 1 |
| von Koch, CS | 1 |
| Smyth, M | 1 |
| Peacock, WJ | 1 |
| Shafton, DH | 1 |
| Hinderer, SR | 3 |
| Dixon, K | 1 |
| Doyle, JS | 1 |
| Huls, C | 1 |
| Tilton, AH | 1 |
| Seifert, V | 1 |
| Autti-Rämö, I | 1 |
| de Louw, AJ | 1 |
| de Vente, J | 1 |
| Steinbusch, HP | 1 |
| Steinbusch, HW | 1 |
| Troost, J | 1 |
| Dachy, B | 1 |
| Schapiro, RT | 1 |
| Di Stefano, MG | 1 |
| Grossi, A | 1 |
| Bono, G | 1 |
| Johnson, H | 1 |
| Parsons, KF | 1 |
| Sunde, N | 1 |
| Christensen, JJ | 1 |
| Cairns, K | 1 |
| Stein, J | 1 |
| Gatscher, S | 1 |
| Uhle, E | 1 |
| Kadies, M | 1 |
| Rösche, J | 1 |
| Sampson, FC | 1 |
| Hayward, A | 1 |
| Evans, G | 1 |
| Morton, R | 1 |
| Collett, B | 1 |
| Davidoff, RA | 2 |
| Herken, H | 1 |
| Meyer-Estorf, G | 1 |
| Halbhübner, K | 1 |
| Loos, D | 1 |
| Milla, PJ | 1 |
| Jackson, AD | 1 |
| Feldman, RG | 2 |
| Kelly-Hayes, M | 1 |
| Conomy, JP | 1 |
| Foley, JM | 1 |
| Sawa, GM | 1 |
| Paty, DW | 1 |
| Reisner, H | 1 |
| Gusta, A | 1 |
| Matwiejko, L | 1 |
| Pienc, A | 1 |
| Duma-Drzewińska, A | 1 |
| Kiwerski, J | 1 |
| Makowski, J | 1 |
| Gautier-Smith, PC | 1 |
| Manelis, J | 1 |
| Giza, T | 1 |
| Slebodzińska, A | 1 |
| Sandford, PR | 1 |
| Spengler, SE | 1 |
| Sawasky, KB | 1 |
| Landau, WM | 1 |
| Frischhut, B | 1 |
| Steers, WD | 2 |
| Haworth, C | 1 |
| Herrell, D | 1 |
| Kronenberg, M | 2 |
| Marosi, MJ | 2 |
| Russegger, L | 3 |
| Gerstenbrand, F | 3 |
| Siegfried, RN | 1 |
| Jacobson, L | 2 |
| Chabal, C | 2 |
| Ossowska, K | 1 |
| Schulze, G | 1 |
| Wolfarth, S | 1 |
| Coper, H | 1 |
| Kaminska, A | 1 |
| Hausmanowa-Petrusewicz, I | 1 |
| Tuel, SM | 1 |
| Cross, LL | 1 |
| Haworth, CS | 1 |
| Narayanaswamy, AS | 1 |
| Milanov, IG | 2 |
| Verhagen, J | 1 |
| Arturo Leis, A | 1 |
| Berić, A | 1 |
| Silver, J | 1 |
| Fodstad, H | 1 |
| Ljunggren, BC | 1 |
| Terman, G | 1 |
| Kravitz, HM | 1 |
| Hansen, G | 1 |
| Cartwright, RD | 1 |
| Stewart-Wynne, EG | 3 |
| Silbert, PL | 1 |
| Buffery, S | 1 |
| Perlman, D | 3 |
| Tan, E | 1 |
| Brouwers, JR | 1 |
| Sahuquillo, J | 1 |
| Muxi, T | 1 |
| Noguer, M | 1 |
| Jodar, R | 1 |
| Closa, C | 1 |
| Rubio, E | 1 |
| Garcia-Fernandez, L | 1 |
| Guitart, JM | 1 |
| Sallerin-Caute, B | 3 |
| Bastide, R | 3 |
| Smith, CR | 1 |
| LaRocca, NG | 1 |
| Giesser, BS | 1 |
| Scheinberg, LC | 1 |
| Anaya, J | 2 |
| Silva, I | 1 |
| Wüllner, U | 2 |
| Klockgether, T | 2 |
| Brar, SP | 1 |
| Smith, MB | 1 |
| Nelson, LM | 1 |
| Franklin, GM | 1 |
| Cobble, ND | 1 |
| Cervi, A | 1 |
| Singletary, J | 1 |
| Sandin, KJ | 1 |
| Russell, KD | 1 |
| Young, MA | 1 |
| Monsarrat, B | 1 |
| Cros, J | 1 |
| Kepplinger, B | 1 |
| Schmutzhard, E | 2 |
| Aichner, F | 2 |
| Lehmann, JF | 1 |
| White, O | 1 |
| deLateur, BJ | 1 |
| Deitz, J | 1 |
| Braunsdorf, WE | 1 |
| Kuhlendahl, HD | 1 |
| Volkheimer, A | 1 |
| Behrens, C | 1 |
| Kleiter, K | 1 |
| Carillo, JP | 1 |
| Sarges, R | 1 |
| Jouaux, J | 1 |
| Runte, W | 1 |
| Lampante, L | 1 |
| Wuis, EW | 2 |
| Dirks, MJ | 1 |
| Vree, TB | 1 |
| Van der Kleijn, E | 1 |
| Satoyoshi, E | 1 |
| Ochs, G | 1 |
| Struppler, A | 1 |
| Meyerson, BA | 1 |
| Linderoth, B | 2 |
| Gybels, J | 1 |
| Gardner, BP | 1 |
| Weinmann, P | 1 |
| Baumgartner, H | 1 |
| Dralle, D | 4 |
| Neuhäuser, G | 1 |
| Tonn, JC | 1 |
| Meyerson, B | 1 |
| Lind, G | 1 |
| Pellkofer, M | 1 |
| Paulig, M | 1 |
| Medici, M | 1 |
| Pebet, M | 1 |
| Ciblis, D | 1 |
| Savoy, SM | 2 |
| Corcos, D | 2 |
| Latash, M | 1 |
| Gottlieb, G | 1 |
| Parke, B | 2 |
| Frost, F | 2 |
| Nanninga, J | 1 |
| Savoy, S | 1 |
| Wu, Y | 1 |
| Nanninga, JB | 1 |
| Morales, F | 1 |
| Gonzalez-Darder, J | 1 |
| Barberá, J | 1 |
| Macdonell, RA | 1 |
| Talalla, A | 1 |
| Swash, M | 1 |
| Grundy, D | 1 |
| Rice, GP | 3 |
| Rudick, RA | 1 |
| Schiffer, RB | 1 |
| Herndon, RM | 1 |
| Zierski, J | 4 |
| Klug, N | 1 |
| Yu, YB | 1 |
| Duchen, MR | 1 |
| Biscoe, TJ | 1 |
| Jones, RF | 1 |
| Anthony, M | 1 |
| Torda, TA | 1 |
| Poulos, C | 1 |
| Gottlieb, GL | 1 |
| Watanabe, K | 1 |
| Tougeron, A | 1 |
| Wurdinger, T | 1 |
| Eyssette, M | 1 |
| Rohmer, F | 1 |
| Serratrice, G | 1 |
| Warter, JM | 1 |
| Katz, RT | 1 |
| Bass, B | 1 |
| Weinshenker, B | 1 |
| Noseworthy, JH | 1 |
| Cameron, MG | 1 |
| Hader, W | 1 |
| Bouchard, S | 1 |
| Ebers, GC | 1 |
| Hoogstraten, MC | 1 |
| van der Ploeg, RJ | 1 |
| vd Burg, W | 1 |
| Vreeling, A | 1 |
| van Marle, S | 1 |
| Minderhoud, JM | 1 |
| Schwarz, M | 1 |
| Turski, L | 1 |
| Sontag, KH | 1 |
| Siegfried, J | 2 |
| Kasdon, DL | 1 |
| Stien, R | 1 |
| Nordal, HJ | 1 |
| Oftedal, SI | 1 |
| Slettebø, M | 1 |
| Börner, U | 2 |
| Hoffmann, O | 1 |
| Hankey, GJ | 2 |
| Basmajian, JV | 1 |
| Giles, KE | 1 |
| Wainapel, SF | 1 |
| Lee, L | 1 |
| Riley, TL | 1 |
| Roy, CW | 1 |
| Wakefield, IR | 1 |
| Hempelmann, G | 1 |
| Roussan, M | 1 |
| Terrence, C | 1 |
| Fromm, G | 1 |
| Claverie, P | 1 |
| Deonna, T | 1 |
| Frerebeau, P | 1 |
| Alexandre, F | 1 |
| Angelini, L | 1 |
| Benezech, J | 1 |
| Hulme, A | 1 |
| MacLennan, WJ | 1 |
| Ritchie, RT | 1 |
| John, VA | 1 |
| Shotton, PA | 1 |
| Ducamp, E | 1 |
| Albin, H | 1 |
| Barat, M | 1 |
| Garabedian-Ruffalo, SM | 1 |
| Ruffalo, RL | 1 |
| Larsen, TA | 1 |
| Teräväinen, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effectiveness of the Neural Mobilization on Upper Limb Functionality in Patients With Acquired Brain Injury: Randomized, Controlled, Multi-Centric, Single-Blind Clinical Trial[NCT04652934] | 24 participants (Actual) | Interventional | 2022-01-26 | Completed | |||
| A Randomized, Controlled, Open-label, Parallel-group, Multi-center Study to Compare the Effect of Intrathecal Baclofen Therapy Versus Best Medical Treatment on Severe Spasticity in Post-stroke Patients After 6 Months Active Treatment[NCT01032239] | Phase 4 | 61 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Long-term Outcomes of Selective Dorsal Rhizotomy Among Individuals With Cerebral Palsy Compared to a Matched Control Group[NCT03789786] | 78 participants (Actual) | Observational | 2018-11-01 | Completed | |||
| Chronic Postsurgical Pain in Cerebral Palsy[NCT05764681] | 500 participants (Anticipated) | Observational | 2023-03-31 | Not yet recruiting | |||
| Neural Operant Conditioning to Improve Walking After Stroke[NCT06113965] | 60 participants (Anticipated) | Interventional | 2024-05-31 | Recruiting | |||
| The Effects of EXOPULSE Mollii Suit on Spasticity and Muscular Oxygenation in Patients With Multiple Sclerosis.[NCT05912595] | 36 participants (Anticipated) | Interventional | 2023-05-18 | Recruiting | |||
| Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS): A Randomized, Controlled, Multi-center, Prospective Study Evaluating Dose Reduction in ITB Patients.[NCT04530955] | 92 participants (Anticipated) | Interventional | 2020-09-24 | Recruiting | |||
| Feasibility of Measuring Cerebrospinal Fluid (CSF) Signatures in Subjects With Intrathecal Catheter-Related Problems[NCT01117090] | 47 participants (Actual) | Observational | 2010-06-30 | Completed | |||
| Effects of Neuromuscular Electrical Stimulation on Walking Ability and Quality of Life in Individuals With Chronic Stroke[NCT04673045] | 40 participants (Anticipated) | Interventional | 2021-02-02 | Recruiting | |||
| Inter-Rater Reliability of a Spasticity Diagnosis Algorithm[NCT01644123] | 72 participants (Actual) | Observational | 2013-04-30 | Completed | |||
| Evaluating the Efficacy of Obturator Cryoneurotomy for Hip Adductor Spasticity[NCT05147441] | 20 participants (Anticipated) | Observational | 2021-08-10 | Recruiting | |||
| Using Telemedicine to Improve Spasticity Diagnosis Rates[NCT03211390] | 60 participants (Actual) | Observational | 2018-01-30 | Completed | |||
| Prevalence of Comorbid Spasticity and Urinary Incontinence in Residents of a Long-Term Care Facility[NCT03250988] | 60 participants (Actual) | Observational | 2018-01-30 | Completed | |||
| Validity and Inter-Rater Reliability of a Novel Bedside Referral Tool for Spasticity[NCT03209960] | 60 participants (Actual) | Observational | 2018-01-30 | Completed | |||
| NARCOMS Global Multiple Sclerosis Registry: A Long-Term Study to Facilitate Research in Multiple Sclerosis[NCT01018537] | 50,000 participants (Anticipated) | Observational [Patient Registry] | 1996-01-31 | Recruiting | |||
| Using Patient-Reported Outcomes To Improve the Care of People With Multiple Sclerosis: A Randomized Trial[NCT04979546] | 356 participants (Anticipated) | Interventional | 2021-11-04 | Recruiting | |||
| Immediate Effect of Transcutaneous Electrical Nerve Stimulation on Muscle Tone in Children With Spastic Cerebral Palsy[NCT05649254] | 22 participants (Anticipated) | Observational | 2022-11-30 | Recruiting | |||
| Intrathecal (IT) Baclofen Drug Distribution Pilot Study[NCT02903823] | Phase 4 | 27 participants (Actual) | Interventional | 2016-04-22 | Completed | ||
| Spasticity Multidisciplinary Management : QoL and Physical Activity Measurement With Connected Health Devices (PEPS)[NCT06138418] | 30 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | |||
| The Use of Penile Vibratory Stimulation to Decrease Spasticity Following Spinal Cord Injury[NCT00223873] | 30 participants | Interventional | 2002-11-30 | Completed | |||
| A Randomized, Placebo Controlled Trial of Botulinum Toxin for Paratonic Rigidity in People With Advanced Cognitive Impairment[NCT02212119] | Phase 2 | 10 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Incobotulinumtoxin Type A for the Functional Improvement of Lower Extremity Spasticity in Patients With Multiple Sclerosis[NCT01968902] | Phase 4 | 27 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Pros and Cons of Botulinum Injection Treatment in Cerebral Palsy: A Qualitative Study Examining the Caregiver's Perspectives[NCT04256187] | 21 participants (Actual) | Observational | 2019-11-01 | Completed | |||
| Intrathecal Baclofen. Evaluation of a Therapy for Refractory Spasticity in Children With Cerebral Palsy[NCT00367068] | Phase 3 | 18 participants | Interventional | 2002-01-31 | Completed | ||
| Role of Functional Neurosurgery in Management of Spasticity[NCT05731648] | 40 participants (Anticipated) | Observational | 2023-03-01 | Not yet recruiting | |||
| Energy Costs of Spasticity in Spinal Cord Injury: A Pilot Investigation[NCT00572845] | 20 participants (Actual) | Interventional | 2008-01-31 | Terminated (stopped due to Unable to recruit enough participants.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in average 10MTWT from baseline to month 6 beetween ITB and BMT arm. Change=10MTWT at month 6 - 10MTWT at baseline (NCT01032239)
Timeframe: Baseline and month 6
| Intervention | seconds (Mean) |
|---|---|
| ITB Therapy | 4.86 |
| Best Medical Treatment (BMT) | -2.48 |
"AS is a manual test, measuring the resistance to passive movement about a joint with varying degrees of velocity. Scores range from 1-5, with 5 choices. A score of 1 indicates no resistance, and 5 indicates rigidity. The following muscle groups in the lower extremities were assessed: hip flexors, hip adductors, knee extensors, knee flexors, plantar flexors and ankle-dorsal flexors. Average AS was calculated as the average of AS scores of the 6 muscles of the affected lower extremity. Change in average AS in affected lower extremities from baseline to month 6 between ITB and BMT arm was assessed.~Change= AS at month 6 - AS at baseline." (NCT01032239)
Timeframe: Baseline and month 6
| Intervention | units on a scale (Mean) |
|---|---|
| ITB Therapy | -0.99 |
| Best Medical Treatment (BMT) | -0.43 |
"AS is a manual test, measuring the resistance to passive movement about a joint with varying degrees of velocity. Scores range from 1-5, with 5 choices. A score of 1 indicates no resistance, and 5 indicates rigidity. The following muscle groups in the upper extremities were assessed: wrist flexors, elbow flexors, elbow extensors, shoulder abductors and shoulder adductors. Average AS was calculated as the average of AS scores of the 5 muscles of the affected lower extremities. Change in average AS in affected upper extremities from baseline to month 6 between ITB and BMT arm was assessed.~Change= AS at month 6 - AS at baseline." (NCT01032239)
Timeframe: Baseline and month 6
| Intervention | units on a scale (Mean) |
|---|---|
| ITB Therapy | -0.66 |
| Best Medical Treatment (BMT) | -0.17 |
FIM contains 18 items composed of 13 motor tasks and 5 cognitive tasks. Tasks are rated on a 7-point ordinal scale that ranges from total assistance (or complete dependence) to complete independence. Ratings should reflect actual observed performance, not capability. Total score ranges from 18 (lowest) to 126 (highest) level of independence. Change in FIM total score from baseline to month 6 between ITB and BMT arm was assessed. Change=FIM score at month 6 - FIM score at baseline. (NCT01032239)
Timeframe: Baseline and month 6
| Intervention | units on a scale (Mean) |
|---|---|
| ITB Therapy | 2.68 |
| Best Medical Treatment (BMT) | -2.58 |
"SS-QoL questionnaire is a self-assessed quality of life questionnaire specifically designed for post-stroke patients. It evaluates 49 items across 12-domains: personality, energy, language, mobility, vision, upper extremity function, thinking, mood, work/productivity, self-care, and family and social roles. Each item is rated on a 5-point Likert Scale, measuring either positive or negative response to a statement. Summary score is composed of an unweighted average of the 12 domain scores, with higher scores indicating better QoL. Total score ranges from 1 to 5. Change in SS-QoL summary score from baseline to month 6 between ITB and BMT arm was assessed.~Change=SS-QoL score at month 6 - SS-QoL score at baseline." (NCT01032239)
Timeframe: Baseline and month 6
| Intervention | units on a scale (Mean) |
|---|---|
| ITB Therapy | 0.26 |
| Best Medical Treatment (BMT) | 0.05 |
"The EQ-5D-3L is a generic measure of health status consisting in the EQ-5D-3L descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system is characterized on five dimensions: mobility, self-care, ability to undertake usual activities, pain and anxiety/depression. Patients were asked to indicate their level of health on each dimension using one of three levels: no health problems, moderate health problems, and severe health problems. Responses from the questionnaire were converted to a single health index utility score; this ranges from -0.595 to 1. EQ VAS records the patient's self-rated health on a vertical visual analogue scale from 0 to 100 where the endpoints are labelled 'Best imaginable health state' (100) and 'Worst imaginable health state' (0). Change in EQ-5D-3L utility score and VAS score from baseline to month 6 between ITB and BMT arm were assessed. Change=EQ-5D-3L utility or VAS score at month 6 - EQ-5D-3L utility or VAS score." (NCT01032239)
Timeframe: Baseline and month 6
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Utility Score | VAS | |
| Best Medical Treatment (BMT) | 0.01 | 4.40 |
| ITB Therapy | 0.09 | 9.68 |
"NPRS is designed to assess the level of pain a patient is feeling at a point in time. The following questions has been presented to patients: What is your actual spasticity-related or spasm-related pain? What was your least spasticity-related or spasm-related pain during the last week? What was your worst spasticity-related or spasm-related pain during the last week? The patient indicated how much pain he is feeling on a scale from 0 to 10. A score of 0 (zero) is no pain while a score of 10 (ten) is worst possible pain. Change in NPRS related to actual, least or worst pain from baseline to month 6 between ITB and BMT arm was assessed. Change=NPRS at month 6 - NPRS at baseline." (NCT01032239)
Timeframe: Baseline and month 6
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Actual pain | Least Pain | Worst Pain | |
| Best Medical Treatment (BMT) | 0.00 | 0.24 | -0.04 |
| ITB Therapy | -1.17 | -1.61 | -1.35 |
The SF-12 is generic assessment of health-related quality of life, which evaluates 8 health dimensions (physical functioning, role physical, bodily pain, vitality, social functioning, role emotional, mental health, and general health). Subscale scores for each dimension were aggregated into summary scores for physical (PCS) and mental health (MCS) components (ranging from 0 to 100, with higher scores indicating better health). Changes in the PCS and MCS from baseline to Month 6 were both compared between the BMT and ITB arms. Change=SF-12 score at month 6 - SF-12 score at baseline. (NCT01032239)
Timeframe: Baseline and month 6
| Intervention | units on a scale (Mean) | |
|---|---|---|
| PCS | MCS | |
| Best Medical Treatment (BMT) | -1.13 | -0.82 |
| ITB Therapy | 3.13 | 1.05 |
Number of patients with healthcare professional contacts outside of study visits in the ITB and BMT between baseline and months 6 (NCT01032239)
Timeframe: baseline, ITB test (only ITB arm), second assessment (only BMT arm), week 6 (only ITB arm), month 3, month 6
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline : general practitioner | Baseline : neurologist | Baseline : nurse (hospital setting) | Baseline : nurse (home care) | Baseline : orthopedic surgeon | Baseline : other | ITB test:general practitioner | ITB test: neurologist | ITB test :other | Second Assessment: general practitioner | Second Assessment: neurologist | Second Assessment: nurse (home care) | Second Assessment: other | week 6: general practitioner | week 6: nurse (hospital setting) | week 6: other | month 3: general practitioner | month 3: neurologist | month 3: other | month 6: general practitioner | month 6: neurologist | month 6: other | |
| Best Medical Treatment (BMT) | 8 | 8 | 0 | 1 | 0 | 13 | NA | NA | NA | 5 | 1 | 1 | 4 | NA | NA | NA | 8 | 3 | 9 | 7 | 2 | 11 |
| ITB Therapy | 14 | 4 | 1 | 0 | 3 | 10 | 1 | 1 | 3 | NA | NA | NA | NA | 4 | 2 | 2 | 7 | 1 | 6 | 8 | 3 | 8 |
Patient was asked to transfer from the wheelchair to bed without human assistance. High level functional patient (HLP) could transfer. Low level functional patient (LLP) was not able to transfer. Comparison of the number and percentage of HLP and LLP between ITB and BMT arms was evaluated. (NCT01032239)
Timeframe: baseline, month 3, month 6
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline72364475 | Baseline72364476 | Month 372364475 | Month 372364476 | Month 672364475 | Month 672364476 | |||||||
| HLP | LLP | |||||||||||
| ITB Therapy | 22 | |||||||||||
| Best Medical Treatment (BMT) | 24 | |||||||||||
| ITB Therapy | 9 | |||||||||||
| Best Medical Treatment (BMT) | 21 | |||||||||||
| ITB Therapy | 6 | |||||||||||
| ITB Therapy | 19 | |||||||||||
| Best Medical Treatment (BMT) | 19 | |||||||||||
| ITB Therapy | 5 | |||||||||||
| Best Medical Treatment (BMT) | 5 | |||||||||||
"Patients were presented with two statements (I am satisfied with the reduction in spasticity provided by my treatment, and I would recommend this therapy to a friend). They agreed, disagreed or were neutral with the statements." (NCT01032239)
Timeframe: month 6
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient Satisfaction with Spasticity Reduction72364475 | Patient Satisfaction with Spasticity Reduction72364476 | Patient Therapy Reccomandation72364475 | Patient Therapy Reccomandation72364476 | |||||||||
| disagree | neutral | agree | ||||||||||
| ITB Therapy | 2 | |||||||||||
| Best Medical Treatment (BMT) | 7 | |||||||||||
| ITB Therapy | 4 | |||||||||||
| ITB Therapy | 16 | |||||||||||
| Best Medical Treatment (BMT) | 11 | |||||||||||
| Best Medical Treatment (BMT) | 5 | |||||||||||
| ITB Therapy | 3 | |||||||||||
| Best Medical Treatment (BMT) | 4 | |||||||||||
| Best Medical Treatment (BMT) | 14 | |||||||||||
Collect and characterize, by comparison with the physician's standard trouble-shooting diagnosis, CSF signatures recorded in subjects who have an infusion system who present with signs and/or symptoms of possible catheter-related problems or failure. (NCT01117090)
Timeframe: 1 day
| Intervention | Subjects whose CSF data agree with MD Dx (Number) |
|---|---|
| Subjects With Normal Catheter Function by Physician Diagnosis | 13 |
| Subjects With Catheter Complications by Physician Diagnosis | 16 |
Characterize the relationship between pressure decay-to-baseline time (in seconds) and the physician's standard trouble-shooting diagnosis (NCT01117090)
Timeframe: 1 day
| Intervention | seconds (Mean) |
|---|---|
| Subjects With Normal Catheter Function by Physician Diagnosis | 6.4 |
| Subjects With Catheter Complications by Physician Diagnosis | 19.9 |
Collect and characterize, by comparison with the physician's standard trouble-shooting diagnosis, the mean change in CSF pressure data during the physical task of a cough (NCT01117090)
Timeframe: 1 day
| Intervention | mmHg (Mean) |
|---|---|
| Subjects With Normal Catheter Function by Physician Diagnosis | 21.0 |
| Subjects With Catheter Complications by Physician Diagnosis | 6.6 |
Collect and characterize, by comparison with the physician's standard trouble-shooting diagnosis, the mean change in CSF pressure data during the physical task of a valsalva maneuver (NCT01117090)
Timeframe: 1 day
| Intervention | mmHg (Mean) |
|---|---|
| Subjects With Normal Catheter Function by Physician Diagnosis | 18.7 |
| Subjects With Catheter Complications by Physician Diagnosis | 4.8 |
"The Modified Ashworth Scale (MAS) is a 6-point scale (Standard MAS scale values: 0, 1, 1.5, 2, 3, or 4) used to evaluate spasticity based on grading muscle tone by moving joints. The MAS scores in this cohort are measured in biceps, triceps and forearm flexor muscles in upper extremities; and quadriceps, hamstrings and gastrocnemius muscles in lower extremities. The score ranges from 0 (no increase in muscle tone) to 4 (affected part(s) rigid in flexion or extension). Improvement in spasticity was a reduction in MAS score by 1 point across a joint tested. Maximal MAS change is the sum of MAS score reduction in all four limbs tested.~This outcome looks at subjects with spasticity of cerebral origin." (NCT02903823)
Timeframe: Baseline to 6 hours post-injection
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Cervical level 4 injection site | Thoracic level 3 injection site | Thoracic level 10 injection site | Lumbar lever 2 injection site | |
| Subjects With Max MAS Change | 8 | 7 | 3 | 3 |
"The Modified Ashworth Scale (MAS) is a 6-point scale (Standard MAS scale values: 0, 1, 1.5, 2, 3, or 4) used to evaluate spasticity based on grading muscle tone by moving joints. The MAS scores in this cohort are measured in biceps, triceps and forearm flexor muscles in upper extremities; and quadriceps, hamstrings and gastrocnemius muscles in lower extremities. The score ranges from 0 (no increase in muscle tone) to 4 (affected part(s) rigid in flexion or extension). Improvement in spasticity was a reduction in MAS score by 1 point across a joint tested. Maximal MAS change is the sum of MAS score reduction in all four limbs tested.~This outcome looks at subjects with spasticity of spinal origin." (NCT02903823)
Timeframe: Baseline to 6 hours post-injection
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Cervical spine level 4 injection site | Thoracic level 3 injection site | Thoracic level 10 injection site | Lumbar level 2 injection site | |
| Subjects With MAS Change - Based on Site of Injection | 4 | 2 | 5 | 3 |
159 reviews available for baclofen and Clasp-Knife Spasticity
| Article | Year |
|---|---|
Intrathecal Baclofen Monotherapy and Polyanalgesia for Treating Chronic Pain in Patients with Severe Spasticity.
Topics: Baclofen; Chronic Pain; Humans; Muscle Relaxants, Central; Muscle Spasticity; Quality of Life | 2021 |
Infectious Complications and Operative Management of Intrathecal Baclofen Pumps in the Pediatric Population: A Systematic Review and Meta-Analysis of 20 Years of Pooled Experience.
Topics: Adult; Baclofen; Child; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Relaxants, C | 2022 |
Intrathecal baclofen pumps: what the neurologist needs to know.
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Relaxants, Central; Muscle | 2022 |
Intrathecal and Oral Baclofen Use in Adults With Spinal Cord Injury: A Systematic Review of Efficacy in Spasticity Reduction, Functional Changes, Dosing, and Adverse Events.
Topics: Activities of Daily Living; Adult; Baclofen; Humans; Injections, Spinal; Muscle Relaxants, Central; | 2023 |
The impact of intrathecal baclofen on the ability to walk: A systematic review.
Topics: Adult; Baclofen; Humans; Injections, Spinal; Muscle Relaxants, Central; Muscle Spasticity; Walking | 2023 |
Neurosurgical management of elevated tone in childhood: interventions, indications and uncertainties.
Topics: Baclofen; Cerebral Palsy; Child; Dystonia; Humans; Muscle Relaxants, Central; Muscle Spasticity; Rhi | 2023 |
Spasticity Interventions: Decision-Making and Management.
Topics: Baclofen; Child; Humans; Muscle Spasticity; Neurosurgical Procedures; Physical Examination; Rhizotom | 2023 |
Deep brain stimulation and intrathecal/intraventricular baclofen for glutaric aciduria type 1: A scoping review, individual patient data analysis, and clinical trials review.
Topics: Baclofen; Deep Brain Stimulation; Dystonia; Dystonic Disorders; Humans; Muscle Relaxants, Central; M | 2023 |
Spasticity and movement disorders in cerebral palsy.
Topics: Baclofen; Cerebral Palsy; Child; Dystonia; Humans; Movement Disorders; Muscle Relaxants, Central; Mu | 2023 |
Spasticity treatment in Norwegian hospitals.
Topics: Baclofen; Botulinum Toxins; Hospitals; Humans; Muscle Spasticity; Norway | 2023 |
[Surgical procedures for treatment of spasticity].
Topics: Baclofen; Cerebral Palsy; Child; Humans; Muscle Spasticity; Quality of Life; Rhizotomy | 2023 |
Intrathecal Drug Delivery.
Topics: Analgesics, Non-Narcotic; Analgesics, Opioid; Baclofen; Cancer Pain; Chronic Pain; Drug Delivery Sys | 2020 |
Severe Neuromuscular Scoliosis Implicated by Dysfunction of Intrathecal Baclofen Pump: Case Report and Review of the Literature.
Topics: Baclofen; Child; Equipment Failure; Female; Humans; Hypoxia, Brain; Infusion Pumps, Implantable; Inj | 2020 |
Surgical Tone Reduction in Cerebral Palsy.
Topics: Baclofen; Cerebral Palsy; Deep Brain Stimulation; Dystonia; Humans; Injections, Spinal; Muscle Relax | 2020 |
Effects of intrathecal baclofen therapy in subjects with disorders of consciousness: a reappraisal.
Topics: Baclofen; Consciousness; gamma-Aminobutyric Acid; Humans; Injections, Spinal; Muscle Relaxants, Cent | 2020 |
Role of Baclofen in Modulating Spasticity and Neuroprotection in Spinal Cord Injury.
Topics: Baclofen; Humans; Injections, Spinal; Muscle Relaxants, Central; Muscle Spasticity; Neuroprotection; | 2022 |
Baclofen Toxicity Mimicking Brain Death: A Case Report of a Pediatric Patient.
Topics: Adult; Baclofen; Brain Death; Child; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; | 2021 |
Effectiveness and safety of cervical catheter tip placement in intrathecal baclofen treatment of spasticity: A systematic review.
Topics: Adult; Arm; Baclofen; Catheterization; Humans; Infusions, Spinal; Leg; Male; Middle Aged; Muscle Rel | 2021 |
Hypertonia.
Topics: Baclofen; Dystonia; Humans; Muscle Hypertonia; Muscle Relaxants, Central; Muscle Spasticity | 2017 |
Interventions for managing skeletal muscle spasticity following traumatic brain injury.
Topics: Baclofen; Botulinum Toxins, Type A; Brain Injuries, Traumatic; Casts, Surgical; Electric Stimulation | 2017 |
A mixed treatment comparison on efficacy and safety of treatments for spasticity caused by multiple sclerosis: a systematic review and network meta-analysis.
Topics: Baclofen; Botulinum Toxins, Type A; Cannabinoids; Clonidine; Diazepam; Humans; Multiple Sclerosis; M | 2018 |
Intrathecal Baclofen Therapy-Practical Approach: Clinical Benefits and Complication Management.
Topics: Baclofen; Cerebral Palsy; Humans; Injections, Spinal; Muscle Relaxants, Central; Muscle Spasticity | 2018 |
A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.
Topics: Baclofen; Cannabidiol; Disease Progression; Dronabinol; Drug Combinations; Gait Disorders, Neurologi | 2018 |
Neurosurgical Management of Spastic Conditions of the Upper Extremity.
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Muscle Relaxants, Central; Muscle Spasticity; Neurosu | 2018 |
Intrathecal Therapies.
Topics: Adult; Baclofen; Female; Humans; Injections, Spinal; Male; Motor Neuron Disease; Muscle Relaxants, C | 2018 |
Management of spasticity revisited.
Topics: Baclofen; Botulinum Toxins; Combined Modality Therapy; Holistic Health; Humans; Injections, Intramus | 2013 |
Examining the effectiveness of intrathecal baclofen on spasticity in individuals with chronic spinal cord injury: a systematic review.
Topics: Baclofen; Humans; Injections, Spinal; Muscle Relaxants, Central; Muscle Spasticity; Spinal Cord Inju | 2014 |
[Role of neurosurgical management in movement disorders other than Parkinson disease].
Topics: Baclofen; Deep Brain Stimulation; Dystonia; Humans; Injections, Spinal; Movement Disorders; Muscle S | 2013 |
Clinical relevance of pharmacological and physiological data in intrathecal baclofen therapy.
Topics: Animals; Baclofen; Drug Tolerance; GABA-B Receptor Agonists; Humans; Infusions, Spinal; Muscle Spast | 2014 |
Spasticity and the use of intrathecal baclofen in patients with spinal cord injury.
Topics: Baclofen; Equipment Failure; GABA-B Receptor Agonists; Humans; Infusion Pumps, Implantable; Infusion | 2014 |
Intrathecal baclofen in multiple sclerosis.
Topics: Baclofen; Humans; Injections, Spinal; Multiple Sclerosis; Muscle Relaxants, Central; Muscle Spastici | 2014 |
Intrathecal baclofen: effects on spasticity, pain, and consciousness in disorders of consciousness and locked-in syndrome.
Topics: Baclofen; Consciousness; Consciousness Disorders; Drug Administration Schedule; Humans; Injections, | 2015 |
Scoliosis, spinal fusion, and intrathecal baclofen pump implantation.
Topics: Baclofen; Cerebral Palsy; Humans; Infusion Pumps, Implantable; Muscle Relaxants, Central; Muscle Spa | 2015 |
Intrathecal baclofen bolus dosing and catheter tip placement in pediatric tone management.
Topics: Adolescent; Baclofen; Catheterization; Cerebral Palsy; Drug Administration Schedule; Humans; Infusio | 2015 |
Spasticity and intrathecal baclofen.
Topics: Adult; Aged; Baclofen; Humans; Injections, Spinal; Middle Aged; Muscle Relaxants, Central; Muscle Sp | 2014 |
[Intrathecal Baclofen Therapy for Cerebral Palsy].
Topics: Animals; Baclofen; Brain; Cerebral Palsy; Humans; Injections, Spinal; Muscle Spasticity; Treatment O | 2015 |
Effectiveness of Oral Baclofen in the Treatment of Spasticity in Children and Adolescents With Cerebral Palsy.
Topics: Adolescent; Baclofen; Cerebral Palsy; Child; Child, Preschool; Female; Humans; Male; Muscle Relaxant | 2016 |
Intrathecal baclofen for treating spasticity in children with cerebral palsy.
Topics: Adolescent; Baclofen; Cerebral Palsy; Child; Child, Preschool; Humans; Injections, Spinal; Muscle Re | 2015 |
Clinical practices in intrathecal baclofen pump implantation in children with cerebral palsy in France.
Topics: Baclofen; Cerebral Palsy; Child; Child, Preschool; France; Humans; Infusion Pumps, Implantable; Infu | 2016 |
Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.
Topics: Amines; Analgesics; Baclofen; Cannabidiol; Clonidine; Cyclohexanecarboxylic Acids; Dantrolene; Diaze | 2016 |
Best Practices for Intrathecal Baclofen Therapy: Dosing and Long-Term Management.
Topics: Baclofen; Dose-Response Relationship, Drug; Humans; Injections, Spinal; Longitudinal Studies; Muscle | 2016 |
Best Practices for Intrathecal Baclofen Therapy: Screening Test.
Topics: Baclofen; Humans; Injections, Spinal; Mass Screening; Muscle Relaxants, Central; Muscle Spasticity; | 2016 |
Best Practices for Intrathecal Baclofen Therapy: Patient Selection.
Topics: Baclofen; Databases, Bibliographic; Humans; Injections, Spinal; Muscle Relaxants, Central; Muscle Sp | 2016 |
Best Practices for Intrathecal Baclofen Therapy: Troubleshooting.
Topics: Baclofen; Humans; Injections, Spinal; Muscle Relaxants, Central; Muscle Spasticity; Practice Guideli | 2016 |
Pharmacological interventions other than botulinum toxin for spasticity after stroke.
Topics: Baclofen; Botulinum Toxins, Type A; Clonidine; Diazepam; Humans; Muscle Relaxants, Central; Muscle S | 2016 |
Intrathecal Baclofen Therapy for the Treatment of Spasticity in Lithuania.
Topics: Adolescent; Adult; Baclofen; Cerebral Palsy; Child; Epidural Abscess; Humans; Infusion Pumps, Implan | 2017 |
Efficacy and safety of oral baclofen in the management of spasticity: A rationale for intrathecal baclofen.
Topics: Administration, Oral; Adult; Baclofen; Disorders of Excessive Somnolence; Dose-Response Relationship | 2017 |
Managing spasticity with intrathecal drug delivery.
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Relaxants, Central; Muscle | 2008 |
Intrathecal baclofen therapy for neurological disorders: a sound knowledge base but many challenges remain.
Topics: Adult; Baclofen; Catheterization; Cerebral Palsy; Child; Child, Preschool; Dose-Response Relationshi | 2008 |
[Intrathecal baclofen for severe spasticity].
Topics: Adult; Aged; Baclofen; Female; GABA Agonists; Humans; Infusion Pumps, Implantable; Injections, Spina | 2008 |
Consensus on the appropriate use of intrathecal baclofen (ITB) therapy in paediatric spasticity.
Topics: Baclofen; Consensus; Guidelines as Topic; Humans; Injections, Spinal; Muscle Relaxants, Central; Mus | 2010 |
Considerations in the treatment of spasticity with intrathecal baclofen.
Topics: Animals; Baclofen; Humans; Injections, Spinal; Muscle Spasticity; Treatment Outcome | 2009 |
Intrathecal baclofen therapy: an update.
Topics: Baclofen; GABA Agonists; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Hypertonia; | 2009 |
Intrathecal baclofen administration during pregnancy: a case series and focused clinical review.
Topics: Adult; Baclofen; Female; Humans; Injections, Spinal; Muscle Relaxants, Central; Muscle Spasticity; P | 2009 |
Reduced level of consciousness from baclofen in people with low kidney function.
Topics: Back Pain; Baclofen; Coma; Female; Humans; Kidney Failure, Chronic; Middle Aged; Muscle Relaxants, C | 2009 |
[New therapies for spastic movement disorders].
Topics: Administration, Oral; Baclofen; Botulinum Toxins, Type A; Cannabinoids; Clonidine; Diazepam; Humans; | 2009 |
Acute intrathecal baclofen withdrawal: a brief review of treatment options.
Topics: Acute Disease; Baclofen; Female; Humans; Injections, Spinal; Middle Aged; Muscle Relaxants, Central; | 2011 |
Spasticity: revisiting the role and the individual value of several pharmacological treatments.
Topics: Amines; Baclofen; Botulinum Toxins; Calcium Channel Blockers; Clonidine; Cyclohexanecarboxylic Acids | 2010 |
Managing spasticity with drugs.
Topics: Administration, Oral; Baclofen; Botulinum Toxins, Type A; Clonidine; Humans; Injections, Spinal; Mus | 2010 |
Imaging evaluation of intrathecal baclofen pump-catheter systems.
Topics: Baclofen; Fluoroscopy; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Relaxants, Ce | 2011 |
Pharmacologic treatment of spasticity in children.
Topics: Age Factors; Baclofen; Botulinum Toxins; Child; Clonidine; Dantrolene; Diazepam; Humans; Injections, | 2010 |
Intrathecal baclofen in multiple sclerosis: too little, too late?
Topics: Baclofen; Cost-Benefit Analysis; Drug Costs; Humans; Infusion Pumps, Implantable; Infusions, Parente | 2011 |
Pharmacotherapy of spasticity in children with cerebral palsy.
Topics: Baclofen; Benzodiazepines; Cerebral Palsy; Child; Clonidine; Dantrolene; Humans; Muscle Spasticity; | 2011 |
Use of intrathecal baclofen therapy in ambulant children and adolescents with spasticity and dystonia of cerebral origin: a systematic review.
Topics: Adolescent; Baclofen; Cerebral Cortex; Child; Databases, Factual; Dystonia; Electronic Health Record | 2011 |
Intrathecal baclofen for progressive neurological disease in childhood: a systematic review of literature.
Topics: Adolescent; Adult; Baclofen; Brain Diseases; Child; Child, Preschool; Female; Humans; Injections, Sp | 2012 |
Spasticity following spinal cord injury.
Topics: Administration, Oral; Baclofen; Botulinum Toxins; Critical Pathways; Humans; Infusions, Spinal; Inje | 2012 |
[Pharmacological treatment of spasticity in multiple sclerosis].
Topics: Algorithms; Amines; Baclofen; Botulinum Toxins, Type A; Clonidine; Cyclohexanecarboxylic Acids; Dant | 2012 |
Advances in intrathecal drug delivery.
Topics: Analgesics; Baclofen; Cerebrospinal Fluid; Chronic Pain; Drug Delivery Systems; Humans; Injections, | 2012 |
Intrathecal baclofen withdrawal: a case report and review of the literature.
Topics: Adolescent; Adrenoleukodystrophy; Baclofen; Equipment Failure; Fever; Humans; Infusion Pumps, Implan | 2002 |
Anti-spasticity medications.
Topics: Baclofen; Benzodiazepines; Botulinum Toxins, Type A; Clonidine; Humans; Muscle Relaxants, Central; M | 2003 |
[Intrathecal baclofen. Experimental and pharmacokinetic studies].
Topics: Animals; Baclofen; GABA Agonists; Humans; Injections, Spinal; Muscle Relaxants, Central; Muscle Spas | 2003 |
[Intrathecal baclofen. Literature review of the results and complications].
Topics: Baclofen; Child; Clinical Trials as Topic; GABA Agonists; Humans; Injections, Spinal; Muscle Relaxan | 2003 |
Long-term modification of spasticity.
Topics: Algorithms; Anti-Dyskinesia Agents; Baclofen; Botulinum Toxins; Chronic Disease; Denervation; Humans | 2003 |
Managing spasticity in spinal cord injury: safe administration of bridge boluses during intrathecal baclofen pump refills.
Topics: Baclofen; Dose-Response Relationship, Drug; Humans; Infusion Pumps, Implantable; Infusions, Parenter | 2003 |
Neurosurgical treatment of spasticity and other pediatric movement disorders.
Topics: Athetosis; Baclofen; Child; Chorea; Dystonia; Electric Stimulation Therapy; GABA Agonists; Humans; I | 2003 |
Clinical application of drug pump for spasticity, pain, and restorative neurosurgery: other clinical applications of intrathecal baclofen.
Topics: Baclofen; Cerebrovascular Circulation; Dystonia; Electric Stimulation Therapy; Humans; Infusion Pump | 2003 |
Infected CNS infusion pumps. Is there a chance for treatment without removal?
Topics: Adult; Baclofen; Device Removal; Female; Humans; Infusion Pumps, Implantable; Infusions, Parenteral; | 2004 |
The treatment of cerebral palsy: What we know, what we don't know.
Topics: Activities of Daily Living; Baclofen; Botulinum Toxins, Type A; Brain; Cerebral Palsy; Complementary | 2004 |
A benefit-risk assessment of baclofen in severe spinal spasticity.
Topics: Administration, Oral; Baclofen; Clinical Trials as Topic; Humans; Injections, Spinal; Multiple Scler | 2004 |
Neurophysiologic evaluation of spastic hypertonia: implications for management of the patient with the intrathecal baclofen pump.
Topics: Baclofen; H-Reflex; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Relaxants, Centr | 2004 |
Antispasticity medications: uses and limitations of enteral therapy.
Topics: 4-Aminopyridine; Acetates; Adrenergic alpha-Agonists; Amines; Baclofen; Benzodiazepines; Cyclohexane | 2004 |
[Pharmacology and upper limb poststroke spasticity: a review. International Society of Prosthetics and Orthotics].
Topics: Arm; Baclofen; Botulinum Toxins, Type A; Clonidine; Combined Modality Therapy; Dantrolene; Ergonomic | 2004 |
[Botulinum toxin type A in the treatment plan for cerebral palsy].
Topics: Activities of Daily Living; Adolescent; Adult; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; C | 2001 |
Spasticity after spinal cord injury.
Topics: Baclofen; Humans; Injections, Spinal; Muscle Relaxants, Central; Muscle Spasticity; Spinal Cord Inju | 2005 |
Pharmacological complications of the chronic baclofen infusion in the severe spinal spasticity. Personal experience and review of the literature.
Topics: Adult; Baclofen; Constipation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug | 2004 |
Prolonged intrathecal baclofen withdrawal syndrome. Case report and discussion of current therapeutic management.
Topics: Adult; Baclofen; Humans; Infusion Pumps; Injections, Spinal; Male; Meningitis; Methicillin Resistanc | 2005 |
Pharmacologic interventions for reducing spasticity in cerebral palsy.
Topics: Administration, Oral; Adrenergic alpha-Agonists; Age Factors; Anti-Infective Agents, Local; Baclofen | 2005 |
GABAB receptor: a site of therapeutic benefit.
Topics: Animals; Baclofen; Brain; Clinical Trials as Topic; Cognition; Drug Evaluation, Preclinical; Epileps | 2006 |
Pharmacological interventions for spasticity following spinal cord injury: results of a Cochrane systematic review.
Topics: Baclofen; Clonidine; Dantrolene; Humans; Muscle Relaxants, Central; Muscle Spasticity; Randomized Co | 2006 |
Management of childhood spasticity: a neurosurgical perspective.
Topics: Baclofen; Cerebral Palsy; Humans; Infant; Injections, Spinal; Muscle Relaxants, Central; Muscle Spas | 2006 |
Intrathecal baclofen therapy in children.
Topics: Baclofen; Child; Child, Preschool; Epilepsy; Humans; Infusion Pumps, Implantable; Injections, Spinal | 2006 |
Selection of treatment modalities in children with spastic cerebral palsy.
Topics: Baclofen; Cerebral Palsy; Child; Child, Preschool; Clinical Protocols; Humans; Muscle Relaxants, Cen | 2006 |
Intrathecal baclofen in the treatment of adult spasticity.
Topics: Administration, Oral; Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Rela | 2006 |
Consensus panel guidelines for the use of intrathecal baclofen therapy in poststroke spastic hypertonia.
Topics: Baclofen; Humans; Injections, Spinal; Muscle Relaxants, Central; Muscle Spasticity; Practice Guideli | 2006 |
[Management of increase in spasticity in patients with intrathecal baclofen pumps].
Topics: Baclofen; Decision Trees; GABA Agonists; Humans; Infusion Pumps, Implantable; Injections, Spinal; Le | 2007 |
The pharmacological management of spasticity.
Topics: Baclofen; Clonidine; Dantrolene; Humans; Muscle Relaxants, Central; Muscle Spasticity | 2006 |
Intrathecal baclofen in current neuromodulatory practice: established indications and emerging applications.
Topics: Baclofen; Electric Stimulation Therapy; Electrodes, Implanted; Humans; Muscle Relaxants, Central; Mu | 2007 |
Intrathecal baclofen therapy in patients with severe spasticity.
Topics: Animals; Baclofen; Female; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; Motor Neur | 2007 |
Intrathecal baclofen in the treatment of spasticity.
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Relaxants, Central; Muscle | 2007 |
Intrathecal baclofen for the treatment of spasticity.
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Relaxants, Central; Muscle | 2007 |
Management of spasticity in multiple sclerosis by intrathecal baclofen.
Topics: Baclofen; Humans; Injections, Spinal; Multiple Sclerosis; Muscle Relaxants, Central; Muscle Spastici | 2007 |
Efficacy of intrathecal baclofen delivery in the management of severe spasticity in upper motor neuron syndrome.
Topics: Baclofen; Drug Delivery Systems; Humans; Injections, Spinal; Motor Neuron Disease; Muscle Relaxants, | 2007 |
Intrathecal baclofen in the treatment of spasticity, dystonia and vegetative disorders.
Topics: Baclofen; Dystonia; Humans; Injections, Spinal; Muscle Relaxants, Central; Muscle Spasticity; Persis | 2007 |
Neurophysiological basis and clinical applications of the H-reflex as an adjunct for evaluating response to intrathecal baclofen for spasticity.
Topics: Baclofen; Dose-Response Relationship, Drug; Drug Delivery Systems; H-Reflex; Humans; Muscle Relaxant | 2007 |
The importance of neurorehabilitation to the outcome of neuromodulation in spasticity.
Topics: Baclofen; Electric Stimulation Therapy; Humans; Infusion Pumps, Implantable; Muscle Relaxants, Centr | 2007 |
Functional effects of spinal baclofen.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Baclofen; Child; Child, Preschool; Female; GABA Agonists | 2007 |
Intracranial hypotension from intrathecal baclofen pump insertion. A case report and review of the literature.
Topics: Baclofen; Cerebrospinal Fluid Pressure; Female; Humans; Infusion Pumps, Implantable; Intracranial Hy | 2008 |
A review of the complications of intrathecal baclofen in patients with cerebral palsy.
Topics: Adolescent; Adult; Baclofen; Cerebral Palsy; Child; Humans; Infusion Pumps, Implantable; Infusions, | 2007 |
Relief of symptoms in end-stage neurological conditions.
Topics: Baclofen; Clinical Trials, Phase I as Topic; Cognition Disorders; Deglutition Disorders; Humans; Moo | 2007 |
[Intrathecal baclofen therapy: a new method of treatment for severe spasticity in Japan].
Topics: Baclofen; Humans; Injections, Spinal; Muscle Relaxants, Central; Muscle Spasticity | 2008 |
[Physical and other methods therapy of the spasticity in children].
Topics: Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Child; Drug Administration Schedule; Humans; Inf | 2007 |
Antispastic medication. A review.
Topics: Baclofen; Dantrolene; Diazepam; Electromyography; Humans; Muscle Spasticity | 1981 |
Spasticity: medical and surgical treatment.
Topics: Ambulatory Care; Ataxia; Baclofen; Dantrolene; Diazepam; Electric Stimulation; Electrodes; Electroen | 1980 |
Drug therapy: spasticity (second of two parts).
Topics: Baclofen; Diazepam; Humans; Muscle Spasticity; Parasympatholytics | 1981 |
Implants for spasticity.
Topics: Baclofen; Brain; Electric Stimulation Therapy; Electrodes, Implanted; Equipment Design; Humans; Infu | 1995 |
Update on multiple sclerosis therapy.
Topics: Amantadine; Baclofen; Fatigue; Humans; Immunosuppression Therapy; Interferons; Multiple Sclerosis; M | 1993 |
The effects of intrathecally administered baclofen on function in patients with spasticity.
Topics: Activities of Daily Living; Baclofen; Humans; Injections, Spinal; Muscle Spasticity; Muscle, Skeleta | 1995 |
Comparative profile of tizanidine in the management of spasticity.
Topics: Activities of Daily Living; Baclofen; Clonidine; Diazepam; Humans; Muscle Relaxants, Central; Muscle | 1994 |
[Treatment of spasticity by intrathecal baclofen treatment].
Topics: Baclofen; Female; Humans; Infusion Pumps; Injections, Spinal; Male; Multiple Sclerosis; Muscle Spast | 1993 |
Spasticity: pathophysiology and management.
Topics: Baclofen; Contracture; Humans; Muscle Spasticity; Nerve Block; Physical Therapy Modalities; Reflex, | 1993 |
Local treatment of spasticity.
Topics: Baclofen; Dantrolene; Diazepam; Humans; Muscle Spasticity; Nerve Block; Phenol; Phenols; Physical Th | 1993 |
Intrathecal baclofen.
Topics: Baclofen; Humans; Injections, Spinal; Muscle Spasticity | 1993 |
Intrathecal baclofen for spinal spasticity: implications for nursing practice.
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Long-Term Care; Muscle Spasticity | 1993 |
Intrathecal baclofen for severe spasticity secondary to spinal cord injury.
Topics: Baclofen; Clinical Trials as Topic; Humans; Injections, Spinal; Muscle Spasticity; Spinal Cord Injur | 1993 |
Intrathecal baclofen in cerebral palsy movement disorders.
Topics: Baclofen; Cerebral Palsy; Health Care Costs; Humans; Infusion Pumps, Implantable; Injections, Spinal | 1996 |
The management of cerebral palsy: how can neurosurgery help?
Topics: Adolescent; Baclofen; Botulinum Toxins; Cerebral Palsy; Child; Child, Preschool; GABA Agonists; Huma | 1997 |
An approach to switching patients from baclofen to tizanidine.
Topics: Baclofen; Clinical Competence; Clonidine; Humans; Multiple Sclerosis; Muscle Relaxants, Central; Mus | 1998 |
EEG changes in intrathecal baclofen overdose: a case report and review of the literature.
Topics: Aged; Baclofen; Electroencephalography; Humans; Injections, Spinal; Male; Multiple Sclerosis; Muscle | 1998 |
Continuous intrathecal baclofen infusions. An introduction and overview.
Topics: Adult; Baclofen; Drug Monitoring; Humans; Infusions, Parenteral; Injections, Spinal; Multiple Sclero | 1999 |
Death after acute withdrawal of intrathecal baclofen: case report and literature review.
Topics: Administration, Oral; Adult; Baclofen; Brain Death; Cervical Vertebrae; Equipment Failure; Fatal Out | 1999 |
Treatment alternatives for spinal cord injury related spasticity.
Topics: Baclofen; Botulinum Toxins; Disability Evaluation; Humans; Injections, Spinal; Muscle Relaxants, Cen | 1999 |
Continuous intrathecal baclofen infusions. An introduction and overview.
Topics: Adult; Baclofen; Drug Monitoring; Humans; Infusions, Parenteral; Muscle Spasticity; Nursing Assessme | 1999 |
Drugs used to treat spasticity.
Topics: Baclofen; Clonidine; Dantrolene; Diazepam; Drug Administration Schedule; Humans; Muscle Relaxants, C | 2000 |
Evidence of the effects of intrathecal baclofen for spastic and dystonic cerebral palsy. AACPDM Treatment Outcomes Committee Review Panel.
Topics: Baclofen; Cerebral Palsy; Child; Clinical Trials as Topic; Humans; Injections, Spinal; Leg; Muscle R | 2000 |
Neurosurgery for spasticity.
Topics: Adolescent; Adult; Baclofen; Cerebral Palsy; Child; Child, Preschool; Combined Modality Therapy; Gai | 2000 |
Selective posterior rhizotomy and intrathecal baclofen for the treatment of spasticity.
Topics: Baclofen; Humans; Injections, Spinal; Muscle Spasticity; Patient Selection; Rhizotomy; Spine; Treatm | 2001 |
Physiologic and clinical monitoring of spastic hypertonia.
Topics: Anti-Dyskinesia Agents; Baclofen; Botulinum Toxins; GABA Agonists; Humans; Motor Neurons; Muscle Spa | 2001 |
The contemporary surgical management of spasticity in children.
Topics: Baclofen; Child; GABA Agonists; Humans; Muscle Spasticity; Orthopedic Procedures; Rhizotomy; Treatme | 2001 |
GABA agonists and gabapentin for spastic hypertonia.
Topics: Acetates; Amines; Animals; Anticonvulsants; Baclofen; Benzodiazepines; Cyclohexanecarboxylic Acids; | 2001 |
Principles of pharmaceutical management of spastic hypertonia.
Topics: Anti-Dyskinesia Agents; Baclofen; Benzodiazepines; Botulinum Toxins; Brain Injuries; Clonidine; Dant | 2001 |
Intrathecal baclofen therapy for spastic hypertonia.
Topics: Baclofen; Cerebral Palsy; Drug Overdose; GABA Agonists; Humans; Injections, Spinal; Multiple Scleros | 2001 |
[Treatment of spasticity].
Topics: Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Clonidine; Humans; Injections, Spinal; Muscle Re | 1999 |
Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis.
Topics: Acetates; Amines; Autoimmune Diseases; Baclofen; Benzodiazepines; Botulinum Toxins, Type A; Cannabin | 2001 |
The surgical management of spasticity.
Topics: Baclofen; Electric Stimulation Therapy; Humans; Infusion Pumps; Microsurgery; Muscle Relaxants, Cent | 2002 |
The management of pain in spasticity.
Topics: Administration, Oral; Analgesics; Baclofen; Botulinum Toxins; Humans; Injections, Spinal; Muscle Rel | 2002 |
Pharmacology of spasticity.
Topics: Baclofen; Benzodiazepines; Dantrolene; Humans; Muscle Spasticity; Neurotransmitter Agents; Phenothia | 1978 |
Neurosurgical treatment of spasticity: selective posterior rhizotomy and intrathecal baclofen.
Topics: Adolescent; Adult; Animals; Baclofen; Cerebral Palsy; Child; Female; Humans; Injections, Spinal; Mal | 1992 |
Intrathecal baclofen overdose: report of 7 events in 5 patients and review of the literature.
Topics: Adult; Aged; Baclofen; Drug Overdose; Female; Humans; Injections, Spinal; Male; Muscle Spasticity; P | 1991 |
Advances in drug delivery systems and applications in neurosurgery.
Topics: Adult; Aged; Aged, 80 and over; Animals; Baclofen; Brain Diseases; Equipment Design; Female; Humans; | 1991 |
Medical and surgical treatment of spasticity.
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Muscle Spasticity; Neurologic Examination; Spinal Ner | 1990 |
[Spasticity: therapy of increased reflexes or movement disorder?].
Topics: Baclofen; Clonidine; Combined Modality Therapy; Dantrolene; Diazepam; Glycine; Humans; Locomotion; M | 1990 |
Drug treatment of multiple sclerosis.
Topics: Adrenocorticotropic Hormone; Baclofen; Benzodiazepines; Cerebellar Ataxia; Female; Humans; Multiple | 1987 |
Antispasticity drugs: mechanisms of action.
Topics: Adrenergic alpha-Antagonists; Animals; Anticonvulsants; Baclofen; Benzodiazepines; Central Nervous S | 1985 |
Drug pumps for treatment of neurologic diseases and pain.
Topics: Alzheimer Disease; Baclofen; Bethanechol; Bethanechol Compounds; Catheters, Indwelling; Chronic Dise | 1985 |
[The stiff-man syndrome].
Topics: Baclofen; Diazepam; Humans; Muscle Rigidity; Muscle Spasticity; Syndrome; Valproic Acid | 1987 |
Management of spasticity.
Topics: Baclofen; Dantrolene; Diazepam; Electric Stimulation Therapy; Humans; Injections, Spinal; Muscle Spa | 1988 |
Pharmacotherapy of spasticity: some theoretical and practical considerations.
Topics: Baclofen; Benzodiazepines; Clonidine; Dantrolene; Humans; Muscle Spasticity; Parasympatholytics | 1987 |
Spasticity and drug therapy.
Topics: Baclofen; Dantrolene; Humans; Muscle Spasticity | 1987 |
[Functional neurosurgery of cerebral palsy].
Topics: Adolescent; Adult; Animals; Baclofen; Benzodiazepines; Brain; Brain Diseases; Cerebellar Cortex; Cer | 1985 |
95 trials available for baclofen and Clasp-Knife Spasticity
| Article | Year |
|---|---|
Neuromodulation and quality of life for patient with spasticity after spinal cord injury.
Topics: Baclofen; Female; Humans; Male; Muscle Relaxants, Central; Muscle Spasticity; Pain; Quality of Life; | 2023 |
[Combination of central and peripheral muscle relaxants in the treatment of post-stroke spasticity].
Topics: Baclofen; Botulinum Toxins, Type A; Humans; Muscle Relaxants, Central; Muscle Spasticity; Stroke; Tr | 2019 |
Intrathecal baclofen therapy versus conventional medical management for severe poststroke spasticity: results from a multicentre, randomised, controlled, open-label trial (SISTERS).
Topics: Adult; Aged; Baclofen; Drug Administration Schedule; Female; Humans; Injections, Spinal; Male; Middl | 2018 |
Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity.
Topics: Administration, Oral; Aged; Baclofen; Benzodiazepines; Clonidine; Dantrolene; Female; Humans; Infusi | 2018 |
Efficacy and Safety of Botulinum Toxin Type A in Spasticity Caused by Spinal Cord Injury: A Randomized, Controlled Trial.
Topics: Adult; Baclofen; Botulinum Toxins, Type A; Female; Humans; Injections, Intramuscular; Male; Muscle S | 2018 |
Comparison of the effect of baclofen and transcutaneous electrical nerve stimulation for the treatment of spasticity in multiple sclerosis.
Topics: Adult; Baclofen; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Relaxants, Central; M | 2013 |
Low-dose baclofen therapy raised plasma insulin-like growth factor-1 concentrations, but not into the normal range in a predictable and sustained manner in men with chronic spinal cord injury.
Topics: Adult; Baclofen; Chronic Disease; Dose-Response Relationship, Drug; Humans; Insulin-Like Growth Fact | 2013 |
Intrathecal baclofen improves psychiatric symptoms in spasticity patients.
Topics: Adult; Baclofen; Female; Follow-Up Studies; Humans; Injections, Spinal; Male; Middle Aged; Muscle Re | 2014 |
Intrathecal baclofen therapy for the symptomatic treatment of hereditary spastic paraplegia.
Topics: Adult; Baclofen; Female; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; Middle Aged; | 2014 |
Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
Topics: Adult; Baclofen; Cannabidiol; Clonidine; Dronabinol; Drug Combinations; Female; Humans; Male; Middle | 2016 |
Comparative study of therapeutic response to baclofen vs tolperisone in spasticity.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Baclofen; Cerebral Palsy; Child; Child, Preschool; Femal | 2017 |
Long-term therapy with intrathecal baclofen improves quality of life in children with severe spastic cerebral palsy.
Topics: Adolescent; Baclofen; Cerebral Palsy; Child; Child, Preschool; Female; Humans; Infusion Pumps, Impla | 2017 |
Effects of intrathecal baclofen on perceived sexual functioning in men with spinal cord injury.
Topics: Adult; Baclofen; Erectile Dysfunction; Health Surveys; Humans; Infusion Pumps, Implantable; Longitud | 2008 |
Limitations of intrathecal baclofen for spastic hemiparesis following stroke.
Topics: Adolescent; Adult; Baclofen; Child; Dose-Response Relationship, Drug; Female; GABA Agonists; Gait Di | 2009 |
Intrathecal baclofen infusion for ambulant children with cerebral palsy.
Topics: Baclofen; Cerebral Palsy; Child; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gait; | 2009 |
Efficacy and tolerability of eperisone and baclofen in spastic palsy: a double-blind randomized trial.
Topics: Administration, Oral; Adult; Analysis of Variance; Baclofen; Chi-Square Distribution; Double-Blind M | 2009 |
Oral baclofen administration in persons with chronic spinal cord injury does not prevent the protective effects of spasticity on body composition and glucose homeostasis.
Topics: Administration, Oral; Adult; Baclofen; Blood Glucose; Body Composition; Cross-Sectional Studies; Dos | 2010 |
Efficacy and safety study of arbaclofen placarbil in patients with spasticity due to spinal cord injury.
Topics: Adult; Baclofen; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Female; Human | 2011 |
Pilot study assessing the impact of intrathecal baclofen administration mode on sleep-related respiratory parameters.
Topics: Baclofen; Disabled Persons; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; | 2012 |
Differential effect of baclofen on cortical and spinal inhibitory circuits.
Topics: Adult; Baclofen; Cerebral Cortex; Female; GABA-B Receptor Agonists; H-Reflex; Humans; Injections, Sp | 2013 |
Cost-effectiveness comparison of tizanidine and baclofen in the management of spasticity.
Topics: Baclofen; Clonidine; Cost-Benefit Analysis; Humans; Muscle Relaxants, Central; Muscle Spasticity; Un | 2002 |
The effect of intrathecal baclofen on muscle co-contraction in children with spasticity of cerebral origin.
Topics: Adolescent; Baclofen; Cerebral Palsy; Child; Electromyography; Female; Follow-Up Studies; Humans; In | 2002 |
Long-term intrathecal baclofen therapy for severe spasticity of cerebral origin.
Topics: Adolescent; Baclofen; Brain Diseases; Cerebral Cortex; Child; Dose-Response Relationship, Drug; Foll | 2003 |
Functional assessment following intrathecal baclofen therapy in children with spastic cerebral palsy.
Topics: Activities of Daily Living; Adolescent; Adult; Baclofen; Cerebral Palsy; Child; Child, Preschool; Co | 2003 |
Improvement in walking speed in poststroke spastic hemiplegia after intrathecal baclofen therapy: a preliminary study.
Topics: Adult; Aged; Baclofen; Female; Hemiplegia; Humans; Infusion Pumps, Implantable; Injections, Spinal; | 2003 |
Time course of the effect of a bolus dose of intrathecal baclofen on severe cerebral spasticity.
Topics: Adult; Baclofen; Brain Diseases; Female; Humans; Infusion Pumps, Implantable; Injections, Spinal; Kn | 2003 |
Long term effect (more than five years) of intrathecal baclofen on impairment, disability, and quality of life in patients with severe spasticity of spinal origin.
Topics: Activities of Daily Living; Adult; Aged; Baclofen; Disability Evaluation; Dose-Response Relationship | 2004 |
The use of hydrotherapy for the management of spasticity.
Topics: Activities of Daily Living; Administration, Oral; Adult; Baclofen; Combined Modality Therapy; Disabi | 2004 |
Intrathecal drug therapy using the Codman Model 3000 Constant Flow Implantable Infusion Pumps: experience with 17 cases.
Topics: Adolescent; Adult; Baclofen; Child; Evaluation Studies as Topic; Female; Humans; Infusion Pumps, Imp | 2005 |
Effect of intrathecal baclofen bolus injection on temporospatial gait characteristics in patients with acquired brain injury.
Topics: Adult; Baclofen; Brain Injuries; Computers; Female; Gait Disorders, Neurologic; Humans; Injections, | 2005 |
Transcutaneous electrical nerve stimulation versus baclofen in spasticity: clinical and electrophysiologic comparison.
Topics: Adult; Baclofen; Female; GABA Agonists; H-Reflex; Humans; Male; Middle Aged; Muscle Relaxants, Centr | 2005 |
Performance and complications associated with the synchromed 10-ml infusion pump for intrathecal baclofen administration in children.
Topics: Adolescent; Age Factors; Baclofen; Body Mass Index; Cerebral Palsy; Child; Child, Preschool; Female; | 2004 |
A clinical study of intrathecal baclofen using a programmable pump for intractable spasticity.
Topics: Adolescent; Adult; Aged; Baclofen; Child; Child, Preschool; Cognition; Female; Humans; Infusion Pump | 2005 |
Dose-response relationship between the H-reflex and continuous intrathecal baclofen administration for management of spasticity.
Topics: Adolescent; Adult; Baclofen; Female; H-Reflex; Humans; Infusion Pumps, Implantable; Injections, Spin | 2006 |
Placebo controlled utility and feasibility study of the H-reflex and flexor reflex in spastic children treated with intrathecal baclofen.
Topics: Adolescent; Baclofen; Child; Dose-Response Relationship, Drug; Double-Blind Method; Electromyography | 2006 |
Oral baclofen in children with cerebral palsy: a double-blind cross-over pilot study.
Topics: Baclofen; Cerebral Palsy; Child; Child, Preschool; Double-Blind Method; Humans; Muscle Spasticity; N | 2006 |
Cost-effectiveness of intrathecal baclofen therapy for the treatment of severe spasticity associated with cerebral palsy.
Topics: Adolescent; Adult; Baclofen; Cerebral Palsy; Child; Child, Preschool; Cost-Benefit Analysis; Female; | 2007 |
Intrathecal antispastic drug application with implantable pumps: results of a 10 year follow-up study.
Topics: Baclofen; Cerebellar Diseases; Dose-Response Relationship, Drug; Drug Administration Routes; Female; | 2007 |
Intrathecal baclofen in children with spastic cerebral palsy: a double-blind, randomized, placebo-controlled, dose-finding study.
Topics: Adolescent; Baclofen; Cerebral Palsy; Child; Double-Blind Method; Female; Humans; Injections, Spinal | 2007 |
Intrathecal baclofen for spasticity-related pain in amyotrophic lateral sclerosis: efficacy and factors associated with pain relief.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Baclofen; Cohort Studies; Female; Humans; Infusion Pumps | 2008 |
Intrathecal baclofen and morphine in multiple sclerosis patients with severe pain and spasticity.
Topics: Adult; Baclofen; Drug Therapy, Combination; Female; Humans; Injections, Spinal; Male; Middle Aged; M | 2007 |
[Assessment of spasticity therapy with baclofen pump in children].
Topics: Adolescent; Adult; Baclofen; Child; Feasibility Studies; Follow-Up Studies; GABA Agonists; Hemiplegi | 2007 |
Tizanidine in the treatment of spasticity.
Topics: Adult; Baclofen; Clinical Trials as Topic; Clonidine; Double-Blind Method; Female; Humans; Male; Mid | 1982 |
[Clinical trial of Baclofen].
Topics: Adult; Baclofen; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Muscle Spasticity | 1981 |
A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.
Topics: Adult; Aged; Baclofen; Chronic Disease; Clinical Trials as Topic; Clonidine; Double-Blind Method; Fe | 1981 |
The assessment of drug treatment of spastic gait.
Topics: Aged; Baclofen; Clinical Trials as Topic; Clonidine; Female; Gait; Humans; Male; Middle Aged; Muscle | 1981 |
Intrathecal baclofen for spasticity of cerebral palsy: project coordination and nursing care.
Topics: Adolescent; Adult; Baclofen; Cerebral Palsy; Child; Follow-Up Studies; Humans; Infusion Pumps, Impla | 1995 |
The treatment of spasticity by intrathecal administration of baclofen: a preliminary personal experience.
Topics: Adult; Baclofen; Female; Follow-Up Studies; Humans; Infusion Pumps, Implantable; Male; Middle Aged; | 1993 |
A comparison of clonidine, cyproheptadine and baclofen in spastic spinal cord injured patients.
Topics: Baclofen; Clonidine; Cyproheptadine; Dose-Response Relationship, Drug; Drug Administration Schedule; | 1994 |
Intrathecal baclofen for treatment of intractable spinal spasticity.
Topics: Adult; Baclofen; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hum | 1994 |
Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study.
Topics: Adult; Aged; Baclofen; Double-Blind Method; Drug Tolerance; Female; Follow-Up Studies; Humans; Infus | 1993 |
Long-term intrathecal baclofen therapy in patients with intractable spasticity.
Topics: Adult; Baclofen; Female; Follow-Up Studies; Humans; Injections, Spinal; Male; Middle Aged; Multiple | 1995 |
Chronic intrathecal baclofen in severely disabling spasticity: selection, clinical assessment and long-term benefit.
Topics: Adult; Aged; Baclofen; Disability Evaluation; Female; Humans; Infusion Pumps, Implantable; Injection | 1995 |
Intrathecal baclofen administration for control of severe spinal spasticity: functional improvement and long-term follow-up.
Topics: Activities of Daily Living; Adult; Baclofen; Drug Overdose; Female; Follow-Up Studies; Humans; Infus | 1996 |
Intrathecal baclofen--a multicentre clinical comparison of the Medtronics Programmable, Cordis Secor and Constant Infusion Infusaid drug delivery systems.
Topics: Adolescent; Adult; Baclofen; Drug Delivery Systems; Evaluation Studies as Topic; Female; Humans; Inj | 1995 |
Continuous intrathecal baclofen infusion in severe spasticity after traumatic or hypoxic brain injury.
Topics: Adult; Aged; Baclofen; Brain Injuries; Dose-Response Relationship, Drug; Female; Humans; Hypoxia, Br | 1997 |
Changes in voluntary motor control induced by intrathecal baclofen in patients with spasticity of different etiology.
Topics: Adaptation, Physiological; Adult; Aged; Baclofen; Child; Double-Blind Method; Electromyography; Fema | 1996 |
Effect of intrathecal baclofen delivered by an implanted programmable pump on health related quality of life in patients with severe spasticity.
Topics: Adult; Aged; Baclofen; Double-Blind Method; Female; Humans; Infusion Pumps, Implantable; Injections, | 1997 |
Intrathecally administered baclofen for treatment of children with spasticity of cerebral origin.
Topics: Adolescent; Baclofen; Brain Injuries; Cerebral Palsy; Child; Child, Preschool; Humans; Infusion Pump | 1997 |
[Treatment of spasticity with the intrathecal administration of baclofen].
Topics: Baclofen; Child; Follow-Up Studies; Humans; Injections, Spinal; Muscle Relaxants, Central; Muscle Sp | 1998 |
Long-term continuously infused intrathecal baclofen for spastic-dystonic hypertonia in traumatic brain injury: 1-year experience.
Topics: Adolescent; Adult; Analysis of Variance; Baclofen; Brain Injuries; Child; Dose-Response Relationship | 1999 |
Cost analysis of the treatment of severe spinal spasticity with a continuous intrathecal baclofen infusion system.
Topics: Adult; Baclofen; GABA Agonists; Humans; Injections, Spinal; Male; Muscle Relaxants, Central; Muscle | 1999 |
Treatment of cerebral origin spasticity with continuous intrathecal baclofen delivered via an implantable pump: long-term follow-up review of 18 patients.
Topics: Adolescent; Adult; Baclofen; Brain Injuries; Cerebral Palsy; Dystonia Musculorum Deformans; Follow-U | 1999 |
Peripheral and central effect of baclofen on ankle joint stiffness in multiple sclerosis.
Topics: Adult; Ankle Joint; Baclofen; Biomechanical Phenomena; Central Nervous System; Electromyography; Ele | 2000 |
Intrathecal baclofen for intractable cerebral spasticity: a prospective placebo-controlled, double-blind study.
Topics: Adolescent; Adult; Baclofen; Cerebral Palsy; Child; Double-Blind Method; Female; Humans; Infusion Pu | 2000 |
Effect of baclofen on gait in spastic MS patients.
Topics: Adult; Analysis of Variance; Baclofen; Cross-Over Studies; Dose-Response Relationship, Drug; Double- | 2000 |
Baclofen increases the soleus stretch reflex threshold in the early swing phase during walking in spastic multiple sclerosis patients.
Topics: Adult; Baclofen; Differential Threshold; Electromyography; Female; Gait; Humans; Male; Middle Aged; | 2000 |
Intrathecal baclofen in tetraplegia of spinal origin: efficacy for upper extremity hypertonia.
Topics: Adult; Arm; Baclofen; Female; Follow-Up Studies; Humans; Infusion Pumps, Implantable; Leg; Male; Mid | 2001 |
Intrathecal baclofen for generalized dystonia.
Topics: Adolescent; Adult; Baclofen; Cerebral Palsy; Child; Child, Preschool; Dystonia; Female; Follow-Up St | 2001 |
Electrophysiological assessment of the effect of intrathecal baclofen in spastic children.
Topics: Adolescent; Baclofen; Child; Child, Preschool; Dose-Response Relationship, Drug; Electric Stimulatio | 2002 |
Long-term intrathecal Baclofen infusion in supraspinal spasticity of adulthood.
Topics: Adolescent; Adult; Baclofen; Brain Injuries; Female; Glasgow Outcome Scale; Humans; Hypoxia, Brain; | 2002 |
Baclofen in spasticity.
Topics: Aminobutyrates; Baclofen; Clinical Trials as Topic; Drug Evaluation; Humans; Muscle Spasticity; Plac | 1977 |
A controlled trial of baclofen in children with cerebral palsy.
Topics: Adolescent; Aminobutyrates; Baclofen; Cerebral Palsy; Child; Child, Preschool; Clinical Trials as To | 1977 |
Baclofen for spasticity in multiple sclerosis. Double-blind crossover and three-year study.
Topics: Activities of Daily Living; Adult; Aminobutyrates; Baclofen; Clinical Trials as Topic; Double-Blind | 1978 |
The use of baclofen in treatment of spasticity in multiple sclerosis.
Topics: Adult; Baclofen; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Middle Aged; M | 1979 |
Effects of acute bolus and chronic continuous intrathecal baclofen on genitourinary dysfunction due to spinal cord pathology.
Topics: Adult; Baclofen; Double-Blind Method; Female; Female Urogenital Diseases; Follow-Up Studies; Humans; | 1992 |
Indication, efficiency and complications of intrathecal pump supported baclofen treatment in spinal spasticity.
Topics: Adult; Baclofen; Female; Follow-Up Studies; Hemangioma; Humans; Infusion Pumps; Injections, Spinal; | 1992 |
Long-term intrathecal baclofen treatment in supraspinal spasticity.
Topics: Adult; Baclofen; Brain Injuries; Cerebral Palsy; Humans; Infusion Pumps; Injections, Spinal; Male; M | 1992 |
Continuous intrathecal baclofen in spinal cord spasticity. A prospective study.
Topics: Adult; Baclofen; Catheters, Indwelling; Dose-Response Relationship, Drug; Double-Blind Method; Femal | 1992 |
Intrathecal baclofen. Effects on nocturnal leg muscle spasticity.
Topics: Adult; Baclofen; Double-Blind Method; Electromyography; Female; Humans; Infusion Pumps; Injections, | 1992 |
Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis.
Topics: Adult; Baclofen; Clinical Protocols; Combined Modality Therapy; Double-Blind Method; Evaluation Stud | 1991 |
Intrathecal baclofen for spasticity in cerebral palsy.
Topics: Adolescent; Adult; Arm; Baclofen; Cerebral Palsy; Child; Child, Preschool; Double-Blind Method; Fema | 1991 |
Continuous infusion of intrathecal baclofen: long-term effects on spasticity in spinal cord injury.
Topics: Administration, Cutaneous; Adult; Baclofen; Humans; Infusion Pumps; Injections, Spinal; Male; Middle | 1991 |
The supraspinal anxiolytic effect of baclofen for spasticity reduction.
Topics: Adult; Anxiety; Baclofen; Drug Evaluation; Humans; Male; Muscle Spasticity; Random Allocation; Spina | 1990 |
Spasticity in spinal cord injured persons: quantitative effects of baclofen and placebo treatments.
Topics: Adult; Baclofen; Double-Blind Method; Electrophysiology; Humans; Male; Muscle Spasticity; Placebos; | 1990 |
Intrathecal baclofen for long-term treatment of spasticity: a multi-centre study.
Topics: Adult; Baclofen; Catheters, Indwelling; Clinical Trials as Topic; Electromyography; Female; Follow-U | 1989 |
[Comparative double-blind study of the effectiveness and tolerance of baclofen, tetrazepam and tizanidine in spastic movement disorders of the lower extremities].
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Baclofen; Benzodiazepines; Benzodiazepinones; Clinical | 1989 |
A double-blind, long-term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions.
Topics: Adult; Aged; Baclofen; Cerebrovascular Disorders; Clinical Trials as Topic; Clonidine; Double-Blind | 1989 |
Intrathecal baclofen for severe spinal spasticity.
Topics: Adult; Baclofen; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Infusion Pumps; Male | 1989 |
Use of intrathecal baclofen administered by programmable infusion pumps in resistent spasticity.
Topics: Adult; Baclofen; Dose-Response Relationship, Drug; Female; Humans; Infusion Pumps; Injections, Spina | 1989 |
Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis.
Topics: Adult; Aged; Baclofen; Clinical Trials as Topic; Clonidine; Double-Blind Method; Female; Humans; Mal | 1988 |
Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis.
Topics: Adult; Aged; Baclofen; Brain; Clonidine; Dose-Response Relationship, Drug; Female; Humans; Male; Mid | 1988 |
The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen.
Topics: Adult; Aged; Baclofen; Clinical Trials as Topic; Clonidine; Double-Blind Method; Drug Tolerance; Fem | 1987 |
Baclofen versus diazepam for the treatment of spasticity and long-term follow-up of baclofen therapy.
Topics: Adult; Baclofen; Clinical Trials as Topic; Diazepam; Double-Blind Method; Female; Follow-Up Studies; | 1985 |
Baclofen in the elderly stroke patient its side-effects and pharmacokinetics.
Topics: Adult; Aged; Baclofen; Cerebrovascular Disorders; Clinical Trials as Topic; Double-Blind Method; Fem | 1985 |
558 other studies available for baclofen and Clasp-Knife Spasticity
| Article | Year |
|---|---|
Intrathecal baclofen therapy for severe spasticity in an adult with tethered cord syndrome: a case report.
Topics: Adult; Baclofen; Female; Humans; Infant, Newborn; Infusion Pumps, Implantable; Injections, Spinal; M | 2021 |
Baclofen bridging, weaning protocol and pain management of a person with T6 paraplegia who required removal of intrathecal baclofen pump due to wound infection.
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Relaxants, Central; Muscle | 2021 |
European expert consensus on improving patient selection for the management of disabling spasticity with intrathecal baclofen and/or botulinum toxin type A.
Topics: Adult; Baclofen; Botulinum Toxins, Type A; Consensus; Humans; Injections, Spinal; Muscle Relaxants, | 2022 |
Neuromodulation as a basic platform for neuroprotection and repair after spinal cord injury.
Topics: Baclofen; Humans; Muscle Relaxants, Central; Muscle Spasticity; Neuroprotection; Spinal Cord Injurie | 2021 |
The use of intrathecal baclofen for management of spasticity in hereditary spastic paraparesis: A case series.
Topics: Adolescent; Baclofen; Child; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Relaxan | 2022 |
Neonatal baclofen withdrawal following intrauterine exposure.
Topics: Baclofen; Cesarean Section; Female; Humans; Infant, Newborn; Injections, Spinal; Male; Muscle Relaxa | 2022 |
Baclofen Withdrawal With Reversible Posterior Leukoencephalopathy Syndrome: Bacterial Meningitis Mimicker.
Topics: Adult; Baclofen; Female; Headache; Humans; Infusion Pumps, Implantable; Injections, Spinal; Meningit | 2022 |
Surgical complications of intrathecal baclofen in children: A single centre, 20-year retrospective cohort study.
Topics: Adolescent; Baclofen; Child; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Relaxan | 2022 |
Supraspinal baclofen for the treatment of secondary generalized dystonia: A case series.
Topics: Baclofen; Cohort Studies; Dystonia; Dystonic Disorders; Humans; Infusion Pumps, Implantable; Muscle | 2022 |
Neuraxial anesthesia for post-operative pain control after hip surgery in children with cerebral palsy and pre-existing intrathecal baclofen pumps.
Topics: Anesthesia; Baclofen; Cerebral Palsy; Child; Humans; Infusion Pumps, Implantable; Muscle Relaxants, | 2022 |
On the recovery of disorders of consciousness under intrathecal baclofen administration for severe spasticity-An observational study.
Topics: Baclofen; Coma; Consciousness; Humans; Injections, Spinal; Muscle Spasticity; Retrospective Studies | 2022 |
Behavioral dysregulation exacerbated by intrathecal baclofen in an adolescent with severe traumatic brain injury.
Topics: Adolescent; Adult; Baclofen; Brain Injuries, Traumatic; Dystonia; Dystonic Disorders; Humans; Infusi | 2022 |
Efficacy of Selective Dorsal Rhizotomy and Intrathecal Baclofen Pump in the Management of Spasticity.
Topics: Baclofen; Cerebral Palsy; Child; Humans; Muscle Spasticity; Quality of Life; Rhizotomy; Treatment Ou | 2022 |
Reasons and Determinants of BoNT-A Treatment Discontinuation in Patients Living with Spasticity: A 10-Year Retrospective Analysis.
Topics: Baclofen; Botulinum Toxins, Type A; Brain Injuries, Traumatic; Humans; Middle Aged; Multiple Scleros | 2022 |
Predictors of muscle hypertrophy responsiveness to electrically evoked resistance training after spinal cord injury.
Topics: Baclofen; Electric Stimulation Therapy; Humans; Hypertrophy; Muscle Spasticity; Muscle, Skeletal; Pr | 2023 |
Psychosocial and medical factors associated with intrathecal baclofen pump explants: A case series.
Topics: Adult; Baclofen; Child; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Relaxants, C | 2023 |
[Intrathecal Baclofen Therapy for Spastic Paralysis].
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Spasticity; Paralysis | 2022 |
[Intrathecal Baclofen Therapy for Spastic Paralysis].
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Spasticity; Paralysis | 2022 |
[Intrathecal Baclofen Therapy for Spastic Paralysis].
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Spasticity; Paralysis | 2022 |
[Intrathecal Baclofen Therapy for Spastic Paralysis].
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Spasticity; Paralysis | 2022 |
[Intrathecal Baclofen Therapy for Spastic Paralysis].
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Spasticity; Paralysis | 2022 |
[Intrathecal Baclofen Therapy for Spastic Paralysis].
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Spasticity; Paralysis | 2022 |
[Intrathecal Baclofen Therapy for Spastic Paralysis].
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Spasticity; Paralysis | 2022 |
[Intrathecal Baclofen Therapy for Spastic Paralysis].
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Spasticity; Paralysis | 2022 |
[Intrathecal Baclofen Therapy for Spastic Paralysis].
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Spasticity; Paralysis | 2022 |
Intrathecal Baclofen and Opioid Therapy: Cerebrospinal Fluid Leak and Infection Incidence, Risk Factors, and Outcomes.
Topics: Analgesics, Opioid; Baclofen; Catheters, Indwelling; Cerebrospinal Fluid Leak; Humans; Incidence; In | 2023 |
Intrathecal Baclofen and Opioid Therapy: Cerebrospinal Fluid Leak and Infection Incidence, Risk Factors, and Outcomes.
Topics: Analgesics, Opioid; Baclofen; Catheters, Indwelling; Cerebrospinal Fluid Leak; Humans; Incidence; In | 2023 |
Intrathecal Baclofen and Opioid Therapy: Cerebrospinal Fluid Leak and Infection Incidence, Risk Factors, and Outcomes.
Topics: Analgesics, Opioid; Baclofen; Catheters, Indwelling; Cerebrospinal Fluid Leak; Humans; Incidence; In | 2023 |
Intrathecal Baclofen and Opioid Therapy: Cerebrospinal Fluid Leak and Infection Incidence, Risk Factors, and Outcomes.
Topics: Analgesics, Opioid; Baclofen; Catheters, Indwelling; Cerebrospinal Fluid Leak; Humans; Incidence; In | 2023 |
Spasticity treatment patterns among people with multiple sclerosis: a Swedish cohort study.
Topics: Baclofen; Cohort Studies; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscl | 2023 |
Letter to the Editor. Intrathecal baclofen pump insertion versus selective dorsal rhizotomy.
Topics: Baclofen; Cerebral Palsy; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Relaxants, | 2022 |
Does intrathecal baclofen therapy decrease the progression of hip displacement in young patients with cerebral palsy?
Topics: Baclofen; Cerebral Palsy; Child; Hip Dislocation; Humans; Muscle Spasticity; Retrospective Studies | 2023 |
Patients' Expectations Before Initiation of Intrathecal Baclofen Treatment: A Longitudinal Study with 1-Year Follow-Up.
Topics: Adolescent; Baclofen; Canada; Follow-Up Studies; Humans; Injections, Spinal; Longitudinal Studies; M | 2023 |
Does intrathecal baclofen alter the natural history of hip displacement?
Topics: Baclofen; Hip Dislocation; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Relaxants | 2023 |
A multicenter initiative to reduce intrathecal baclofen pump surgical site infection: a Cerebral Palsy Research Network quality improvement project.
Topics: Baclofen; Cerebral Palsy; Child; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Rel | 2023 |
A critical evaluation of oral baclofen in pediatric patients with cerebral palsy.
Topics: Baclofen; Cerebral Palsy; Child; Humans; Infusion Pumps, Implantable; Muscle Relaxants, Central; Mus | 2023 |
Interaction between a smartphone and intrathecal baclofen pump case report.
Topics: Adult; Baclofen; Catheters; Humans; Male; Muscle Spasticity; Paraplegia; Smartphone; United States | 2023 |
Assessment of Health Care Costs and Total Baclofen Use Associated With Targeted Drug Delivery for Spasticity.
Topics: Adult; Baclofen; Health Care Costs; Humans; Injections, Spinal; Muscle Relaxants, Central; Muscle Sp | 2023 |
Status Dystonicus: Emergent Treatment With Intrathecal Baclofen Pump.
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Relaxants, Central; Muscle | 2023 |
CNS adverse effects of intrathecal baclofen treatment for spasticity in children with cerebral palsy and epilepsy: a case report.
Topics: Baclofen; Cerebral Palsy; Child; Epilepsy; Humans; Injections, Spinal; Muscle Relaxants, Central; Mu | 2023 |
Is baclofen the least worst option for spasticity management in children?
Topics: Baclofen; Cerebral Palsy; Child; Humans; Injections, Spinal; Muscle Relaxants, Central; Muscle Spast | 2023 |
Benefit of enteral baclofen in the management of spasticity in cerebral palsy.
Topics: Baclofen; Cerebral Palsy; Humans; Infusion Pumps, Implantable; Muscle Relaxants, Central; Muscle Spa | 2023 |
Safety of baclofen versus tizanidine for older adults with musculoskeletal pain.
Topics: Aged; Baclofen; Delirium; Female; Humans; Male; Muscle Relaxants, Central; Muscle Spasticity; Muscul | 2023 |
Baclofen and the Risk of Encephalopathy: A Real-World, Active-Comparator Cohort Study.
Topics: Adolescent; Adult; Baclofen; Brain Diseases; Cohort Studies; Humans; Muscle Relaxants, Central; Musc | 2023 |
Effects of intrathecal Baclofen in reducing tremors in patients with multiple sclerosis.
Topics: Adult; Baclofen; Humans; Injections, Spinal; Male; Multiple Sclerosis; Muscle Relaxants, Central; Mu | 2023 |
Use of intraoperative topical antibiotics to reduce intrathecal baclofen pump surgical site infections: a single institution's experience over 24 years.
Topics: Anti-Bacterial Agents; Baclofen; Cerebral Palsy; Humans; Infusion Pumps, Implantable; Injections, Sp | 2023 |
Management of high-dose intrathecal baclofen pump explant: A case report.
Topics: Amyotrophic Lateral Sclerosis; Baclofen; Chronic Pain; Diazepam; Humans; Infusion Pumps, Implantable | 2023 |
Case Study of Intrathecal Baclofen Pump Motor Shutdown Secondary to the Effect of the Magnetic Field Created by a Personal Digital Tablet and Magnetic Cover.
Topics: Abdomen; Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Magnetic Fields; Male; M | 2023 |
The use of botulinum toxin and intrathecal baclofen in hip dysplasia in cerebral palsy.
Topics: Baclofen; Botulinum Toxins; Cerebral Palsy; Hip Dislocation; Humans; Injections, Spinal; Muscle Rela | 2023 |
Intrathecal baclofen therapy does not prevent hip displacement in children with cerebral palsy.
Topics: Baclofen; Cerebral Palsy; Child; Hip Dislocation; Humans; Infusion Pumps, Implantable; Injections, S | 2023 |
Identification of risk factors for reconstructive hip surgery after intrathecal baclofen therapy in children with cerebral palsy.
Topics: Baclofen; Cerebral Palsy; Child; Child, Preschool; Humans; Male; Muscle Spasticity; Radiography; Ris | 2023 |
Decompression for lumbar spinal stenosis at the intrathecal catheter insertion site during intrathecal baclofen therapy: a case report.
Topics: Baclofen; Catheters; Decompression; Humans; Injections, Spinal; Male; Middle Aged; Muscle Relaxants, | 2023 |
[Methods and results of neurosurgical treatment of cerebral palsy].
Topics: Baclofen; Cerebral Palsy; Dystonia; Humans; Muscle Spasticity; Neurosurgical Procedures; Paralysis; | 2023 |
Pendulum test parameters are useful for detecting knee muscle hypertonia and quantifying response to an intrathecal baclofen bolus injection.
Topics: Baclofen; Humans; Lower Extremity; Muscle Hypertonia; Muscle Relaxants, Central; Muscle Spasticity; | 2023 |
Twenty years of intrathecal baclofen therapy in Slovenia: a retrospective single-center analysis of complications.
Topics: Baclofen; Female; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Relaxants, Central | 2023 |
Brief pump externalization without ITB wean to treat a probable pocket infection.
Topics: Baclofen; Female; Humans; Infusion Pumps, Implantable; Muscle Relaxants, Central; Muscle Spasticity; | 2023 |
Intracerebroventricular baclofen therapy improves function and quality of life in a child with severe cerebral palsy.
Topics: Baclofen; Cerebral Palsy; Child; Humans; Infusion Pumps, Implantable; Movement Disorders; Muscle Rel | 2023 |
Does baclofen for the management of spasticity increase the risk of seizures?
Topics: Baclofen; Humans; Muscle Relaxants, Central; Muscle Spasticity; Seizures | 2023 |
The presence of Candida parapsilosis with intrathecal baclofen pump in a person with high cervical spinal cord injury; infection or colonization? A Case Report.
Topics: Adult; Baclofen; Candida parapsilosis; Cervical Cord; Humans; Infusion Pumps, Implantable; Male; Mus | 2023 |
Intrathecal baclofen therapy for treatment of spasticity in infants and small children under 6 years of age.
Topics: Baclofen; Catheters, Indwelling; Cerebral Palsy; Child; Child, Preschool; Humans; Infant; Infusion P | 2020 |
Intrathecal baclofen trial using a temporary indwelling intrathecal catheter - A single institution experience.
Topics: Aged; Baclofen; Catheters, Indwelling; Female; Humans; Infusion Pumps, Implantable; Injections, Spin | 2019 |
Restoration of rostral cerebrospinal fluid flow to solve treatment failure caused by obstruction in long-term intrathecal baclofen administration.
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Relaxants, Central; Muscle | 2021 |
Efficiency and Safety of Aftercare With Intrathecal Baclofen on Location.
Topics: Adolescent; Adult; Aftercare; Aged; Aged, 80 and over; Baclofen; Child; Female; Home Care Services; | 2019 |
The Palliative Use of Intrathecal Baclofen in Niemann-Pick Disease Type C.
Topics: Baclofen; Child; Fatal Outcome; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; Muscl | 2019 |
Italian consensus on treatment of spasticity in multiple sclerosis.
Topics: Baclofen; Botulinum Toxins; Clonidine; Consensus; Disease Management; Gabapentin; Humans; Injections | 2020 |
Intrathecal baclofen as emergency treatment alleviates severe intractable autonomic dysreflexia in cervical spinal cord injury.
Topics: Autonomic Dysreflexia; Baclofen; Cervical Cord; Emergency Treatment; Humans; Infusion Pumps, Implant | 2021 |
The beneficial aspects of spasticity in relation to ambulatory ability in mice with spinal cord injury.
Topics: Animals; Baclofen; Behavior, Animal; Disease Models, Animal; Female; Locomotion; Mice; Mice, Inbred | 2020 |
Reducing Intrathecal Baclofen Related Infections: Service Evaluation and Best Practice Guidelines.
Topics: Baclofen; Humans; Infections; Infusion Pumps, Implantable; Injections, Spinal; Muscle Relaxants, Cen | 2020 |
Intrathecal Baclofen Infusion Pumps in the Treatment of Spasticity: A Retrospective Cohort Study in a Portuguese Centre.
Topics: Adolescent; Adult; Aged; Baclofen; Child; Device Removal; Equipment Failure; Female; Follow-Up Studi | 2019 |
Intrathecal Baclofen for Severe Spasticity: Longitudinal Data From the Product Surveillance Registry.
Topics: Adult; Baclofen; Child; Female; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; Muscl | 2020 |
Knee Muscle Stretch Reflex Responses After an Intrathecal Baclofen Bolus in Neurological Patients With Moderate-to-Severe Hypertonia.
Topics: Baclofen; Electromyography; Humans; Injections, Spinal; Knee; Muscle Hypertonia; Muscle Spasticity; | 2020 |
Screening Intrathecal Baclofen Pump Systems for Catheter Patency via Catheter Access Port Aspiration.
Topics: Adult; Baclofen; Catheters; Child; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle R | 2020 |
Intrathecal Baclofen Overdose With Paradoxical Autonomic Features Mimicking Withdrawal.
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; Muscle Relaxants, Central; | 2020 |
Intrathecal baclofen pump exchange in multiple sclerosis. Factors affecting baclofen efficacy and dose adjustement. A case report.
Topics: Baclofen; Humans; Multiple Sclerosis; Muscle Relaxants, Central; Muscle Spasticity; Quality of Life | 2021 |
Classifying Device-Related Complications Associated With Intrathecal Baclofen Pumps: A MAUDE Study.
Topics: Baclofen; Catheter-Related Infections; Catheters; Databases, Factual; Equipment Failure; Female; For | 2020 |
Baclofen pump with pre-brainstem catheter tip placement: technical note and case series.
Topics: Baclofen; Brain Stem; Cerebral Palsy; Humans; Infusion Pumps, Implantable; Muscle Relaxants, Central | 2021 |
Long term outcome of Selective Dorsal Rhizotomy for the management of childhood spasticity-functional improvement and complications.
Topics: Activities of Daily Living; Baclofen; Cerebral Palsy; Humans; Muscle Spasticity; Rhizotomy; Treatmen | 2020 |
Spasticity Management in Persons with Disorders of Consciousness.
Topics: Baclofen; Botulinum Toxins; Consciousness Disorders; Humans; Injections, Spinal; Muscle Relaxants, C | 2021 |
Intrathecal baclofen infusion for spastic intractable hiccups.
Topics: Baclofen; Hiccup; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Relaxants, Central | 2021 |
Adverse events associated with paediatric intrathecal baclofen in Australia: 5 years of data collection.
Topics: Australia; Baclofen; Child; Data Collection; Humans; Infusion Pumps, Implantable; Injections, Spinal | 2021 |
Evaluation of the impact of intrathecal baclofen on the walking ability of people with Multiple Sclerosis related spasticity.
Topics: Baclofen; Female; Humans; Injections, Spinal; Male; Middle Aged; Multiple Sclerosis; Muscle Relaxant | 2020 |
Spinal cord stimulation and intrathecal baclofen therapy for patients with severe spasticity after spinal cord injury.
Topics: Baclofen; Female; Humans; Injections, Spinal; Male; Muscle Spasticity; Spinal Cord Injuries; Spinal | 2020 |
Baclofen Boluses Via Lumbar Puncture for Diagnosing Loss of Intrathecal Baclofen Efficacy: A Case Series.
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Relaxants, Central; Muscle | 2021 |
Utility of intrathecal baclofen pump in primary lateral sclerosis.
Topics: Baclofen; Humans; Injections, Spinal; Middle Aged; Motor Neuron Disease; Muscle Relaxants, Central; | 2021 |
Complications of intrathecal baclofen pump treatment in children with spastic cerebral palsy. A comparative analysis of patients weighing over or under 20 kg at the time of implantation.
Topics: Baclofen; Cerebral Palsy; Child; Humans; Injections, Spinal; Male; Muscle Relaxants, Central; Muscle | 2022 |
Improvement of Memory Functions in Chronic Spinal Cord Injury After Long-Term Intrathecal Baclofen Delivery for Spasticity Relief.
Topics: Animals; Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Relaxants, Centra | 2021 |
Intrathecal Baclofen Pump Infection With Meningitis: Effective Treatment by Radical Debridement and Intrareservoir Baclofen-Vancomycin Co-Infusion.
Topics: Baclofen; Debridement; Humans; Infusion Pumps, Implantable; Injections, Spinal; Meningitis; Muscle R | 2021 |
Evaluation of the cognitive benefits of intrathecal baclofen pump implantation in people with intractable multiple sclerosis related spasticity.
Topics: Baclofen; Cognition; Humans; Injections, Spinal; Middle Aged; Multiple Sclerosis; Muscle Relaxants, | 2021 |
Paradoxical reaction to increased doses of intrathecal baclofen in a patient with Leigh syndrome.
Topics: Baclofen; Child; Child, Preschool; Humans; Infusion Pumps, Implantable; Injections, Spinal; Leigh Di | 2021 |
Unusual mechanical failures of intrathecal baclofen pump systems: symptoms, signs, and trouble shooting.
Topics: Baclofen; Cerebral Palsy; Child; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Rel | 2021 |
Intrathecal baclofen pumps in the management of hypertonia in childhood: a UK and Ireland wide survey.
Topics: Adolescent; Baclofen; Cerebral Palsy; Child; Child, Preschool; Cross-Sectional Studies; Humans; Inje | 2021 |
Intestinal Perforation: A Very Rare Complication in Intrathecal Baclofen Therapy.
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Intestinal Perforation; Muscle Re | 2021 |
Low Rate of Intrathecal Baclofen Pump Catheter-Related Complications: Long-Term Study in Over 100 Adult Patients Associated With Reinforced Catheter.
Topics: Adult; Baclofen; Catheters; Female; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; M | 2021 |
Treatment of spasticity in children and adolescents with cerebral palsy in Northern Europe: a CP-North registry study.
Topics: Adolescent; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Child; Child, Preschool; Cohort Stud | 2021 |
Characterization of standard work tools for intrathecal baclofen therapy.
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Relaxants, Central; Muscle | 2021 |
Characterizing Baclofen Withdrawal: A National Survey of Physician Experience.
Topics: Attitude of Health Personnel; Baclofen; Health Care Surveys; Humans; Muscle Relaxants, Central; Musc | 2021 |
The impact of strategies to manage the COVID-19 pandemic on patients with intrathecal baclofen therapy.
Topics: Adult; Baclofen; Communicable Disease Control; COVID-19; Humans; Injections, Spinal; Middle Aged; Mu | 2023 |
[Neurosurgery for Spasticity].
Topics: Baclofen; Humans; Injections, Spinal; Muscle Relaxants, Central; Muscle Spasticity; Neurosurgery; Ne | 2021 |
Lumbar translaminar fenestration for insertion of intrathecal baclofen catheter: a novel technique.
Topics: Adolescent; Baclofen; Catheters, Indwelling; Cerebral Palsy; Humans; Lumbar Vertebrae; Male; Muscle | 2017 |
Management of intrathecal baclofen therapy for severe acquired brain injury: consensus and recommendations for good clinical practice.
Topics: Baclofen; Brain Injuries; Clinical Trials as Topic; Female; Humans; Injections, Spinal; Male; Muscle | 2017 |
Intrathecal baclofen therapy in paediatrics: a study protocol for an Australian multicentre, 10-year prospective audit.
Topics: Adolescent; Australia; Baclofen; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; I | 2017 |
Nurse Practitioner Lead Pediatric Baclofen Pump Program: Impact on Safety and Quality of Care.
Topics: Baclofen; Cerebral Palsy; Child; Humans; Infusion Pumps, Implantable; Muscle Relaxants, Central; Mus | 2017 |
Outcomes of intrathecal baclofen therapy in patients with cerebral palsy and acquired brain injury.
Topics: Adult; Baclofen; Brain Injuries; Cerebral Palsy; Female; Humans; Infusion Pumps, Implantable; Inject | 2017 |
Intrathecal baclofen treatment an option in X-linked adrenoleukodystrophy.
Topics: Adrenoleukodystrophy; Baclofen; Child; Dystonia; Dystonic Disorders; Humans; Infusion Pumps, Implant | 2018 |
Generalized Itching and Lower-Extremity Spasticity in a Patient with Intrathecal Baclofen Pump.
Topics: Adult; Baclofen; Diagnosis, Differential; Humans; Infusions, Intravenous; Injections, Spinal; Lower | 2018 |
Subarachnoid-to-Subarachnoid Shunt for Correction of Nonfunctioning Baclofen Pump in a Severe Case of Chronic Debilitating Post-Spinal Cord Injury Spasticity.
Topics: Baclofen; Humans; Injections, Spinal; Male; Middle Aged; Muscle Relaxants, Central; Muscle Spasticit | 2018 |
Intrathecal baclofen in dyskinetic cerebral palsy: effects on function and activity.
Topics: Baclofen; Cerebral Palsy; Child; Dystonia; Female; Humans; Injections, Spinal; Male; Motor Activity; | 2018 |
Early outcomes after intrathecal baclofen therapy in ambulatory patients with multiple sclerosis.
Topics: Administration, Oral; Aged; Ambulatory Care; Baclofen; Clonidine; Drug Therapy, Combination; Female; | 2018 |
Intrathecal baclofen in progressive neurological disease: To be considered before all other options fail.
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Relaxants, Central; Muscle | 2018 |
Experiences from intrathecal baclofen treatment based on medical records and patient- and proxy-reported outcome: a multicentre study.
Topics: Adult; Aged; Baclofen; Cross-Sectional Studies; Female; Humans; Injections, Spinal; Male; Middle Age | 2019 |
Baclofen and sleep apnoea syndrome: analysis of VigiBase, the WHO pharmacovigilance database.
Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Alcoholism; Apnea; Baclofen; Database | 2018 |
Hidden Medical Devices in the School Setting: What the School Nurse Needs to Know About the Safe Use of Baclofen Pumps.
Topics: Baclofen; Cerebral Palsy; Child; Clinical Competence; Humans; Infusion Pumps, Implantable; Male; Mus | 2018 |
How to assess goals in intrathecal baclofen therapy.
Topics: Baclofen; Goals; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Relaxants, Central; | 2018 |
Spasticity Treatment Ameliorates the Efficacy of Melatonin Therapy in Experimental Autoimmune Encephalomyelitis (EAE) Mouse Model of Multiple Sclerosis.
Topics: Animals; Baclofen; Biomarkers; Cytokines; Disease Models, Animal; Encephalomyelitis, Autoimmune, Exp | 2018 |
An Unreported Cause of Intrathecal Baclofen Withdrawal Symptoms in a Woman With Spastic Cerebral Palsy Who Received Intrathecal Gablofen.
Topics: Adult; Baclofen; Cerebral Palsy; Female; Humans; Injections, Spinal; Muscle Relaxants, Central; Musc | 2018 |
Placement of Baclofen Pump Catheter Tip for Upper Extremity Spasticity Management.
Topics: Amyotrophic Lateral Sclerosis; Baclofen; Humans; Infusion Pumps, Implantable; Male; Middle Aged; Mus | 2018 |
Readmission and complications within 30 days after intrathecal baclofen pump placement.
Topics: Adolescent; Baclofen; Child; Female; Humans; Infusion Pumps, Implantable; Infusions, Spinal; Male; M | 2018 |
Balancing the benefits of intrathecal baclofen pump surgery with potential postoperative complications.
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Relaxants, Central; Muscle | 2018 |
Eleven years' experience with Intrathecal Baclofen - Complications, risk factors.
Topics: Adolescent; Adult; Aged; Baclofen; Catheterization; Child; Child, Preschool; Female; Humans; Infusio | 2018 |
Effect of oral baclofen on spasticity poststroke: responders versus non-responders.
Topics: Administration, Oral; Adult; Aged; Ankle Joint; Baclofen; Electromyography; Female; Humans; Male; Mi | 2018 |
Intrathecal baclofen in mucopolysaccharidosis type II (Hunter syndrome): case report.
Topics: Baclofen; Child; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; Mucopolysaccharidosi | 2018 |
Intrathecal Baclofen Therapy for Painful Muscle Spasms in a Patient with Friedreich's Ataxia.
Topics: Aged; Baclofen; Female; Follow-Up Studies; Friedreich Ataxia; Humans; Injections, Spinal; Muscle Rel | 2018 |
Problems with an intrathecal pump in a paraplegic scuba diver.
Topics: Adult; Baclofen; Diving; Humans; Male; Muscle Relaxants, Central; Muscle Spasticity; Quality of Life | 2018 |
The dosage and administration of long-term intrathecal baclofen therapy for severe spasticity of spinal origin.
Topics: Baclofen; Drug Tolerance; Follow-Up Studies; Humans; Infusion Pumps, Implantable; Injections, Spinal | 2018 |
Title: Quantifying the change of spasticity after intrathecal baclofen administration: A descriptive retrospective analysis.
Topics: Adult; Aged; Baclofen; Cerebral Palsy; Female; Humans; Infusion Pumps, Implantable; Injections, Spin | 2018 |
Rectal Administration of Baclofen at the End of Life.
Topics: Administration, Rectal; Aged; Baclofen; Fatal Outcome; Humans; Male; Middle Aged; Muscle Relaxants, | 2018 |
Delirium tremens in an AUD patient after an intrathecal baclofen pump induced total alcohol abstinence.
Topics: Alcohol Abstinence; Alcohol Drinking; Alcohol Withdrawal Delirium; Alcoholism; Baclofen; Diazepam; H | 2018 |
The use ultrasound guided for refilling intrathecal baclofene pump in complicated clinical cases: A practical approach.
Topics: Aged; Baclofen; Female; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; Middle Aged; | 2018 |
An intoxication mimicking brain death: baclofen.
Topics: Adolescent; Baclofen; Brain Death; Diagnosis, Differential; Female; GABA-B Receptor Agonists; Humans | 2020 |
Intrathecal baclofen in paroxysmal sympathetic hyperactivity: Impact on oral treatment.
Topics: Administration, Oral; Adolescent; Adult; Antihypertensive Agents; Autonomic Nervous System Diseases; | 2018 |
Intrathecal baclofen for multiple sclerosis related spasticity: A twenty year experience.
Topics: Adult; Aged; Baclofen; Female; Humans; Injections, Spinal; Male; Middle Aged; Multiple Sclerosis; Mu | 2019 |
A Case of Pocket Fill Causing Baclofen Withdrawal.
Topics: Adult; Baclofen; Equipment Design; Female; Humans; Infusion Pumps, Implantable; Muscle Relaxants, Ce | 2019 |
Extracorporeal Shockwave Lithotripsy Procedure in Children With Intrathecal Baclofen Pump.
Topics: Adolescent; Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Lithotripsy; Male; Mu | 2019 |
Inherited Ataxia and Intrathecal Baclofen for the Treatment of Spasticity and Painful Spasms.
Topics: Adult; Aged; Baclofen; Female; Friedreich Ataxia; Humans; Injections, Spinal; Male; Middle Aged; Mus | 2019 |
Accuracy and Precision of the SynchroMed II Pump.
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Muscle Relaxants, Central; Muscle Spasticity; Retrosp | 2019 |
Pharmacological management of abnormal tone and movement in cerebral palsy.
Topics: Adolescent; Baclofen; Botulinum Toxins; Cerebral Palsy; Child; Child Health Services; Child, Prescho | 2019 |
The use of opioids in children receiving intrathecal baclofen therapy.
Topics: Adolescent; Analgesics, Opioid; Baclofen; Child; Dystonic Disorders; Female; Humans; Injections, Spi | 2019 |
Intrathecal Baclofen Trial Before Device Implantation: 12-Year Experience With Continuous Administration.
Topics: Adult; Back Muscles; Baclofen; Female; Gait; Humans; Infusion Pumps, Implantable; Infusions, Spinal; | 2019 |
Froin Syndrome After Spinal Cord Injury.
Topics: Baclofen; Bilirubin; Cerebrospinal Fluid; Cerebrospinal Fluid Proteins; Humans; Injections, Spinal; | 2019 |
Use of botulinum toxin A in children with cerebral palsy.
Topics: Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Child; Cross-Sectional Studies; Female; Humans; | 2019 |
Intrathecal Baclofen Therapy in Patients With Multiple Sclerosis: Improved Outcomes and Reduced Costs Through Identification of Catheter Malfunction.
Topics: Adult; Aged; Baclofen; Catheters, Indwelling; Female; Health Care Costs; Humans; Infusion Pumps, Imp | 2019 |
Comparing the effects of two spasticity management strategies on the long-term outcomes of individuals with bilateral spastic cerebral palsy: a multicentre cohort study protocol.
Topics: Baclofen; Cerebral Palsy; Child; Child, Preschool; Disease Management; Female; Follow-Up Studies; Fo | 2019 |
Low-Dose Intrathecal Ziconotide for Spasticity From Primary Lateral Sclerosis: A Case Report.
Topics: Adult; Baclofen; Female; Humans; Injections, Spinal; Motor Neuron Disease; Muscle Spasticity; omega- | 2019 |
Late recovery of responsiveness after intra-thecal baclofen pump implantation and the role of diffuse pain and severe spasticity: a case report.
Topics: Adult; Baclofen; Coma; Decompressive Craniectomy; Hematoma; Humans; Infusion Pumps, Implantable; Inj | 2019 |
Investigating the Feasibility of a Modified Quantitative Sensory Testing Approach to Profile Sensory Function and Predict Pain Outcomes Following Intrathecal Baclofen Implant Surgery in Cerebral Palsy.
Topics: Adolescent; Adult; Baclofen; Cerebral Palsy; Child; Feasibility Studies; Female; Humans; Infusion Pu | 2020 |
Improvements in children with cerebral palsy following intrathecal baclofen: use of the Rehabilitation Institute of Chicago Care and Comfort Caregiver Questionnaire (RIC CareQ).
Topics: Activities of Daily Living; Adolescent; Adult; Baclofen; Caregivers; Cerebral Palsy; Child; Child, P | 2014 |
Adherence associated with oral medications in the treatment of spasticity.
Topics: Administration, Oral; Adult; Baclofen; Clonidine; Dantrolene; Female; Humans; Male; Medication Adher | 2013 |
Costs and quality of life in multiple sclerosis patients with spasticity.
Topics: Absenteeism; Adult; Aged; Aged, 80 and over; Baclofen; Botulinum Toxins; Caregivers; Cost of Illness | 2014 |
Aspergillus arachnoiditis post intrathecal baclofen pump insertion.
Topics: Adult; Arachnoiditis; Aspergillus; Baclofen; Catheter-Related Infections; Humans; Infusion Pumps, Im | 2013 |
Permanent mechanical deformation of an intrathecal baclofen pump secondary to scuba diving: a case report.
Topics: Accidents; Adult; Baclofen; Diving; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; M | 2013 |
Intrathecal baclofen in multiple sclerosis and spinal cord injury: complications and long-term dosage evolution.
Topics: Baclofen; Belgium; Dose-Response Relationship, Drug; Female; Humans; Infusion Pumps, Implantable; In | 2013 |
Long-term follow-up on continuous intrathecal Baclofen therapy in non-ambulant children with intractable spastic Cerebral Palsy.
Topics: Adolescent; Baclofen; Caregivers; Cerebral Palsy; Child; Female; Humans; Injections, Spinal; Longitu | 2013 |
Intrathecal baclofen therapy in children with severe spasticity: Outcome and complications.
Topics: Adolescent; Baclofen; Brain Diseases; Brain Injuries; Child; Child, Preschool; Female; Follow-Up Stu | 2014 |
Timing of intrathecal baclofen therapy in persons with acquired brain injury: influence on outcome.
Topics: Adolescent; Adult; Baclofen; Brain Injuries; Dose-Response Relationship, Drug; Drug Administration S | 2013 |
The effect of continuous intrathecal baclofen on sitting in children with severe cerebral palsy.
Topics: Adolescent; Baclofen; Cerebral Palsy; Child; Child, Preschool; Female; Humans; Infusion Pumps, Impla | 2014 |
Fibrin glue to treat spinal fluid leaks associated with intrathecal drug systems.
Topics: Adult; Baclofen; Catheterization; Cerebrospinal Fluid Leak; Female; Fibrin Tissue Adhesive; Fluorosc | 2014 |
Intrathecal baclofen associated with improvement of consciousness disorders in spasticity patients.
Topics: Adult; Baclofen; Consciousness Disorders; Female; Humans; Infusion Pumps, Implantable; Injections, S | 2014 |
Long-term intrathecal baclofen: outcomes after more than 10 years of treatment.
Topics: Adult; Aged; Baclofen; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Administratio | 2014 |
Effects of intrathecal baclofen therapy on CSF neurotransmitter metabolite levels.
Topics: Adult; Baclofen; Biomarkers; Catecholamines; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic | 2014 |
Analysis of complications in 430 consecutive pediatric patients treated with intrathecal baclofen therapy: 14-year experience.
Topics: Adolescent; Baclofen; Catheters, Indwelling; Cerebral Palsy; Child; Child, Preschool; Dystonia; Dyst | 2014 |
Occurrence of adverse events in long-term intrathecal baclofen infusion: a 1-year follow-up study of 158 adults.
Topics: Adolescent; Adult; Age Distribution; Aged; Baclofen; Cerebral Palsy; Dose-Response Relationship, Dru | 2014 |
[Comparative effectiveness of different muscle relaxants in the rehabilitation of post-stroke patients with spasticity].
Topics: Aged; Baclofen; Clonidine; Comparative Effectiveness Research; Dantrolene; Female; Humans; Male; Mus | 2013 |
Complications of intrathecal baclofen pumps in children: experience from a tertiary care center.
Topics: Adolescent; Baclofen; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Infusion Pumps, Im | 2013 |
Pharyngeal spasticity due to dantrolene.
Topics: Baclofen; Child; Dantrolene; Deglutition Disorders; Drug Therapy, Combination; Humans; Male; Muscle | 2014 |
Sexual dysfunction induced by intrathecal baclofen administration: is this the price to pay for severe spasticity management?
Topics: Adolescent; Adult; Baclofen; Erectile Dysfunction; Humans; Injections, Spinal; Male; Middle Aged; Mu | 2014 |
Cardiac arrest due to baclofen withdrawal syndrome.
Topics: Adult; Baclofen; Equipment Failure; Heart Arrest; Humans; Injections, Spinal; Male; Muscle Relaxants | 2014 |
Intrathecal baclofen therapy.
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Relaxants, Central; Muscle | 2014 |
Subcutaneous use of baclofen.
Topics: Aged; Ambulatory Care; Baclofen; Fatal Outcome; Humans; Infusions, Subcutaneous; Intubation, Gastroi | 2014 |
Efficacy of intraoperative vancomycin powder use in intrathecal baclofen pump implantation procedures: single institutional series in a high risk population.
Topics: Academic Medical Centers; Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Baclofen; Female; Hu | 2014 |
Role of dorsal rhizotomy in spinal cord injury-induced spasticity.
Topics: Accidental Falls; Adolescent; Baclofen; Cervical Vertebrae; Child; Dose-Response Relationship, Drug; | 2014 |
Patient experiences with intrathecal baclofen as a treatment for spasticity - a pilot study.
Topics: Activities of Daily Living; Adult; Aged; Baclofen; Cerebral Palsy; Female; Humans; Injections, Spina | 2015 |
Indwelling intrathecal catheter with subcutaneous abdominal reservoir: a viable baclofen delivery system in severely cachectic patients.
Topics: Baclofen; Cachexia; Catheters, Indwelling; Cerebral Palsy; Child; Dystonia; Humans; Infusion Pumps, | 2014 |
Medical cost impact of intrathecal baclofen therapy for severe spasticity.
Topics: Adolescent; Adult; Age Distribution; Aged; Baclofen; Cost-Benefit Analysis; Databases, Factual; Drug | 2015 |
Use of intrathecal baclofen in children and adolescents: interdisciplinary consensus table 2013.
Topics: Adolescent; Baclofen; Child; Consensus; Dystonic Disorders; Female; Follow-Up Studies; Humans; Injec | 2014 |
[Intrathecal baclofen therapy and management of severe spasticity].
Topics: Baclofen; Humans; Injections, Spinal; Muscle Relaxants, Central; Muscle Spasticity; Patient Selectio | 2014 |
Intrathecal baclofen therapy in children with acquired brain injuries after drowning: A case series.
Topics: Baclofen; Brain Injuries; Child; Child, Preschool; Female; Humans; Injections, Spinal; Male; Muscle | 2015 |
Intrathecal Pump: An Abrupt Intermittent Pump Failure.
Topics: Adult; Baclofen; Equipment Failure; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; M | 2015 |
Understanding the reasons for delayed referral for intrathecal baclofen therapy in pediatric patients with severe spasticity.
Topics: Adolescent; Baclofen; Child; Child, Preschool; Drug Delivery Systems; Female; Humans; Male; Muscle R | 2015 |
Spasticity.
Topics: Baclofen; Botulinum Toxins; Cerebral Palsy; Humans; Multiple Sclerosis; Muscle Relaxants, Central; M | 2015 |
Influence of intrathecal baclofen on the level of consciousness and mental functions after extremely severe traumatic brain injury: brief report.
Topics: Adult; Baclofen; Brain Injuries; Consciousness; Humans; Male; Mental Processes; Middle Aged; Muscle | 2015 |
Increased spasticity from a fracture in the baclofen catheter caused by Charcot spine: case report.
Topics: Aged; Arthropathy, Neurogenic; Baclofen; Catheterization; Equipment Failure; Humans; Injections, Spi | 2015 |
Baclofen dosage after traumatic spinal cord injury: a multi-decade retrospective analysis.
Topics: Accidents, Traffic; Adolescent; Adult; Aged; Baclofen; Child; Cohort Studies; Female; Humans; Inject | 2015 |
Positive experience with intrathecal baclofen treatment in children with severe cerebral palsy.
Topics: Adolescent; Baclofen; Cerebral Palsy; Child; Child, Preschool; Denmark; Dystonia; Female; Humans; In | 2015 |
Infectious Complications of Intrathecal Drug Administration Systems for Spasticity and Chronic Pain: 145 Patients From a Tertiary Care Center.
Topics: Adolescent; Adult; Aged; Analgesics; Baclofen; Child; Chronic Pain; Female; Humans; Injections, Spin | 2015 |
[Complete remission of consciousness disturbances and spasticity due to a severe subarachnoid hemorrhage after intrathecal baclofen therapy: a case report].
Topics: Adolescent; Baclofen; Confusion; Consciousness; Female; Humans; Injections, Spinal; Muscle Spasticit | 2015 |
Clinical Experience With Continuous Intrathecal Baclofen Trials Prior to Pump Implantation.
Topics: Adult; Baclofen; Dose-Response Relationship, Drug; Female; Humans; Infusion Pumps, Implantable; Inje | 2015 |
Encephalopathy and hypotonia due to baclofen toxicity in a patient with end-stage renal disease.
Topics: Baclofen; Brain Diseases; Female; Humans; Kidney Failure, Chronic; Middle Aged; Muscle Hypotonia; Mu | 2015 |
Comparison of Efficacy and Side Effects of Oral Baclofen Versus Tizanidine Therapy with Adjuvant Botulinum Toxin Type A in Children With Cerebral Palsy and Spastic Equinus Foot Deformity.
Topics: Administration, Oral; Adolescent; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Child; Child, | 2016 |
Baclofen pump catheter leakage after migration of the abdominal catheter in a pediatric patient with spasticity.
Topics: Abdomen; Adolescent; Baclofen; Catheters, Indwelling; Cerebral Palsy; Foreign-Body Migration; Humans | 2015 |
The need for and provision of intrathecal baclofen therapy for the management of spasticity in England: an assessment of the Hospital Episode Statistics database.
Topics: Baclofen; Delivery of Health Care; Drug Implants; England; Hospitalization; Humans; Injections, Spin | 2015 |
Intrathecal Baclofen therapy in Germany: Proceedings of the IAB-Interdisciplinary Working Group for Movement Disorders Consensus Meeting.
Topics: Baclofen; Germany; Humans; Infusion Pumps, Implantable; Injections, Spinal; Movement Disorders; Musc | 2015 |
Profound Bradycardia After Intrathecal Baclofen Injection in a Patient With Hydranencephaly.
Topics: Baclofen; Bradycardia; Cerebral Palsy; Child; Female; Humans; Hydranencephaly; Injections, Spinal; M | 2015 |
Intrathecal Versus Oral Baclofen: A Matched Cohort Study of Spasticity, Pain, Sleep, Fatigue, and Quality of Life.
Topics: Baclofen; Cohort Studies; Cross-Sectional Studies; Female; Humans; Injections, Spinal; Male; Middle | 2016 |
Intrathecal Baclofen Dosing Regimens: A Retrospective Chart Review.
Topics: Adult; Aged; Baclofen; Brain Injuries; Cerebral Palsy; Dose-Response Relationship, Drug; Female; Hum | 2016 |
Spinal Surgery and Abrupt Intrathecal Baclofen Withdrawal.
Topics: Baclofen; Female; Humans; Infusion Pumps, Implantable; Middle Aged; Muscle Relaxants, Central; Muscl | 2015 |
Selective dorsal rhizotomy as an alternative to intrathecal baclofen pump replacement in GMFCS grades 4 and 5 children.
Topics: Adolescent; Baclofen; Cerebral Palsy; Child; Female; Humans; Infusion Pumps, Implantable; Infusions, | 2016 |
Isotopic Scintigraphy Coupled With Computed Tomography for the Investigation of Intrathecal Baclofen Device Malfunction.
Topics: Adolescent; Adult; Aged; Baclofen; Equipment Failure; Female; Humans; Infusion Pumps, Implantable; I | 2016 |
Long-term follow-up for lumbar intrathecal baclofen catheters placed using the paraspinal subfascial technique.
Topics: Adolescent; Adult; Baclofen; Catheterization; Catheters, Indwelling; Child; Child, Preschool; Dyston | 2016 |
Unusual placement of intrathecal baclofen pumps: report of two cases.
Topics: Adult; Baclofen; Humans; Infusion Pumps, Implantable; Male; Muscle Relaxants, Central; Muscle Spasti | 2016 |
Fractional anisotropy in children with dystonia or spasticity correlates with the selection for DBS or ITB movement disorder surgery.
Topics: Adolescent; Anisotropy; Baclofen; Child; Child, Preschool; Deep Brain Stimulation; Diffusion Tensor | 2016 |
Treatment of severe, disabling spasticity with continuous intrathecal baclofen therapy following acquired brain injury: the experience of a tertiary institution in Singapore.
Topics: Baclofen; Brain Injuries; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Infus | 2016 |
THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms.
Topics: Adult; Amines; Baclofen; Calcium Channel Blockers; Cannabidiol; Cohort Studies; Cyclohexanecarboxyli | 2016 |
Long-term effects of intrathecal baclofen in multiple sclerosis.
Topics: Adult; Baclofen; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Infusion Pumps | 2016 |
The effect of intrathecal baclofen treatment on activities of daily life in children and young adults with cerebral palsy and progressive neurological disorders.
Topics: Activities of Daily Living; Adolescent; Adult; Baclofen; Cerebral Palsy; Child; Cross-Sectional Stud | 2016 |
Effects of severe spasticity treatment with intrathecal Baclofen in multiple sclerosis patients: Long term follow-up.
Topics: Adult; Baclofen; Female; Follow-Up Studies; Humans; Infusion Pumps, Implantable; Injections, Spinal; | 2016 |
A pharmacokinetic-pharmacodynamic model for intrathecal baclofen in patients with severe spasticity.
Topics: Adult; Baclofen; Female; Humans; Injections, Spinal; Male; Middle Aged; Models, Biological; Muscle R | 2016 |
Cost-effectiveness of Intrathecal Baclofen Therapy in severe refractory non-focal disabling spasticity: a Spanish hospital perspective.
Topics: Adult; Baclofen; Cost-Benefit Analysis; Female; Humans; Injections, Spinal; Length of Stay; Male; Ma | 2017 |
Comparison between an Ascenda and a silicone catheter in intrathecal baclofen therapy in pediatric patients: analysis of complications.
Topics: Adolescent; Baclofen; Catheters, Indwelling; Cerebrospinal Fluid Leak; Child; Child, Preschool; Dyst | 2016 |
Psychosis Following an Increase in Intrathecal Baclofen.
Topics: Baclofen; Brain Injuries, Traumatic; Humans; Injections, Spinal; Male; Muscle Relaxants, Central; Mu | 2016 |
Upper Antero-Medial Thigh as an Alternative Site for Implantation of Intrathecal Pumps: A Case Series.
Topics: Adult; Aged; Baclofen; Female; Follow-Up Studies; Humans; Infusion Pumps, Implantable; Male; Middle | 2016 |
Can Cerebrospinal Fluid Pressure Detect Catheter Complications in Patients Who Experience Loss of Effectiveness With Intrathecal Baclofen Therapy?
Topics: Adolescent; Adult; Aged; Algorithms; Baclofen; Catheters, Indwelling; Cerebrospinal Fluid Pressure; | 2017 |
Does Every Patient Require an Intrathecal Baclofen Trial Before Pump Placement?
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Relaxants, Central; Muscle | 2016 |
Stiff Person Syndrome.
Topics: Adult; Antibodies; Anticonvulsants; Autoimmunity; Baclofen; Clonazepam; Electromyography; Glutamate | 2015 |
Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
Topics: Activities of Daily Living; Adult; Baclofen; Cannabidiol; Dronabinol; Drug Combinations; Female; Hum | 2016 |
Letter to the Editor: Ascenda catheter versus silicone catheter in intrathecal baclofen therapy.
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Relaxants, Central; Muscle | 2017 |
Long-Term Dosing of Intrathecal Baclofen in the Treatment of Spasticity After Acquired Brain Injury.
Topics: Academic Medical Centers; Adult; Ambulatory Care; Baclofen; Brain Injuries, Traumatic; Cohort Studie | 2017 |
[Utility of Intraoperative Catheter Myelography during Intrathecal Baclofen Pump Implantation:Report of 2 Cases].
Topics: Adult; Baclofen; Catheterization; Female; Humans; Infusion Pumps, Implantable; Intraoperative Care; | 2017 |
Changes in body composition after spasticity treatment with intrathecal baclofen.
Topics: Adult; Aged; Baclofen; Body Composition; Body Weight; Female; Humans; Injections, Spinal; Male; Midd | 2017 |
Image-guided intrathecal baclofen pump catheter implantation: a technical note and case series.
Topics: Adolescent; Adult; Anesthesia, General; Baclofen; Catheters, Indwelling; Cerebral Palsy; Cone-Beam C | 2017 |
[Usefulness of Bolus Administration Using the FLEX Mode(Bolus Infusion Mode)for Baclofen Tolerance].
Topics: Baclofen; Female; Humans; Injections, Spinal; Male; Middle Aged; Muscle Spasticity; Nervous System D | 2017 |
Intrathecal Baclofen Therapy for the Treatment of Spasticity in Sjögren-Larsson Syndrome.
Topics: Baclofen; Child, Preschool; Female; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; M | 2017 |
Sexual dysfunction associated with intrathecal baclofen use: a report of two cases.
Topics: Baclofen; Female; Humans; Injections, Spinal; Male; Muscle Relaxants, Central; Muscle Spasticity; Se | 2008 |
Life-threatening constipation induced by intrathecal baclofen therapy.
Topics: Adult; Baclofen; Constipation; Female; Humans; Hypoxia, Brain; Ileal Diseases; Infusion Pumps, Impla | 2008 |
Effect of intrathecal baclofen concentration on spasticity control: case series.
Topics: Adult; Baclofen; Brain Injuries; Cerebral Palsy; Female; GABA Agonists; Humans; Infusion Pumps; Inje | 2008 |
Epidural analgesia in labor for a woman with an intrathecal baclofen pump.
Topics: Adult; Analgesia, Epidural; Anesthesia, Obstetrical; Baclofen; Catheterization; Cerebral Palsy; Fema | 2009 |
Catheter migration after implantation of an intrathecal baclofen infusion pump for severe spasticity: a case report.
Topics: Baclofen; Foreign-Body Migration; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; Mid | 2008 |
Intrathecal ziconotide and baclofen provide pain relief in seven patients with neuropathic pain and spasticity: case reports.
Topics: Adult; Baclofen; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Muscle Relaxants, Cen | 2009 |
Retraction of an intrathecal baclofen infusion catheter following suprapubic cystotomy: a case report.
Topics: Adrenoleukodystrophy; Adult; Baclofen; Cystotomy; Equipment Failure; Humans; Infusion Pumps, Implant | 2009 |
[Case report of intrathecal baclofen administration in a child with severe spasticity attributable to traumatic brain injury].
Topics: Adolescent; Baclofen; Brain Injuries; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; | 2009 |
The incidence and management of tolerance in intrathecal baclofen therapy.
Topics: Adolescent; Adult; Aged; Baclofen; Cohort Studies; Dose-Response Relationship, Drug; Drug Tolerance; | 2009 |
Clinical and neurophysiologic assessment of strength and spasticity during intrathecal baclofen titration in incomplete spinal cord injury: single-subject design.
Topics: Administration, Oral; Adult; Baclofen; Dose-Response Relationship, Drug; Electromyography; Evoked Po | 2009 |
The occurrence of the Babinski sign in complete spinal cord injury.
Topics: Adult; Aged; Aged, 80 and over; Baclofen; Chronic Disease; Female; Humans; Male; Middle Aged; Muscle | 2010 |
[Intrathecal baclofen therapy. Overdose during replacement of a medication pump].
Topics: Anesthesia, General; Baclofen; Cerebral Palsy; Child; Drug Overdose; Humans; Infusion Pumps, Implant | 2009 |
In situ treatment of an infected intrathecal baclofen pump implant with gentamicin-impregnated collagen fleece.
Topics: Anti-Bacterial Agents; Baclofen; Collagen; Debridement; Drug Implants; Gentamicins; Humans; Infusion | 2010 |
Concomitant correction of spinal deformity and spasticity management with posterior instrumentation and baclofen pump implantation.
Topics: Adolescent; Baclofen; Bone Nails; Cerebral Palsy; Female; Humans; Infusion Pumps, Implantable; Injec | 2009 |
Continuous intrathecal baclofen for children with spasticity and/or dystonia: Goal attainment and complications associated with treatment.
Topics: Adolescent; Baclofen; Child; Child, Preschool; Dystonia; Female; Humans; Injections, Spinal; Male; M | 2009 |
Infections related to intrathecal baclofen therapy in children and adults: frequency and risk factors.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Baclofen; Bacterial Infections; Child; Child, Presch | 2009 |
Drug treatments for spasticity.
Topics: Administration, Oral; Adult; Alcohols; Algorithms; Anti-Dyskinesia Agents; Baclofen; Botulinum Toxin | 2009 |
Continuous intrathecal baclofen therapy in children with cerebral palsy - when does improvement emerge?
Topics: Adolescent; Baclofen; Cerebral Palsy; Child; Child, Preschool; Disability Evaluation; Disabled Child | 2010 |
Do baclofen pumps influence the development of scoliosis in children?
Topics: Adolescent; Aging; Baclofen; Cerebral Palsy; Child; Child, Preschool; Disease Progression; Dystonia; | 2010 |
Spasticity treatment facilitates direct care delivery for adults with profound intellectual disability.
Topics: Activities of Daily Living; Adult; Aged; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Comorbi | 2010 |
Intrathecal baclofen therapy for spasticity of cerebral origin--does the position of the intrathecal catheter matter?
Topics: Adolescent; Baclofen; Catheters, Indwelling; Child; Child, Preschool; Humans; Infant; Infusion Pumps | 2010 |
Intrathecal baclofen for spasticity management: a comparative analysis of spasticity of spinal vs cortical origin.
Topics: Adult; Aged; Aged, 80 and over; Baclofen; Botulinum Toxins, Type A; Brain Injuries; Cerebral Cortex; | 2010 |
Consciousness recovery induced by intrathecal baclofen administration after subarachnoid hemorrhage -two case reports-.
Topics: Adult; Aged; Baclofen; Female; Follow-Up Studies; GABA Agonists; Humans; Infusion Pumps, Implantable | 2010 |
Malfunction of SynchroMed II baclofen pump delivers a near-lethal baclofen overdose.
Topics: Baclofen; Cerebral Palsy; Child; Drug Overdose; Equipment Failure; Female; Humans; Infusion Pumps, I | 2010 |
Discordance in informed consent response on the basis of demographic factors: brief report.
Topics: Baclofen; Black or African American; Botulinum Toxins, Type A; Caregivers; Female; Humans; Informed | 2010 |
Incidence and identification of intrathecal baclofen catheter malfunction.
Topics: Adolescent; Adult; Aged; Baclofen; Catheters; Child; Child, Preschool; Cohort Studies; Equipment Fai | 2010 |
Spasticity therapy reacts to astrocyte GluA1 receptor upregulation following spinal cord injury.
Topics: Animals; Astrocytes; Baclofen; Humans; Injections, Spinal; Isoquinolines; Muscle Relaxants, Central; | 2010 |
Intrathecal baclofen therapy: complication avoidance and management.
Topics: Adolescent; Adult; Baclofen; Brain Injuries; Cerebral Palsy; Child; Child, Preschool; Equipment Fail | 2011 |
Clinical outcome and complications of intrathecal baclofen pump in multiple sclerosis patients: a retrospective study.
Topics: Adult; Baclofen; Equipment Failure; Female; Foreign-Body Migration; Humans; Infusion Pumps, Implanta | 2010 |
Effect of intrathecal baclofen, botulinum toxin type A and a rehabilitation programme on locomotor function after spinal cord injury: a case report.
Topics: Adult; Baclofen; Botulinum Toxins, Type A; Drug Therapy, Combination; Ependymoma; Female; Gait; Huma | 2010 |
Suppression of stretch reflex activity after spinal or systemic treatment with AMPA receptor antagonist NGX424 in rats with developed baclofen tolerance.
Topics: Animals; Baclofen; Dose-Response Relationship, Drug; Drug Tolerance; GABA-B Receptor Agonists; Injec | 2010 |
Reversible electrocardiogram changes and cardiomyopathy secondary to baclofen withdrawal syndrome.
Topics: Adult; Autonomic Dysreflexia; Baclofen; Bundle-Branch Block; Electrocardiography; Fever; GABA-B Rece | 2010 |
Outcomes of intrathecal baclofen (ITB) therapy in spacticity.
Topics: Adolescent; Adult; Baclofen; Child; Child, Preschool; Disability Evaluation; Female; Follow-Up Studi | 2011 |
Baclofen-loaded solid lipid nanoparticles: preparation, electrophysiological assessment of efficacy, pharmacokinetic and tissue distribution in rats after intraperitoneal administration.
Topics: Animals; Baclofen; Behavior, Animal; Drug Carriers; Drug Compounding; Drug Delivery Systems; Drug Ev | 2011 |
Simultaneous treatment of intractable pain and spasticity: observations of combined intrathecal baclofen-morphine therapy over a 10-year clinical experience.
Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Baclofen; Drug Therapy, Combination; Female; Follow-Up | 2012 |
Continual infusion of intrathecal baclofen (ITB): long-term effect on spasticity.
Topics: Adolescent; Adult; Baclofen; Child; Female; Humans; Infusion Pumps, Implantable; Injections, Spinal; | 2010 |
Treatment of spasticity related to multiple sclerosis with intrathecal baclofen: a long-term follow-up.
Topics: Adult; Baclofen; Disability Evaluation; Drug Implants; Female; Follow-Up Studies; Humans; Injections | 2011 |
Ultrasound-guided intrathecal baclofen trial: a retrospective case series examining a novel approach.
Topics: Baclofen; Fluoroscopy; GABA-B Receptor Agonists; Humans; Injections, Spinal; Muscle Spasticity; Spin | 2011 |
Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS): typical clinical and neuroimaging features in a Brazilian family.
Topics: Adult; Amitriptyline; Baclofen; Female; Humans; Magnetic Resonance Imaging; Male; Muscle Relaxants, | 2011 |
[From physical therapy to botulinum toxin: treatments in distressing spasticity].
Topics: Baclofen; Botulinum Toxins, Type A; Humans; Muscle Relaxants, Central; Muscle Spasticity; Paraplegia | 2011 |
Cardiovascular alterations heralded by intrathecal baclofen bolus.
Topics: Adult; Baclofen; Bradycardia; Electrocardiography; Heart Rate; Humans; Injections, Spinal; Male; Mid | 2011 |
The effect of pulsatile flow on intrathecal drug delivery in the spinal canal.
Topics: Algorithms; Baclofen; Cerebrospinal Fluid; Computer Simulation; Humans; Injections, Spinal; Models, | 2011 |
Intrathecal baclofen therapy: benefits and complications.
Topics: Adolescent; Australia; Baclofen; Cerebral Palsy; Child; Child, Preschool; Female; Humans; Infusion P | 2011 |
Potential correlation of intrathecal baclofen concentration and clinical improvement after high dose intrathecal intoxication: a case report.
Topics: Baclofen; Critical Care; Drainage; Humans; Hypoxia, Brain; Infusion Pumps; Injections, Spinal; Male; | 2011 |
Intrathecal baclofen therapy in non-ambulant and ambulant children and adolescents with spasticity of cerebral origin.
Topics: Baclofen; Cerebral Cortex; Dystonia; Humans; Muscle Relaxants, Central; Muscle Spasticity | 2011 |
Intrathecal baclofen therapy for severe spasticity: analysis on a series of 112 consecutive patients and future prospectives.
Topics: Adolescent; Adult; Baclofen; Child; Consciousness Disorders; Disabled Persons; Dose-Response Relatio | 2012 |
Assessing competency in spasticity management: a method of development and assessment.
Topics: Baclofen; Botulinum Toxins; Clinical Competence; Curriculum; Documentation; Educational Measurement; | 2012 |
Paraspinal subfascial placement of lumbar intrathecal baclofen catheters: short-term outcomes of a novel technique.
Topics: Adolescent; Adult; Baclofen; Catheters, Indwelling; Cerebral Palsy; Child; Child, Preschool; Dystoni | 2012 |
Goals and outcomes for non ambulant children receiving continuous infusion of intrathecal baclofen.
Topics: Adolescent; Baclofen; Child; Child, Preschool; Disabled Persons; Female; Goals; Humans; Infusion Pum | 2012 |
Quality of intrathecal baclofen from different sources.
Topics: Adult; Baclofen; Chromatography, High Pressure Liquid; Female; Humans; Infusion Pumps; Injections, S | 2012 |
Cervical catheter placement for intrathecal baclofen test dose: is it safe?
Topics: Adolescent; Baclofen; Brain Diseases, Metabolic, Inborn; Catheterization; Catheters, Indwelling; Cer | 2012 |
Intrathecal baclofen for progressive neurological disease in childhood.
Topics: Baclofen; Female; Humans; Male; Muscle Relaxants, Central; Muscle Spasticity | 2012 |
Cervical implantation of intrathecal baclofen pump catheter in children with severe scoliosis.
Topics: Adolescent; Baclofen; Catheters, Indwelling; Cervical Vertebrae; Child; Female; Humans; Infusion Pum | 2012 |
Spasticity in children and young people with non-progressive brain disorders: summary of NICE guidance.
Topics: Adolescent; Baclofen; Botulinum Toxins, Type A; Brain Diseases; Cerebral Palsy; Child; Humans; Injec | 2012 |
Neuromodulation using intrathecal baclofen therapy for spasticity and dystonia.
Topics: Adult; Baclofen; Dystonia; Female; GABA-B Receptor Agonists; Humans; Infusion Pumps, Implantable; In | 2012 |
Cost-effectiveness analysis of intrathecal baclofen therapy in Japan.
Topics: Adult; Baclofen; Cost-Benefit Analysis; Female; Humans; Injections, Spinal; Japan; Male; Middle Aged | 2012 |
Peripheral (limb) myokymic discharges in motor neuron disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Baclofen; Deltoid Muscle; Directive | 2012 |
Intraventricular baclofen as an alternative to intrathecal baclofen for intractable spasticity or dystonia: outcomes and technical considerations.
Topics: Adolescent; Adult; Aged; Baclofen; Brain Injuries; Cerebral Palsy; Child; Child, Preschool; Dystonic | 2012 |
Intrathecal baclofen for progressive neurological disease in children.
Topics: Baclofen; Female; Humans; Male; Muscle Relaxants, Central; Muscle Spasticity | 2013 |
Effects of chronic baclofen use on active movement in an individual with a spinal cord injury.
Topics: Baclofen; Fatigue; Humans; Locomotion; Lower Extremity; Male; Motor Activity; Movement; Muscle Relax | 2012 |
Intrathecal baclofen therapy--how we do it.
Topics: Adolescent; Baclofen; Child; Child, Preschool; Female; Humans; Infant; Infusion Pumps, Implantable; | 2012 |
Weight changes in children receiving intrathecal baclofen for the treatment of spasticity.
Topics: Adolescent; Analysis of Variance; Baclofen; Child; Child, Preschool; Female; Humans; Infusion Pumps, | 2012 |
Evaluation of salvage techniques for infected baclofen pumps in pediatric patients with cerebral palsy.
Topics: Adolescent; Anti-Bacterial Agents; Baclofen; Cerebral Palsy; Child; Child, Preschool; Device Removal | 2012 |
[Results of intrathecal baclofen therapy on spasticity in patients with brain injury].
Topics: Adult; Baclofen; Brain Injuries; Drug Administration Schedule; Female; Humans; Hungary; Infusion Pum | 2012 |
A comparison of hip dislocation rates and hip containment procedures after selective dorsal rhizotomy versus intrathecal baclofen pump insertion in nonambulatory cerebral palsy patients.
Topics: Adolescent; Baclofen; Cerebral Palsy; Child; Child, Preschool; Disease Progression; Female; Follow-U | 2012 |
Effects of acute intrathecal baclofen in an animal model of TBI-induced spasticity, cognitive, and balance disabilities.
Topics: Animals; Baclofen; Behavior, Animal; Brain Injuries; Cognition; Disease Models, Animal; Evoked Poten | 2013 |
[Spasticity in children cerebral palsy: diagnosis and treatment strategies].
Topics: Anti-Dyskinesia Agents; Baclofen; Botulinum Toxins; Cerebral Palsy; Child; Child, Preschool; Humans; | 2012 |
Continuous intrathecal infusion of baclofen in patients with spasticity caused by spinal cord injuries.
Topics: Baclofen; Blood Pressure; Catheterization; Dose-Response Relationship, Drug; Humans; Infusion Pumps; | 2002 |
How should an infected perinephric haematoma be drained in a tetraplegic patient with baclofen pump implanted in the abdominal wall? - A case report.
Topics: Abdominal Wall; Anesthetics, Intravenous; Baclofen; Drainage; Hematoma; Humans; Infusion Pumps, Impl | 2002 |
Measurement of the effect of a bolus dose of intrathecal baclofen by continuous measurement of force under fibreglass casts.
Topics: Adult; Baclofen; Casts, Surgical; Electromyography; Female; Humans; Injections, Spinal; Male; Middle | 2002 |
Long-term safety and efficacy of continuous intrathecal baclofen.
Topics: Adolescent; Adult; Baclofen; Cerebral Palsy; Child; Child, Preschool; Cross-Sectional Studies; Equip | 2002 |
Windup of flexion reflexes in chronic human spinal cord injury: a marker for neuronal plateau potentials?
Topics: Adult; Aged; Baclofen; Chronic Disease; Electric Stimulation; Electromyography; Female; Humans; Inte | 2003 |
Spasticity in multiple sclerosis.
Topics: Adult; Aged; Anti-Dyskinesia Agents; Baclofen; Botulinum Toxins; Disability Evaluation; Female; Huma | 2003 |
Baclofen withdrawal following removal of an intrathecal baclofen pump despite oral baclofen replacement.
Topics: Adult; Baclofen; GABA Agonists; GABA-A Receptor Agonists; Hemodynamics; Humans; Injections, Spinal; | 2003 |
Bladder stones - red herring for resurgence of spasticity in a spinal cord injury patient with implantation of Medtronic Synchromed pump for intrathecal delivery of baclofen - a case report.
Topics: Adult; Baclofen; Equipment Failure; Humans; Infusion Pumps, Implantable; Male; Muscle Relaxants, Cen | 2003 |
Oral motor, communication, and nutritional status of children during intrathecal baclofen therapy: a descriptive pilot study.
Topics: Adolescent; Adult; Baclofen; Cerebral Palsy; Child; Communication; Cross-Sectional Studies; Disabled | 2003 |
Intrathecal baclofen therapy in children with cerebral palsy.
Topics: Baclofen; Cerebral Palsy; Child; Clinical Trials as Topic; Humans; Infusion Pumps, Implantable; Inje | 2003 |
Cyproheptadine for intrathecal baclofen withdrawal.
Topics: Acute Disease; Adult; Baclofen; Cerebral Palsy; Cyproheptadine; Diagnosis, Differential; Female; Fev | 2003 |
Intrathecal baclofen in subjects with spastic hemiplegia: assessment of the antispastic effect during gait.
Topics: Adult; Ankle; Baclofen; Biomechanical Phenomena; Body Weight; Brain Injuries; Cerebral Palsy; Electr | 2003 |
Intrathecal baclofen withdrawal mimicking sepsis.
Topics: Baclofen; Child, Preschool; Clinical Protocols; Decerebrate State; Diagnosis, Differential; Emergenc | 2003 |
[History of neurosurgical treatment of spasticity].
Topics: Baclofen; History, 20th Century; Humans; Muscle Relaxants, Central; Muscle Spasticity; Neurosurgical | 2003 |
[Intrathecal baclofen in spasticity].
Topics: Baclofen; GABA Agonists; Humans; Injections, Spinal; Muscle Relaxants, Central; Muscle Spasticity | 2003 |
[Intrathecal baclofen in the treatment of severe spastic tetraplegia and dystonia in children and adolescents].
Topics: Adolescent; Baclofen; Child; Child, Preschool; Dystonia; GABA Agonists; Humans; Infusion Pumps; Inje | 2003 |
Complications of intrathecal baclofen pumps in children.
Topics: Adolescent; Adult; Age Factors; Baclofen; Child; Equipment Design; Equipment Failure; Humans; Infusi | 2003 |
Intrathecal baclofen for spasticity management in Rett syndrome.
Topics: Adult; Baclofen; Female; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Relaxants, | 2003 |
Monitoring of creatinine kinase during weaning of intrathecal baclofen and with symptoms of early withdrawal.
Topics: Adult; Baclofen; Creatine Kinase; Equipment Contamination; Humans; Infusion Pumps, Implantable; Inje | 2003 |
Spasticity in a child with myelomeningocele treated with continuous intrathecal baclofen.
Topics: Baclofen; Child; Humans; Infusion Pumps, Implantable; Infusions, Parenteral; Male; Meningomyelocele; | 2003 |
Treatment of spasticity in a spinal cord-injured patient with intrathecal morphine due to intrathecal baclofen tolerance--a case report and review of literature.
Topics: Adult; Baclofen; Drug Tolerance; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; Morp | 2003 |
Intrathecal baclofen therapy; patient selection & team approach.
Topics: Baclofen; Humans; Injections, Spinal; Japan; Muscle Spasticity; Patient Care Team; Patient Selection | 2003 |
Intrathecal baclofen pump implantation during pregnancy.
Topics: Adult; Baclofen; Dose-Response Relationship, Drug; Female; Humans; Infusion Pumps, Implantable; Inje | 2003 |
Implantable baclofen pump as an adjuvant in treatment of pressure sores.
Topics: Adult; Baclofen; GABA Agonists; Humans; Infusion Pumps, Implantable; Injections, Spinal; Middle Aged | 2003 |
[Intrathecal baclofen in the treatment of spasticity. Our experience].
Topics: Baclofen; Brain Diseases; GABA Agonists; Humans; Injections, Spinal; Muscle Spasticity; Spinal Cord | 2003 |
Subdural catheter migration may lead to baclofen pump dysfunction.
Topics: Accidental Falls; Adult; Baclofen; Catheterization; Equipment Failure; Follow-Up Studies; Foreign-Bo | 2003 |
Spasticity in adults living in a developmental center.
Topics: Activities of Daily Living; Adult; Aged; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Comorbi | 2003 |
Spasticity in adults living in a developmental center.
Topics: Activities of Daily Living; Adult; Aged; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Comorbi | 2003 |
Spasticity in adults living in a developmental center.
Topics: Activities of Daily Living; Adult; Aged; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Comorbi | 2003 |
Spasticity in adults living in a developmental center.
Topics: Activities of Daily Living; Adult; Aged; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Comorbi | 2003 |
Spasticity in adults living in a developmental center.
Topics: Activities of Daily Living; Adult; Aged; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Comorbi | 2003 |
Spasticity in adults living in a developmental center.
Topics: Activities of Daily Living; Adult; Aged; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Comorbi | 2003 |
Spasticity in adults living in a developmental center.
Topics: Activities of Daily Living; Adult; Aged; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Comorbi | 2003 |
Spasticity in adults living in a developmental center.
Topics: Activities of Daily Living; Adult; Aged; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Comorbi | 2003 |
Spasticity in adults living in a developmental center.
Topics: Activities of Daily Living; Adult; Aged; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Comorbi | 2003 |
Spasticity in adults living in a developmental center.
Topics: Activities of Daily Living; Adult; Aged; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Comorbi | 2003 |
Spasticity in adults living in a developmental center.
Topics: Activities of Daily Living; Adult; Aged; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Comorbi | 2003 |
Spasticity in adults living in a developmental center.
Topics: Activities of Daily Living; Adult; Aged; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Comorbi | 2003 |
Spasticity in adults living in a developmental center.
Topics: Activities of Daily Living; Adult; Aged; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Comorbi | 2003 |
Spasticity in adults living in a developmental center.
Topics: Activities of Daily Living; Adult; Aged; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Comorbi | 2003 |
Spasticity in adults living in a developmental center.
Topics: Activities of Daily Living; Adult; Aged; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Comorbi | 2003 |
Spasticity in adults living in a developmental center.
Topics: Activities of Daily Living; Adult; Aged; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Comorbi | 2003 |
[Intrathecal baclofen for treatment of spasticity in patient with cerebral palsy--a preliminary report].
Topics: Adolescent; Adult; Baclofen; Cerebral Palsy; Electromyography; Female; Humans; Infusion Pumps, Impla | 2003 |
Baclofen toxicity in an 8-year-old with an intrathecal baclofen pump.
Topics: Baclofen; Cerebral Palsy; Child; Drug Overdose; Equipment Design; Equipment Failure; Equipment Failu | 2004 |
Correlation between withdrawal symptoms and medication pump residual volume in patients with implantable SynchroMed pumps.
Topics: Adult; Aged; Aged, 80 and over; Analgesia, Epidural; Analgesics, Opioid; Baclofen; Bupivacaine; Clon | 2004 |
Care provider assessment of intrathecal baclofen in children.
Topics: Adolescent; Adult; Baclofen; Brain Injuries; Cerebral Palsy; Child; Child, Preschool; Female; Humans | 2004 |
Treatment of spasticity with intrathecal Baclofen administration: long-term follow-up, review of 40 patients.
Topics: Adult; Baclofen; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Fe | 2004 |
Comparison of Tc99m-DTPA and indium-111 DTPA studies of baclofen pump function.
Topics: Adolescent; Adult; Baclofen; Equipment Failure Analysis; Female; Humans; Indium Radioisotopes; Infus | 2004 |
Prevalence and treatment of spasticity reported by multiple sclerosis patients.
Topics: Administration, Oral; Adult; Baclofen; Cross-Sectional Studies; Disability Evaluation; Female; Human | 2004 |
Prevalence and treatment of spasticity reported by multiple sclerosis patients.
Topics: Administration, Oral; Adult; Baclofen; Cross-Sectional Studies; Disability Evaluation; Female; Human | 2004 |
Prevalence and treatment of spasticity reported by multiple sclerosis patients.
Topics: Administration, Oral; Adult; Baclofen; Cross-Sectional Studies; Disability Evaluation; Female; Human | 2004 |
Prevalence and treatment of spasticity reported by multiple sclerosis patients.
Topics: Administration, Oral; Adult; Baclofen; Cross-Sectional Studies; Disability Evaluation; Female; Human | 2004 |
Prevalence and treatment of spasticity reported by multiple sclerosis patients.
Topics: Administration, Oral; Adult; Baclofen; Cross-Sectional Studies; Disability Evaluation; Female; Human | 2004 |
Prevalence and treatment of spasticity reported by multiple sclerosis patients.
Topics: Administration, Oral; Adult; Baclofen; Cross-Sectional Studies; Disability Evaluation; Female; Human | 2004 |
Prevalence and treatment of spasticity reported by multiple sclerosis patients.
Topics: Administration, Oral; Adult; Baclofen; Cross-Sectional Studies; Disability Evaluation; Female; Human | 2004 |
Prevalence and treatment of spasticity reported by multiple sclerosis patients.
Topics: Administration, Oral; Adult; Baclofen; Cross-Sectional Studies; Disability Evaluation; Female; Human | 2004 |
Prevalence and treatment of spasticity reported by multiple sclerosis patients.
Topics: Administration, Oral; Adult; Baclofen; Cross-Sectional Studies; Disability Evaluation; Female; Human | 2004 |
Effects of baclofen on spinal reflexes and persistent inward currents in motoneurons of chronic spinal rats with spasticity.
Topics: Acute Disease; Animals; Baclofen; Chronic Disease; Excitatory Postsynaptic Potentials; Female; GABA | 2004 |
Salvage of baclofen pump pocket infection with muscle flap.
Topics: Adult; Astrocytoma; Baclofen; Cerebral Ventricle Neoplasms; Drug Resistance; Humans; Infusion Pumps, | 2004 |
Does general anesthesia potentiate the GABA-ergic action of intrathecal baclofen?
Topics: Adolescent; Anesthesia, General; Baclofen; Drug Overdose; Drug Synergism; Electrocardiography; GABA | 2004 |
Total knee replacement in patients with multiple sclerosis.
Topics: Aged; Arthroplasty, Replacement, Knee; Baclofen; Braces; Casts, Surgical; Humans; Immobilization; Kn | 2004 |
Intrathecal baclofen withdrawal syndrome caused by low residual volume in the pump reservoir: a report of 2 cases.
Topics: Adult; Baclofen; Humans; Infusion Pumps, Implantable; Male; Muscle Relaxants, Central; Muscle Spasti | 2004 |
Pharmacological risks following stroke.
Topics: Animals; Baclofen; Benzodiazepines; Humans; Muscle Relaxants, Central; Muscle Spasticity; Stroke | 2005 |
Intrathecal baclofen therapy over 10 years.
Topics: Adolescent; Adult; Baclofen; Brain Injuries; Cerebral Palsy; Child; Child, Preschool; Drug Implants; | 2004 |
An unusual cause of overdose after baclofen pump implantation: case report.
Topics: Adolescent; Baclofen; Cerebral Palsy; Consciousness Disorders; Contrast Media; Drug Overdose; Dyston | 2005 |
Intracranial fat embolization due to baclofen pump.
Topics: Adult; Baclofen; Brain; Embolism, Fat; Female; Headache; Humans; Hyperacusis; Infusion Pumps, Implan | 2005 |
Pruritus after intrathecal baclofen withdrawal: A retrospective study.
Topics: Baclofen; GABA Agonists; Humans; Incidence; Infusion Pumps, Implantable; Injections, Spinal; Muscle | 2005 |
[A child case treated with intrathecal baclofen: effectiveness for the spasticity in lower extremities].
Topics: Baclofen; Cerebral Palsy; Child; Female; GABA Agonists; Humans; Injections, Spinal; Muscle Spasticit | 2005 |
Incidence of seizures in patients with multiple sclerosis treated with intrathecal baclofen.
Topics: Adult; Baclofen; Brain; Case-Control Studies; Cohort Studies; Female; GABA Agonists; Humans; Inciden | 2005 |
Intrathecal baclofen for spasticity in primary lateral sclerosis.
Topics: Aged; Baclofen; Follow-Up Studies; Humans; Injections, Spinal; Male; Motor Neuron Disease; Muscle Re | 2005 |
Functional outcome of intrathecal baclofen administration for severe spasticity.
Topics: Activities of Daily Living; Adult; Baclofen; Female; Follow-Up Studies; Humans; Infusion Pumps, Impl | 2005 |
Prevention of severe contractures might replace multilevel surgery in cerebral palsy: results of a population-based health care programme and new techniques to reduce spasticity.
Topics: Anti-Dyskinesia Agents; Baclofen; Botulinum Toxins; Cerebral Palsy; Child; Child, Preschool; Contrac | 2005 |
Placement of baclofen pumps through the foramen magnum and upper cervical spine.
Topics: Adolescent; Adult; Baclofen; Catheters, Indwelling; Cerebral Palsy; Cervical Vertebrae; Child; Femal | 2006 |
Epilepsy and intrathecal baclofen therapy in children with cerebral palsy.
Topics: Baclofen; Cerebral Palsy; Child, Preschool; Epilepsy, Generalized; Humans; Infant; Infusion Pumps, I | 2005 |
Efficacy of early use of intrathecal baclofen therapy for treating spastic hypertonia due to acquired brain injury.
Topics: Adolescent; Adult; Aged; Baclofen; Brain Injuries; Child; Disability Evaluation; Drug Delivery Syste | 2005 |
Prolonged anti-spasticity effects of bolus intrathecal baclofen.
Topics: Adult; Baclofen; Brain Injuries; Electromyography; Humans; Injections, Spinal; Male; Muscle Relaxant | 2005 |
Comparison of clinical and neurophysiologic responses to intrathecal baclofen bolus administration in moderate-to-severe spasticity after acquired brain injury.
Topics: Adolescent; Adult; Analysis of Variance; Baclofen; Brain Injuries; Dose-Response Relationship, Drug; | 2005 |
Posterior cervical approach for intrathecal baclofen pump insertion in children with previous spinal fusions. Technical note.
Topics: Adolescent; Adult; Baclofen; Cerebral Palsy; Cervical Vertebrae; Female; Humans; Infusion Pumps; Inj | 2005 |
Long-term intrathecal baclofen therapy in ambulatory patients with spasticity.
Topics: Adult; Aged; Baclofen; Disabled Persons; Female; Follow-Up Studies; Humans; Infusion Pumps, Implanta | 2006 |
Baclofen pump intervention for spasticity affecting pulmonary function.
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Lung; Male; Middle Aged; Muscle R | 2005 |
Intrathecal baclofen for treatment of spasticity of multiple sclerosis patients.
Topics: Adult; Aged; Baclofen; Disabled Persons; Humans; Injections, Spinal; Middle Aged; Multiple Sclerosis | 2006 |
[Treatment of severe spacticity in multiple sclerosis by continuous intrathecal baclofen].
Topics: Adult; Baclofen; Female; Humans; Infusion Pumps, Implantable; Injections, Spinal; Middle Aged; Multi | 2006 |
Identification and management of intrathecal baclofen pump complications: a comparison of pediatric and adult patients.
Topics: Adult; Age Factors; Baclofen; Child; Dystonia; GABA Agonists; Humans; Infusion Pumps, Implantable; M | 2006 |
Best-practice surgical techniques for intrathecal baclofen therapy.
Topics: Baclofen; Catheters, Indwelling; Cerebral Palsy; Child; Dystonia; Equipment Design; GABA Agonists; H | 2006 |
Baclofen pump pocket infection: a case report of successful salvage with muscle flap.
Topics: Adult; Baclofen; Follow-Up Studies; Graft Survival; Humans; Infusion Pumps, Implantable; Injections, | 2006 |
[Radiculopathy following intrathecal baclofen pump implantation].
Topics: Adult; Baclofen; Female; Humans; Infusion Pumps, Implantable; Male; Muscle Relaxants, Central; Muscl | 2006 |
Intrathecal baclofen therapy: ten steps toward best practice.
Topics: Baclofen; Documentation; Humans; Infusion Pumps, Implantable; Injections, Spinal; Mass Screening; Mu | 2006 |
[Spasticity management and progress in ambulatory cerebral palsy].
Topics: Ambulatory Care; Baclofen; Biomechanical Phenomena; Botulinum Toxins, Type A; Cerebral Palsy; Child; | 2006 |
[Intrathecal baclofen. Twenty years later].
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Muscle Relaxants, Central; Muscle Spasticity | 2006 |
Development of baclofen tolerance in a rat model of chronic spasticity and rigidity.
Topics: Animals; Baclofen; Chronic Disease; Drug Tolerance; GABA-A Receptor Agonists; Injections, Spinal; Is | 2006 |
Development of GABA-sensitive spasticity and rigidity in rats after transient spinal cord ischemia: a qualitative and quantitative electrophysiological and histopathological study.
Topics: Acetyltransferases; Analysis of Variance; Animals; Baclofen; Dose-Response Relationship, Radiation; | 2006 |
Intrathecal baclofen toxicity and deep coma in minutes.
Topics: Adult; Baclofen; Coma; Humans; Injections, Spinal; Male; Muscle Relaxants, Central; Muscle Spasticit | 2006 |
Cervical catheter tip placement for intrathecal baclofen administration.
Topics: Adolescent; Adult; Aged; Baclofen; Catheters, Indwelling; Cervical Vertebrae; Female; Follow-Up Stud | 2006 |
Continuous intrathecal baclofen administration by a fully implantable electronic pump for severe spasticity treatment: our experience.
Topics: Adult; Aged; Baclofen; Female; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; Middle | 2006 |
Effect of intrathecal baclofen on sleep and respiratory function in patients with spasticity.
Topics: Adult; Baclofen; Circadian Rhythm; Female; Humans; Injections, Spinal; Middle Aged; Multiple Scleros | 2006 |
Intrathecal baclofen for muscle spasticity and pain--two case reports.
Topics: Adult; Baclofen; Female; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; Middle Aged; | 2006 |
The guidelines for the diagnosis and treatment of spasticity.
Topics: Baclofen; Botulinum Toxins, Type A; Gait; Humans; Muscle Spasticity; Occupational Therapy | 2006 |
Intrathecal baclofen use in children with spasticity--a physicians' survey.
Topics: Attitude of Health Personnel; Baclofen; Health Care Surveys; Humans; Injections, Spinal; Muscle Rela | 2006 |
[Efficacy of intrathecal baclofen in the treatment of spasticity in stroke].
Topics: Baclofen; Hemiplegia; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; Middle Aged; Mu | 2007 |
Oral baclofen and clonidine for treatment of spasticity in children.
Topics: Administration, Oral; Adolescent; Adrenergic alpha-Agonists; Adult; Age Factors; Baclofen; Brain Inj | 2006 |
Intrathecal baclofen for spasticity in primary lateral sclerosis.
Topics: Aged; Baclofen; Electromyography; Humans; Male; Muscle Relaxants, Central; Muscle Spasticity | 2007 |
Interaction of ventriculoperitoneal shunt and baclofen pump.
Topics: Baclofen; Brain; Cerebrospinal Fluid Shunts; Child; Child, Preschool; Combined Modality Therapy; Equ | 2007 |
An unexpected recovery from permanent vegetative state.
Topics: Adult; Baclofen; Consciousness; Follow-Up Studies; Humans; Male; Muscle Relaxants, Central; Muscle S | 2007 |
Inflammatory mass of an intrathecal catheter in patients receiving baclofen as a sole agent: a report of two cases and a review of the identification and treatment of the complication.
Topics: Adult; Aged; Baclofen; Catheterization; Female; Granuloma; Humans; Inflammation; Infusion Pumps, Imp | 2007 |
Paralytic ileus: a complication after intrathecal baclofen therapy.
Topics: Baclofen; Brain Stem Infarctions; Humans; Intestinal Pseudo-Obstruction; Male; Middle Aged; Muscle R | 2006 |
Intrathecal baclofen therapy for spastic hypertonia in chronic traumatic brain injury.
Topics: Adult; Baclofen; Brain Injury, Chronic; Humans; Infusion Pumps, Implantable; Infusions, Parenteral; | 2007 |
The use of intrathecal baclofen pump implants in children and adolescents: safety and complications in 200 consecutive cases.
Topics: Adolescent; Baclofen; Cerebral Palsy; Child; Child, Preschool; Female; Humans; Infusion Pumps, Impla | 2007 |
[Therapeutic methods for patients with spastic paralysis: recent progress].
Topics: Baclofen; Child; Female; Humans; Muscle Relaxants, Central; Muscle Spasticity; Paralysis; Peripheral | 2007 |
Intrathecal baclofen therapy: indications, pharmacology, surgical implant, and efficacy.
Topics: Baclofen; Catheters, Indwelling; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Rel | 2007 |
Surgical management of spasticity of cerebral origin in children.
Topics: Baclofen; Cerebral Palsy; Child; Child, Preschool; Female; Humans; Infusion Pumps, Implantable; Inje | 2007 |
Opisthotonus and intrathecal treatment with baclofen (ITB) in children.
Topics: Adolescent; Adult; Baclofen; Belgium; Child; Child, Preschool; Dystonia; Epilepsy; Female; Follow-Up | 2008 |
Surgical treatment of spasticity in children: comparison of selective dorsal rhizotomy and intrathecal baclofen pump implantation.
Topics: Baclofen; Child, Preschool; Humans; Infusion Pumps, Implantable; Injections, Spinal; Motor Skills; M | 2008 |
Intrathecal Baclofen: a discussion on impact that medical advances can have on the individual and the implications this has for a society that is built on an ethic of social medicine.
Topics: Adult; Baclofen; Cerebral Palsy; Female; Humans; Infusion Pumps, Implantable; Muscle Relaxants, Cent | 2008 |
Heart conduction problems in a tetraplegic patient caused by a single therapeutic dosage of Baclofen.
Topics: Adult; Baclofen; Bradycardia; Cervical Vertebrae; GABA Agonists; Heart Conduction System; Humans; Ma | 2008 |
Infusion of intrathecal baclofen for acute withdrawal. Technical note.
Topics: Acute Disease; Adult; Analgesia, Patient-Controlled; Baclofen; Humans; Infusion Pumps, Implantable; | 2007 |
[Baclofen dose in a screening test and in a baclofen pump filling--is there any differences].
Topics: Adolescent; Baclofen; Child; Clinical Protocols; Dose-Response Relationship, Drug; Drug Tolerance; F | 2007 |
[Sudden improvement of all neurological functions after general anesthesia and two-day intrathecal infusion of baclofen in a child with primary brain-stem injury].
Topics: Accidents, Traffic; Anesthesia, General; Aphasia; Baclofen; Brain Stem; Child; Diffuse Axonal Injury | 2007 |
[The parents expectations after baclofen pump implantation in child with severe spasticity in physical rehabilitation and psychological aspects].
Topics: Activities of Daily Living; Adult; Baclofen; Cerebral Palsy; Child; Female; Follow-Up Studies; Hemip | 2007 |
[Psychological aspects of intrathecal baclofen pump implantation in children].
Topics: Adaptation, Psychological; Adolescent; Adult; Baclofen; Caregivers; Child; Disabled Children; Family | 2007 |
Combined treatment with BTX-A and ITB for spasticity: case report.
Topics: Adult; Baclofen; Botulinum Toxins, Type A; Drug Therapy, Combination; Female; Follow-Up Studies; Hum | 2007 |
Unexpected benefit of propofol in stiff-person syndrome.
Topics: Aged; Autoantibodies; Baclofen; Diazepam; Drug Resistance; Female; GABA Agonists; GABA-A Receptor Ag | 2008 |
[Intrathecal baclofen therapy to spasticity].
Topics: Baclofen; Humans; Injections, Spinal; Muscle Relaxants, Central; Muscle Spasticity | 2007 |
Oral baclofen increases maximal voluntary neuromuscular activation of ankle plantar flexors in children with spasticity due to cerebral palsy.
Topics: Administration, Oral; Adolescent; Ankle Joint; Baclofen; Cerebral Palsy; Child; Child, Preschool; Do | 2008 |
Intrathecal baclofen bolus complicated by deep vein thrombosis and pulmonary embolism. A case report.
Topics: Aged; Baclofen; Diagnosis, Differential; Echocardiography; Female; Humans; Injections; Motor Neuron | 2008 |
Tangled catheter as a rare cause of baclofen pump malfunction.
Topics: Baclofen; Catheters, Indwelling; Female; Humans; Infusion Pumps, Implantable; Middle Aged; Multiple | 2009 |
Propofol for stiff-person syndrome: learning new tricks from an old dog.
Topics: Aged; Autoantibodies; Baclofen; Diazepam; Drug Resistance; Female; GABA Agonists; GABA-A Receptor Ag | 2008 |
Intrathecal baclofen alleviates spinal cord spasticity.
Topics: Adult; Baclofen; Female; Humans; Injections, Spinal; Muscle Spasticity; Muscle Tonus; Spinal Cord In | 1984 |
The effects of baclofen on gamma motoneurones supplying gastrocnemius muscle in the rabbit.
Topics: Animals; Ankle; Baclofen; Motor Neurons; Motor Neurons, Gamma; Muscle Spasticity; Muscle Spindles; M | 1982 |
A possible neurochemical basis for the neuropsychiatric aspects of baclofen therapy.
Topics: Adult; Baclofen; Bipolar Disorder; Brain; Delusions; Depressive Disorder; Dose-Response Relationship | 1983 |
Treatment of writer's cramp with sodium valproate and baclofen. A case report.
Topics: Adult; Baclofen; Drug Therapy, Combination; Handwriting; Humans; Male; Muscle Spasticity; Valproic A | 1983 |
Management of spasticity on neurophysiological basis.
Topics: Baclofen; Chlorpromazine; Cryosurgery; Curare; Dantrolene; Diazepam; Humans; Moxisylyte; Muscle Spas | 1980 |
Drug therapy: spasticity (first of two parts).
Topics: Baclofen; Dantrolene; Diazepam; Humans; Motor Neurons; Muscle Contraction; Muscle Spasticity; Muscle | 1981 |
The drug treatment of spasticity.
Topics: Baclofen; Clonidine; Dantrolene; Diazepam; Humans; Muscle Spasticity; Parasympatholytics | 1983 |
Dyskinesia and psychosis in a patient following baclofen withdrawal.
Topics: Adult; Baclofen; Humans; Male; Movement Disorders; Muscle Spasticity; Pain; Paraplegia; Psychoses, S | 1984 |
Medical treatment of spasticity.
Topics: Baclofen; Dantrolene; Diazepam; Humans; Injections, Spinal; Mephenesin; Muscle Relaxants, Central; M | 1980 |
[Urological complications in patients with multiple sclerosis (author's transl)].
Topics: Adolescent; Adult; Aged; Baclofen; Electric Stimulation; Emepronium; Female; Humans; Male; Middle Ag | 1980 |
Antispastic medication.
Topics: Baclofen; Dantrolene; Diazepam; Humans; Muscle Spasticity | 1980 |
Discriminative electrophysiological tests to study the mode of action of myorelaxant drugs.
Topics: Anti-Anxiety Agents; Baclofen; Benzodiazepines; Benzodiazepinones; Diazepam; Electrophysiology; Huma | 1982 |
Managing spasticity.
Topics: Adult; Baclofen; Child, Preschool; Cold Temperature; Dantrolene; Diazepam; Female; Humans; Muscle Sp | 1982 |
The assessment of drug treatment of spastic gait.
Topics: Baclofen; Gait; Humans; Muscle Spasticity; Spinal Cord Diseases | 1982 |
Management of pediatric spasticity.
Topics: Baclofen; Child; Child, Preschool; Dantrolene; Diazepam; Humans; Infant; Muscle Spasticity; Occupati | 1982 |
Double-blind comparison of single doses of DS103-282, baclofen and placebo for suppression of spasticity.
Topics: Adolescent; Adult; Aged; Baclofen; Clonidine; Double-Blind Method; Electromyography; Female; Hemiple | 1980 |
Pharmacologic and surgical therapy for spasticity.
Topics: Baclofen; Dantrolene; Diazepam; Humans; Muscle Spasticity; Spinal Cord | 1981 |
Complications of baclofen overdosage.
Topics: Adult; Arrhythmia, Sinus; Baclofen; Epilepsy; Female; Humans; Muscle Spasticity | 1980 |
Baclofen in the treatment of stiff-man syndrome.
Topics: Aged; Baclofen; Female; Humans; Muscle Rigidity; Muscle Spasticity; Syndrome | 1981 |
Baclofen and tricyclic antidepressants: possible interaction.
Topics: Antidepressive Agents, Tricyclic; Baclofen; Drug Synergism; Female; Humans; Male; Middle Aged; Muscl | 1981 |
Management of spasticity in spinal cord injury.
Topics: Baclofen; Benzodiazepines; Dantrolene; Humans; Muscle Spasticity; Phenothiazines; Spinal Cord Injuri | 1981 |
[When and how to prescribe muscle relaxants in spasticity ?].
Topics: Baclofen; Dantrolene; Diazepam; Humans; Muscle Relaxants, Central; Muscle Spasticity | 1981 |
[Multiple sclerosis. Treatment interactions].
Topics: Adult; Baclofen; Carbamazepine; Drug Interactions; Humans; Male; Multiple Sclerosis; Muscle Spastici | 1981 |
Treatment of spasticity.
Topics: Baclofen; Benzodiazepines; Curare; Dantrolene; Humans; Muscle Spasticity; Phenols; Propylene Glycols | 1981 |
[Drug therapy of spasticity].
Topics: Baclofen; Diazepam; Humans; Muscle Spasticity | 1981 |
[Neurophysiologic tests of the antispasmodic action of baclofen].
Topics: Adult; Baclofen; H-Reflex; Humans; Middle Aged; Motor Neurons, Gamma; Muscle Spasticity; Parasympath | 1981 |
Intrathecal L-baclofen for cerebral spasticity: case report.
Topics: Adult; Baclofen; Cerebral Palsy; Humans; Injections, Spinal; Male; Muscle Spasticity; Muscles | 1995 |
Cost analysis of continuous intrathecal baclofen versus selective functional posterior rhizotomy in the treatment of spastic quadriplegia associated with cerebral palsy.
Topics: Adolescent; Baclofen; Cerebral Palsy; Child; Costs and Cost Analysis; Hospitalization; Humans; Injec | 1995 |
Comparison of the antinociceptive and antispastic action of (-)-baclofen after systemic and intrathecal administration in intact, acute and chronic spinal rats.
Topics: Animals; Baclofen; Decerebrate State; Drug Tolerance; Injections, Spinal; Injections, Subcutaneous; | 1995 |
Catheter systems for intrathecal drug delivery.
Topics: Adolescent; Adult; Aged; Baclofen; Catheters, Indwelling; Child; Equipment Design; Equipment Failure | 1995 |
Management of intractable spasticity of supraspinal origin by chronic cervical intrathecal infusion of baclofen.
Topics: Adolescent; Adult; Baclofen; Case-Control Studies; Female; Humans; Infusion Pumps, Implantable; Male | 1994 |
The distribution of medication along the spinal canal after chronic intrathecal administration.
Topics: Analgesia, Epidural; Baclofen; Endometrial Neoplasms; Female; Humans; Hydromorphone; Infusion Pumps, | 1993 |
Dantrolene treatment for abrupt intrathecal baclofen withdrawal.
Topics: Adult; Baclofen; Dantrolene; Fever; Humans; Male; Muscle Spasticity; Spinal Cord Injuries; Substance | 1995 |
Influence of baclofen upon the alpha-motoneuron in spasticity by means of F-wave analysis.
Topics: Baclofen; Electrophysiology; Humans; Infusion Pumps; Injections, Spinal; Motor Neurons; Muscle Spast | 1995 |
Hyperbaric oxygen therapy: implications for spinal cord injury patients with intrathecal baclofen infusion pumps. Case report.
Topics: Adult; Baclofen; Humans; Hyperbaric Oxygenation; Infusion Pumps; Injections, Spinal; Male; Muscle Sp | 1994 |
Psychological and emotional effects of the use of oral baclofen: a preliminary study.
Topics: Adolescent; Adult; Affect; Anxiety; Baclofen; Emotions; Humans; Male; Muscle Spasticity; Psychiatric | 1994 |
Complications of spinal opioid therapy: myoclonus, spastic muscle tone and spinal jerking.
Topics: Administration, Oral; Analgesia; Analgesia, Epidural; Baclofen; Clonazepam; Female; Humans; Infusion | 1994 |
Intrathecal baclofen for spasticity.
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Spasticity; Subarachnoid S | 1994 |
Management of severe spasticity with intrathecal baclofen delivered by a manually operated pump.
Topics: Adult; Aged; Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Middle Aged; Multipl | 1994 |
Neurological manifestations of baclofen withdrawal.
Topics: Adult; Baclofen; Diplopia; Epilepsy, Absence; Female; Humans; Male; Muscle Spasticity; Psychoses, Su | 1993 |
Continuous intrathecal baclofen infusion for spasticity of cerebral origin.
Topics: Adolescent; Adult; Baclofen; Cerebral Palsy; Child; Child, Preschool; Humans; Infusion Pumps, Implan | 1993 |
Errors and limitations of the multimodality checking methods of defective spinal intrathecal pump systems. Case report.
Topics: Adult; Baclofen; Equipment Failure; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; M | 1993 |
Pathophysiology and treatment of spasticity.
Topics: Adult; Baclofen; Female; Humans; Muscle Spasticity | 1993 |
Epileptic seizures associated with intrathecal baclofen application.
Topics: Adolescent; Adult; Anticonvulsants; Baclofen; Brain Injuries; Epilepsy; Humans; Infusion Pumps, Impl | 1994 |
Status of baclofen pump.
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Muscle Spasticity | 1993 |
Baclofen toxicity in a patient with subclinical renal insufficiency.
Topics: Adult; Baclofen; Female; Humans; Muscle Spasticity; Renal Insufficiency; Spinal Cord Injuries | 1994 |
Intrathecal baclofen--the importance of catheter position.
Topics: Adult; Baclofen; Catheterization; Encephalomyelitis; Female; Humans; Injections, Spinal; Magnetic Re | 1993 |
Effect of subarachnoid catheter position on the efficacy of intrathecal baclofen for spinal spasticity.
Topics: Adult; Baclofen; Catheters, Indwelling; Humans; Injections, Spinal; Male; Muscle Spasticity; Spinal | 1993 |
Intrathecal baclofen: does tolerance occur?
Topics: Baclofen; Dose-Response Relationship, Drug; Drug Tolerance; Humans; Infusion Pumps, Implantable; Inj | 1993 |
Hyperthermia associated with baclofen withdrawal and increased spasticity.
Topics: Adolescent; Baclofen; Fever; Humans; Male; Muscle Spasticity; Quadriplegia; Substance Withdrawal Syn | 1993 |
Intrathecal baclofen for the management of severe spasticity.
Topics: Adult; Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; Muscle Spasticity | 1993 |
Effect of intrathecal baclofen on the monosynaptic reflex in humans: evidence for a postsynaptic action.
Topics: Adolescent; Adult; Baclofen; Female; Humans; Injections, Spinal; Leg; Male; Middle Aged; Muscle Spas | 1993 |
Intrathecal baclofen for motor disorders.
Topics: Adolescent; Adult; Baclofen; Cerebral Palsy; Craniocerebral Trauma; Dystonia; Female; Humans; Inject | 1995 |
Effects of continuous intrathecal baclofen infusion and selective posterior rhizotomy on upper extremity spasticity.
Topics: Arm; Baclofen; Cerebral Palsy; Child; Humans; Infant, Newborn; Injections, Spinal; Leg; Muscle Relax | 1995 |
Clinical assessment of spasticity in spinal cord injury: a multidimensional problem.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Baclofen; Diazepam; Female; Humans; Male | 1996 |
Intrathecal clonidine and baclofen in the management of spasticity and neuropathic pain following spinal cord injury: a case study.
Topics: Adult; Baclofen; Clonidine; Female; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle | 1996 |
Lasting reduction of severe spasticity after ending chronic treatment with intrathecal baclofen.
Topics: Adult; Aged; Baclofen; Female; Humans; Injections, Spinal; Male; Middle Aged; Multiple Sclerosis; Mu | 1996 |
Long-term clinical, electrophysiological and urodynamic effects of chronic intrathecal baclofen infusion for treatment of spinal spasticity.
Topics: Adolescent; Adult; Aged; Baclofen; Female; Follow-Up Studies; Humans; Infusion Pumps, Implantable; I | 1995 |
The management of cerebral palsy: subjectivity and a conundrum.
Topics: Baclofen; Botulinum Toxins; Cerebral Palsy; Dantrolene; Humans; Muscle Relaxants, Central; Muscle Sp | 1996 |
Baclofen in the treatment of cerebral palsy.
Topics: Administration, Oral; Baclofen; Cerebral Palsy; Drug Tolerance; Humans; Infusion Pumps; Injections, | 1996 |
Complications associated with infusion pumps implanted for spasticity.
Topics: Adult; Aged; Baclofen; Equipment Failure; Female; Humans; Infusion Pumps; Male; Middle Aged; Morphin | 1995 |
[The pharmacology of spasticity].
Topics: Baclofen; Benzodiazepines; Dantrolene; GABA Agents; Humans; Muscle Relaxants, Central; Muscle Spasti | 1980 |
Clinical use of polysynaptic flexion reflexes in the management of spasticity with intrathecal baclofen.
Topics: Adult; Baclofen; Dose-Response Relationship, Drug; Female; Humans; Infusion Pumps; Injections, Spina | 1997 |
New approaches to managing spasticity in children with cerebral palsy.
Topics: Baclofen; Botulinum Toxins; Cerebral Palsy; Child; Child, Preschool; Humans; Injections, Spinal; Mus | 1997 |
Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report.
Topics: Adolescent; Adult; Baclofen; Brain Injuries; Female; Humans; Infusions, Parenteral; Injections, Spin | 1997 |
Diazepam usage in veterans with spinal cord injury.
Topics: Baclofen; Data Collection; Diazepam; Hospitals, Veterans; Humans; Muscle Relaxants, Central; Muscle | 1997 |
Effect on ambulation of continuous intrathecal baclofen infusion.
Topics: Adolescent; Adult; Baclofen; Brain Injuries; Cerebral Palsy; Child; Crutches; Female; Follow-Up Stud | 1997 |
Hyperthermia, rhabdomyolysis, and disseminated intravascular coagulation associated with baclofen pump catheter failure.
Topics: Adult; Baclofen; Catheters, Indwelling; Dantrolene; Disseminated Intravascular Coagulation; Equipmen | 1998 |
Patient management of cerebral origin spasticity with intrathecal baclofen.
Topics: Baclofen; Brain Injuries; Cerebral Palsy; Drug Monitoring; Hospital Units; Humans; Infusion Pumps, I | 1998 |
Quality of life: effect of reduced spasticity from intrathecal baclofen.
Topics: Adult; Aged; Baclofen; Female; Humans; Infusion Pumps, Implantable; Infusions, Parenteral; Male; Mid | 1998 |
Intrathecal baclofen infusion and subsequent orthopedic surgery in patients with spastic cerebral palsy.
Topics: Adolescent; Adult; Baclofen; Cerebral Palsy; Child; Child, Preschool; Contracture; Femur; Follow-Up | 1998 |
Intrathecal baclofen and homeopathy for the treatment of painful muscle spasms associated with malignant spinal cord compression.
Topics: Aged; Baclofen; Holistic Health; Homeopathy; Humans; Injections, Spinal; Male; Muscle Relaxants, Cen | 1998 |
Baclofen withdrawal presenting as multiorgan system failure.
Topics: Adult; Baclofen; Humans; Male; Multiple Organ Failure; Muscle Relaxants, Central; Muscle Spasticity; | 1998 |
[Continuous intrathecal infusion of baclofen. A new therapeutic method for spasticity].
Topics: Adolescent; Adult; Baclofen; Child; Female; Follow-Up Studies; Humans; Infusion Pumps, Implantable; | 1998 |
Continuous intrathecal baclofen infusion alleviates autonomic dysfunction in patients with severe supraspinal spasticity.
Topics: Adult; Autonomic Nervous System Diseases; Baclofen; Female; Follow-Up Studies; Humans; Infusions, Pa | 1999 |
Management of spasticity in children: part 2: oral medications and intrathecal baclofen.
Topics: Administration, Oral; Baclofen; Child; Drug Administration Schedule; Humans; Infusion Pumps, Implant | 1999 |
Lessons to be learned: a case study approach: prolonged methaemoglobinaemia due to inadvertent dapsone poisoning; treatment with methylene blue and exchange transfusion.
Topics: Adult; Antidotes; Baclofen; Dapsone; Exchange Transfusion, Whole Blood; Folic Acid Antagonists; Hemo | 1999 |
[Current data on bipolar disorders, epilepsy and spasticity. 4. Neuro-Forum, Dresden].
Topics: Baclofen; Bipolar Disorder; Clonidine; Epilepsy; Female; Humans; Male; Muscle Relaxants, Central; Mu | 1999 |
Regression of vasomotor disorders under intrathecal baclofen in a case of spastic paraplegia.
Topics: Adult; Baclofen; Disability Evaluation; Humans; Infusion Pumps, Implantable; Male; Motor Skills; Mus | 1999 |
Intrathecal baclofen for intractable spasticity in amyotrophic lateral sclerosis.
Topics: Adult; Amyotrophic Lateral Sclerosis; Baclofen; Catheters, Indwelling; Disease Progression; Dose-Res | 1999 |
Drug interactions and spasticity.
Topics: Adrenergic alpha-Agonists; Antidepressive Agents; Baclofen; Clonidine; Drug Interactions; Humans; Mu | 1999 |
Epidural blood patch under fluoroscopic control: non-surgical treatment of lumbar cerebrospinal fluid fistula following implantation of an intrathecal pump system.
Topics: Adult; Baclofen; Blood Patch, Epidural; Cerebrospinal Fluid; Cutaneous Fistula; Fluoroscopy; Humans; | 1999 |
Midthoracic catheter tip placement for intrathecal baclofen administration in children with quadriparetic spasticity.
Topics: Baclofen; Catheters, Indwelling; Child; Dose-Response Relationship, Drug; Female; Follow-Up Studies; | 1999 |
Measurement of the effect of a bolus dose of intrathecal baclofen by a repetitive movement test.
Topics: Adolescent; Adult; Ankle Joint; Baclofen; Dose-Response Relationship, Drug; Electromyography; Female | 1999 |
Continuous intrathecal pump infusion of baclofen with antibiotic drugs for treatment of pump-associated meningitis. Case report.
Topics: Adult; Anti-Bacterial Agents; Baclofen; Dose-Response Relationship, Drug; Drug Therapy, Combination; | 2000 |
Ziconotide for the treatment of severe spasticity after spinal cord injury.
Topics: Adult; Analgesics, Opioid; Baclofen; Calcium Channel Blockers; Drug Resistance; Humans; Male; Morphi | 2000 |
Quantitative assessment of intrathecally administered baclofen in spasticity.
Topics: Adult; Ankle Joint; Baclofen; Case-Control Studies; Electromyography; Female; Humans; Injections, Sp | 2000 |
Pseudomonas aeruginosa infection in an intrathecal baclofen pump: successful treatment with adjunct intra-reservoir gentamicin.
Topics: Adult; Baclofen; Equipment Contamination; Gentamicins; Humans; Infusion Pumps; Injections, Spinal; M | 2000 |
Intrathecal baclofen pump implantation complicated by epidural lipomatosis.
Topics: Adolescent; Baclofen; Cerebral Palsy; Epidural Space; Humans; Infusion Pumps, Implantable; Injection | 2000 |
[Optimized therapy of spastic syndrome by combination intrathecal baclofen with botulinum toxin].
Topics: Adult; Baclofen; Botulinum Toxins, Type A; Drug Therapy, Combination; Female; Humans; Injections, In | 2000 |
[Pharmacology of spasticity. Does therapy remain in deep sleep?].
Topics: Animals; Baclofen; Botulinum Toxins, Type A; Clonidine; Drug Industry; Humans; Injections, Spinal; M | 2000 |
Caudal epidural blood patch for treating intractable vomiting in a child after placement of a permanent intrathecal catheter.
Topics: Baclofen; Blood Patch, Epidural; Catheters, Indwelling; Child, Preschool; Epidural Space; Humans; In | 2001 |
Intrathecal baclofen for spasticity caused by thrombotic stroke.
Topics: Baclofen; Female; Humans; Infusion Pumps, Implantable; Injections, Spinal; Middle Aged; Muscle Relax | 2001 |
Dysesthesia perceived as painful spasticity: A report of 3 cases.
Topics: Aged; Aged, 80 and over; Baclofen; Female; Humans; Injections, Spinal; Male; Middle Aged; Muscle Con | 2001 |
Improvement of sleep apnea in a patient with cerebral palsy.
Topics: Adult; Baclofen; Cerebral Palsy; Dystonia; Female; Humans; Injections, Spinal; Muscle Spasticity; Po | 2001 |
Radioisotopic control for baclofen pump catheter failure.
Topics: Adult; Baclofen; Equipment Failure; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; M | 2001 |
Continuous intrathecal baclofen infusion for children with cerebral palsy: a pilot study.
Topics: Baclofen; Cerebral Palsy; Child; Drug Administration Schedule; Female; Humans; Injections, Spinal; M | 2001 |
Subfascial implantation of intrathecal baclofen pumps in children: technical note.
Topics: Adolescent; Baclofen; Child; Child, Preschool; Dystonia; Follow-Up Studies; Humans; Infusion Pumps, | 2001 |
Use of intrathecal baclofen for treatment of spasticity in amyotrophic lateral sclerosis.
Topics: Adult; Baclofen; Follow-Up Studies; Humans; Injections, Spinal; Male; Motor Neuron Disease; Muscle S | 2002 |
Baclofen inhibits ANP-mediated cyclic GMP synthesis in the rat cervical spinal cord.
Topics: Aging; Animals; Atrial Natriuretic Factor; Baclofen; Cervical Vertebrae; Cyclic GMP; GABA Agonists; | 2002 |
Extra corporeal shock wave lithotripsy of calculi located in lower calyx of left kidney in a spinal cord injury patient who has implantation of baclofen pump in the ipsilateral loin.
Topics: Adult; Baclofen; Humans; Infusion Pumps, Implantable; Kidney Calculi; Lithotripsy; Male; Muscle Rela | 2002 |
Evidence of tolerance to baclofen in treatment of severe spasticity with intrathecal baclofen.
Topics: Adult; Baclofen; Catheterization; Drug Administration Schedule; Female; Humans; Injections, Spinal; | 2002 |
Motor function improvement following intrathecal baclofen pump placement in a patient with locked-in syndrome.
Topics: Adult; Baclofen; Brain Stem Infarctions; Humans; Infusion Pumps, Implantable; Male; Muscle Relaxants | 2002 |
Combined intrathecal baclofen and morphine infusion for the treatment of spasticity related pain and central deafferentiation pain.
Topics: Afferent Pathways; Analgesics, Opioid; Baclofen; Central Nervous System Diseases; Denervation; Drug | 2002 |
Spasticity in kids. An intrathecal option.
Topics: Baclofen; Child; Humans; Infusion Pumps, Implantable; Injections, Spinal; Muscle Relaxants, Central; | 2001 |
Treatment of spasticity.
Topics: Acetates; Amines; Aminopyridines; Baclofen; Benzodiazepines; Botulinum Toxins, Type A; Clonidine; Cy | 2002 |
Functional benefits and cost/benefit analysis of continuous intrathecal baclofen infusion for the management of severe spasticity.
Topics: Adolescent; Adult; Aged; Baclofen; Child; Child, Preschool; Cost-Benefit Analysis; Female; Humans; I | 2002 |
Spastic paresis after 6-aminonicotinamide: metabolic disorders in the spinal cord and electromyographically recorded changes in the hind limbs of rats.
Topics: 6-Aminonicotinamide; Action Potentials; Animals; Baclofen; Brain; Chlorpromazine; Electromyography; | 1976 |
[Pharmacological treatment of pathological increases in muscle tonus].
Topics: Baclofen; Chlorzoxazone; Female; Humans; Multiple Sclerosis; Muscle Spasticity; Neural Pathways; Par | 1978 |
C0-contraction and stretch reflexes in spasticity during treatment with baclofen.
Topics: Adolescent; Adult; Aminobutyrates; Baclofen; Electromyography; Female; Humans; Male; Middle Aged; Mo | 1977 |
[Effect of lioresal on the rehabilitation of spastics].
Topics: Aminobutyrates; Baclofen; Cerebral Palsy; Humans; Muscle Spasticity; Spinal Cord Diseases | 1977 |
Baclofen.
Topics: Aminobutyrates; Baclofen; Drug Evaluation; Humans; Multiple Sclerosis; Muscle Spasticity | 1977 |
[Lioresal in the treatment of spasticity].
Topics: Adolescent; Adult; Aged; Aminobutyrates; Baclofen; Drug Evaluation; Female; gamma-Aminobutyric Acid; | 1976 |
Clinical management of spastic states.
Topics: Baclofen; Dantrolene; Diazepam; Humans; Muscle Spasticity; Neurosurgery; Propylene Glycols; Sclerosi | 1976 |
[The use of Beclofen in spastic cases].
Topics: Aminobutyrates; Baclofen; Humans; Muscle Spasticity | 1975 |
[The physically and mentally handicapped child. 2. Spastic syndrome].
Topics: Age Factors; Aminobutyrates; Baclofen; Child; Child, Preschool; Humans; Infant; Muscle Spasticity; S | 1976 |
Clonidine in the treatment of brainstem spasticity. Case report.
Topics: Adult; Baclofen; Cerebral Infarction; Clonidine; Female; Humans; Medulla Oblongata; Muscle Spasticit | 1992 |
Baclofen for spasticity.
Topics: Baclofen; Dose-Response Relationship, Drug; Humans; Multiple Sclerosis; Muscle Spasticity | 1992 |
[Treatment concepts of tertiary damage of the locomotor system after craniocerebral trauma].
Topics: Anesthetics, Local; Baclofen; Brain Damage, Chronic; Brain Injuries; Catheters, Indwelling; Combined | 1992 |
Development of an acute withdrawal syndrome following the cessation of intrathecal baclofen in a patient with spasticity.
Topics: Adult; Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; Muscle Spasticity; Q | 1992 |
Muscle stiffness and continuous electromyographic activity in old rats; an animal model for spasticity?
Topics: Aging; Animals; Atrophy; Baclofen; Benserazide; Drug Combinations; Electromyography; Female; Levodop | 1992 |
Pathophysiology and treatment of spasticity: report of two cases.
Topics: Adult; Arachnoiditis; Baclofen; Diazepam; Female; Humans; Male; Muscle Spasticity; Paraplegia; Tuber | 1992 |
Flexor reflex for assessment of common interneurone activity in spasticity.
Topics: Adult; Aged; Anti-Anxiety Agents; Baclofen; Benzodiazepines; Benzodiazepinones; Cerebrovascular Diso | 1992 |
Pregnancy in a quadriplegic patient treated with continuous intrathecal baclofen infusion to manage her severe spasticity. Case report.
Topics: Adult; Baclofen; Cesarean Section; Drug Implants; Female; Humans; Injections, Spinal; Muscle Spastic | 1992 |
Prolonged seizure activity after baclofen withdrawal.
Topics: Baclofen; Humans; Male; Middle Aged; Muscle Spasticity; Seizures | 1992 |
Effects of intrathecal baclofen on lumbosacral and cortical somatosensory evoked potentials.
Topics: Adult; Baclofen; Cerebral Cortex; Evoked Potentials, Somatosensory; Female; Humans; Injections, Spin | 1992 |
Complications of intrathecal baclofen delivery.
Topics: Adolescent; Adult; Baclofen; Drug Overdose; Female; Follow-Up Studies; Humans; Infusion Pumps, Impla | 1992 |
Mechanisms of baclofen action on spasticity.
Topics: Baclofen; Cerebrovascular Disorders; Electromyography; Equipment Design; Female; Hemiplegia; Humans; | 1992 |
Baclofen and carbamazepine in supraspinal spasticity.
Topics: Administration, Oral; Adult; Baclofen; Brain Injuries; Carbamazepine; Drug Therapy, Combination; Fem | 1991 |
Intrathecal fentanyl alleviates spasticity in the presence of tolerance to intrathecal baclofen.
Topics: Adult; Baclofen; Drug Tolerance; Fentanyl; Humans; Injections, Spinal; Male; Muscle Spasticity | 1992 |
Intrathecal baclofen for severe spasticity: five years experience.
Topics: Adult; Baclofen; Catheters, Indwelling; Humans; Injections, Spinal; Middle Aged; Muscle Spasticity; | 1991 |
Intraspinal baclofen in the treatment of severe spasticity and spasms.
Topics: Adolescent; Adult; Aged; Baclofen; Child; Dose-Response Relationship, Drug; Electromyography; Female | 1991 |
High-dose oral baclofen: experience in patients with multiple sclerosis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Baclofen; Female; Humans; Male; Middle Aged; Multiple | 1991 |
Chronic intrathecal baclofen administration in severe spasticity.
Topics: Adolescent; Adult; Baclofen; Brain Damage, Chronic; Cerebral Palsy; Female; Follow-Up Studies; Human | 1990 |
Is the antispastic action of baclofen mediated by GABAB receptors? GABAB receptors and spasticity.
Topics: Animals; Baclofen; Humans; Muscle Spasticity; Rats; Receptors, GABA-A | 1990 |
Intrathecal baclofen: not all spasticity is bad.
Topics: Baclofen; Cerebral Palsy; Humans; Muscle Spasticity | 1991 |
CSF baclofen levels after intrathecal administration in severe spasticity.
Topics: Adult; Baclofen; Chromatography, High Pressure Liquid; Female; Half-Life; Humans; Injections, Spinal | 1991 |
[Treatment of spinal and supraspinal spasticity by intrathecal administration of baclofen using a computer-assisted pump system].
Topics: Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Microcomputers; Muscle Spasticity | 1990 |
[Continuous intrathecal baclofen therapy using an implantable pump system in severe spasticity].
Topics: Baclofen; Dose-Response Relationship, Drug; Humans; Infusion Pumps, Implantable; Motor Neurons; Musc | 1990 |
Chronic intrathecal baclofen administration for control of severe spasticity.
Topics: Baclofen; Coma; Drug Overdose; Drug Tolerance; Evaluation Studies as Topic; Humans; Infusion Pumps, | 1990 |
[Intraoperative suppression of spasticity using intrathecal baclofen].
Topics: Adult; Aged; Baclofen; Humans; Injections, Spinal; Intraoperative Period; Male; Muscle Spasticity; P | 1990 |
Pharmacokinetics of baclofen in spastic patients receiving multiple oral doses.
Topics: Baclofen; Female; Humans; Male; Middle Aged; Muscle Spasticity | 1990 |
[Satoyoshi's syndrome: a syndrome of progressive muscle spasm, alopecia, and diarrhea].
Topics: Adolescent; Adult; Alopecia; Baclofen; Child; Dantrolene; Diarrhea; Humans; Male; Muscle Spasticity; | 1990 |
Intrathecal baclofen for intractable spasticity due to severe brain injury.
Topics: Adult; Baclofen; Brain Injuries; Chronic Disease; Dose-Response Relationship, Drug; Humans; Injectio | 1989 |
Intrathecal baclofen for cerebral spasticity.
Topics: Adolescent; Baclofen; Cerebral Palsy; Child; Child, Preschool; Humans; Injections, Spinal; Muscle Sp | 1989 |
[Treatment of spasticity using an intrathecal infusion of baclofen].
Topics: Adult; Baclofen; Female; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; Middle Aged; | 1989 |
Treatment of spastic paresis.
Topics: Baclofen; Humans; Infusion Pumps; Muscle Spasticity; Paralysis; Spinal Cord Diseases; Subarachnoid S | 1989 |
Intrathecal baclofen infusion. Effect on bladder management programs in patients with myelopathy.
Topics: Adult; Baclofen; Female; Humans; Injections, Spinal; Male; Muscle Spasticity; Paraplegia; Urinary Bl | 1989 |
Effect of intrathecal baclofen on bladder and sphincter function.
Topics: Baclofen; Female; Humans; Infusion Pumps; Injections, Spinal; Male; Morphine; Muscle Spasticity; Mye | 1989 |
Intrathecal baclofen and the H-reflex.
Topics: Adult; Baclofen; H-Reflex; Humans; Injections, Spinal; Male; Muscle Spasticity; Reflex, Monosynaptic | 1989 |
Tizanidine vs. baclofen in the treatment of spasticity in patients with multiple sclerosis.
Topics: Baclofen; Clonidine; Drug Tolerance; Humans; Multiple Sclerosis; Muscle Spasticity | 1989 |
Continuous intrathecal baclofen for severe spasticity.
Topics: Adult; Baclofen; Female; Humans; Infusions, Parenteral; Middle Aged; Muscle Rigidity; Muscle Spastic | 1985 |
Intrathecal baclofen for spasticity.
Topics: Baclofen; Child, Preschool; Humans; Injections, Spinal; Male; Muscle Spasticity | 1985 |
Primary afferent terminal excitability in the normal and spastic mutant mouse spinal cord.
Topics: Animals; Anti-Anxiety Agents; Baclofen; Benzodiazepines; Bicuculline; Electric Stimulation; gamma-Am | 1987 |
Epidural baclofen for intractable spasticity.
Topics: Adult; Baclofen; Female; Humans; Injections, Epidural; Male; Middle Aged; Muscle Spasticity; Spinal | 1988 |
Short-term effects of intrathecal baclofen in spasticity.
Topics: Administration, Oral; Adult; Baclofen; Electromyography; Humans; Injections, Spinal; Knee Joint; Mid | 1989 |
Functional outcome after delivery of intrathecal baclofen.
Topics: Activities of Daily Living; Adult; Baclofen; Female; Humans; Injections, Spinal; Male; Middle Aged; | 1989 |
[Antispastic treatment of paraplegic patients].
Topics: Baclofen; Contracture; Dantrolene; Diazepam; Humans; Muscle Spasticity; Nursing Care; Paraplegia | 1988 |
Implanted pump systems for treatment of spasticity.
Topics: Adolescent; Adult; Aged; Baclofen; Child; Child, Preschool; Drug Administration Schedule; Equipment | 1988 |
Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients.
Topics: Adult; Aged; Baclofen; Clonidine; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Age | 1988 |
The physiology of spasticity and its response to therapy.
Topics: Animals; Baclofen; Central Nervous System Diseases; Dantrolene; Diazepam; Humans; Motor Neurons; Mus | 1988 |
Intrathecal baclofen for severe spasticity.
Topics: Activities of Daily Living; Baclofen; Electroencephalography; Electromyography; Equipment Failure; E | 1988 |
Delta-aminovaleric acid antagonizes the pharmacological actions of baclofen in the central nervous system.
Topics: Animals; Baclofen; Bicuculline; Drug Antagonism; Electric Stimulation; Female; gamma-Aminobutyric Ac | 1988 |
Intrathecal application of baclofen in the treatment of spasticity.
Topics: Adolescent; Adult; Baclofen; Female; gamma-Aminobutyric Acid; Humans; Injections, Spinal; Male; Midd | 1987 |
Controversies in the surgical management of spasticity.
Topics: Baclofen; Electric Stimulation Therapy; Humans; Injections, Spinal; Morphine; Muscle Spasticity; Spi | 1986 |
The effect of intrathecal baclofen on electrical muscle activity in spasticity.
Topics: Adult; Aged; Baclofen; Brain Damage, Chronic; Child, Preschool; Electromyography; Humans; Infusion P | 1987 |
Intrathecal baclofen for severe spasticity.
Topics: Baclofen; Humans; Infusion Pumps; Multiple Sclerosis; Muscle Spasticity | 1987 |
Muscle relaxants in multiple sclerosis.
Topics: Baclofen; Dantrolene; Humans; Multiple Sclerosis; Muscle Spasticity | 1987 |
Intrathecal baclofen for severe spasticity.
Topics: Baclofen; Humans; Muscle Spasticity | 1987 |
Reversible electroencephalogram changes associated with administration of baclofen in a quadriplegic patient: case report.
Topics: Adult; Baclofen; Cervical Vertebrae; Delta Rhythm; Electroencephalography; Fractures, Bone; Humans; | 1986 |
Intrathecal baclofen for severe spasticity.
Topics: Adult; Baclofen; Catheters, Indwelling; Female; Humans; Injections, Spinal; Multiple Sclerosis; Musc | 1986 |
Baclofen pseudopsychosis: case report.
Topics: Adult; Baclofen; Diagnosis, Differential; Hallucinations; Humans; Male; Muscle Spasticity; Psychotic | 1986 |
Intrathecal baclofen for treatment of tetanus-induced spasticity.
Topics: Baclofen; Electroencephalography; Electromyography; Humans; Injections, Spinal; Male; Middle Aged; M | 1987 |
Long-term intrathecal baclofen infusion for treatment of spasticity.
Topics: Adult; Baclofen; Drug Evaluation; Female; Humans; Infusion Pumps; Male; Middle Aged; Muscle Spastici | 1987 |
[Antispastic agents].
Topics: Adult; Baclofen; Benzodiazepines; Child; Dantrolene; Diazepam; Drug Tolerance; Humans; Muscle Spasti | 1986 |
Electrophysiological analysis of the mode of action of muscle relaxants in spasticity.
Topics: Baclofen; Clonidine; Diazepam; Electrophysiology; Ethanolamines; Female; Humans; Male; Middle Aged; | 1985 |
Adverse effects secondary to baclofen withdrawal.
Topics: Adult; Baclofen; Female; gamma-Aminobutyric Acid; Hallucinations; Humans; Intestinal Absorption; Mus | 1985 |
[Spasticity and its treatment].
Topics: Baclofen; Diazepam; Humans; Muscle Spasticity | 1985 |